{"Topic 1": {"198603": "heart_failure_hf prevalent global health issue characterized heart impaired ability pump fill blood affect million worldwide continues pose significant challenge despite advancement treatment review delf critical increasingly recognized role inflammation development progression complex syndrome incidence hf seen decline region due improved cardiac care overall prevalence rising particularly among younger adult heart_failure_preserved_ejection_fraction_hfpef given persistently high rate hospitalization mortality associated hf understanding underlying_mechanism including contribution inflammation crucial identifying novel therapeutic_strategy inflammation heart_failure multifaceted process involving activation immune system innate adaptive encompasses various mechanism release pro inflammatory mediator endothelial_dysfunction neurohormonal activation myocardial damage trigger innate immune response humoral immunity chronic systemic inflammation often linked cardiovascular_risk_factor autoimmune disease also play significant role notably heart_failure inflammation reciprocal relationship hf contributing inflammatory process within cardiac_tissue systemically understanding intricate pathway including involvement specific immune cell molecular mediator essential comprehending pathogenesis heart_failure exploring potential therapeutic_intervention review examines various inflammatory biomarkers implicated heart_failure cytokine including tnf_alpha il c_reactive_protein crp marker often correlate severity prognosis hf clinical_trial targeting specific inflammatory mediator largely yielded disappointing result highlighting complexity inflammatory_response context exploration biomarkers challenge encountered translating anti_inflammatory strategy effective_treatment underscore need continued research unravel precise role inflammation across different hf subtypes develop targeted effective anti_inflammatory therapy:0.0447474843276403", "127956": "heart_failure_preserved_ejection_fraction_hfpef represents one greatest challenge facing cardiovascular medicine today despite common form heart_failure worldwide limited success developing therapeutic syndrome largely due incomplete understanding biology driving systemic pathophysiology heterogeneity clinical phenotype increasingly recognized distinct hfpef phenogroups development efficacious therapeutic fundamentally relies robust preclinical model faithfully recapitulate key feature clinical syndrome also enable rigorous investigation putative mechanism disease context clinically_relevant phenotype review propose preclinical research strategy conceptually grounded model diversification aim better align evolving understanding heterogeneity clinical hfpef although heterogeneity often viewed major obstacle preclinical hfpef research challenge notion argue embracing may key demystifying pathobiology first provide overarching guideline developing hfpef model stepwise approach comprehensive cardiac extra cardiac phenotyping present overview currently available model focused leading phenogroups primarily based aging cardiometabolic stress chronic hypertension discus well model reflect clinically_relevant phenogroup highlight recent mechanistic insight providing complex pathophysiology underlying hfpef:0.0446942178779769", "196067": "cardiovascular_disease cvds remain leading_cause morbidity_mortality worldwide despite advance medical research therapeutic emerging evidence_suggests significant role gut brain axis complex communication network involving gut microbiota central nervous_system cardiovascular_system modulating cardiovascular health gut microbiota influence systemic inflammation neurohumoral pathway metabolic process critical pathogenesis cvd dysbiosis imbalance gut microbiota implicated various cardiovascular condition including hypertension atherosclerosis heart_failure comprehensive review aim elucidate intricate relationship gut microbiome brain cardiovascular_system highlighting mechanism gut derived signal affect cardiovascular function key microbial metabolite short chain fatty_acid scfas trimethylamine n oxide tmao impact vascular health blood_pressure regulation discussed furthermore review explores potential therapeutic_strategy targeting gut brain axis including probiotic prebiotics dietary modification pharmacological intervention improve cardiovascular_outcome despite promising finding field face challenge individual variability microbiome composition complexity gut brain interaction need robust clinical_trial establish causality addressing challenge interdisciplinary research could pave way innovative personalized therapeutic_approach review provides comprehensive understanding gut brain cardiovascular axis underscoring potential novel target preventing treating cvd:0.0428166601208537", "90575": "nanotechnology impacted tremendously medical research increasing importance development new therapeutic_approach application among application use nanocarriers gained particular interest order achieve successful delivery therapeutic imaging agent treatment diagnostics different disease cancer infection diabetes lung brain cardiovascular_disease heart_failure_hf complex clinical syndrome derived multiple cause arise secondary inherited acquired abnormality cardiac structure_function myocardial_infarction_mi major cause hf continues increasing problem term morbidity_mortality healthcare cost worldwide currently established pharmacological drug proven effective reducing hypertrophy remodeling myocardium reducing morbidity_mortality patient_hf however despite optimal treatment existing drug prognosis hf poor also possible deleterious effect therapeutic agent must considered used dos required desired therapeutic effect therefore novel therapeutic_strategy urgently needed prevent high morbidity_mortality associated mi hf review present recent development nanomedicine research envisaged important impact treatment cardiovascular_disease particularly mi addition discus use different advanced modified nanosystems molecular imaging therapeutic mi presenting several vitroand vivoexamples finally conclude overview potential nanomedicines future treatment cardiovascular_disease:0.0421614093952257", "133836": "cardiovascular_disease_cvd primary source global morbidity_mortality crucial understand molecular pathophysiological mechanism play recently numerous pro inflammatory cytokine linked several different cvds often considered adversely pro inflammatory state cytokine notably include interleukin il tumor_necrosis_factor tnf_alpha interleukin il family amongst others inflammation intricate complex interaction pathophysiological process oxidative_stress calcium mishandling also play_role balance tissue repair destruction regard pre clinical clinical evidence clearly demonstrated involvement dynamic nature pro inflammatory cytokine many heart condition however clinical utility finding far remains_unclear whether cytokine serve marker risk predictor disease state act potential therapeutic_target extensive research needed fully understand complex network interaction molecule encompass context heart_disease review highlight significant advance understanding contribution pro inflammatory cytokine cvds including ischemic_heart_disease atherosclerosis thrombosis acute_myocardial_infarction ischemia_reperfusion injury cardiac_remodeling hypertension cardiac_hypertrophy cardiac_fibrosis cardiac apoptosis heart_failure different cardiomyopathy well ventricular_arrhythmia atrial_fibrillation addition article focused discussing shortcoming pathological therapeutic aspect pro inflammatory cytokine cvd still need addressed future study:0.0421293102210987", "199391": "obesity chronic multifactorial disease major global public_health challenge defined excessive fat accumulation obesity significantly increase_risk numerous disease including type_diabetes_mellitus_dm cardiovascular_disease heart_failure metabolic dysfunction associated steatotic liver_disease contributing rising morbidity_mortality rate worldwide although several pharmacological treatment demonstrated notable efficacy weight management concern regarding drug safety remain significant challenge metabolic bariatric surgery mb emerged effective intervention achieving long_term sustained weight_loss however typically reserved advanced stage disease moreover role mb managing obesity related comorbidities remains topic ongoing debate review provide comprehensive analysis epidemiology obesity associated comorbidities along latest insight mechanism_underlying obesity induced chronic complication growing evidence highlight crucial role imbalance white brown adipose_tissue alteration gut microbiota genetic epigenetic modification immune system dysregulation driving obesity related condition emerging insight unveiled numerous potential therapeutic_target promising weight reducing effect furthermore advancement understanding signal transduction pathway may pave way future multimodal therapeutic_strategy obesity management ushering new era precision medicine:0.0420857274166564", "198861": "introduction cardiovascular disorder cvds remain leading_cause global mortality surpassing chronic illness alarming rise cvd related death particularly among younger population intensified research effort better understand disease complication among myocardial_fibrosis play central role development cardiac_dysfunction heart_failure given multifactorial nature diverse therapeutic_strategy required manage progression effectively method comprehensive literature review conducted using database pubmed scopus elsevier clinicaltrials_gov peer reviewed english language study focusing molecular_mechanism therapeutic_strategy myocardial_fibrosis included irrelevant non english non peer reviewed source excluded data selected preclinical clinical investigation qualitatively synthesized result myocardial_fibrosis arises various pathological condition including ischemia hyperlipidemia genetic disorder promote maladaptive cardiac_remodeling although traditional treatment raas inhibitor beta_blocker offer symptomatic relief halt disease_progression recent evidence_suggests multiple molecular pathway involved development fibrosis opening opportunity explore alternative therapeutic_target discussion due complex pathophysiology myocardial_fibrosis cannot addressed monotherapy alone anti tgf_beta agent emerged promising candidate alongside newer therapy like sglt_inhibitor mmp inhibitor additionally regenerative approach stem_cell gene therapy offer future avenue though technical safety challenge accompany conclusion myocardial_fibrosis remains critical contributor heart_failure current treatment insufficient reverse course multifaceted therapeutic_approach targeting different molecular_mechanism hold key improved clinical_outcome continued translational research crucial advancing emerging therapy bench bedside:0.0419545203390092", "168380": "hypertension predominant cause cardiovascular_disease cvds globally essential hypertension eh represents significant public_health challenge due multifactorial etiology involving complex interaction genetic environmental factor however pathogenesis eh still unclear hypertension dysregulation renin_angiotensin_aldosterone_system sympathetic nervous_system regulating saline homeostasis cardiovascular function however current therapeutic_intervention targeting system limited efficacy approximately case suggesting involvement alternative mechanism inflammation associated occurrence progression hypertension underlying_mechanism remains elusive chronic inflammation lead tissue damage fibrosis irreversible organ dysfunction development maintenance eh caused endothelial_dysfunction oxidative_stress chronic inflammation neutrophil involved acute chronic inflammation since represent primary line defense inflammatory insult recruited inflamed site remove harmful impurity process involving formation neutrophil extracellular trap net called netosis involved pathogenesis progression cvds including coronary_artery_disease acute_myocardial_infarction peripheral arterial disease heart_failure atrial_fibrillation recent investigation demonstrated net facilitate development hypertension however precise role net hypertension remains largely elusive therefore review aim provide overview current understanding regarding involvement netosis hypertension explore potential therapy targeting net future intervention:0.0419063159504175", "94946": "purpose_review despite major advance term prevention diagnosis risk_stratification management rehabilitation atherosclerosis atherothrombosis continue major morbidity_mortality implication worldwide since unraveling pivotal role inflammation atherothrombosis pathophysiology several focused treatment proposed ultimate goal preventing treating myocardial_infarction_stroke peripheral artery disease particular given centrality interleukin il targeted anti il agent attracted substantial attention effort yet uncertainty persists real risk benefit cost benefit balance anti il agent patient_risk atherothrombosis recent_finding several trial recently completed atherothrombosis prevention treatment anti il agent ranging instance large canakinumab antiinflammatory thrombosis outcome study canto trial series translational study_conducted within virginia commonwealth university anakinra remodeling trial vcu art platform light present scoping umbrella review appears evident anti il agent reduce systemic inflammation improve surrogate marker cardiac vascular function potential benefit risk new worsening_heart_failure one trial suggested increased_risk major adverse_event anti interleukin agent possibly due rebound phenomenon based post_hoc analysis small number event supported pertinent trial canto study showed potential hazard due increased_risk fatal infection effect size rather small addition cost issue limit foreseeable scope treatment_strategy unselected patient calling instead refined prescribing evidence base risk benefit cost benefit profile anti il agent atherothrombosis prevention treatment expanded substantially last decade largely dominated landmark canto trial effect estimate also including vcu art trial suggest complex short long_term effect may prove favorable carefully selected patient_acute chronically sustained inflammation conversely liberal use appears less promising study currently available agent novel one eagerly needed better define role era precision molecular medicine:0.0416705262796724", "171771": "aberrant change cell behavior proliferation apoptosis migration contributing factor development various cardiovascular_disease cvds pathology including atherosclerosis neointimal hyperplasia heart_failure recent_year numerous study identified survivin key player anti apoptotic pathway extensively involved modulating cellular functioning cancer many reaching clinical_trial though seemingly different cvds cancer share abundant similarity regarding abnormal cell modification behavior overlap sparked growing interest investigating survivin therapeutic_target context cvd new finding emerging rapidly comprehensive understanding survivin role cardiovascular pathology crucial revealing full therapeutic potential translating discovery effective_treatment review discusses recent_finding survivin cvds related pathology focusing dual role promoting proliferation inhibiting apoptosis specifically atherosclerosis neointimal hyperplasia stroke hypertension myocardial_infarction_heart_failure across different cell type pathological context survivin play pivotal role throughout disease_progression onset disease development facilitation compensatory mechanism post injury primarily function regulating cell proliferation apoptosis furthermore given limited research survivin therapeutic_target cvds potential clinical avenue including ym survivin inhibitor adenoviral adeno associated lentiviral vector also discussed overall review highlight survivin promising target mitigating detrimental effect cvds provide new perspective advance research intervention cvds associated pathology:0.0415788041325780"}, "Topic 2": {"199245": "background disturbance protein synthesis degradation play crucial role various biological pathological process e ubiquitin ligase substrate binding adaptor spop speckle type poz poxvirus zinc finger protein substantially involved cancer progression study_aim investigate biological function spop cardiac_hypertrophy heart_failure method generated cardiac specific transgenic knockout mouse evaluate functional role spop transverse_aortic_constriction induced cardiac_hypertrophy heart_failure rna sequencing proteomics protein mass spectrometry analysis multiple molecular biological methodology employed investigate function mechanism cardiac hypertrophic mouse result spop significantly upregulated human heart_failure hypertrophic mouse heart ang_ii angiotensin_ii treated neonatal mouse ventricular cardiomyocytes spop induced expression hypertrophic marker anp atrial natriuretic_peptide bnp b_type_natriuretic_peptide beta mhc beta myosin heavy chain increased cardiomyocyte size whereas spop deficiency exhibited opposite effect hypertrophic neonatal mouse ventricular cardiomyocytes furthermore cardiac specific overexpression spop led cardiac_hypertrophy heart_failure mouse contrast cardiac specific knockout spop markedly attenuated transverse_aortic_constriction induced cardiac_hypertrophy improved heart_failure parallel spop presented prohypertrophic effect spop loss function substantially rescued ang_ii induced hypertrophic phenotype neonatal mouse ventricular cardiomyocytes mechanistically spop transcriptionally activated p cardiac_hypertrophy subsequently interacting promoting ubiquitination mediated degradation tfeb transcription_factor eb independently phosphorylation status key regulator transcription lysosomal biogenesis autophagy related gene leading blockage autophagy mitophagy eventually cause cardiac_hypertrophy heart_failure overexpression tfeb rescued spop induced alteration noticeably specific inhibitor spop able prevent development cardiac_hypertrophy heart_failure conclusion spop detrimental factor pathological cardiac_hypertrophy via promoting ubiquitination induced degradation tfeb critical regulator autophagy lysosomal pathway targeting spop represents promising therapeutic_strategy hypertrophy related heart_failure:0.0469601096844485", "200374": "background hypertension induced cardiac_hypertrophy constitutes principal cause_heart_failure malignant arrhythmia sudden_cardiac_death nek never mitosis gene nima related protein_kinase member serine threonine kinase family multifunctional protein_kinase play crucial role regulating cell cycle mitosis inflammation role cardiac_hypertrophy remains_unclear method subjected aav ctnt si nek mouse pressure_overload mean transverse_aortic_constriction evaluated cardiac_function cardiac_hypertrophy inflammasome activation neonatal mouse cardiomyocytes treated ang angiotensin_ii effect si nek small interfering rna targeting nek nlrp nod like receptor family pyrin domain containing inhibition cardiomyocyte hypertrophy examined effect nek regulating cardiac_hypertrophy examined administering si mbnl muscleblind like splicing regulator tail vein knockdown transverse_aortic_constriction treated mouse result nek expression significantly upregulated transverse_aortic_constriction induced cardiac_hypertrophy model vivo ang_ii stimulated neonatal mouse cardiomyocytes vitro knockdown nek attenuated ang_ii induced cardiomyocyte hypertrophy inhibited activation nlrp inflammasome knockdown nek aav si nek significantly_improved cardiac_function reduced hypertrophy transverse_aortic_constriction mouse conversely nek overexpression exacerbated hypertrophy promoted nlrp inflammasome assembly leading pyroptosis via ro dependent pathway mechanistically nek directly bound nlrp prohypertrophic effect abrogated nlrp inhibition additionally mbnl rna binding protein bind nek mrna thereby regulating nek transcription affecting expression_level mbnl identified upstream regulator nek knockdown mbnl suppressing nek expression alleviating cardiac_hypertrophy vivo conclusion nek drive pathological cardiac_hypertrophy activating nlrp inflammasome promoting cardiomyocyte pyroptosis mbnl acting upstream regulator targeting mbnl nek nlrp axis may offer novel therapeutic_strategy preventing cardiac_hypertrophy heart_failure:0.0469448364994295", "73383": "rationale cardiac_fibrosis play critical role pathogenesis heart_failure excessive accumulation extracellular_matrix ecm resulting cardiac_fibrosis impairs cardiac contractile_function increase arrhythmogenicity current treatment_option cardiac_fibrosis however limited clear need identify novel mediator cardiac_fibrosis facilitate development better therapeutic exploiting coexpression gene network analysis rna sequencing data failing human_heart identified txndc thioredoxin domain containing cardiac_fibroblast cf enriched endoplasmic reticulum protein potential novel mediator cardiac_fibrosis completed experiment test hypothesis directly objective objective_study determine functional role txndc pathogenesis cardiac_fibrosis method_result rna sequencing western_blot analysis_revealed txndc mrna protein highly upregulated failing human left_ventricle hypertrophied failing mouse left_ventricle addition cardiac txndc mrna expression_level positively correlated transcript encoding transforming growth_factor beta ecm protein vivo txndc mrna protein increased human cf hcf transforming growth_factor beta stimulation vitro knockdown txndc attenuated transforming growth_factor beta induced hcf activation ecm protein upregulation independent smad smad family member whereas increasing expression txndc triggered hcf activation proliferation increased ecm protein production experiment showed txndc protein disulfide isomerase facilitated ecm protein folding depletion txndc led ecm protein misfolding degradation cf addition txndc promotes hcf activation proliferation enhancing c jun n_terminal kinase activity via increased reactive_oxygen_specie derived nad p h oxidase transforming growth_factor beta induced txndc upregulation hcf dependent endoplasmic reticulum stress activating transcription_factor mediated transcriptional control targeted disruption txndc mouse txndc revealed protective_effect isoproterenol induced cardiac_hypertrophy reduced fibrosis approximately markedly improved left_ventricle function post isoproterenol left_ventricular_ejection_fraction versus_p txndc versus wild_type mouse respectively_conclusion endoplasmic reticulum protein txndc promotes cardiac_fibrosis facilitating ecm protein folding cf activation via redox sensitive c jun n_terminal kinase signaling loss txndc protects beta agonist induced cardiac_fibrosis contractile dysfunction targeting txndc therefore could powerful new therapeutic_approach mitigate excessive cardiac_fibrosis thereby improving cardiac_function outcome patient_heart_failure:0.0468914727409194", "184990": "pathological cardiac_hypertrophy involves multiple regulator several signal transduction pathway currently mechanism well understood differentially expressed fdcp homolog def reported participate immunity bone remodeling cancer effect def pathological cardiac_hypertrophy however yet fully characterized initially determined expression profile def found def upregulated hypertrophic heart cardiomyocytes vivo result revealed def deficiency mouse alleviated transverse_aortic_constriction tac induced cardiac_hypertrophy fibrosis dilation dysfunction left_ventricle conversely cardiomyocyte specific def overexpression aggravated hypertrophic phenotype mouse chronic pressure_overload similar animal experiment vitro data showed adenovirus mediated knockdown def remarkably inhibited phenylephrine pe induced cardiomyocyte hypertrophy whereas def overexpression exerted opposite effect mechanistically exploration signal pathway showed mitogen activated extracellular signal regulated kinase mek extracellular signal regulated kinase erk cascade might involved prohypertrophic effect def coimmunoprecipitation gst glutathione transferase pulldown analysis demonstrated def directly interact small gtpase ra related c botulinum toxin substrate rac rac activity assay revealed activity rac altered def expression tac cardiac_hypertrophy pe triggered cardiomyocyte hypertrophy end western_blot rescue experiment using rac inhibitor nsc constitutively active mutant rac g v verified requirement rac mek erk activation def mediated pathological cardiac_hypertrophy study substantiates def act deleterious regulator cardiac_hypertrophy activating rac mek erk signaling_pathway suggests def may potential treatment target heart_failure:0.0459969658070283", "169022": "background cardiac_hypertrophy characterized upregulation fetal gene increased protein synthesis enlargement cardiac_myocytes mechanistic target rapamycin complex mtorc responds fluctuation cellular nutrient energy level play pivotal role regulating protein synthesis cellular growth attempt inhibit mtorc activity application rapamycin analog demonstrated limited efficacy investigation warranted method_result show serinc expression downregulated transverse_aortic_constriction tac induced hypertrophic myocardium vivo vitro reduction serinc expression result pathological hypertrophic growth whereas serinc overexpression exhibit protective_effect rna sequencing analysis following serinc knockdown reveals transcriptomic shift toward pro hypertrophic profile suggests significant interplay serinc amino acid mtor lysosome hub mtor activation moreover show serinc localizes lysosome hinders mtorc recruitment lysosomal membrane response amino acid stimulation playing critical role regulating amino acid signaling_pathway involved activation p k ebp hela cell deficiency exacerbates mtorc activity mtorc dependent subsequent protein synthesis abrogated rapamycin line vitro finding serinc knockout mouse subjected tac surgery exhibit elevated phosphorylation p k ebp inhibition mtorc signaling amino acid deprivation prevents activation impedes progression pathological cardiac_remodeling conclusion illustrated serinc localizes lysosomal membrane modulates amino acid mtorc signaling cardiomyocytes serinc therefore present potential therapeutic_target mitigating excessive protein synthesis improving heart_failure hemodynamic stress:0.0455887476127262", "137397": "cardiac_hypertrophy complex pathological process molecular_mechanism underlying hypertrophic remodeling clearly elucidated leukocyte immunoglobulin like receptor b lilrb inhibitory transmembrane protein necessary regulation various cellular signaling_pathway investigate whether lilrb play_role cardiac_hypertrophy performed aortic banding lilrb knockout mouse lilrb cardiac specific transgenic mouse wild_type littermates cardiac_hypertrophy evaluated echocardiographic hemodynamic pathological molecular analysis found lilrb expressed myocardial_tissue cultured cardiomyocytes basal condition expression obviously decreased mouse heart following aortic banding cardiomyocytes treated angiotensin_ii lilrb disruption aggravated cardiac_hypertrophy fibrosis dysfunction response pressure_overload conversely cardiac overexpression lilrb led opposite effect moreover lilrb overexpression inhibited angiotensin_ii induced cardiomyocyte hypertrophy vitro mechanistically determined cardioprotective_effect lilrb mediated interaction shp preservation phosphorylated shp inhibition nf_kappab pathway addition shp knockdown cardiomyocytes eliminated inhibitory effect lilrb angiotensin_ii induced hypertrophy nf_kappab activation result_suggest lilrb protects pathological cardiac_hypertrophy via shp dependent inhibition nf_kappab pathway may act potential therapeutic_target cardiac_hypertrophy key message lilrb expression decreased hypertrophic stimulus lilrb protects pathological cardiac_hypertrophy lilrb interacts shp inhibits nf_kappab pathway:0.0454195807496401", "145540": "background cardiac_hypertrophy important prepathology ultimately lead heart_failure however mechanism_underlying pathological cardiac_hypertrophy remain largely unknown study_aim elucidate effect mechanism hint histidine triad nucleotide binding protein cardiac_hypertrophy heart_failure method hint downregulated human hypertrophic heart sample compared nonhypertrophic sample mass spectrometry analysis hint knockout mouse challenged transverse_aortic_constriction surgery cardiac specific overexpression hint mouse intravenous injection adeno associated virus aav encoding hint ctnt cardiac_troponin promoter subjected transverse aortic construction unbiased transcriptional analysis used_identify downstream target hint aav bearing shrna hoxa homeobox administrated investigate whether effect hint cardiac_hypertrophy hoxa dependent rna sequencing analysis_performed recapitulate possible change transcriptome profile coimmunoprecipitation assay cellular fractionation analysis conducted examine mechanism hint regulates expression hoxa result reduction hint expression observed heart hypertrophic patient pressure overloaded induced hypertrophic mouse respectively hint deficient mouse cardiac_hypertrophy deteriorated transverse aortic construction conversely cardiac specific overexpression hint alleviated cardiac_hypertrophy dysfunction unbiased profiler polymerase chain reaction array showed hoxa target hint cardioprotective role hint abolished hoxa knockdown vivo hoxa identified affect hypertrophy tgf_beta transforming growth_factor beta signal pathway mechanically hint inhibited pkcbeta protein_kinase c beta type membrane translocation phosphorylation via direct interaction attenuating mek erk yy mitogen activated protein_kinase extracellular signal regulated kinase kinase yin yang signal pathway downregulating hoxa expression eventually attenuating cardiac_hypertrophy conclusion hint protects cardiac_hypertrophy suppressing hoxa expression finding indicate hint may potential target therapeutic_intervention cardiac_hypertrophy heart_failure:0.0451912072198452", "155713": "background pathological cardiac_hypertrophy regarded critical precursor independent_risk_factor heart_failure inhibition prevents progression_heart_failure switch associated protein swap confirmed important immunoregulation cell maturation cell transformation however role pathological cardiac_hypertrophy remains_unclear method_result effect swap pathological cardiac_hypertrophy investigated swap knockout mouse swap overexpression knockdown cardiomyocytes bioinformatic analysis combined multiple molecular biological methodology adopted elucidate mechanism_underlying effect swap pathological cardiac_hypertrophy result_showed swap protein_level significantly_increased failing human_heart tissue experimental transverse_aortic_constriction induced mouse hypertrophic heart phenylephrine stimulated isolated primary cardiomyocytes intriguingly phenylephrine treatment decreased lysosomal degradation swap disrupting interaction swap granulin precursor vitro vivo experiment revealed swap knockdown knockout accelerated progression pathological cardiac_hypertrophy swap overexpression restrained cardiomyocyte hypertrophy swap restrained binding transforming growth_factor beta activated kinase tak tak binding protein thus blocking phosphorylation tak downstream c jun n_terminal kinase p signaling tak interacted n_terminal swap swap overexpression failed inhibit cardiac_hypertrophy tak swap interaction disrupted either inhibiting phosphorylation suppressing expression tak rescued exaggerated cardiac_hypertrophy induced swap knockdown conclusion swap suppressed progression cardiac_hypertrophy possibly inhibiting mitogen activated protein_kinase signaling_pathway tak dependent manner lysosome involved regulation swap expression_level:0.0451667098648656", "129287": "background calcium ca key regulator energy_metabolism impaired ca homeostasis damage mitochondrion causing cardiomyocyte death pathological hypertrophy heart_failure study investigates regulation role mitochondrial ca uniporter mcu chronic stress induced pathological cardiac_remodeling method mcu knockout transgenic mouse infused isoproterenol iso mg_kg per day week cardiac_hypertrophy remodeling evaluated echocardiography histology primary cultured rodent adult cardiomyocytes treated iso nmol l hour intracellular ca handling cell_death pathway monitored adenovirus mediated gene manipulation used vitro result chronic administration beta_adrenergic receptor_agonist iso increased level mcu mcu complex cardiac mitochondrion raising mitochondrial ca concentration vivo vitro iso also upregulated mcu without affecting regulatory protein adult cardiomyocytes interesting iso induced cardiac_hypertrophy fibrosis contractile dysfunction cardiomyocyte death exacerbated global mcu knockout mouse cardiomyocytes knockout mouse overexpressing dominant negative mcu exhibited defective intracellular ca handling activation multiple cell_death pathway conversely cardiac specific overexpression mcu maintained intracellular ca homeostasis contractility suppressed cell_death prevented iso induced heart hypertrophy iso upregulated mcu expression activation ca calmodulin kinase ii deltab camkiideltab promotion nuclear translocation via calcineurin mediated dephosphorylation serine nuclear camkiideltab phosphorylated creb camp response element binding protein bound mcu promoter enhance mcu gene transcription conclusion beta_adrenergic receptor camkiideltab creb pathway upregulates mcu gene_expression heart mcu upregulation compensatory mechanism counteracts stress induced pathological cardiac_remodeling preserving ca homeostasis cardiomyocyte viability:0.0450574439575888", "151153": "background renin_angiotensin_system play crucial role development_heart_failure ang_ii angiotensin_ii act critical effector renin_angiotensin_system regulating cardiac_fibrosis however mechanism cardiac_fibrosis complex still fully understood igf r insulin like growth_factor receptor multiple function maintaining cardiovascular homeostasis low_dose igf treatment effective relieving ang_ii induced cardiac_fibrosis aimed investigate molecular_mechanism igf r ang_ii induced cardiac_fibrosis method_result using primary mouse cardiac microvascular endothelial_cell fibroblast vitro experiment performed using c bl j mouse clustered regularly interspaced short palindromic repeat crispr crispr associated ca mediated igf r heterozygous knockout igf r mouse cardiac_fibrosis mouse_model induced ang_ii week expression igf r examined quantitative reverse transcription polymerase chain reaction immunohistochemistry western_blot mouse heart histologic change evaluated_using masson picro sirius red staining fibrotic marker signal molecule indicating function akt protein_kinase b erk extracellular signal regulated kinase nuclear factor kappab pathway detected using quantitative reverse transcription polymerase chain reaction western_blot rna sequencing used explore igf r mediated target gene heart mouse association igf r g_protein coupled receptor kinase identified coimmunoprecipitation important blocking igf r signaling significantly suppressed endothelial mesenchymal transition primary mouse cardiac microvascular endothelial_cell mouse response transforming growth_factor beta ang_ii respectively deficiency inhibition igf r signaling remarkably attenuated ang_ii induced cardiac_fibrosis primary mouse cardiac_fibroblast mouse observed patient_heart_failure exhibited higher blood level igf igf r healthy individual moreover ang_ii treatment significantly_increased cardiac igf r wild_type mouse led slight downregulation igf r mouse interestingly igf r deficiency significantly alleviated cardiac_fibrosis ang_ii treated mouse mechanistically phosphorylation level akt erk upregulated ang_ii treated mouse whereas blocking igf r signaling mouse inhibited change akt erk phosphorylation concurrently phosphorylated p nuclear factor kappab exhibited similar alteration corresponding group mouse intriguingly igf r directly interacted g_protein coupled receptor kinase association decreased approximately igf r mouse addition grk deletion downregulated expression akt erk nuclear factor kappab signaling_pathway primary mouse cardiac_fibroblast conclusion igf r signaling deficiency alleviates ang_ii induced cardiac_fibrosis least partially inhibiting endothelial mesenchymal transition via akt erk nuclear factor kappab pathway interestingly g_protein coupled receptor kinase associate igf r signaling directly concurrently act igf r downstream effector study suggests promising potential igf r therapeutic_target cardiac_fibrosis:0.0450078675357391"}, "Topic 3": {"129861": "background dissecting aneurysm sinus valsalva sov interventricular septum rare entity multilobulated form dissection rupturing left_ventricle lv never reported literature case summary year_old male presented dyspnoea palpitation wide pulse pressure peripheral sign distal run continuous murmur along left parasternal area echocardiography revealed dilated right coronary cusp rcc burrowed interventricular septum iv forming multi loculated cystic lesion ruptured lv associated restrictive ventricular septal_defect vsd severe aortic regurgitation computed_tomography ct angiography confirmed cm x cm x cm multiseptated aneurysm surgery involved excision aortic_valve av sinus ligation penetrating portion crest iv closure vsd av replacement postoperative echocardiography showed complete collapse iv component sov aneurysm normally functioning mechanical av discussion dissecting aneurysm iv rare variant sov aneurysm usually arising rcc mostly congenital origin wide variety presentation like congestive_heart_failure palpitation recurrent syncope chest_pain sudden cardiac_arrest infective_endocarditis cerebral infarction asymptomatic aortic regurgitation present_case conduction disturbance first degree block complete heart block common echocardiogram ct angio magnetic_resonance_imaging useful diagnosis surgical repair option treatment:0.0463840197008911", "176799": "background clinical significance congenital malformation right atrium rare clinical_presentation varies widely absence symptom sudden_death often diagnosed incidentally cardiac imaging first described right_atrial diverticulum usually characterized pouch like structure originating free atrial wall right_atrial appendage prevalence congenital malformation right atrium unknown clinical case reported associated complication include arrhythmia pulmonary thromboembolism progressive dilatation marked high_risk compression rupture case optimal therapeutic_approach surgical resection case presentation present case_year_old hypertensive female history covid coronavirus disease admitted persistent dyspnea chest_pain electrocardiogram arrival showed arrhythmia ischemic change echocardiography revealed severe systolic_dysfunction left_ventricular_ejection_fraction_lvef moderate mitral tricuspid_regurgitation pericardial collection adjacent right atrium considered localized pericardial effusion coronary_angiography excluded ischemic etiology viral myocarditis suspected cardiac_magnetic_resonance_imaging irm showed non ischemic scar pattern interventricular septum also detected well defined large mass communicated right atrium mm opening suggestive right_atrial diverticulum contrast echocardiography confirmed communication cavity right atrium surgical resection large diverticulum performed conclusion particularity case consists incidental identification rare cardiac malformation adult_patient:0.0420676860337852", "173754": "infective_endocarditis ie life_threatening condition caused infection heart endocardial surface often involving native prosthetic valve present diverse symptom ranging isolated fever heart_failure severe manifestation ischemic_stroke septic thrombus embolization rare serious complication ie mitral_valve aneurysm mva localized outpouching mitral_valve often leading mitral_regurgitation mr heart_failure severe case rupture report highlight case delayed diagnosis ie year_old female presented prolonged fever progressive dyspnea sign heart_failure echocardiography revealed severe mr anterior mitral_valve leaflet perforation large pseudoaneurysm suggesting mva advanced presentation patient_developed refractory heart_failure electrical storm leading fatal outcome surgery could performed case underscore importance early recognition ie mva challenge managing complicated case mitral_valve replacement preferred surgical option early_diagnosis timely intervention crucial prevent severe complication improve prognosis:0.0416067904435966", "150142": "severe tricuspid_regurgitation especially caused pulmonary_hypertension primary tricuspid_regurgitation absence pulmonary_hypertension unknown etiology rare condition scarce data diagnosis_treatment follow particularity surgery indication outcome still clearly known year_old_woman medical_history coronary_artery_bypass_grafting three year ago presented shortness breath low limb edema physical_examination revealed prominent bilateral jugular turgescence hepatomegaly peripheral edema left midsternal border holosystolic murmur suggestive tricuspid_regurgitation echocardiogram confirmed diagnosis showed preserved right left_ventricular dimension function coronary_angiography showed new obstructive lesion patent surgical graft right cardiac catheterization revealed mild pulmonary_hypertension increased right atrium pressure cardiac_magnetic_resonance showed mild right_ventricular dilation normal systolic_function normal left chamber late gadolinium enhancement detected persistent symptom even optimization medical_therapy patient submitted tricuspid_valve replacement surgery immediately surgery patient_developed significant right_ventricular dysfunction need continuous hemodynamic support progressive clinical recovery confirmed serial echocardiogram showed improvement right_ventricular volume function patient discharged sign_symptom right_heart_failure histopathological examination showed significant diffuse myxomatous degeneration leaflet sign infection vegetation disruption strand observed report illustrates rare case symptomatic primary isolated severe tricuspid_regurgitation caused myxomatous degeneration leaflet thoroughly diagnostic workup presented histopathological analysis leaflet revealed etiologic process surgical treatment indicated onset right_ventricular failure essential patient full recovery:0.0407351735375195", "186419": "background coronary cameral fistula rare diagnosis may picked incidentally cardiac imaging majority case asymptomatic complicated myocardial ischaemia arrhythmia heart_failure infective_endocarditis rarely rupture thrombosis fistula leading sudden_death case summary year_old female present fever lethargy examination finding continuous cardiac murmur ct coronary angiogram confirmed presence coronary cameral fistula aneurysmal rca seen arising right coronary sinus following extensive tortuous course wrapping around heart terminating right atrium initial streptococcus bacteraemia identified blood culture sampling obvious mass detected valve chamber along course fistula time develops anginal chest_pain heart_failure_symptom progressive dilatation right_ventricle functional tricuspid_regurgitation secondary shunting fistula right chamber surgical intervention pursued successfully addressed complication discussion case_report highlight importance advanced imaging modality accurate diagnosis coronary cameral fistula addressing late manifestation disease necessity collaborative multidisciplinary approach managing complex cardiac anomaly:0.0404949199319615", "127257": "background takayasu arteritis ta included large vessel vasculitis unknown aetiopathogenesis ta one rare disease predilection young woman diagnosis ta difficult due variation clinical_presentation non specific initial symptom case demonstrates rare ta young male congestive_heart_failure predominant manifestation case presentation report year_old male presented severe dyspnea palpitation orthopnea paroxysmal nocturnal dyspnea claudication left arm four limb blood_pressure discrepancy present chest x_ray showed cardiomegaly calcification aortic arch pulmonary_edema echocardiography revealed left_ventricular_ejection_fraction decreased severe aortic mitral_valve regurgitation computed_tomography angiography showed stenosis left common carotid artery total occlusion left subclavian artery collateral artery vascular thickness calcification peri aortic_valve ascending aorta aortic arch thoracic descending aorta abdominal aorta high grade stenosis inferior side renal artery branching accompanied post stenotic dilatation conclusion patient_heart_failure precipitated secondary hypertension aortic regurgitation caused vasculitis ta general difference management congestive_heart_failure patient ta optimized pharmacology therapy combination steroid methotrexate successfully inducing remission ta month_follow:0.0403100966672958", "131582": "background haemoptysis rare symptom associated endocarditis describe unusual clinical_manifestation endocarditis regurgitant bicuspid aortic_valve probably secondarily perimembranous ventricular septal_defect vsd massive haemoptysis case summary year_old male aortic coarctation bicuspid aortic_valve vsd since birth previously asymptomatic came episode haemoptysis computed_tomography ct scan showed cavitated lesion lung streptococo viridans identified serial blood culture transthoracic_echocardiography showed bicuspid aortic_valve vegetation suggesting infectious involvement severe aortic insufficiency transoesophageal echocardiography tee study showed bicuspid aortic_valve complete fusion coronary valve elongated oscillating tumour mm length observed centre ventricular side non coronary valve another vegetation seen vsd hospital_stay antibiotic treatment reported abdominal pain computed_tomography examination showed splenic infarction echocardiogram vegetation mass observed aortic_valve vsd closure aneurysm discussion main debate patient treatment concerned indication surgery especially onset fever splenic septic embolism appropriate antibiotic treatment stable sign heart_failure echocardiogram repeated septic splenic embolism showed residual vegetation aortic_valve vsd tee study ruled local complication finally multidisciplinary team decided surgical management:0.0400917587133357", "199923": "nonbacterial thrombotic endocarditis nbte rare form endocarditis characterized sterile vegetation typically affecting mitral aortic_valve commonly associated hypercoagulable state secondary malignancy systemic inflammatory disease condition often asymptomatic frequently diagnosed patient present sign systemic embolization heart_failure uncommon initial presentation case involving multiple valve rare report describes case_year_old man presented progressive dyspnea sign cardiac_failure imaging revealed pulmonary_embolism mass left lateral segment liver suggestive cholangiocarcinoma patient exhibited feature hypercoagulable state including two prior admission lower limb deep vein thromboses sign peripheral cutaneous ischemia transesophageal echocardiography tee identified vegetation affecting mitral tricuspid aortic_valve associated severe regurgitation context malignancy persistently negative blood culture diagnosis nbte involving three valve made case represents one rare instance nbte simultaneously involving mitral tricuspid aortic_valve nbte typically affect left side heart right_sided valve involvement rare pulmonary_embolism heart_failure uncommon presenting feature case underscore importance maintaining high index suspicion nbte patient malignancy present embolic event new murmur sign heart_failure:0.0396955290836549", "185400": "background endomyocardial fibrosis grim disease common restrictive cardiomyopathy worldwide exact etiology pathogenesis remain unknown endomyocardial fibrosis recurrently associated chronic eosinophilia probable dietary environmental infectious factor contribute onset disease inflammatory process also progression maintenance endomyocardial damage scar formation trademark disease fibrotic obliteration affected ventricle combination process produce focal diffuse endocardial thickening fibrosis lead restrictive physiology endomyocardial fibrosis affect apex right left_ventricle around case often extends posterior leaflet mitral_valve sometimes involves papillary muscle chordae tendineae causing atrioventricular valve dysfunction fibrosis affect extracardiac organ cardiomyopathy recurrent tropical area world case presentation year_old black male past medical_history schistosomiasis infection childhood presented progressive dyspnea lower extremity edema weakness year diagnosed endomyocardial fibrosis echocardiogram showed increased thickness septum mm free left_ventricular wall mm obliteration left_ventricular apex inflow tract mitral_valve regurgitation cardiac_magnetic_resonance_imaging revealed apical left_ventricle wall thickening left_ventricular apical obliteration associated enlargement respective atrium delayed enhancement imaging showed endomyocardium enhancement involving left_ventricular apex mitral_valve regurgitation due annulus dilation thrombus left_ventricular apex underwent open heart surgery mitral_valve replacement endocardial decortication endomyocardiectomy two vessel coronary_artery_bypass_grafting preoperative coronary angiogram showed mild right coronary_artery proximal left_anterior_descending artery severe lesion postoperative course uncomplicated discharged successfully hospital six_month surgery new_york_heart_association_functional_class conclusion purpose case_report illustrate aspect endomyocardial fibrosis reporting case entity conclusion progress imaging technique treatment reference institution cardiac_disease contribute earlier diagnosis survival patient endomyocardial fibrosis:0.0396361219430117", "131170": "cardiac hemangioma exceedingly rare condition case described literature valvular report case_year_old woman prior cardiovascular_disease presented abdominal infection caused enterococcus faecalis complicated recrudescent fever new_onset systolic mitral murmur transesophageal echocardiogram revealed large vegetation posterior leaflet mitral_valve high embolic risk leading diagnosis acute endocarditis patient began antibiotic clinical improvement developing severe_heart_failure coronary cerebrovascular embolic phenomenon underwent excision mass placement biological mitral prosthesis histopathologic analysis_revealed cavernous hemangioma eight month later patient_presented recurrence acute bacterial endocarditis septic shock underwent replacement prosthetic valve histologic exam showed sign hemangioma rarity case complication make presentation relevant:0.0392398813240947"}, "Topic 4": {"170537": "background cardiovascular_disease common cause_death worldwide highlighting need study determine option palliative_care within management patient_heart_failure although promising example integrated palliative_care heart_failure intervention heterogeneity term country healthcare setting multidisciplinary team delivery mode delivery intervention component hence review vital identify work circumstance integrating palliative_care heart_failure objective develop programme theory context desired outcome occur use programme theory co produce stakeholder key implication inform best practice future_research design realist review literature underpinned realist meta narrative evidence synthesis evolving standard quality reporting standard data source search bibliographic database conducted november using following database embase medline psycinfo amed hmic cinahl relevant document identified via alert stakeholder group review method realist review theory orientated explanatory approach synthesis evidence realist synthesis used synthesise evidence successful implementation integrated palliative_care heart_failure depends context people involved realist synthesis followed pawson five iterative stage locating existing theory searching evidence document selection extracting organising data synthesising evidence drawing conclusion recruited international stakeholder group_n including national_health service management healthcare professional involved delivery palliative_care heart_failure policy community group plus member public patient advise give u feedback throughout project along health education england disseminate finding result_total document identified met inclusion_criterion narrowed included document based programme theory discussion stakeholder realist analysis developed refined overarching context mechanism outcome configuration sub context mechanism outcome configuration realist synthesis literature stakeholder feedback helped uncover key intervention strategy likely support integration palliative_care heart_failure management included protected time evidence_based palliative_care education choice educational setting e_g online face face hybrid importance increased awareness benefit palliative_care key intervention strategy emotive intellectual need integrating palliative_care heart_failure via credible champion seeing direct patient benefit prioritising palliative_care heart_failure guideline practice implication finding outlined capability opportunity motivation behaviour model limitation realist approach analysis mean finding based interpretation data future work future work use implication initiate optimise palliative_care heart_failure management conclusion ongoing refinement programme theory stakeholder meeting allowed u co produce implication implication outline required step ensure core component determinant behaviour place key player capacity opportunity motivation integrate palliative_care heart_failure management study registration study registered prospero crd funding award funded national institute health_care research nihr health social care delivery research programme nihr award ref nihr published full health social care delivery research vol see nihr funding award website award information:0.0728412660098247", "167000": "background nonadherence diet medical_therapy heart_failure_hf contributes poor hf outcome mobile apps may promising way improve adherence increase knowledge behavior change via education monitoring well designed apps input health_care provider hcps lead successful adoption apps practice however little_known hcps perspective use mobile apps support hf management objective aim_study determine hcps perspective need motivation challenge use mobile apps support patient_hf management method qualitative descriptive study using one one semistructured interview informed diffusion innovation theory conducted among hf hcps including cardiologist nurse nurse practitioner transcript independently coded researcher analyzed_using content analysis result hcps cardiologist n nurse n nurse practitioner n identified challenge opportunity app adoption across theme participant perceived factor affect app adoption include patient age technology savviness technology access ease use improved delivery care apps support remote care collect share assess health information identify adverse_event prevent hospitalization limit clinic visit facilitating patient engagement care apps provide feedback reinforcement facilitate connection communication patient hcps support monitoring track self_care providing patient support education apps provide hf_related information ie diet medication participant view app feature patient hcps felt useful apps would reminder alarm participative element gamification food scanner quiz conclusion hcps positive view use mobile apps support patient_hf management finding inform effective development implementation strategy hf management apps clinical_practice:0.0690955313080784", "87792": "background north america industrialized country heart_failure_hf become national public_health priority study indicate significant heterogeneity approach treat manage hf suggest targeted change health_care delivery needed reduce unnecessary health_care utilization optimize patient_outcome recent published study reported care hf_patient tertiary care hospital perspective non specialist stakeholder hf management general practitioner clinic hospital administrator rarely considered study explores current state community based hf care canada experienced various healthcare stakeholder providing coordinating care hf_patient method_study employed qualitative exploratory research design consisting semi structured telephone interview conducted health_care provider health_care administrator working outside tertiary care four populous canadian province modified thematic analysis process used different data source triangulated finding collectively interpreted author result twenty eight participant recruited study eight cardiologist five general practitioner family physician eight nurse practitioner registered nurse four hospital pharmacist three health_care administrator director participant reported lack stakeholder engagement throughout continuum care hinders implementation coordinated approach quality hf care four substantive theme emerged indicated challenge gap optimal treatment management hf community setting challenge risk_assessment early_diagnosis hf challenge ensuring efficient consistent transition acute care setting community challenge primary_care provider optimally treat manage hf_patient challenge promoting holistic approach hf management conclusion health system evolve tertiary based care community based outpatient service management chronic_disease study finding pinpoint challenge observed canadian context stimulate orient dialogue toward solution coordinated approach improve care hf_patient reduce pressure healthcare system:0.0684264249529642", "131281": "background demand health service meet chronic health need aging population significant remains unmet limited supply clinical resource specifically managing heart_failure_hf digital health sought address gap covid pandemic highlighted access issue could use technology mediated health_care service without support informal caregiver ic complexity managing hf symptom recurrent exacerbation requires many patient comanage illness ic care dyad working together optimize patient_outcome health_related_quality_life however hf program missed opportunity consider dyadic perspective despite interdependency hf outcome objective_study aim characterize value technology supporting caregiving individual living hf method motivated observed unique pattern engagement patient_enrolled medly hf management program peter munk cardiac centre toronto canada conducted semistructured interview convenience sample ic interview analyzed_using iterative refinement codeveloped codebook team maintained reflexivity journal reflect impact positionality coding theme first derived deductively using hf typology patient oriented dyad caregiver oriented dyad collaboratively oriented dyad inductively refined recategorized based concept van houtven et al framework result believe need formally intentionally expand hf technology include dyadic need goal suggest defining opportunity value added technological design first identify technology may leveraged increase psychological bandwidth reducing uncertainty providing peace mind found actionable feedback highly desired partner second develop technology serve member dyad support system experience automated prompt patient take measurement mimic support typically provided ic ease workload third consider technology mitigate dyad clinical knowledge requirement learning curve approach includes real_time actionable feedback paired human loop nurse led model care conclusion finding identified need focus improving dyadic experience whole building ic functionality digital health self_management intervention shared model care support role patient_hf management includes ic expand enhance patient capacity care acknowledges need ic care anticipate improved outcome partner:0.0671033691961700", "168460": "context heart_failure high growing global prevalence morbidity_mortality leading_cause_death serious health_related suffering low middle income country person centred care pcc critical component high quality healthcare particularly vital context serious illness heart_failure however limited data exploring pcc population low middle income setting aim aim_study explore clinical service could respond pcc need individual living_heart_failure thailand potential adaptation setting specific objective understand experience need person living_heart_failure caregiver hcps ii explore specific practical action help deliver pcc heart_failure_patient setting method cross_sectional qualitative study depth semi structured interview conducted thailand heart_failure_patient n caregiver n healthcare professional n framework analysis conducted deductive coding populate priori coding frame based santana et al pcc model giusti et al systematic_review inductive coding novel finding expand frame study reported accordance consolidated criterion reporting qualitative research guideline coreq result finding reveal specific practice action deliver pcc person living_heart_failure thailand compassionate communication healthcare professional ii effective teamwork amongst multidisciplinary healthcare professional iii proactive response physical psychosocial relational information need patient caregiver iv engaging patient family symptom management v providing opportunity patient cared community vi responding social determinant health illness healthcare access conclusion person centred healthcare system must aim address social determinant illness place focus community home based care heart_failure_patient caregiver must supported self manage including recognise symptom take appropriate action delivering pcc way potential improve outcome_patient enhance patient sense agency experience care improve health equity reduce hospital_admission relieving pressure hospital system reducing overall cost care:0.0668707860605816", "192357": "introduction heart_failure complex disorder require hospitalization specialist care patient may experience challenge accessing northamptonshire innovative approach heart_failure service introduced address challenge study_aimed explore understand diffusion dynamic heart_failure service northamptonshire focusing adoption implementation determinant method qualitative study involved depth interview four patient two community carers one general practitioner one nurse one programme director two interview community cardiologist diffusion innovation guided inductive deductive thematic analysis used_identify theme subthemes result community heart_failure service incorporated community cardiology clinic community asset group implementation innovation characterized competent leadership positive managerial relationship community cardiologist general practitioner third sector professional tension change reduce hospital_admission improve access dedicated funding slack resource relative advantage identified service provider patient access specialist care closer home rehabilitation education nutrition service heart_failure innovation aligned organizational value primary_care third sector organization facilitating readiness adoption implementation challenge emerged limited management accountability inadequate administrative information technology support hindering implementation conclusion heart_failure innovation perceived improve care navigating facilitator challenge diffusion innovation theory highlighted importance governance performance community heart_failure service within complex intervention context:0.0664447872802543", "159759": "background information communication technology ict offer considerable potential supporting older_adult managing health including chronic_disease however mixed opinion benefit effectiveness ict intervention older_adult chronic_disease objective aim map use ict intervention health_care identified barrier enablers use among older_adult chronic_disease method scoping review conducted using database ovid medline embase scopus psycinfo proquest identify eligible article january july publication incorporating use ict intervention otherwise known ehealth mobile health telehealth telemedicine decision support system electronic health record remote monitoring people aged_year chronic_disease included conducted strength weakness opportunity threat framework analysis explore implied enablers barrier use ict intervention result identified article n participant met inclusion_criterion article mentioned use various ehealth intervention range technology reported including mobile health telehealth electronic health record mixed ict intervention various chronic_disease affecting older_adult identified including congestive_heart_failure diabetes chronic respiratory disease mental health disorder ict intervention designed help people self manage chronic_disease demonstrated positive effect however patient related health_care provider related challenge integrating ict intervention routine practice identified barrier using ict intervention older_adult included knowledge gap lack willingness adopt new skill reluctance use technology implementation challenge related ict intervention slow internet connectivity lack appropriate reimbursement policy reported advantage using ict intervention include nonpharmacological nature provision health education encouragement continued physical_activity maintenance healthy diet participant reported use ict fun effective way increasing motivation supporting self_management task gave reassurance peace mind promoting sense security reducing anxiety conclusion ict intervention potential support care older_adult chronic_disease however effectively integrated routine health_care need improve awareness education ict intervention among could benefit including older_adult caregiver health_care provider sustainable funding required promote adoption ict intervention recommend involving clinician caregiver time designing ict intervention:0.0663536807157159", "35483": "background disease_management shown great promise mean reorganizing chronic care optimizing patient_outcome nevertheless disease_management program widely heterogeneous lack shared definition disease_management limit ability compare evaluate different program address problem american heart_association disease_management taxonomy writing group developed system classification used categorize compare disease_management program inform effort identify specific factor_associated effectiveness method aha writing group began conceptual model disease_management component subsequently validated model wide range disease_management program systematic medline search performed term heart_failure diabetes depression together disease_management case management care management search encompassed article published english selected study incorporated intervention designed improve_outcome reduce medical resource utilization patient_heart_failure diabetes depression clearly defined protocol least prespecified component traditionally associated disease_management analyzed study protocol used qualitative research method develop disease_management taxonomy conceptual model organizing framework result final taxonomy includes following domain patient_population characterized risk status demographic profile level comorbidity intervention recipient describes primary target disease_management intervention includes patient caregiver physician allied healthcare provider healthcare delivery system intervention content delineates individual component patient education medication management peer support form postacute care included disease_management delivery personnel describes network healthcare provider involved delivery disease_management intervention including nurse case manager physician pharmacist case worker dietitian physical therapist psychologist information system specialist method communication identifies broad range disease_management delivery system may include person visitation audiovisual information packet form electronic telecommunication technology intensity complexity distinguish frequency duration exposure well mix program component respect target disease_management environment defines context disease_management intervention typically delivered includes inpatient hospital affiliated outpatient program community home based program combination factor clinical_outcome include traditional frequently assessed primary secondary_outcome well patient centered measure adherence medication self_management caregiver burden conclusion statement present taxonomy disease_management describes critical program attribute allows comparison across intervention routine application taxonomy may facilitate better comparison structure process outcome_measure across range disease_management program promote uniformity design conduct study seek validate disease management_strategy:0.0660732193890258", "197565": "background heart_failure complex syndrome affecting million people globally average patient age_year management challenge include medication titration difficulty patient self_management issue care home housing approximately resident heart_failure face unique challenge managing condition study_aimed_investigate care home staff experience supporting resident heart_failure method glaserian grounded theory approach employed explore perception challenge strategy used care home staff supporting resident heart_failure twenty care home staff member northern ireland varied role experience level participated online semi structured interview interview audio recorded transcribed verbatim data collection analysis occurred concurrently following theoretical sampling principle february march three stage coding process open axial selective used analysis rigour ensured member checking data source triangulation reflexivity ethical approval obtained prior data collection result three main category developed data training support communication training revealed care home staff received limited education heart_failure management primarily focused acute setting rather chronic care needed care home support highlighted various facilitator barrier staff faced making clinical decision regarding heart_failure care communication addressed experience staff engaging resident family managing heart_failure category linked core category c empowerment encompassed challenge staff faced training support communication empowerment illustrated staff navigated obstacle provide effective heart_failure care within unique context care home discussion study highlight significant challenge managing heart_failure care home including inadequate training limited professional development insufficient support system key barrier include lack specialist education tailored long_term care setting restricted access heart_failure specialist effective communication proactive care identified critical need alongside holistic care approach addressing gap targeted education specialist integration evidence_based strategy could empower staff optimise care quality potentially improve_outcome resident:0.0658307744576579", "139905": "introduction despite evidence cardiac_rehabilitation cr essential component care people heart_failure uptake low centre based format known barrier suggesting home based programme might improve accessibility aim scot rehabilitation enablement chronic_heart_failure reach hf assess implementation reach hf home based cr intervention context national_health service nh scotland paper present design protocol observational implementation study specific objective scot reach hf assess service level facilitator barrier implementation reach hf compare real_world patient caregiver outcome seen prior clinical_trial estimate economic health social impact implementing reach hf scotland method analysis reach hf intervention delivered partnership four beacon site across six nh scotland health board covering rural urban area health professional site trained facilitate delivery week programme people heart_failure caregiver patient caregiver outcome assessed baseline month_follow assessment include minnesota living_heart_failure questionnaire mlhfq five dimension euroqol l hospital anxiety depression scale caregiver burden questionnaire qualitative interview conducted health professional involved programme delivery eg cardiac nurse physiotherapist facilitator patient consultation audio recorded assessed fidelity integrative analysis address key research question fidelity context cr participant related outcome scot reach hf finding inform future potential roll reach hf scotland ethic dissemination study given ethical approval west scotland research ethic service reference w approved march written informed consent obtained participant study listed isrctn registry study id isrctn research team ensure study_conducted accordance general data protection regulation university glasgow research governance framework finding reported funder shared beacon site facilitate service evaluation planning good practice broaden interest understanding reach hf seek publish peer reviewed scientific journal present stakeholder event national international conference:0.0652444514320425"}, "Topic 5": {"75826": "background previous clinical_trial reported ivabradine effectively treat heart_failure_hf however systematic_review explored efficacy_safety hf systematic_review aim evaluate efficacy_safety ivabradine treatment patient_hf method search literature following electronic database inception january cochrane central register controlled_trial embase mediline web_science cumulative index nursing allied health literature allied complementary medicine database chinese biomedical literature database china national knowledge infrastructure vip information wanfang data randomized_controlled_trial rcts ivabradine hf fully considered inclusion without restriction additionally grey literature including clinical_trial registry dissertation reference list included_study conference abstract also searched two researcher review literature extract data assess risk bias included rcts separately data pooled either fixed effect model random_effect model meta_analysis conducted appropriate result primary_outcome cause_mortality secondary_outcome comprise change body_weight urine output change serum sodium adverse_event conclusion result_study summary provide dated evidence assessing efficacy_safety ivabradine hf ethic dissemination necessary acquire ethical approval systematic_review individual patient data used study result systematic_review published peer reviewed journal systematic_review registration prospero crd:0.0610111513707092", "187598": "introduction chronic_disease self_management cdsm vital component congestive_heart_failure_chf programme recent chf guideline downgraded cdsm programme citing lack gold_standard evidence protocol describes aim method systematic_review collate synthesise published research evidence determine effectiveness cdsm programme intervention patient_treated chf method medline pubmed_embase central cinahl cochrane central register controlled_trial psycinfo scopus web_science science citation index register clinical_trial searched addition reference list shortlisted article reviewed randomised controlled_trial case management intervention cdsm chf reported major_adverse_cardiovascular_event_mace extracted analysed restriction language study protocol template developed cochrane collaboration reporting adheres preferred reporting item systematic_review_meta_analysis protocol guideline systematic_review_meta_analysis two independent author apply inclusion exclusion criterion limit article search assess bias certainty evidence rating data extraction study description included_study include quality appraisal study quantitative synthesis data undertaken ascertain evidence study_aim subgroup_analysis conducted different cdsm programme primary_outcome significant_change mace parameter intervention control arm meta_analysis conducted using statistical software feasible ethic dissemination ethic approval sought study collecting primary patient data result_study disseminated peer reviewed scientific journal also presented audience meeting scientific conference prospero registration number crd:0.0599743477054241", "132881": "objective whether glucose insulin potassium gik used adjuvant therapy ischaemic myocardial disease remains controversial nowadays reperfusion era meta_analysis aimed assess effect preinitiated gik patient_undergoing planned percutaneous_coronary_intervention_pci design systematic_review_meta_analysis data source pubmed web_science medline embase cochrane_library clinicaltrials_gov searched november eligibility criterion randomised controlled_trial involving participant preinitiated gik placebo planned pci included data extraction synthesis two independent reviewer used standardised method search screen code included trial risk bias assessed cochrane tool pooled analysis conducted using random_effect model according heterogeneity subgroup_analysis carried dosage gik ongoing myocardial ischaemia result randomised controlled_trial rcts including participant evaluated found patient preconditioned gik pci showed significant_increase thrombolysis myocardial_infarction flow event angioplasty ci_p also revealed improved hospital left_ventricular_ejection_fraction weighed mean_difference wmd ci_p myocardial salvage index wmd ci_p nevertheless benefit observed cause_mortality neither day ci_p month ci_p furthermore gik intervention associated_higher occurrence complication phlebitis ci_p hypoglycaemia ci_p hyperkalaemia ci_p liquid overload ci_p hospital heart_failure ci_p conclusion_study show preconditioning gik exhibit myocardial reperfusion cardiac_function benefit patient planning receive pci intervention also complication phlebitis hypoglycaemia accompany prospero registration number crd:0.0581143761229882", "69622": "background chronic_heart_failure_chf one important cardiovascular_disease worldly high morbidity_mortality fuling sini decoction fsd used management chf widely china effective evidence clear systematic_review_meta_analysis evaluate fsd chf lacking hence propose protocol systematic evaluation efficacy_safety chf method search following electronic database inception october including embase cochrane center registration controlled_trial cochrane_library pubmed medline international clinical_trial registry platform china biomedical literature database cbm china national knowledge infrastructure cnki chinese scientific journal database vip wan fang database randomized_controlled_trial rcts fsd alone combined management chf included two independent reviewer screen literature extract data according cochrane handbook method assessment bias risk data synthesis subgroup_analysis meta_analysis finally meta_analysis performed using revman v software result systematic_review provide high quality evidence may first evaluate efficacy_safety fsd treatment chf conclusion systematic_review provide evidence judging whether fsd effective management chf prospero registration number crd:0.0567815687160546", "99215": "background sacubitril_valsartan first class angiotensin_receptor neprilysin_inhibitor used treat heart_failure evidence novel medication largely based one pivotal phase iii trial stopped early due significant clinical_benefit shown however potential limitation trial design highlighted recent literature necessitating thorough review evidence sacubitril_valsartan method review conducted using prisma reporting guideline relevant randomised controlled_trial rcts sacubitril_valsartan systematically searched medline pubmed_embase cochrane_library google scholar web_science toxline scopus clinical_trial registry searched eight grey literature database addition unpublished clinical_study report csrs relevant trial requested european medicine agency ema clinical_study data request database study_included involve randomising adult patient_heart_failure either sacubitril_valsartan usual_care either active comparator placebo control heart_failure subtype nyha_class included relevant clinical safety outcome reviewed particularly hospitalisation due heart_failure cardiovascular_mortality two reviewer assess eligibility selected study inclusion data extraction performed separately trial publication clinical_trial registry csrs using piloted form methodological quality included trial published source assessed separately using cochrane risk bias tool rob narrative synthesis included_study conducted appropriate meta_analysis clinical efficacy_safety outcome discussion review collate available rct data sacubitril_valsartan including published unpublished source order obtain complete picture evidence base sacubitril_valsartan registration protocol registered prospero reference crd:0.0566594677643142", "195735": "background effectiveness adverse_effect coenzyme q heart_failure remain unclear owing small sample size variation quality existing study literature method database embase pubmed web_science cinahl database scopus cochrane central register controlled_trial vip wanfang cnki searched randomized_controlled_trial coenzyme q assisted treatment_heart_failure relevant literature retrieved data extracted risk bias included_study evaluated two investigator independently using review manager software stata software result_total study_included meta_analysis showed cause_mortality rr_ci_p grade moderate quality hospitalization_heart_failure rr_ci_p grade moderate quality new_york_heart_association classification md ci_p grade low quality brain_natriuretic_peptide level md ci_p grade low quality lower coenzyme q group control_group meanwhile left_ventricular_ejection_fraction md ci_p grade low quality min walk test result md ci_p grade moderate quality better control_group conclusion according existing evidence coenzyme q reduces cause_mortality hospitalization_heart_failure new_york_heart_association classification brain_natriuretic_peptide level improves left_ventricular_ejection_fraction min walk test result heart_failure without major_adverse effect trial_registration study protocol registered international prospective register systematic_review prospero http_www crd york ac uk prospero registration number crd:0.0564557622244606", "172536": "background_heart_failure_hf global health concern affecting million individual worldwide leading significant morbidity_mortality despite advance conventional therapeutic_strategy prognosis hf_patient remains challenging constant search novel therapeutic_option among panax quinquefolius saponin pqs demonstrated promising pharmacological property may benefit hf however efficacy_safety pqs hf comprehensively evaluated objective systematic_review_meta_analysis aim provide reliable estimation efficacy_safety pqs hf help clinician make informed decision regarding potential use pqs managing hf_patient method comprehensively systematically searched published randomized_controlled_trial rcts following eight electronic database pubmed cochrane_library embase web_science wos china national knowledge infrastructure cnki china science technology journal database vip wanfang data china biology medicine database cbm database inception march cochrane risk bias rob assessment tool used quality assessment review manager revman version used meta_analysis mean_difference md credible interval ci relative_risk rr estimate calculated random_effect model also used grade profiler gradepro version analyze quality outcome addition protocol registered international platform registered systematic_review_meta_analysis protocol inplasy registry number result_study included nine rcts involving total patient_hf result meta_analysis random_effect model showed adjuvant pqs therapy significantly_increased lvef md ci_p mwtd md ci_p decreased bnp nt_pro_bnp md ci_p lvedv md ci_p lvedd md ci_p lvesv md ci_p patient_hf conclusion evidence provided systematic_review suggests adjunctive pqs therapy hf improved clinical efficacy hold potential advantage improving cardiac_function increasing exercise_tolerance however given limitation inherent review conclusion_study interpreted cautiously therefore clinical_practice recommended physician tailor treatment_strategy according specific circumstance individual patient systematic_review registration http inplasy com:0.0562096932017314", "122165": "objective estimate combined effect educational intervention ei decreased readmission time hospital_stay adult heart_failure compared usual_care method systematic_review sr meta_analysis randomized_controlled_trial followed recommendation prisma statement protocol registered prospero crd search made inception july database pubmed medline embase cochrane central lilac web_science scopus conducted random_effect model effect measure used dichotomous outcome relative_risk rr continuous outcome mean_difference md used confidence_interval_ci heterogeneity evaluated inconsistency statistic result_study identified included sr study follow six_month showed decrease readmission rr_ci month_follow evidenced reduction rr_ci analysis favor ei group regarding time hospital_stay reduction found approximately two day patient_received ei md ci_conclusion finding support benefit ei reduce readmission day hospital_stay adult patient_heart_failure:0.0558376809668234", "160535": "background patient_heart_failure high rehospitalisation rate poor cardiovascular_outcome home based monitoring hbm emerged promising result different setting however long_term effect patient recently admitted acute_decompensated_heart_failure adhf remain uncertain method systematically searched pubmed_embase cochrane_library randomised controlled_trial rcts comparing hbm usual_care uc published database inception june included_study patient_admitted adhf previous month minimum follow month excluded study_patient hospitalised reason adhf study disproportional education intervention arm statistical analysis_performed using r software version pooled risk_ratio rr mean_difference md confidence_interval_ci categorical continuous outcome respectively cochrane collaboration tool assessing risk bias rcts rob used_assess study quality publication bias assessed via funnel plot egger test heterogeneity assessed statistic sensitivity_analysis protocol systematic_review_meta_analysis registered international prospective register systematic_review prospero crd finding included rcts comprising patient randomised hbm men follow ranged six fifteen month compared uc hbm significantly_reduced cause_mortality rr_ci_p cause hospitalisation rr_ci_p cardiovascular_cv mortality rr_ci_p hospitalisation heart_failure rr_ci_p cv hospitalisation rr_ci_p significant_difference length hospital_stay md day ci_p interpretation patient recently admitted adhf hbm significantly reduces long_term cause_mortality hospitalisation cv mortality hospitalisation hospitalisation heart_failure compared uc support implementation hbm standard practice optimise patient_outcome following admission adhf however future study warranted evaluate efficacy_safety implementing hbm real_world setting funding none:0.0547461697500918", "89130": "background cell transplantation offer potential therapeutic_approach repair regeneration damaged vascular cardiac_tissue acute_myocardial_infarction_ami resulted multiple randomised controlled_trial rcts across world objective_determine safety_efficacy autologous adult bone_marrow stem_cell treatment acute_myocardial_infarction_ami focusing clinical_outcome search method cochrane review update previous version published searched cochrane central register controlled_trial central issue medline march embase march cinahl march transfusion evidence library march addition searched several international ongoing trial database march handsearched relevant conference proceeding january selection criterion rcts comparing autologous bone_marrow derived cell cell patient_diagnosed ami eligible data collection analysis two review author independently screened reference assessed risk bias included trial extracted data conducted meta_analysis using random_effect model throughout analysed outcome short_term less month long_term month_follow dichotomous outcome reported risk_ratio rr continuous outcome reported mean_difference md standardised md smd performed sensitivity_analysis evaluate result context risk selection performance attrition bias exploratory subgroup_analysis investigated effect baseline cardiac_function left_ventricular_ejection_fraction_lvef cell dose type timing administration well use heparin final cell solution main result forty one rcts total participant cell therapy control eligible inclusion cell treatment associated change risk cause_mortality versus rr_ci participant study moderate quality evidence cardiovascular_mortality versus rr_ci participant nine study moderate quality evidence composite measure mortality reinfarction hospitalisation heart_failure versus rr_ci participant six study moderate quality evidence long_term_follow statistical heterogeneity low serious periprocedural adverse_event rare generally unlikely related cell therapy additionally cell therapy effect morbidity quality_life performance lvef measured magnetic_resonance_imaging meta_analysis lvef measured echocardiography single photon emission computed_tomography left_ventricular angiography showed evidence difference mean lvef treatment_group although mean_difference ranged accepted clinically_relevant result robust risk selection performance attrition bias individual study author conclusion_result review suggest insufficient evidence beneficial_effect cell therapy ami patient however evidence come small trial showed difference clinically_relevant outcome adequately powered trial needed efficacy intervention remains unproven:0.0540813658593066"}, "Topic 6": {"191674": "background_aim tuberculous pericarditis tbp severe life_threatening complication yet diagnosis highly challenging due lack sufficient diagnostic tool aim_study develop validate diagnostic prediction_model suitable primary healthcare institution predict risk tbp method collected detailed medical_history imaging examination result laboratory test data clinical_characteristic patient used least absolute shrinkage selection operator lasso technique combined logistic_regression_analysis construct predictive model diagnostic efficacy model assessed_using receiver_operating_characteristic roc_curve calibration curve decision curve analysis dca result_total_patient included_study median_age_year diagnosed tuberculous pericarditis patient randomly_assigned training validation set ratio lasso logistic_regression_analysis revealed weight_loss p body_mass_index_bmi p history tuberculosis p history dust exposure p moderate_severe kidney_disease p erythrocyte sedimentation rate esr p b_type_natriuretic_peptide_bnp p independent_risk_factor tbp based factor constructed nomogram area receiver_operating_characteristic_curve auc training validation set indicating high discriminative ability model calibration curve analysis_showed good consistency model dca result indicated model significant clinical_application value threshold probability set training set validation set conclusion successfully developed nomogram model predicting tuberculous pericarditis assist clinician improving diagnostic accuracy reducing misdiagnoses missed diagnosis primary healthcare setting:0.0481404093205065", "194293": "background early prediction heart_failure_hf acute_myocardial_infarction_ami essential personalized treatment aimed use interpretable machine_learning ml method develop risk prediction_model hf ami patient_method retrospectively included_patient initially ami received percutaneous_coronary_intervention_pci hospital november february primary_endpoint occurrence hf within_year operation developing predictive model hf_risk ami patient least absolute shrinkage selection operator lasso regression used feature selection four ml algorithm including random forest rf extreme gradient boost xgboost support vector machine svm logistic_regression lr employed develop model training set performance evaluation prediction_model carried training set testing set utilizing metric including auc area receiver_operating_characteristic_curve calibration plot decision curve analysis dca addition used shapley additive explanation shap value determine importance selected feature interpret optimal model result_total ami patient included_patient developed hf follow among four evaluated ml model xgboost model exhibited exceptional accuracy auc value shap method showed left_ventricular_ejection_fraction_lvef left_ventricular end_systolic diameter lvds lactate dehydrogenase ldh identified three important characteristic predict hf_risk ami patient individual risk_assessment performed using shap plot waterfall plot analysis conclusion research demonstrates potential ml method early prediction hf_risk ami patient furthermore enhances interpretability xgboost model shap analysis guide clinical decision_making:0.0475122616950246", "177498": "objective_evaluate potential value machine_learning ml model using radiomic feature late gadolinium enhancement lge cine image magnetic_resonance_imaging mri along relevant clinical information conventional mri parameter prediction major_adverse_cardiac_event mace st_segment_elevation_myocardial_infarction stemi patient method_retrospective study included_patient first stemi mace consisted new_onset congestive_heart_failure ventricular_arrhythmia cardiac_death radiomic feature extracted cine lge image inter class correlation coefficient icc calculated assess inter observer reproducibility lasso least absolute shrinkage selection operator method_used radiomic feature selection seven separate model using different combination available information investigated classification repeat random sampling done using adaptive boosting k nearest neighbor naive bayes neural network random forest stochastic gradient descent support vector machine algorithm result extracted radiomic feature showed good inter observer agreement lasso feature selected among ml algorithm neural network showed highest predictive performance average area_curve auc best calculated model one using clinical parameter cmri parameter selected radiomic feature model diagnostic performance follows auc classification accuracy sensitivity_specificity positive predictive_value ppv negative predictive_value npv conclusion radiomics based ml model incorporating clinical conventional mri parameter promising predicting mace occurrence stemi patient follow_period key point acute_coronary occlusion result variable change cellular level ranging myocyte swelling myonecrosis depending duration ischemia metabolic state heart cause subtle heterogeneous signal change imperceptible human eye cardiac mri radiomics based machine_learning analysis cardiac mr image promising risk prediction combining mri derived parameter clinical_variable increase accuracy predictive model:0.0473057154113858", "182984": "objective risk_stratification patient congestive heart_failure_hf vital clinical_practice aim_study construct machine_learning model predict hospital cause_mortality intensive_care_unit icu patient_hf method extreme gradient boosting algorithm xgboost used construct new prediction_model xgboost model medical information mart intensive_care iv database mimic iv training set eicu collaborative research database dataset eicu crd used external validation test set xgboost model performance compared logistic_regression_model existing model get guideline heart_failure model mortality test set area receiver_operating_characteristic cure brier score employed evaluate discrimination calibration three model shapley additive explanation shap value applied explain xgboost model calculate importance feature result_total_patient congestive hf training set test set respectively included_study hospital cause_mortality occurred_patient respectively training set feature highest predictive_value selected model lasso regression acute physiology score iii aps iii age sequential organ failure assessment sofa strongest predictor shap external validation xgboost model performance superior conventional risk predictive method area_curve confidence_interval brier score evaluation clinical effectiveness machine_learning model brought positive net benefit threshold probability prompting evident competitiveness compare two model model translated online calculator accessible freely public http nkuwangkai app mortality prediction app mhkf streamlit app conclusion_study developed valuable machine_learning risk_stratification tool accurately assess stratify risk hospital cause_mortality icu patient congestive hf model translated web based calculator access freely:0.0470788643517347", "148128": "background study_aimed develop validate nomogram predicting acute_kidney_injury aki intensive_care_unit icu stay patient diabetic ketoacidosis dka method total_patient diagnosed dka medical information mart intensive_care iii mimic iii database included randomly divided training set n validation set n clinical_characteristic data set utilized establish nomogram prediction aki icu stay least absolute shrinkage selection operator lasso regression utilized identified candidate predictor meanwhile multivariate logistic_regression_analysis performed based variable derived lasso regression variable p included final model nomogram constructed applying significant risk predictor based multivariate logistic_regression_model discriminatory ability model determined illustrating receiver_operating curve roc calculating area_curve auc moreover calibration plot hosmer lemeshow goodness fit test hl test conducted evaluate performance newly bullied nomogram decision curve analysis dca performed evaluate clinical net benefit result multivariable model included type_diabetes_mellitus_dm microangiopathy history congestive_heart_failure_chf history hypertension diastolic blood_pressure dbp urine output glasgow coma scale gc respiratory rate rr represented nomogram predictive model demonstrated satisfied discrimination auc ci training dataset ci validation set nomogram showed well calibrated according calibration plot hl test p dca showed model clinically useful conclusion nomogram predicted model predicting aki patient dka constructed predicted model help clinical physician identify_patient high_risk earlier prevent occurrence aki intervene timely improve prognosis:0.0463473114301388", "163782": "background_heart_failure_hf end_stage manifestation cause_death coronary_heart_disease chd objective_study establish validate non_invasive diagnostic nomogram identify hf_patient chd method retrospectively analyzed clinical_data chd patient five tertiary hospital univariate logistic_regression_analysis least absolute shrinkage selection operator lasso regression_analysis used_identify independent factor nomogram based multivariate logistic_regression_model constructed using independent factor concordance index c index receiver_operating_characteristic roc_curve calibration curve decision curve analysis dca clinical impact curve cic used_evaluate predictive accuracy clinical value nomogram result predictive factor multivariate model included hypertension age total bilirubin uric_acid urea nitrogen triglyceride total cholesterol level area_curve auc value nomogram training set internal validation set external validation set external validation set ci_ci ci_ci ci_ci respectively calibration curve indicated nomogram strong calibration dca cic indicated nomogram used effective tool clinical_practice conclusion developed predictive model combine clinical laboratory factor patient chd useful individualized prediction hf probability clinical decision_making treatment management:0.0459183551526967", "190786": "purpose study_aimed develop integrative dynamic nomogram including n_terminal_pro b type natural peptide nt_probnp estimated_glomerular_filtration_rate egfr predicting risk cause_mortality hfmref patient patient_method hfmref patient prospectively enrolled development cohort model least absolute shrinkage selection operator lasso regression random survival forest rsf employed select predictor cause_mortality develop nomogram based cox_proportional_hazard_model predicting long_term_mortality year hfmref internal validation conducted using bootstrap final model validated external cohort consecutive adult_patient discrimination predictive performance evaluated calculating time dependent concordance index c index area roc_curve auc calibration curve clinical value assessed via decision curve analysis dca integrated discrimination improvement idi net reclassification improvement nri used_assess contribution nt_probnp egfr nomogram finally develop dynamic nomogram using dynnom package result optimal independent_predictor cause_mortality apselnh angiotensin_converting_enzyme_inhibitor angiotensin_receptor_blocker angiotensin_receptor neprilysin_inhibitor acei_arb arni p percutaneous_coronary_intervention coronary_artery_bypass graft pci cabg stroke e egfr l lg nt_probnp n nyha h healthcare incorporated dynamic nomogram c index development cohort validation cohort respectively auc exceeding indicating good discrimination predictive ability dca curve calibration curve demonstrated clinical applicability good consistency nomogram nt_probnp egfr provided significant net benefit nomogram conclusion_study dynamic apselnh nomogram developed serf accessible functional effective clinical decision support calculator offering accurate prognostic assessment patient hfmref:0.0457501637819970", "180835": "background construct validate risk_assessment model acute_kidney_injury aki patient_acute pancreatitis ap intensive_care_unit icu method total_patient diagnosed acute pancreatitis ap medical information mart intensive_care iv mimic iv database included_patient randomly divided training set n validation set n ratio clinical_characteristic utilized establish nomogram prediction aki icu stay variable selected least absolute shrinkage selection operation lasso regression included multivariate logistic_regression_analysis variable p_value less included final model nomogram constructed based final model predicted accuracy nomogram assessed calculating receiver_operating_characteristic_curve roc area_curve auc moreover calibration curve hosmer lemeshow goodness fit test hl test performed evaluate model performance decision curve analysis dca evaluated clinical net benefit model result multivariable model included variable weight sofa score white blood_cell count albumin chronic_heart_failure sepsis c index nomogram area receiver_operating_characteristic_curve auc training set validation set confidence_interval confidence_interval respectively calibration plot showed good consistency predicted observed outcome training validation set dca confirmed clinical value model good impact actual decision_making conclusion identified risk_factor associated development aki patient ap risk prediction_model aki icu patient ap constructed improving treatment_strategy relevant factor model reduce_risk aki ap patient:0.0456667618332008", "199656": "introduction bleeding serious complication cardiac_surgery especially among_patient receiving combined anticoagulant antiplatelet therapy current prediction_model rarely include undergoing valve surgery coronary_artery_bypass_grafting cabg account postoperative factor dual antithrombotic therapy limiting clinical utility aim_study aimed develop validate machine_learning model individualized prediction bleeding event within three month discharge patient_receiving warfarin plus aspirin following combined cabg valve surgery method data adult patient_underwent cardiac_surgery received combined anticoagulant antiplatelet therapy june december retrospectively analyzed patient randomly_assigned training internal validation cohort eleven key bleeding predictor selected using least absolute shrinkage selection operator lasso method seven machine_learning algorithm logistic_regression decision tree random forest rf support vector machine extreme gradient boosting xgboost light gradient boosting machine lightgbm k nearest neighbor subsequently trained using predictor model performance evaluated based area receiver_operating_characteristic_curve auc accuracy sensitivity_specificity positive predictive_value ppv negative predictive_value npv f score brier score external validation performed temporally independent cohort_patient model interpretability assessed shapley additive explanation shap used visualize global individual risk contribution result eleven clinical_variable including anemia diabetes heart_failure atrial_fibrillation age postoperative drainage previous bleeding stroke body_mass_index estimated_glomerular_filtration_rate intraoperative bleeding identified predictor among model rf algorithm demonstrated best performance internal validation auc accuracy sensitivity_specificity ppv npv f score external validation rf model maintained strong performance auc accuracy sensitivity_specificity ppv npv f score decision curve analysis confirmed clinical utility model shap visualization provided transparent interpretation individualized bleeding risk conclusion_study demonstrates feasibility clinical utility ml based prediction short_term bleeding risk cardiac_surgery patient dual antithrombotic therapy rf model enables individualized risk_assessment shap interpretation supporting clinical applicability:0.0456171488312754", "175909": "background_heart_failure_hf diabetes_mellitus dm frequently coexist exacerbating disease_progression increasing hospital_readmission risk accurate prediction readmission hf_patient dm remains clinical challenge study_aim develop validate machine_learning ml based model incorporating inflammatory metabolic biomarkers enhance risk_stratification method_retrospective cohort_study included hf_patient dm hospitalized january february total_patient randomly divided training validation set seven ml model developed using clinical parameter inflammatory marker metabolic index model performance assessed_using area receiver_operating_characteristic_curve auc roc calibration sensitivity_specificity brier score among others external validation conducted using independent cohort_patient shapley additive explanation shap analysis applied model interpretability web based dynamic nomogram developed clinical implementation result among_patient readmitted within one_year random forest rf model demonstrated superior performance auc brier score outperforming ml model external validation confirmed generalizability auc shap analysis identified age brain_natriuretic_peptide_bnp new_york_heart_association_nyha_class hf classification triglyceride glucose body_mass_index tyg bmi key predictor dynamic nomogram provided individualized risk prediction enhancing clinical applicability conclusion_study developed ml based model integrating inflammatory metabolic biomarkers predicting readmission hf_patient dm model demonstrated robust performance interpretability showing potential supportive tool early risk identification personalized risk communication clinical_setting:0.0455959743822108"}, "Topic 7": {"90982": "medical management chronic illness consumes percent every health_care dollar spent united_state provision economical accessible high quality chronic_disease care continuing concern across health_care setting type_diabetes hypertension hyperlipidemia congestive_heart_failure prime example common chronic_disease cause substantial morbidity_mortality require long_term medical management support disease condition majority care occurs outpatient setting well_established clinical_practice guideline used guide treatment decision despite availability guideline practice recommendation often implemented contributes suboptimal clinical_outcome shortage primary_care clinician outpatient care setting identified barrier provision comprehensive chronic_disease care provides impetus develop test strategy expanding role responsibility member interdisciplinary team help meet continually increasing need chronic_disease care effort serve veteran improve quality efficiency chronic_disease care department veteran affair va implementing patient aligned care team pact model primary_care transformation build widely disseminated effort chronic care model va pact adaptation patient centered medical home includes following core principle wide ranging team based care patient centered orientation toward whole person care coordinated across element health_care system patient community enhanced access care us alternative method communication system based approach quality safety va pact clinical team may include nurse registered nurse rn licensed practical nurse lpn well primary_care provider clinical pharmacist behavioral health specialist clinic facilitator organizing principle care team utilize personnel highest level skill set institute medicine recommended expansion nurse role responsibility allow practice full extent education training report contribution nurse improving access quality care patient selected chronic_condition using detailed structured protocol developed consultation physician began late robust evidence supporting effectiveness nurse providing patient education chronic_disease treatment self_care management secondary_prevention strategy well ability nurse practitioner np provide effective cost_effective primary_care largest segment health_care workforce nurse ideally suited collaborate professional meeting increasing demand chronic care nurse experienced accustomed working multidisciplinary team clearly defined clinical protocol additional training safely practice beyond usual scope practice may well able order relevant diagnostic test adjust routine medication regimen appropriately refer complicated unstable patient medical evaluation va process developing protocol policy expanding nurse role member pact team protocol contains series action accordance current clinical guideline standard practice implemented nurse manage patient condition va emerging interest allowing nurse practice expanded role includes medication initiation titration guideline protocol lack certainty regarding outcome associated use clinical protocol non np nurse expanded role led va commission evidence synthesis thus synthesized current literature describe effect nurse managed protocol outpatient management adult high impact chronic_condition type_diabetes hypertension hyperlipidemia congestive_heart_failure_chf:0.0493801954914797", "170489": "mobile health mhealth solution potential improve self_management clinical care successful integration routine clinical_practice healthcare professional hcps need accepted criterion helping mhealth solution selection patient require transparency trust use information evidence safety security may hard obtain consensus lacking level required evidence new medical device regulation stringent predecessor yet scope span intended us several difficulty remain european society_cardiology regulatory affair committee set task force explore existing assessment framework clinical cost_effectiveness evidence knowledge used propose criterion hcps could evaluate mhealth solution spanning diagnostic support therapeutic remote follow education specifically cardiac rhythm management heart_failure preventive cardiology curated national library health apps may helpful requirement rigour initial follow assessment may vary significantly recently developed cen iso t health app quality assessment framework potential address issue become widely_used efficient tool help drive decision_making internationally task force would like stress importance co development solution relevant stakeholder maintenance health information apps ensure remain evidence_based consistent best practice several general domain specific criterion advised assist hcps assessment clinical evidence provide informed advice patient mhealth utilization:0.0471480379117069", "66866": "heart_failure life_threatening disease addressing considered global health priority present approximately million people worldwide living_heart_failure outlook patient poor survival_rate worse bowel breast prostate cancer furthermore heart_failure place great stress patient caregiver healthcare system demand healthcare service particular predicted increase dramatically next decade patient number rise owing ageing population detrimental lifestyle change improved survival go develop heart_failure final stage another disease time ease strain healthcare system clear policy initiative prioritize heart_failure prevention champion equity care despite burden heart_failure imposes society awareness disease poor result many premature death occur spite fact type heart_failure preventable healthy lifestyle reduce_risk even heart_failure developed premature death could prevented people taught recognize symptom seek immediate medical attention public awareness campaign focusing message great potential improve_outcome patient_heart_failure ultimately save life compliance clinical_practice guideline also associated_improved outcome patient_heart_failure however many country considerable variation closely physician follow guideline recommendation promote equity care improvement encouraged use hospital performance measure incentive appropriate locality end policy promote research required establish evidence base performance measure reflect improved outcome_patient continuing research essential address unmet need caring patient_heart_failure new therapy required patient type heart_failure current treatment relieve symptom address disease affordable therapy desperately needed economically developing world international collaborative research focusing cause treatment_heart_failure worldwide potential benefit ten million people change policy level power drive improvement prevention care save life time make difference across globe confronting problem heart_failure call action policy recommendation urge policymakers local national international level collaborate act following recommendation promote heart_failure prevention support development implementation public awareness programme heart_failure define heart_failure simple accessible language explain recognize symptom emphasize type heart_failure preventable highlight need healthcare professional across clinical discipline identify_patient illness increase_risk heart_failure prescribe preventive medication prioritize elimination infectious disease part world still cause_heart_failure improve heart_failure awareness amongst healthcare professional encourage development use heart_failure education programme appropriate healthcare professional aim improve prevention diagnosis_treatment long_term management heart_failure raise awareness clinical_practice guideline ensure equity care patient_heart_failure provide healthcare system delivers timely access diagnostic service treatment_heart_failure well seamless transition long_term management ensure best available appropriate care consistently provided patient_heart_failure efficient use resource support empower patient caregiver provide resource education practical support patient_heart_failure family caregiver empowering engage proactively long_term care promote heart_failure research fund encourage international collaborative research improve understanding pattern cause effect modern day heart_failure disease prevented across globe fund encourage research new affordable therapy medical device type heart_failure fund encourage research evidence_based healthcare performance measure reflect improved clinical_outcome patient_heart_failure:0.0454867766174320", "2021": "morbidity_mortality associated cardiovascular_disease present enormous humanistic economic burden united_state texas cardiovascular_disease leading_cause_death since risk_factor modification targeted secondary_prevention cardiovascular_disease including lipid management smoking cessation improved control blood_pressure physical_activity weight management use antiplatelet agent anticoagulant angiotensin_converting_enzyme ace_inhibitor congestive_heart_failure beta_blocker myocardial_infarction estrogen replacement_therapy heart care partnership hcp multifaceted interactive program designed improve risk_factor management secondary_prevention cardiovascular_disease physician education participation consensus development addition practice improvement process patient education development implementation texas hcp joint effort texas medical association texas affiliate american heart_association merck co program help hospital improve quality care outcome_patient heart_disease program resource include educational workshop quality improvement process patient educational material hcp workshop address treatment gap define optimal care help define institution specific plan treating heart_disease quality improvement process provide hospital baseline data tool improve measure outcome time hcp workshop provided combination lecture interactive discussion small group planning session designed encourage audience participation upon completing hcp program participant able describe evidence_based medicine supporting secondary_prevention cardiovascular_disease identify prioritize cardiovascular_disease risk_factor secondary_prevention identify barrier solution implementing secondary_prevention develop site based plan cardiovascular_risk_factor modification definite time line implementation care map hcp initial audit medical practice indicates texas appears share deficiency secondary_prevention cardiovascular_disease rest country however improvement demonstrated hospital physician office setting hcp hcp facilitated cooperation medical community state texas work together synchronized communicative manner decrease coronary event partnership represents watershed event history texas medicine first_time statewide team approach address public_health issue initiated past medical organization within state disparate goal multiple strategy achieving:0.0454792497025780", "190365": "heart_transplantation critical treatment_option end_stage heart_failure_patient offering lifeline severe cardiac condition however africa unmet need heart_transplantation significant issue pose challenge healthcare system patient_outcome africa face multiple barrier heart_transplantation including limited infrastructure shortage skilled healthcare professional lack funding inadequate organ donation system challenge result considerable gap demand heart_transplant available resource meet need result many patient africa access life saving heart_transplantation procedure leading high mortality_rate among awaiting transplant addressing unmet need heart_transplantation africa requires multifaceted approach author recommend africa continent build heart_transplantation workforce involving multidisciplinary team consists transplant surgeon transplant physician nurse anesthetist pharmacist etc heart_transplant education training program well constructed ensure delivery safe effective transplantation service international collaboration proven effective encouraged african institution transplant center worldwide facilitate knowledge transfer foreign local organization promote public awareness organ donation address myth heart_transplantation promote heart donation african country improve access heart_transplantation enhance patient_outcome save life region ultimately reduce mortality_rate africa:0.0454224989660396", "18566": "heart_failure clinical syndrome normally requires health_care provided specialist nonspecialists advantageous patient benefit complementary skill set experience present challenge development common shared treatment plan canadian cardiovascular society published comprehensive set recommendation diagnosis management heart_failure january prevention management intercurrent illness acute decompensation use biomarkers january present update build core recommendation based feedback obtained national program heart_failure workshop several topic identified priority challenge pose health_care professional new evidence_based recommendation developed using structured approach review assessment evidence adopted previously described society specific recommendation practical tip written best practice transition care heart_failure_patient recognition investigation treatment specific cardiomyopathy specific clinical question addressed include information referring physician provide specialist consultation instruction consultant provide referring physician process place ensure expectation need physician met cardiomyopathy suspected recognized investigated diagnosed treated patient referred special test available assist diagnosis_treatment goal present update translate best evidence practice apply clinical wisdom evidence specific strategy weaker aid physician health_care provider optimally treat heart_failure_patient resulting measurable impact patient health clinical_outcome canada:0.0453418249698868", "127163": "objective increasing burden heart_failure_hf middle east region africa mea imperative shift focus prevention early_detection cardiovascular_disease present broad consensus real_world challenge strategic recommendation optimising hf care mea region method bridge gap awareness prevention diagnosis hf assembly expert mea shared collective opinion urgent unmet need result lack awareness community high_prevalence risk_factor poor accessibility affordability care diagnostics major barrier delayed missed diagnosis hf mea enhancing patient awareness digital social medium campaign alongside raising knowledge healthcare provider policymakers training programme pave way influencing policy decision implementation robust hf programme multicountry registry foster development guideline factoring local challenge roadblock hf care region specific guideline including simplified diagnostic algorithm provide blueprint care early_detection risk patient facilitate efficient referral thus mitigating clinician therapeutic inertia multidisciplinary care team hf clinic expanded role nurse streamline lifestyle modification optimum control dyslipidaemia blood_pressure glycaemia guideline recommended prevention therapy sodiumglucose co transporter inhibitor thus supporting pleiotropic effect high_risk population conclusion development regional guideline enhancing awareness leveraging digital technology commitment adequate funding reimbursement pivotal overcoming structural health system related barrier mea region:0.0449203950952147", "115605": "background research team undertaken implementation evidence form practice guideline recommendation population hospital community long_term care setting diverse provider patient_population people chronic wound e_g pressure leg ulcer heart_failure stroke diabetes palliative_care cancer maternity care translating evidence clinical_practice point care complex often overwhelming challenge health system well individual practitioner purpose ensure best available evidence integrated practice local evidence need generated process accomplishes number thing focus involved page identifies important facilitating factor well barrier provides empirical support planning key aspect implementation work developed roadmap queen university research roadmap knowledge implementation qurki outline three major phase linked research implementation activity issue identification clarification solution building implementation evaluation nurturing change paper describe practical experience researcher working point care research used facilitate implementation evidence exemplar used illustrate fluid interplay research implementation activity present range supporting research implication qurki serf guide researcher formation strategic alliance practice community undertaking evidence informed reorganization care using collaborative approach researcher play integral role focusing using evidence discussion welcome evaluation usefulness field:0.0445363348952167", "31660": "purpose_review much improvement treatment_heart_failure past decade implementation multidisciplinary team approach disease_management focused optimizing medication application device based therapy surgical intervention promoting education patient carers self_management multidisciplinary strategy extended try improve care advanced_heart_failure latter phase disease trajectory nearing end life recent_finding growing consensus emerged literature confirms need extend multidisciplinary management beyond early target reducing heart_failure related mortality_morbidity address significant care need decline due often inexorable progression syndrome multidisciplinary management facilitates development comprehensive care plan specifically tailored accommodate requirement individual patient family foster collaborative approach care optimize symptom management avoid potential treatment conflict fulfil supportive care need partnership working three principal clinical discipline cardiology specialist palliative_care general practice central process promotes coordinated care across hospital hospice community based service summary advanced_heart_failure management improved time however incorporation multidisciplinary care model appears offer significant promise dealing complex care need heart_failure_patient towards end life delivery practice requires development bespoke care structure relevant spectrum healthcare service environment:0.0439808754351924", "176578": "background chronic_heart_failure_chf progressive life limiting condition necessitates early implementation advance care planning acp however patient caregiver encounter emotional informational cultural barrier effective acp engagement meta synthesis consolidates qualitative evidence deepen understanding acp practice chf care aim_study aimed explore experience chf_patient caregiver acp defined proactive decision_making process establish future treatment plan based patient value study also aimed identify barrier facilitator influencing acp decision assess impact flexible personalized acp approach care quality method using qualitative meta synthesis analyzed qualitative study chf_patient caregiver acp experience data thematically synthesized identify emotional relational practical factor influence engagement acp result three theme emerged heart_failure_patient caregiver face difficulty acp difficulty patient difficulty family difficulty society multidimensional driver impact acp advance care planning driver acceptance implementation acp emotion effect acp flexible personalized acp delivers tangible benefit timing effectiveness acp discussion patient caregiver personalized need acp patient caregiver affirm acp benefit linking evidence action acp play critical role improving end life care quality reducing emotional decision_making burden caregiver flexible personalized acp strategy supported trained healthcare professional effectively meet unique need patient family overcome persistent barrier promote broader acp adoption healthcare system prioritize provider communication training acp education support system tailored diverse cultural context:0.0439713352262227"}, "Topic 8": {"145593": "type_diabetes leading_cause chronic_kidney_disease worldwide continues increase prevalence turn significant implication healthcare provision economy recent_year multiple advance glucose lowering agent available treatment diabetes modify disease also important benefit term associated cardiovascular_outcome cardiovascular_outcome trial agent glucagon like peptide receptor_agonist glp_ra sodium_glucose_cotransporter_inhibitor sglt demonstrated significant benefit reducing major_adverse_cardiovascular_event admission heart_failure case mortality secondary analysis trial also indicated significant renoprotective benefit canagliflozin renal outcome type_diabetes_mellitus nephropathy credence renal specific trial shown major benefit canagliflozin renal outcome diabetic kidney_disease similar trial sglt_inhibitor either underway awaiting analysis article_review current goal treatment diabetes implication advancing renal impairment choice treatment area discussed include diagnosis diabetic kidney_disease current treatment_strategy diabetic kidney_disease ranging lifestyle modification glycaemic control review_focus role glp_ra sglt_inhibitor treating diabetes chronic_kidney_disease illustrative case clear agent considered first choice combination metformin diabetes increased cardiovascular_risk reduced renal_function preference class dipeptidyl peptidase dpp inhibitor sulphonylureas:0.0624038729669918", "144234": "pharmacotherapy type_diabetes_mellitus_dm markedly evolved last two decade classical antidiabetic agent sulphonylureas metformin insulin competition new glucose lowering medication alpha glucosidase inhibitor thiazolidinediones glitazones able replace older agent insufficient efficacy poor tolerability safety contrast incretin based therapy dipeptidyl peptidase inhibitor dpp gliptins oral agent glucagon like peptide receptor_agonist glp_ra subcutaneous injection major breakthrough management dm associated hypoglycaemia weight gain dpp tend replace sulphonylureas add metformin glp_ra tend replace basal insulin therapy failure oral therapy furthermore placebo controlled cardiovascular_outcome trial demonstrated neutrality dpp cardiovascular protection glp_ra patient dm high cardiovascular_risk recently sodium_glucose_cotransporter_inhibitor sglt gliflozins oral agent also showed cardiovascular protection especially reduction hospitalization_heart_failure well renal protection patient_without dm high cardiovascular_risk established heart_failure chronic_kidney_disease thus glp_ra sglt considered preferred drug dm patient high_risk atherosclerotic cardiovascular_disease whereas sglt specifically recommended patient_risk heart_failure renal albuminuric disease_management dm moving glucocentric approach broader strategy focusing risk_factor including overweight obesity organ disease targeted personalized approach:0.0607704286893950", "67327": "randomized_controlled_trial rcts intensive glucose control patient type_diabetes lead modest reduction major cardiovascular_event mace associated reduction kidney event reduction eye event fda issued guidance led conduct numerous cardiovascular_outcome cvot trial assess cardiovascular safety new antihyperglycemic therapy_patient type_diabetes result trial show insulin glargine three different dipeptidyl peptidase dpp inhibitor saxagliptin alogliptin sitagliptin lixisenatide glucagon like peptide receptor_agonist produce significant_difference cvot compared usual_care placebo trial newer diabetes drug including empagliflozin canagliflozin two sodium_glucose co transporter inhibitor liraglutide semaglutide two glp receptor_agonist succeeded demonstrating cv benefit people type_diabetes last two decade equation diabetes equal myocardial_infarction contributed development preventive therapy risk_factor diabetes primary secondary_prevention diabetic_patient high rate statin aspirin treatment improved cv outcome compared_non user drug used reduce glucose level patient type_diabetes seem important ultimate cardiovascular_outcome combination intensive glycemic control safely attainable newer diabetes drug empagliflozin canagliflozin liraglutide semaglutide may decrease incidence mace nephropathy retinopathy moreover depending drug used cv mortality heart_failure may_also reduced:0.0599939667986745", "121040": "future newer class glucose lowering drug namely dipeptidyl peptidase dpp inhibitor glucagon like peptide receptor_agonist glp_ra sodium_glucose co transporter sglt_inhibitor redefined large prospective cardiovascular_outcome trial cvots trial confirmed cardiovascular_cv safety indeed various cardio renal parameter improved trial glp_ra sglt_inhibitor type_diabetes benefit included reduction major_adverse_cardiovascular_event fatal non_fatal myocardial_infarction_stroke decreased hospitalization_heart_failure slower decline glomerular_filtration_rate reduced onset progression albuminuria consequence cvots raised expectation newer glucose lowering agent offer advantage extend beyond glycaemic control weight management address complication comorbidities type_diabetes particularly cardio renal_disease although large prospective outcome trial incur high cost may prompt reconsideration design trial generating evidence enable exacting effective management type_diabetes accompanying cardio renal_disease:0.0587874598234012", "188879": "primary treatment autoimmune diabetes_mellitus type_diabetes_mellitus_dm insulin therapy unfortunately multitude clinical case demonstrated use insulin sole therapeutic_intervention fails address issue comprehensively therefore non insulin adjunct treatment investigated shown successful result clinical_trial various hypoglycemia inducing drug metformin glucagon like peptide glp receptor_agonist dipeptidyl peptidase dpp inhibitor amylin analog sodium_glucose cotransporters sglt_inhibitor developed good outcome_patient dm currently sglt_inhibitor remarkably improved treatment_patient diabetes preventing cardiovascular_event heart_failure_hospitalization progression renal_disease however pharmacological potential explored enough thus substantial interest sglt_inhibitor sglt underline present review begin overview carrier mediated cellular glucose uptake evidencing insulin independent transport system contribution glucose homeostasis essential role sodium_glucose cotransporters pharmacological property sglt detailed leading potential application treating dm patient automated insulin delivery aid system result several study_demonstrated improvement glycemic control increase time range tir decrease glycemic variability reduced daily insulin requirement without increasing hyperglycemic event benefit weight management however advantage counterbalanced increased_risk particularly concerning diabetic ketoacidosis dka several clinical_trial reported higher incidence dka patient dm received sglt_inhibitor sotagliflozin empagliflozin hand patient dm body_mass_index_bmi kg treated dapagliflozin showed similar reduction hyperglycemia body_weight insignificantly increased dka incidence compared overall trial population additional multicenter randomized study required establish safer effective long_term strategy based patient_selection education continuous ketone body monitoring optimal integration sglt_inhibitor dm therapeutic protocol:0.0586899666063893", "108496": "diabetes_mellitus major risk_factor cardiovascular_cv disease conversely cv disease responsible majority death patient_diabetes many drug trial concentrated blood glucose hemoglobin c reduction strategy reducing microvascular outcome like nephropathy neuropathy little effect reducing macrovascular event like heart attack stroke_heart_failure postulated hypoglycemia may counterbalance beneficial_effect anti hyperglycemic agent proven trial evidence thiazolidinediones rosiglitazone pioglitazone showed increased_risk heart_failure raised concern increased myocardial_infarction heightened awareness potentially harmful cv effect otherwise effective hypoglycemic drug resulted regulatory mandate cv outcome trial ascertain safety newer anti hypoglycemic agent appearing market three new class anti hyperglycemic agent introduced recent_year dipeptidyl peptidase dpp inhibitor exhibited increased heart_failure_hospitalization savor timi trial evaluating saxagliptin secondary analysis examine trial alogliptin effect glucagon like peptide glp analog sodium_glucose co transporter sglt_inhibitor cv outcome diabetes largely positive leader sustain trial evaluating safety_efficacy glp analog liraglutide semaglutide respectively showed statistically_significant reduction primary_outcome major_adverse_cardiac_event mace cv_death myocardial_infarction_stroke secondary combined outcome compared_placebo result tecos trial sitagliptin however neutral net cv benefit harm questioning class effect glp analog result sglt_inhibitor trial uniform empa reg evaluating empagliflozin canvas evaluating canagliflozin showed reduction mace end_point dapagliflozin net neutral effect mace declare timi three sglt_inhibitor however showed significant_reduction heart_failure_hospitalization although initially designed keep potentially harmful anti hyperglycemic agent market cv outcome trial provided clinician new set anti hyperglycemic drug proven cv benefit patient_diabetes cv disease thus expanding field cv secondary_prevention need inculcate glp analog sglt_inhibitor reduce major cv_event heart_failure_hospitalization alongside lifestyle management metformin treatment_patient diabetes cv disease:0.0585811046995855", "107325": "patient type_diabetes_mellitus_dm substantially increased_risk heart_failure_hf hf mortality despite lack evidence tight glycemic control reduces incidence cardiovascular cv_event growing body evidence_suggests choice glucose lowering agent may influence outcome including hf thiazolidinediones associated significant risk_hf metformin sulphonylureas insulin little data_available indicate impact hf glucagon like peptide glp agonist liraglutide semaglutide shown reduce major cv_event affect rate hospitalization_hf clinical_trial demonstrated diverse effect dipeptidyl peptidase dpp inhibitor hf saxagliptin showed increased_risk hf admission alogliptin associated_higher rate new hf admission sitagliptin neutral effect sodium_glucose_cotransporter sglt_inhibitor empagliflozin canagliflozin recently shown reduce incidence hf cardiovascular_mortality patient_without history hf review summarize key finding impact glucose lowering agent cv safety hf associated outcome present available data underlying_mechanism benefit sglt_inhibitor hf discus strategy improve outcome_patient dm high cv risk:0.0568595468923838", "98526": "sodium_glucose_cotransporter sglt_inhibitor novel class oral hypoglycemic agent increase urinary glucose excretion suppressing glucose reabsorption proximal tubule kidney sglt_inhibitor lower glycated hemoglobin hba_c mmol mol without increasing risk hypoglycemia induce weight_loss improve various metabolic parameter including blood_pressure lipid profile hyperuricemia recent cardiovascular_cv outcome trial shown improvement cv renal outcome treatment sglt_inhibitor empagliflozin canagliflozin dapagliflozin mechanism sglt_inhibitor improve cv outcome appear glucose lowering anti atherosclerotic effect rather hemodynamic effect osmotic diuresis natriuresis generally sglt_inhibitor well_tolerated adverse_effect include genitourinary tract infection dehydration euglycemic diabetic ketoacidosis rare severe adverse_event patient sglt_inhibitor treatment carefully monitored possibility increase_risk lower extremity amputation bone fracture also reported canagliflozin clinical_trial real_world data suggested sglt_inhibitor improve cv renal outcome mortality_patient type_diabetes dm especially prior cv_event heart_failure chronic_kidney_disease result recent trial including individual without diabetes may change positioning drug drug cardiorenal protection review summarizes potential sglt_inhibitor discusses role treatment dm:0.0562609494994006", "145382": "purpose_review review summarizes recent cardiovascular_outcome trial cvots glucose lowering drug recent_finding majority recent cvots glucose lowering drug tested dipeptidyl peptidase inhibitor dpp glucagon like peptide receptor_agonist glp_ra sodium_glucose_cotransporter_inhibitor sglt study also performed agent including thiazolidinediones insulin cvots dpp glp_ra sglt demonstrated cardiovascular_cv safety agent compared usual_care however certain glp_ra liraglutide subcutaneous semaglutide albiglutide dulaglutide sglt empagliflozin canagliflozin demonstrated cv benefit showing significant_reduction composite cardiovascular_outcome furthermore sglt also significantly_decreased risk hospitalization_heart_failure result_study altered clinical guideline worldwide resulted new indication glucose lowering drug patient high_risk cvd glp_ra sglt proven cardiovascular benefit recommended irrespective glycemic control:0.0560893293776753", "94745": "treatment_option type_diabetes expanded metformin remains first_line treatment case choice second line treatment extend beyond sulfonylurea include sodium_glucose_cotransporter sglt_inhibitor glucagon like peptide glp receptor_agonist dipeptidyl peptidase dpp inhibitor sglt_inhibitor recommended people atherosclerotic cardiovascular_disease heart_failure kidney_disease diabetic ketoacidosis uncommon important side_effect occurrence minimised appropriate patient education management especially perioperative period time illness glp receptor_agonist recommended people atherosclerotic cardiovascular_disease gastrointestinal side_effect common less prominent longer acting agent minimised slow titration shorter acting agent dpp inhibitor generally well_tolerated alogliptin saxagliptin used caution people risk_factor heart_failure optimise management type_diabetes clinician need aware pharmacological characteristic class blood glucose lowering medication effect cardiovascular health renal_function balanced potential adverse_effect medication cardiovascular renal benefit prescribed patient comorbidities reflected recent international guideline:0.0559998646787653"}, "Topic 9": {"103638": "background echocardiographic evaluation longitudinal axis left_ventricular_lv function used diagnosis assessment heart_failure normal ejection_fraction hfnef evaluation global segmental peak systolic longitudinal_strain pslss two dimensional speckle_tracking echocardiography ste may correlate conventional echocardiography finding aimed use ste evaluate longitudinal function lv patient hfnef method_study patient hfnef diastolic_dysfunction normal subject conventional echocardiography underwent ste evaluation including lv_end_diastolic end_systolic dimension interventricular septal thickness posterior wall_thickness lv volume lv_ejection_fraction left_atrial volume_index early diastolic peak flow velocity late diastolic peak flow velocity ratio deceleration time early diastolic myocardial velocity e late diastolic myocardial velocity systolic myocardial velocity global basal mid apical pslss correlation method assessed result mean_age_year hfnef patient_year control_group hfnef group comprised male_female normal group consisted male_female global basal mid apical pslss significantly_lower hfnef group_p value significant positive correlation global psls septal e p_value negative correlation global psls e_e ratio p_value significant negative correlation e_e ratio mid psls p_value basal psls p_value weak positive correlation septal e mid psls p_value basal psls p_value also weak negative correlation isovolumic relaxation time global psls p_value mid psls p_value also new_york_heart_association_functional_class mid psls p_value basal psls p_value conclusion hfnef patient conventional echocardiography different ste finding compared normal subject indicative diastolic_dysfunction longitudinal systolic_function lv measured ste reduced segment denoting degree subclinical systolic_dysfunction patient:0.0541312090308899", "199048": "objective research investigated application real_time three dimensional speckle_tracking imaging rt sti evaluate left_atrial la function individual suffering hypertensive heart_disease hhd heart_failure_preserved_ejection_fraction_hfpef material_method retrospective_study included_patient hhd hfpef hospitalized august june hfpef group healthy individual undergoing physical_examination comprised control_group patient data_collected echocardiography performed measure la diameter lad left_ventricular_end_diastolic diameter lvedd interventricular septal thickness ivst left_ventricular posterior wall_thickness lvpwt left_ventricular outflow tract diameter lvotd early diastolic maximum velocity mitral_valve inflow mve late diastolic maximum velocity mitral_valve inflow mva early diastolic late diastolic velocity mitral annulus measured tissue_doppler ultrasound e tricuspid annular plane systolic excursion tapse left_ventricular_ejection_fraction_lvef la image analyzed_using ge software following parameter measured l emptying fraction laef la emptying volume laev lavolume onset contraction lavprea minimum la volume lavmin maximum la volume lavmax la strain reservoir phase lasr la strain contraction phase lasct la strain conduit phase lascd roc_curve adopted evaluate diagnostic value la parameter hfpef pearson correlation analysis examined relationship parameter n_terminal_pro_b_type_natriuretic_peptide nt_probnp result compared control_group blood_pressure hfpef group significantly_higher p lt hfpef group nt_probnp concentration significantly_greater observed control_group p lt statistically_significant variance detected lvef lvedd lvotd tapse mve mva ratio e wave velocity wave velocity e laev lavmin lavprea two_group p gt compared control_group hfpef group dramatically higher lad ivst lvpwt p lt hfpef group also lower e laef lasr lascd lasct e_e maximum la volume_index lav imax lavmax higher p lt lasr negatively associated nt_probnp r_p whereas significant_correlation found among lascd lasct nt_probnp p gt conclusion la strain parameter serve non_invasive method quantitatively assessing la dysfunction patient_hfpef:0.0519553128078452", "142883": "background propionic acidemia pa myocardial involvement common includes development cardiomyopathy life_threatening acute_heart_failure acquired long qt syndrome sought investigate echocardiographic_parameter left_ventricular systolic diastolic_function indicate early cardiac_disease manifestation pa method prospective observational_study cross_sectional design tertiary medical care center individual confirmed pa enrolled following cardiac investigation performed study individual echocardiographic measurement systolic_diastolic left_ventricular_lv function lv fractional_shortening lv f lv_ejection_fraction biplane modified simpson lv ef mitral annular plane systolic excursion mapse lv global_longitudinal_strain lv gls speckle_tracking echocardiography ste pulsed doppler analysis mitral_valve mv inflow velocity mv e mv deceleration time dt e tissue_doppler imaging tdi mitral annulus mv e_e lv myocardial performance index lv mpi lv left_atrial la diameter assessed lead electrocardiogram ecg recorded corrected qt interval qtc calculated clinical phenotype laboratory parameter time cardiac investigation assessed besides descriptive analysis analyzed frequency onset combination echocardiographic ecg data well correlation clinical biochemical finding effect age visit lv functional parameter qtc analyzed multiple regression result_total_patient confirmed pa enrolled median_age pa onset day range day median_age visit cardiac evaluation year range year lv gls abnormal lv ef mapse mv e_e lv mpi lv f mv e case normal near normal lv f lv gls pathological lv ef mapse probability developing lv_dysfunction systolic_diastolic increase age lv mpi reliable parameter indicate systolic lv_dysfunction combination dilated lv e dilated_cardiomyopathy_dcm pa multiple regression reveals significant positive association lv diameter qtc abnormal lv gls significantly correlate reduced muscle strength muscle tone abnormal gross motor function conclusion data suggests high_prevalence cardiac_disease manifestation pa considerably higher previous_study lv f used_assess lv_function usage advanced echocardiographic technique lv gls assessment may allow early_detection subtle lv_dysfunction pa may_lead timely cardiac treatment also consideration liver transplantation prevent development manifest cardiac_complication:0.0514899116652988", "14596": "background spectrum diabetic heart_disease involves progression normal heart preclinical left_ventricular diastolic systolic_dysfunction followed overt echocardiographic evidence left_ventricular_lv dysfunction finally symptomatic heart_failure objective compare value tissue_doppler imaging tdi conventional echocardiography assessment early myocardial dysfunction type diabetic correlation serum n_terminal_pro_brain_natriuretic_peptide nt_pro_bnp state metabolic control diabetes duration method sixty subject included type diabetic aged_year twenty matched subject served control subjected clinical examination assessment cardiovascular reflex autonomic neuropathy laboratory investigation included mean random blood sugar mrbs hemoglobin c hba_c urinary microalbumin serum determination nt_pro_bnp echocardiography chamber dimension systolic diastolic_function tie index longitudinal myocardial global biventricular function pulsed tdi lv wall right_ventricle rv free wall result diabetic control normal lv dimension lv mass_index systolic_function except higher left_ventricular posterior wall lvpw diabetic p lv rv diastolic_dysfunction diagnosed diabetic conventional doppler higher peak p_p lower e p_p compared_control diabetic larger tie index p tdi showed delayed myocardial relaxation diabetic lower lv rv peak em p_p em p_p compared_control nt_pro_bnp elevated diabetic p best cut value fmol ml sensitivity_specificity detection isolated diastolic_dysfunction diabetic correlated negatively lv em p em p positively p impaired diastolic velocity associated_higher hba_c conclusion asymptomatic diabetic evidence subtle right lv_dysfunction delayed myocardial relaxation related metabolic control tissue_doppler td additional value evaluating ventricular filling nt_pro_bnp considered sensitive specific predictive marker diastolic_dysfunction:0.0514083513002404", "117781": "background cardiotoxicity one serious chronic complication anthracyclines therapy assessment left_ventricular_ejection_fraction_lvef fails detect subtle cardiac_dysfunction left_ventricular_lv study_aimed detect evaluate new parameter subclinical anthracyclines cardiotoxicity child solid tumor method detailed echocardiographic examination performed child hepatoblastoma rhabdomyosarcoma receiving anthracyclines chemotherapy healthy_control january_december lvef ratio early diastolic peak velocity transmitral flow e septal diastolic e mitral annular peak velocity e tricuspid annular plane systolic excursion tapse lv global_longitudinal_strain gls evaluated_using mode tissue_doppler imaging tdi two dimensional speckle_tracking echocardiography ste respectively echocardiographic_parameter compared_patient group healthy_control patient_divided two subgroup based anthracyclines cumulative dosage mg subgroup mg subgroup result_patient presentation heart_failure lvef within normal range compared healthy_control mean e_e increased significantly v_p mean tapse decreased significantly mm v mm p mean lv gls decreased significantly v_p patient group_compared subgroup anthracyclines cumulative dosage mg mean lv gls decreased significantly v_p mean e_e increased significantly v_p mean tapse decreased significantly mm v mm p subgroup anthracyclines cumulative dosage mg conclusion lv gls helpful early_detection subclinical lv_dysfunction using ste e_e tapse sensitive parameter detecting subclinical cardiac_dysfunction ventricle tdi parameter show significant_change different anthracyclines cumulative dosage cumulative dosage controlled clinical treatment:0.0513606532171248", "84386": "background b_type_natriuretic_peptide_bnp used widely objective marker severity prognostic predictor heart_failure recently reported plasma bnp_level associated left_ventricular_lv diastolic_dysfunction color kinesis ck technique based acoustic quantification developed facilitate evaluation regional wall motion lv_function aim_study investigate relationship plasma bnp_level lv diastolic_function using diastolic ck imaging method_result study_included subject sinus_rhythm referred echocardiography evaluate cardiac_function simultaneous measurement plasma bnp thirty five patient new_york_heart_association_class ii class iii_iv performed echocardiography assessment lv_function including lv_ejection_fraction ef transmitral flow e early diastolic mitral annular velocity e diastolic ck diastolic ck image obtained lv mid papillary short axis view analyzed_using ick software ck diastolic index ck di defined calculated lv segmental filling fraction first diastole expressed percentage mean ck di determined average ck di six segment anterior anteroseptal septal inferior posterior lateral wall blood bnp collected day echocardiographic study found significant_correlation mean ck di log bnp r_p whereas log bnp correlated weakly ef r e r dt r e_e r conclusion result_suggest plasma bnp_level may related lv relaxation analysis diastolic ck may_useful quantitative assessment lv diastolic_function patient_heart_failure:0.0498051159680205", "51541": "background according previous_study deformation property left_atrium systolic strain strain rate represent atrial reservoir function early late diastolic strain rate show conduit booster function respectively objective sought evaluate intra interatrial asynchrony using strain strain rate imaging systolic heart_failure_patient patient_method twenty five patient systolic_heart_failure lvef enrolled study asynchrony quantification performed according standard_deviation time peak tp sd deformation three segment manually located along perimeter left_atrium free wall right atrium free wall interatrial septum imaged apical four chamber view also calculated classic echocardiography parameter lv_end_diastolic dimension index la volume_index ra area well deceleration time dt transmitral pulsed wave doppler e_e ratio mitral annular tissue_doppler imaging result heart_failure_patient either inter intra atrial asynchrony far common comparison normal subject p_p respectively_conclusion left_ventricular systolic_heart_failure may result inter intra atrial asynchrony even clinically stable patient_without significant pulmonary_hypertension diastolic_dysfunction:0.0495964770628095", "150937": "background diabetes_mellitus dm documented among strongest risk_factor developing heart_failure_preserved_ejection_fraction_hfpef earliest imaging change patient dm left_atrial la functional volumetric change aim_study determine correlation epicardial fat thickness eft longitudinal la reservoir strain lars patient type dm dm compared_non diabetic control result_study sample case_control study comprised consecutive_patient dm n matched non diabetic control n echocardiography performed_patient eft volumetric longitudinal lars left_ventricular_lv global_longitudinal_strain lvgls pulsed wave doppler derived transmitral early e wave late wave diastolic velocity tissue_doppler derived mitral annular early diastolic e peak systolic velocity obtained study result demonstrated patient dm thicker eft v mm increased la volume_index lavi v ml comparison non diabetic one p_value respectively hand direct association observed eft e_e ratio inverse correlation established eft lars patient dm r_p value r_p value respectively however regression_analysis showed lv mass_index lvmi beta ci_p value lavi beta ci_p value eft beta ci_p value independently correlated lars conclusion lars considered important early marker subclinical cardiac_dysfunction thickened epicardial fat may independent_risk_factor decreased la reservoir strain diabetic especially considered high_risk group due increased epicardial adipose_tissue thickness:0.0492183221452558", "38325": "objective_determine short_term effect cardiac_resynchronization_therapy_crt measurement left_ventricular_lv diastolic_function patient_severe heart_failure background cardiac_resynchronization_therapy improves systolic performance however effect diastolic_function load dependent pulsed wave doppler transmitral index variable method fifty patient_severe heart_failure evaluated two dimensional doppler echocardiography immediately prior month crt measurement included lv volume ejection_fraction_ef pulsed wave doppler pwd derived transmitral filling index e wave velocity e ratio deceleration time dt diastolic filling time dft isovolumic relaxation time tissue_doppler imaging used measurement systolic_diastolic em velocity four mitral annular site mitral e wave em ratio calculated estimate lv filling_pressure color mode flow propagation velocity also obtained result crt lv volume decreased significantly p lvef increased patient accompanied reduction pwd mitral e wave velocity e ratio p increased dt dft p lower filling_pressure e_e wave em septal p_patient lvef response crt significant_change measurement diastolic_function lv relaxation e em velocity worsened group_conclusion heart_failure_patient receiving crt improvement lv diastolic_function coupled improvement lv systolic_function:0.0484896831282493", "99096": "left_ventricular_lv diastolic_function conveniently assessed echocardiography provides reliable assessment lv structure_function patient structural heart_disease variable degree myocardial dysfunction lv structural change pathologic hypertrophy systolic functional abnormality depressed lv long axis systolic_function associated diastolic_dysfunction recognition structural abnormality abnormal lv long axis function index diastolic_dysfunction important difference guideline addition doppler finding indicative diastolic_dysfunction abnormally elevated lv filling_pressure absence clinical echocardiographic specific doppler index diastolic_dysfunction mitral annulus early diastolic velocity e left_atrium la maximum volume_index peak velocity tricuspid_regurgitation jet continuous wave doppler ratio mitral inflow early diastolic velocity e velocity used draw inference lv diastolic_function presence diastolic_dysfunction mean la pressure grade diastolic_dysfunction determined la pressure rest normal reasonable proceed diastolic stress testing attempt identify_patient dyspnea due heart_failure specific algorithm recommended patient atrial_fibrillation moderate_severe mitral annular calcification noncardiac pulmonary_hypertension:0.0483945203631717"}, "Topic 10": {"107902": "background cardiac_resynchronization_therapy_crt established therapy_patient cardiomyopathy left_bundle_branch_block heart_failure bundle pacing hbp may_also improve clinical_outcome narrowing qrs_duration qrs narrowing hbp may always optimal aim_study determine crt could optimized sequential hbp followed left_ventricular_lv pacing optimized crt hot crt maximize electrical resynchronization method attempted permanent hbp patient left_bundle_branch_block intraventricular conduction defect right_ventricular pacing referred crt addition lv lead hbp followed lv pacing delay equal ventricular interval qrs_duration baseline hbp biventricular_pacing hot crt measured echocardiographic_parameter new_york_heart_association_functional_class assessed baseline follow result hot crt successful patient age_year men ischemic qrs_duration baseline m significantly narrowed m biventricular_pacing p m hbp p m hot crt p mean_follow month lv_ejection_fraction improved p new_york_heart_association_functional_class changed twenty one_patient clinical responder showed echocardiographic response conclusion feasibility cohort hot crt resulted improved electrical resynchronization hot crt may_improve clinical echocardiographic outcome advanced heart_failure_patient requiring crt:0.0566608044055589", "188647": "background patient_heart_failure non left_bundle_branch_block non lbbb qrs pattern limited response biventricular_pacing bvp objective personalized cardiac_resynchronization_therapy_crt implantation approach guided real_time electrocardiographic imaging ecgi studied method twenty patient left_ventricular_ejection_fraction_lvef qrs_duration m non lbbb right bundle_branch_block intraventricular conduction delay recruited crt implantation right_atrial right_ventricular coronary sinus bundle left bundle lead inserted total activation time tat different pacing combination measured real_time implantation ecgi configuration producing shortest tat chosen clinical response defined new_york_heart_association_class improvement echocardiographic response defined left_ventricular end_systolic_volume reduction lvef improvement month result ecgi guided crt implantation lvef improved p new_york_heart_association_class improved p clinical echocardiographic response rate ecgi approach resulted better acute electrical resynchronization bvp measured tat reduction v_p percentage tat reduction found strong predictor echocardiographic response area_curve receiver_operating_characteristic_curve confidence_interval strong positive correlation percentage tat reduction percentage lvef improvement pearson r_p found conclusion ecgi guided crt implantation patient_non lbbb generates superior acute electrical resynchronization compared bvp associated favorable clinical echocardiographic outcome:0.0552034698212853", "113956": "aim present_study evaluate feasibility clinical_outcome left bundle_branch area pacing lbbap cardiac_resynchronization_therapy_crt indicated patient method_result lbbap performed via transventricular septal approach patient rescue strategy patient failed left_ventricular_lv lead placement primary strategy remaining patient pacing parameter procedural characteristic electrocardiographic echocardiographic data assessed implantation follow enrolled crt indicated patient left_bundle_branch_block lbbb right bundle_branch_block rbbb intraventricular conduction delay ivcd ventricular pacing dependence qrs_duration qrsd significantly shortened lbbap intrinsic m v lbbap m p mean_follow month new_york_heart_association_functional_class improved baseline p left_ventricular_ejection_fraction_lvef increased baseline p lv_end_diastolic dimension lvedd decreased mm baseline mm p significant_improvement v_p lvef patient lbbb conclusion present_study demonstrates clinical feasibility lbbap crt indicated patient left bundle_branch area pacing generated narrow qrsd led reversal remodelling lv improvement cardiac_function lbbap may alternative crt patient failure lv lead placement first_line option selected patient lbbb heart_failure:0.0547971607368599", "130454": "background left bundle_branch area pacing lbbap emerged promising technique deliver cardiac_resynchronization_therapy_crt however safety_efficacy ventricular_arrhythmia sensing via left bundle implantable_cardioverter_defibrillator_icd recipient remain unclear sought evaluate feasibility single lbbap lead connected dual chamber icd patient indicated crt implantation method cross left pilot study prospectively included consecutive_patient reduced_ejection_fraction complete left_bundle_branch_block indicated prophylactic crt df lead implanted right_ventricular_rv apex lbbap lead interventricular septum ventricular fibrillation induced implantation conventional rv left bundle_branch area sensing configuration latter final sensing configuration patient implanted dual chamber df icd connected atrial lead ra port lbbap lead rv port defibrillation lead rv df port pin capped atrioventricular delay optimized ensure fusion lbbap native conduction right bundle patient_followed month result difference configuration observed regarding r wave sensing sinus_rhythm p ventricular fibrillation median interval detection p total induced episode duration p lbbap resulted significant_reduction median qrs width m p median ventricular sensing significantly_improved implantation mv month p median lvef also significantly_improved month p_conclusion ventricular_arrhythmia sensing defibrillation performed via single lbbap lead connected dual chamber icd associated significant electromechanical reverse_remodeling clinical_trial registration number nct patient_presenting left_bundle_branch_block left_ventricular_systolic_dysfunction left bundle_branch area pacing lead connected df dual chamber implantable_cardioverter_defibrillator provides safe ventricular_arrhythmia sensing efficient electro mechanical resynchronization:0.0519187489879438", "93459": "background cardiac_resynchronization_therapy_crt via biventricular_pacing demonstrated clinical_benefit patient_heart_failure_hf ventricular dyssynchrony approach crt little_known objective purpose_study assess feasibility safety_efficacy left bundle_branch area pacing lbbap patient_hf left_bundle_branch_block lbbb method eleven consecutive patient_hf reduced left_ventricular_ejection_fraction lbbb indicated crt recruited lbbap achieved via transventricular septal approach characterized narrower qrs_duration shortened peak left_ventricular activation time right bundle_branch conduction delay electrocardiogram electrocardiogram echocardiogram cardiac_function evaluated baseline follow interventricular mechanical delay dimensional tissue synchronization imaging lbbap intrinsic lbbb status measured echocardiography follow result lbbap significantly shortened qrs_duration baseline m m p left_ventricular activation time baseline m m p interventricular mechanical delay standard_deviation tissue synchronization imaging left_ventricular_lv segment significantly shorter lbbap intrinsic lbbb status p mean_follow period month new_york_heart_association_functional_class plasma_level b_type_natriuretic_peptide lv end_systolic diameter left_ventricular_ejection_fraction significantly_improved p v baseline conclusion_study demonstrates lbbap clinically feasible patient systolic hf lbbb lbbap new crt technique correct lbbb provide ventricular synchrony improve clinical symptom lv reverse_remodeling:0.0518422578291456", "173525": "cardiac_resynchronization_therapy_crt using biventricular biv pacing standard treatment heart_failure_hf_patient reduced left_ventricular_ejection_fraction_lvef electrical dyssynchrony however one three_patient remains non responder left bundle_branch area pacing lbbap could represent physiological alternative effectiveness limited case atypical left_bundle_branch_block lbbb intraventricular conduction delay ivcd left bundle_branch pacing optimized cardiac_resynchronization_therapy lot crt integrates lbbap coronary sinus c lead pacing improve electrical synchrony clinical_outcome review evaluates feasibility advantage disadvantage clinical_outcome lot crt additionally describe center experience propose evidence_based implantation algorithm review published study investigating lot crt conducted comparing effectiveness biv crt lbbap alone using qrs narrowing lvef improvement left_ventricular remodeling new_york_heart_association_nyha_class change nt_probnp_level found lot crt outperforms biv crt lbbap alone selected population cost higher clinical skill longer procedural time specific device setup randomized_trial underway define role clinical_practice:0.0511755982088892", "75682": "background_heart_failure_hf affect million individual united_state million hospital_admission per_year cardiac_resynchronization_therapy_crt benefit patient_advanced hf prolonged qrs significant percentage patient however respond crt electrical dyssynchrony isolated might good predictor response last left_ventricular_lv segment contract influence response objective_assess electromechanical dyssynchrony crt lv lead implantation guided gated spect method_study included_patient functional_class ii iv hf clinically optimized ejection_fraction sinus_rhythm left_bundle_branch_block qrs m patient_underwent electrocardiography answered minnesota living_heart_failure questionnaire mlhfq underwent gated myocardial perfusion spect week crt reassessed month later primary analysis aimed determining proportion_patient reduction qrs_duration favorable response crt depending concordance lv lead position using chi square test pre post crt variable analyzed use student test adopting significance level result implanted crt device patient_died follow duration qrs m v m pr interval m v m significantly_reduced p_patient lead position concordant maximal delay site responder group lateral position prevalent mlhfq showed significant_improvement quality_life p_conclusion crt determines improvement quality_life electrical synchronism electromechanical synchronism relates response crt positioning lv lead maximal delay site limitation:0.0508434452507463", "41895": "background_aim cardiac_resynchronization_therapy_crt improves ventricular dyssynchrony associated improvement symptom quality_life prognosis patient_severe heart_failure intraventricular conduction delay different pacing modality produce variable activation pattern may cause different haemodynamic change aim_study investigate acute haemodynamic change different crt configuration optimization procedure method_study included_patient severe left_ventricular_systolic_dysfunction left_bundle_branch_block wide qrs ef qrs m new_york_heart_association iii_iv implanted crt device whole group_patient severe mitral_regurgitation order measure dp_dt implantation discharge patient_underwent optimization procedure guided doppler echocardiography left right_ventricular pre ejection interval lvpei rvpei interventricular mechanical delay ivd maximal rate ventricular pressure rise early systole max dp_dt measured left biventricular_pacing three different atrioventricular av delay result crt device optimization optimal av delay crt mode defined left_ventricular pre ejection interval changed p rvpei p ivd p dp_dt p_conclusion patient_receiving crt echocardiographic assessment acute haemodynamic response crt useful tool optimization procedure variability doppler parameter different crt modality emphasizes necessity individualized approach optimization procedure:0.0506831752636697", "176854": "background cardiac_resynchronization_therapy_crt established key component management patient_heart_failure_hf reduced_ejection_fraction addition pharmacologic therapy several automatic algorithm developed optimize timing cycle setting crt especially av delay associated improvement response crt present_study aim investigate whether novel device based syncav algorithm could elicit better synchrony acute hemodynamic response method thirty six patient age_year male ischemic_cardiomyopathy lv_ejection_fraction qrs_duration m intact atrioventricular conduction pr interval range m left_bundle_branch_block undergoing crt implantation prospectively studied device programmed two biventricular biv pacing mode procedure nominal av delay m optimization group syncav algorithm optimized offset minimizing qrs_duration qrsd group_b setting clinical electrocardiographic echocardiographic data_collected month post implantation result intrinsic qrsd m reduced m month m month among group however intrinsic qrsd m reduced m month m month among group_b p versus nominal mode significant_improvement clinical echo criterion without qrsd prolongation patient conclusion post implant electrical optimization already well selected patient left_bundle_branch_block optimized lv lead position facilitated patient tailored biv pacing adjusted intrinsic atrioventricular timing using automatic device based algorithm:0.0499743769962430", "109825": "aim optimization coronary sinus c lead position latest activated left_ventricular_lv area important increase cardiac_resynchronization_therapy_crt response aimed detect relationship coronary sinus lead delay index csdi echocardiographic electrocardiographic response crt treatment method prospectively included consecutive_patient heart_failure_hf diagnosis qrs m left_bundle_branch_block lbbb new_york_heart_association score nyha ii iv lv_ejection_fraction lvef scheduled crt male_female mean_age_year echocardiographic crt response defined reduction lv end_systolic_volume lvesv c lead sensing delay calculated time interval onset surface qrs wave onset depolarization wave recorded c lead using c pacing lead bipolar electrode csdi calculated dividing c lead sensing delay qrs_duration result lvesv reduction associated baseline qrs width r_p qrs narrowing r_p csdi r_p nt_probnp r_p bivariate analysis logistic_regression_analysis csdi found independent parameter predicting significant lvesv reduction beta_p csdi also found significantly_associated lvef increase r_p qrs narrowing r p_conclusion csdi may used marker predict favorable response crt may_useful integrate csdi crt implantation procedure order minimize nonresponders:0.0496659645319364"}, "Topic 11": {"18907": "objective levitronix centrimag ventricular_assist_device vad centrifugal pump designed short_term extracorporeal support cardiogenic_shock aim_study report clinical experience levitronix centrimag uni biventricular support method july december patient supported using levitronix centrimag device nineteen male mean_age range year indication support implantation cardiogenic_shock included end_stage_heart_failure ill undergo transplantation questionable neurologic status subject right_ventricular failure left vad lvad_implantation subject post cardiotomy status subject acute donor graft failure heart_transplantation subject result post vad day survival patient mean support time day patient range day mean support time levitronix biventricular vads range day mean support time levitronix lvads range day highest survival_rate levitronix support donor graft failure cardiotomy levitronix right vad rvad support long_term lvad insertion incurred hospital_mortality survived patient discharged home vad support remain alive date two_patient bridged primary another bridged repeat heart_transplantation five patient weaned recovery operation bleeding occurred_patient clinical evidence cerebral thromboembolism overwhelming sepsis aortic thrombus formation clot formation tubing observed_patient necessitating emergent replacement bedside successful conclusion levitronix centrimag system reliable facile temporary circulatory_support system bridge decision patient refractory acute cardiogenic_shock:0.0601314491909805", "86141": "recent advance medical device therapy heart_failure improved survival patient_heart_failure however due limited availability suitable heart donor left_ventricular_assist_device lvads become important tool bridge heart_transplantation patient refractory heart_failure singapore report experience heartmate ii hmii lvad thoratec corporation pleasanton ca usa bridge heart_transplant center retrospective review consecutive patient_underwent hmii lvad_implantation center may december patient classified interagency registry mechanically assisted circulatory_support intermacs level underwent lvad_implantation bridge heart_transplant male_female patient mean_age_year old range etiology heart_failure included ischemic_heart_disease idiopathic dilated_cardiomyopathy viral myocarditis chemotherapy induced cardiomyopathy nine patient intermacs level patient level two_patient level patient successfully underwent hmii lvad_implantation mortality within first postoperative day postoperative complication included stroke full neurological recovery mediastinal infection cardiac tamponade mediastinal collection requiring reopening chest cardiac_arrhythmia pump thrombosis pump replacement patient discharged hospital lvad_implantation three patient_experienced driveline infection outpatient follow readmission due following condition sub therapeutic anticoagulation gastrointestinal bleeding suspected pump thrombosis transient_ischemic_attack arrhythmia congestive cardiac_failure due severe aortic regurgitation right_ventricular failure rhabdomyolysis hematuria post lvad_implantation patient functionally new_york_heart_association_nyha_class reported nyha iii symptom three_patient successfully bridged heart_transplantation one_patient successfully explanted month lvad_implantation two mortality follow_period average duration lvad support day range day heartmate ii lvad proven effective asian population driveline infection rate remains low even tropical hot humid climate singapore patient ending extended period lvad support increased emphasis detection management long_term complication ventricular_assist_device needed:0.0586233962591431", "171501": "objective patient_advanced_heart_failure heart_transplantation currently effective_treatment however low organ donation environment usually necessary proceed long_term mechanical_circulatory_support left_ventricular_assist_device lvad_implantation bridge transplantation method_study included_patient advanced_heart_failure underwent continuous_flow lvad_implantation bridge transplant strategy center n following lvad_implantation period patient lvad support pump thrombosis stroke gastrointestinal bleeding right_heart_failure occurrence rate recorded outcome compared_patient implanted heartmate hm heartware lvads well patient reach heart_transplantation htx group nohtx group result_total_patient underwent heart_transplantation mean time day received heartware hm device hm patient significantly better survival p lower complication rate p addition nohtx group significantly_higher complication rate compared htx group_p year estimated kaplan_meier survival_rate following heart_transplantation conclusion patient_advanced_heart_failure gain substantial benefit lvads awaiting heart_transplantation low organ donation environment need reliable lvads improve_outcome reduction complication provided current device:0.0574375610628279", "55307": "left_ventricular_assist_device lvads emerged beneficial therapeutic_strategy proven improve morbidity_mortality patient_advanced_heart_failure continuous_flow rotary lvads developed hope delivering circulatory_support durable manner fewer device related complication heartmate r ii continuous_flow left_ventricular assist system lvas thoratec corporation pleasanton ca usa become standard_care heart_failure_patient require long_term mechanical_circulatory_support efficacy heartmate ii demonstrated patient temporary support lvad needed suitable donor organ found transplant termed bridge transplantation well terminally ill heart_failure_patient candidate transplant destination therapy directly compared pulsatile lvad_implantation heartmate ii lvas resulted overall improvement survival reduction number device related complication adverse_event purpose article threefold describe history development continuous_flow lvads describe technology heartmate ii finally review clinical_outcome patient implanted device:0.0572756360568087", "61213": "aim_study institutional experience year continuous_flow cf left_ventricular_assist_device_lvad method evaluated institution lvad database analyzed patient_received cf lvad bridge transplant btt destination therapy march june identified_patient implanted heartmate ii device thoratec corp pleasanton ca received heartware hvad heartware inc framingham result mean_age lvad recipient year range male implanted indication btt survival_rate lvad patient mo mo year_year year_year respectively mean duration lvad support range gastrointestinal bleeding common adverse_event followed right_ventricular failure stroke exploration bleeding ventilator dependent respiratory_failure pneumonia driveline infection rate pump thrombosis occurred_patient device exchanged needed patient multivariate_analysis preoperative liver dysfunction ventilator dependent respiratory_failure tracheostomy right_ventricular failure requiring right_ventricular assist_device support significant_predictor post lvad survival conclusion short long_term_survival patient lvad support excellent although outcome still remain inferior compared heart_transplantation incidence driveline infection pump thrombosis pump exchange declined significantly recent_year:0.0571538477284883", "73038": "background heart_transplantation gained recognition gold_standard therapy advanced_heart_failure scarcity donor organ become important concern evolution surgical alternative ventricular_assist_device vads allow recovery myocardium ensure patient survival heart_transplantation becomes possible report elaborates role vads bridge heart_transplantation infant child year_old end_stage_heart_failure method_retrospective review medical_record heart_transplant recipient may september identified child mean_age_year old iqr year advanced_heart_failure supported vad left vad lvad biventricular vad bvad bridge heart_transplantation fourteen patient less year_old child cardiac_arrest underwent cardiopulmonary resuscitation patient also requiring extracorporeal_membrane_oxygenation ecmo support prior implantation vad aetiology heart_failure primarily cardiomyopathy dilative restrictive endocardial fibrosis idiopathic toxic induced reported patient vads employed primarily berlin heart excor r n heartware n berlin heart incor r n toyobo n result mean duration vad support day range day iqr day donor heart became available primary complication encountered patient bridged transplant mediastinal bleeding main indication pump exchange thrombus formation valve incidence technical failure blood pump driving system component skin infection around cannulae occurred adverse neurological symptom thromboembolism cerebral haemorrhage occurred permanent neurological sequela could detected clinical examination study mean duration follow year iqr year cumulative survival_rate patient bridged transplantation vad day year respectively statistically significant_difference p survival_rate patient bridged heart_transplantation vad compared underwent primary heart_transplantation post transplant survival_rate stratified according type vad implanted number ventricle supported statistically different p respectively addition post transplant survival_rate significantly_different age_gender diagnosis adjusted furthermore statistically significant_difference found post transplant survival_rate child episode rejection compared episode rejection conclusion_result series demonstrate vads satisfactorily support paediatric patient_advanced_heart_failure variety aetiology heart_transplantation data suggests patient bridged vads comparable long_term post transplant survival undergoing primary heart_transplantation:0.0567772278487717", "80594": "child heart_failure unresponsive medical_therapy left option survival ventricular_assist_device vads life saving option patient allowing bridge transplantation cardiac recovery retrospective review case may october undertaken fourteen patient_underwent implantation vads refractory heart_failure mean_age_year range year weight kg range kg indication support end_stage cardiomyopathy n myocarditis n univentricular failure n congenital_heart_disease postcardiotomy n level limitation time implant included critical cardiogenic_shock six progressive decline eight extracorporeal_membrane_oxygenation used bridge vad five patient preimplant variable patient requiring mechanical_ventilation mean day hyperbilirubinemia acute renal_insufficiency device selection systemic vad biventricular assist_device three berlin heart excor used eight patient six patient_received thoratec implantable vad paracorporeal vad mean duration support day range day overall survival ten patient successfully bridged transplantation three died device one remains support patient weaned vad child supported single ventricle heart_failure survival none currently bridged transplantation complication included bleeding requiring reoperation n stroke n driveline infection n two_patient total six pump exchange performed thrombus formation survival pediatric patient age excellent using current device technology majority patient successfully bridged transplantation morbidity acceptably low considering severity illness significant challenge exist long_term extracorporeal support due lack donor availability high incidence preformed alloantibody especially failing single ventricle:0.0556560068076025", "132820": "background ventricular_assist_device vads play critical increasing role treating end_stage_heart_failure pediatric patient growing number_patient supported vads bridge heart_transplantation experience vads pediatric population limited experience israel published objective describe life saving technology experience vad implantation child heart_failure including characteristic outcome method_conducted retrospective chart review patient_underwent vad implantation schneider child medical_center result analyzed result child underwent vad implantation youngest year_old weighed kg implantation eight patient heartmate continuous_flow device implanted seven patient_received berlin heart pulsatile flow device three child required biventricular support underwent heart_transplant median duration day two patient_died due complication awaiting transplant two still vad support time submission article successful vad support achieved patient last year heart_transplant patient_received vad support prior transplant conclusion circulatory assist_device excellent bridge transplantation pediatric patient reaching end_stage_heart_failure vads carefully selected implantation technique tailored patient weight diagnosis centralized pediatric cardiac_transplantation center israeli healthcare provider cognizant therapeutic alternative:0.0549773703934783", "78412": "recent outstanding clinical advance new mechanical circulatory system mc led additional strategy treatment end_stage heart_failure_hf heart_transplantation htx postponed certain patient even replaced smaller implantable left_ventricular_assist_device_lvad mechanical support failing left_ventricle enables appropriate hemodynamic stabilisation recovery secondary organ failure often seen severely ill patient new device may great help bridge patient suitable cardiac allograft available also discussed definitive treatment_patient qualify transplantation main indication lvad_implantation bridge recovery bridge transplantation destination therapy lvad may important tool patient expected prolonged period waiting list instance blood group_b body_weight kg potentially reversible secondary organ failure pulmonary_artery hypertension however lvad_implantation mean additional heart operation inherent peri operative risk complication waiting period finally cardiac_transplantation patient prior implantation lvad represents surgical challenge review summarises current knowledge lvad continuous_flow device especially since latter increasingly used worldwide recent_year review also based institutional experience berne university_hospital apart short_term device impella cardiac assist deltastream ecmo used approximately case pulsatile long_term lvad rvad bi vad non pulsatile lvad mainly heartmateii heartware implanted initial learning curve one year_mortality dropped last patient:0.0543544859425535", "90801": "objective left_ventricular_assist_device lvads routine treatment patient_advanced_heart_failure bridge transplantation aim_study present institutional experience mid term outcome implantation continuous_flow cf lvads bridge transplantation method one_hundred thirty nine consecutive lvad_implantation performed institution july august mean_age population year patient female substantial number_patient preoperative mechanical support intra aortic balloon pump extracorporeal membrane oxygenator previous lvad lvad exchange result mean support duration day whereas longest support duration day year overall cumulative survival_rate following cflvad implantation day year_year fig statistically significant_difference survival favour first lvad_implantation compared vad exchange v day v_year v_year log_rank_p postoperatively patient significant_improvement end organ function month lvad_implantation addition comparison two different device heartmate ii hm ii heartware using propensity_score_matching showed significant_difference survival postoperative adverse_event however patient supported hm ii required significantly unit fresh frozen plasma p trend towards higher use red blood_cell p also likely develop percutaneous site infection p_conclusion hm ii heartware cflvads excellent early postoperative outcome good mid term survival despite considerable number_patient needing vad exchange:0.0541467072598161"}, "Topic 12": {"146689": "fluid challenge rapid infusion saline help discriminate pre post capillary pulmonary_hypertension ph allows unmasking hidden post capillary ph systemic sclerosis ssc patient may present biventricular systolic diastolic_dysfunction aim_study_evaluate hemodynamic change pulmonary circulation ssc patient_without ph fluid challenge twenty five ssc patient control underwent right_heart_catheterization basal condition volume loading saline infusion ml_kg_min baseline difference hemodynamics ssc patient control rapid volume loading resulted significant_increase pressure flow group increase right_atrial pressure v mmhg p mean pulmonary_artery_pressure v mmhg p pulmonary_artery wedge_pressure pawp v mmhg p larger ssc patient control conversely cardiac_index v l_min p increased less ssc patient control pulmonary_vascular_resistance differ group volume loading four ssc patient one control reached pawp mmhg suggesting latent left heart_failure even difference small diagnostic heart_failure ssc patient_without ph larger increase pulmonary vascular pressure smaller increase cardiac_output control acute volume loading probably due subclinical left_ventricular diastolic_dysfunction:0.0472129595016879", "181735": "background pulmonary_arterial_hypertension pah characterized persistently increased pressure pulmonary_artery new defining criterion different hemodynamic type pulmonary_hypertension ph occur left heart_disease proposed task force ph consideration change general definition ph left heart_disease proposed hemodynamic definition isolated postcapillary ph pulmonary_artery wedge_pressure mm_hg mean pulmonary arterial_pressure mpap mm_hg pulmonary_vascular_resistance pvr wood unit wu combined post precapillary ph pulmonary_artery wedge_pressure mm_hg mpap mm_hg pvr wu secondary ph initially reversible eventually become fixed remodeling process pulmonary vascular system limitation defining time amount reversibility lack clarity discus case ph framework better understand key principle addressing patient candidacy heart heart lung transplantation method performed literature search available contemporary data following term pulmonary_hypertension reversal impella temporary mechanical support lvad using national library medicine pubmed pubmed central total published paper found search addressed issue ph reversibility setting lhd durable lvad placement paper found using impella ph timeframe given paucity data field regarding temporary mechanical_circulatory_support pulmonary_hypertension present_case based discussion guide reader understanding potential impact method_patient class pulmonary_hypertension case_year_old woman medical_history acute chronic biventricular systolic_diastolic heart_failure american college cardiology stage stevenson profile c new_york_heart_association_class iv ejection_fraction secondary nonischemic cardiomyopathy cardiac_resynchronization_therapy pulmonary_hypertension bilateral deep vein thrombosis segmental pulmonary_embolism presented heart_transplant evaluation cardiac_output central hemodynamics measured found pulmonary_artery pa pressure mean pa pressure pulmonary_capillary wedge_pressure pcwp transpulmonary pressure gradient tpg thermodilution cardiac_output co l_min cardiac input ci l_min pvr wu provocative pharmacologic testing reversibility ph performed using sodium nitroprusside resulted blood_pressure heart_rate min pa pressure mean pa pressure pcwp tpg co l_min ci l_min pvr wu following patient_underwent impella placement right axillary artery optimize afterload reduction improve end organ perfusion post impella hemodynamics milrinone mcg kg_min demonstrated following blood_pressure heart_rate min pa pressure mean pa pressure pcwp tpg co l_min ci l_min pvr wu conclusion left_ventricular_assist_device support impella associated reduction mpap pvr week month thus play crucial role bridge transplant case review highlight characteristic ph resulting heart_failure reduced_ejection_fraction discusses important clinical issue related treatment_patient shown left_ventricular_assist_device therapy impella effectively reduce left_sided filling_pressure lead ph improvement demonstrate potential benefit impella management_patient ph cardiogenic_shock impaired hemodynamics:0.0467673705495238", "73675": "restrictive cardiomyopathy rcm rare form cardiomyopathy characterized restrictive ventricular filling elevated filling_pressure lead pulmonary_hypertension ph often progress combined post pre capillary ph cpc ph increased diastolic pulmonary vascular pressure gradient dpg pulmonary_vascular_resistance pvr caused longstanding backward hemodynamic consequence left heart_disease lhd leading morphological change pulmonary vasculature patient_high pvr undergoing left_ventricular_assist_device lvad_implantation increased_risk postoperative right_sided heart_failure requiring concomitant implantation right_ventricular assist_device rvad report_case rcm severe cpc ph due extremely elevated dpg pvr patient_presented recurrent syncope caused severe ph right_heart_catheterization rhc revealed highly elevated dpg mmhg pvr wood unit wu subsequent significant_reduction right_ventricular afterload vasoreactivity testing inhaled nitric_oxide dpg mmhg pvr wu administration pulmonary vasodilator pulmonary congestion worsened second rhc revealed elevated pulmonary arterial wedge_pressure pawp modest decrease pulmonary arterial_pressure pap mmhg pvr wu therefore inotropic agent systemic vasodilator added treatment left_sided heart_failure targeting elevated filling_pressure pah specific heart_failure treatment decrease right_ventricular afterload dpg mmhg pvr wu achieved next step lvad successfully implanted without need rvad bridge transplantation first reported case cpc ph revealed potential reversibility extremely elevated dpg pvr suggests importance preoperative rhc guided optimized medical pah specific heart_failure treatment lvad_implantation:0.0460151248239563", "60593": "rationale hemodynamic effect adaptive servoventilation asv patient pulmonary_hypertension ph unknown method series clinically stable patient pre post capillary ph underwent asv therapy endexpiratory positive airway pressure support cm h pressure support cm h right_heart_catheterization hemodynamics measured rest end min episode asv therapy min asv completion hemodynamic variable included heart_rate blood_pressure right_atrial pressure rap mean pulmonary_artery_pressure papm pulmonary arterial wedge_pressure pawp cardiac_output pulmonary_vascular_resistance pvr result_study enrolled patient_patient post capillary ph due heart_failure_preserved_ejection_fraction patient pre capillary ph due pulmonary_arterial_hypertension n chronic thromboembolic pulmonary_hypertension n asv well_tolerated patient resulted reduction systolic_blood_pressure mmhg p papm mmhg p pvr p right left filling_pressure increased cardiac_output decreased l_min p hemodynamic effect asv similar patient_population conclusion asv moderate hemodynamic effect patient ph various origin importantly decline systolic_blood_pressure papm cardiac_output asv safe well_tolerated short_term study observed drop blood_pressure cardiac_output may concern asv applied patient_advanced ph severely impaired right_ventricular function:0.0458643801370335", "2734": "background elevated plasma endothelin et level patient_chronic_heart_failure correlate pulmonary_artery_pressure pulmonary_vascular_resistance et receptor vascular smooth_muscle cell mediate pulmonary vascular contraction hypertrophy determined acute hemodynamic effect sitaxsentan selective et receptor_antagonist patient_chronic stable heart_failure receiving conventional therapy method_result multicenter double_blind placebo controlled_trial enrolled patient_chronic new_york_heart_association_functional_class iii_iv heart_failure mean left_ventricular_ejection_fraction treated ace_inhibitor diuretic patient baseline pulmonary_capillary wedge_pressure mm_hg cardiac_index l_min randomized dos mg_kg sitaxsentan placebo intravenous infusion minute hemodynamic response assessed catheterization right side heart hour sitaxsentan decreased pulmonary_artery systolic_pressure pulmonary_vascular_resistance mean pulmonary_artery_pressure right_atrial pressure p respectively effect heart_rate mean arterial_pressure pulmonary_capillary wedge_pressure cardiac_index systemic vascular_resistance plasma et level elevated baseline decreased sitaxsentan conclusion_patient moderate_severe heart_failure receiving conventional therapy acute et receptor blockade caused selective pulmonary vasodilation associated reduction plasma et sitaxsentan may value treatment_patient pulmonary_hypertension secondary chronic_heart_failure:0.0441669937425061", "153257": "aim pulmonary_hypertension ph pulmonary vascular_disease pvd common associated adverse_outcome left heart_disease lhd study sought characterize pathophysiology pvd across spectrum ph lhd method_result patient ph lhd mean pulmonary_artery pa pressure mmhg pa wedge_pressure pawp mmhg control free ph lhd underwent invasive haemodynamic exercise testing simultaneous echocardiography expired air blood gas analysis lung ultrasound prospective_study patient ph lhd divided isolated post capillary ph ipcph pvd combined post pre capillary ph cpcph based upon pulmonary_vascular_resistance pvr wu compared_control n ipcph lhd n participant cpcph lhd n displayed poorer left_atrial function severe right_ventricular_rv dysfunction rest exercise patient cpcph lhd displayed similar pawp ipcph lhd severe rv pa uncoupling greater ventricular interaction severe impairment cardiac_output delivery peak consumption despite higher pvr participant cpcph developed severe lung congestion compared ipcph lhd control associated_lower arterial tension reduced alveolar ventilation decreased pulmonary diffusion greater ventilation perfusion mismatch conclusion pulmonary vascular_disease lhd associated distinct pathophysiologic signature marked greater exercise induced lung congestion arterial hypoxaemia rv pa uncoupling ventricular interdependence impairment delivery impairing aerobic capacity study required identify novel treatment targeting pulmonary vasculature ph lhd:0.0434944012788526", "124945": "pulmonary_arterial_hypertension pah rare dyspnoea fatigue syndrome caused progressive increase pulmonary_vascular_resistance eventual right_ventricular_rv failure spite extensive pulmonary vascular remodelling lung function pah generally well preserved hyperventilation increased physiological dead space minimal change lung mechanic mild_moderate hypoxaemia hypocapnia hypoxaemia mainly caused low mixed venous oxygen tension decreased cardiac_output hypocapnia mainly caused increased chemosensitivity exercise limitation pah cardiovascular rather ventilatory muscular extent pulmonary vascular_disease pah defined multipoint pulmonary vascular pressure flow relationship correction haematocrit pulsatile pulmonary vascular pressure flow relationship pah allow assessment rv hydraulic load analysis possible either frequency domain time domain rv pah adapts increased afterload increased contractility preserve coupling pulmonary circulation homeometric mechanism exhausted rv dilates preserve flow output additional heterometric mechanism right_heart_failure diagnosed imaging increased right_heart dimension clinical systemic congestion sign_symptom coupling rv pulmonary circulation assessed ratio end_systolic arterial elastance measurement difficult simplified estimate rv pulmonary_artery coupling obtained magnetic_resonance echocardiographic imaging ejection_fraction:0.0434536649258975", "58237": "objective_determine influence normal pulmonary_artery_pressure mild moderate_severe pulmonary_hypertension early hemodynamics morbidity_mortality orthotopic heart_transplantation method sixty seven heart_disease patient male_female aged including ischemic_heart_disease n myocardiopathy n heart_disease n underwent orthotopic heart_transplantation transplantation routine right_heart_catheterization conducted according preoperative pulmonary arterial_pressure patient_divided group group_n without pulmonary_hypertension ph pulmonary_vascular_resistance pvr wood unit group ii n mild_moderate ph pvr wood unit group iii n severe ph pvr wood unit heart_rate hr mean artery pressure map central venous pressure cvp mean pulmonary_artery_pressure mpap pulmonary_artery wedge_pressure pawp pvr cardiac_output index ci mixed venous oxygen saturation v measured preoperatively immediately hour postoperatively day month post operatively echocardiography conducted measure left_ventricular_end_diastolic diameter lvedd left_ventricular_ejection_fraction ef mitral valvular regurgitation mvr tricuspid valvular regurgitation tvr postoperative complication mortality recorded result day_mortality zero group cardiovascular support used weaning cpb postoperative period included dopamine ephedrine isoproterenol addition nitroglycerin iloprost administered pulmonary_artery vasodilation pulmonary_artery_pressure higher mm_hg ef value group iii significantly_lower compared group_p heart_transplantation patient mild severe ph patient_severe ph patient_group iii longer cpb time tracheal intubation time comparison patient group_p postoperatively patient_group group ii group iii acute right_ventricular failure patient_group ii group iii renal_failure basiliximab cyclosporine mycophenolate mofetil methylprednisolone administered immunosuppressive treatment perioperatively conclusion patient_severe ph pre operatively significantly_lower pulmonary resistance pressure complication acute right_heart_failure post operatively active treatment cardiac stimulant diuretic helpful smooth anesthetic induction maintenance peri operative stable hemodynamic management especially protection right_ventricle function first week transplantation myocardial protection donor heart immunosuppressive regimen play_important_role successive heart_transplantation:0.0433336131383989", "174517": "critically_ill patient intensive_care_unit icu require continuous hemodynamic monitoring guide therapeutic decision prevent clinical deterioration echocardiography emerged cornerstone noninvasive hemodynamic assessment offering real_time bedside evaluation key parameter venous congestion pulmonary pressure left_atrial pressure lap systemic vascular_resistance cardiac_output ventricular arterial coupling systemic venous congestion right_atrial pressure rap assessed inferior vena cava diameter measurement respiratory variation additional accuracy provided vexus score incorporates hepatic portal renal vein doppler profile internal jugular vein assessment left_ventricular_lv stroke_volume variability refine rap estimation pulmonary_hypertension ph right_ventricular dysfunction evaluated echocardiographic marker differentiate precapillary postcapillary ph enabling tailored treatment_strategy addition echocardiography fundamental detecting right_ventricular failure particularly ph cardiogenic_shock lap systemic hemodynamics integral assessing lv diastolic systolic_dysfunction pivotal heart_failure cardiogenic_shock management echocardiography also provides insight vascular system property interaction cardiac performance lung ultrasound aid detecting interstitial edema cardiac origin fast reliable reproducible tool echocardiography gold_standard noninvasive hemodynamic assessment icu patient facilitating prompt precise therapeutic decision:0.0425208636200631", "50623": "background invasive hemodynamic exercise testing commonly_used evaluation patient suspected heart_failure_preserved_ejection_fraction_hfpef pulmonary_hypertension saline loading suggested alternative provocative maneuver hemodynamic change induced stress compared method_result twenty six subject aged_year n hfpef n control underwent right_heart_catheterization rest supine exercise acute saline loading prospective_study exercise saline increased cardiac_output pressure right atrium pulmonary_artery pulmonary_capillary wedge position change heart_rate blood_pressure rate pressure product cardiac_output greater exercise compared saline control subject right_atrial pressure pulmonary arterial_pressure pulmonary_capillary wedge_pressure increased similarly saline exercise whereas hfpef subject exercise led approximately fold greater increase right_atrial pressure versus mm_hg p pulmonary arterial_pressure versus mm_hg p pulmonary_capillary wedge_pressure versus mm_hg p compared saline systolic reserve assessed stroke work cardiac power output lower hfpef subject exercise saline systemic pulmonary arterial compliance enhanced saline reduced exercise conclusion exercise elicits greater pulmonary_capillary wedge_pressure elevation compared saline hfpef control suggesting hemodynamic stress beyond passive stiffness increased venous return explain development pulmonary venous hypertension hfpef exercise testing sensitive saline loading detect hemodynamic derangement indicative hfpef clinical_trial registration url http_www clinicaltrials_gov unique identifier_nct:0.0420005818028708"}, "Topic 13": {"107551": "observational_study investigate efficacy_safety nonvitamin k antagonist oral anticoagulant noacs atrial_fibrillation_af patient bioprosthetic valve prior surgical valve repair clinical_practice total_patient mean_age female bioprosthetic heart valve surgical valve repair af treated noacs included analysis mean cha_d_vasc congestive_heart_failure hypertension age_year diabetes_mellitus prior stroke transient_ischemic_attack vascular_disease bled hypertension abnormal renal liver function stroke bleeding labile inr international normalized ratio elderly drug alcohol score value respectively total study_population taking apixaban mg twice daily bid apixaban mg bid dabigatran mg bid dabigatran mg bid rivaroxaban mg daily qd rivaroxaban mg qd also study_population previously warfarin replaced noacs due lack compliance labile inr control time therapeutic range noac therapy af started average day bioprosthetic heart valve implantation surgical repair average duration day study_population included_patient bioprosthetic mitral_valve patient bioprosthetic aortic_valve patient previous surgical mitral repair patient previous surgical aortic repair concomitant use noacs patient evaluated thromboembolic event ischemic_stroke transient_ischemic_attack systemic embolism well major_bleeding event follow_period study_population recorded low mean annual incidence thromboembolism major_bleeding according data anticoagulation therapy noacs seems effective safe treatment_strategy nonvalvular af_patient bioprosthetic valve prior surgical valve repair:0.0581626882817209", "73123": "background management atrial_fibrillation_af evolved development direct oral anticoagulant doacs data clinical effectiveness safety outside clinical_trial setting limited method raffine registry observational multicenter prospective registry japanese patient_af designed follow clinical_event year patient enrollment conducted university_hospital general hospital private clinic ensure inclusion broad spectrum representative af_patient primary_outcome event study ischemic_stroke systemic embolism major_bleeding result enrolled ambulatory patient_af university_hospital general hospital clinic japan mean patient age_year male type af paroxysmal persistent permanent major coexisting disease hypertension diabetes_mellitus congestive_heart_failure history ischemic_stroke transient_ischemic_attack coronary_artery_disease entire cohort treated warfarin treated doacs prescription doacs exceeded warfarin general hospital clinic risk_score chad score cha_d_vasc_score bled score higher patient university_hospital patient general hospital clinic conclusion raffine registry baseline described current status anticoagulation therapy japan long_term_follow data identify outcome vary stratified group_patient af doac era umin clinical_trial registry umin:0.0539640699725216", "142208": "objective identified factor_associated thromboembolic bleeding event two contemporary cohort anticoagulated patient atrial_fibrillation_af treated either vitamin k antagonist vka non vka oral anticoagulant noacs design prospective multicentre observational_study setting centre seven european country participant patient_receiving vka prevention thromboembolic event european registry atrial_fibrillation prefer af derivation cohort patient_receiving noac prefer af prolongation validation cohort stroke prevention af outcome_measure risk_factor thromboembolic event ischaemic stroke systemic embolism major_bleeding gastrointestinal bleeding intracerebral haemorrhage life_threatening bleeding result mean_age patient_enrolled prefer af registry year female mean cha_d_vasc_score incidence thromboembolic major_bleeding event ci_ci year_follow respectively abnormal liver function prior stroke transient ischaemic attack labile international normalised ratio inr concomitant therapy antiplatelet non steroidal anti_inflammatory drug heart_failure older age_year independently_associated thromboembolic major_bleeding event exception unstable inr value risk_factor validated patient_treated noacs prefer af prolongation study year female cha_d_vasc single point decrease modifiable bleeding risk scale observed lower_risk major_bleeding event ci_p lower rate thromboembolic event ci_p_conclusion attending modifiable risk_factor important treatment target anticoagulated af_patient reduce thromboembolic bleeding event initiation anticoagulation risk stroke prevented elevated bleeding risk_score:0.0529825734510304", "114284": "objective_study sought investigate clinical_outcome associated left_atrial appendage occlusion laao versus direct oral anticoagulant doacs patient high_risk atrial_fibrillation_af background laao shown noninferior warfarin stroke prevention af however anticoagulation doacs preferred warfarin thromboprophylaxis af method patient_af enrolled amulet observational registry n successful laao amplatzer amulet device n compared propensity_score matched_control cohort incident af_patient n treated doacs identified danish national patient registry propensity_score_matching based covariates cha_d_vasc congestive_heart_failure hypertension age_year diabetes_mellitus prior stroke transient_ischemic_attack thromboembolism vascular_disease age_year sex category bled hypertension abnormal renal liver function stroke bleeding labile international normalized ratio elderly drug alcohol score predicting stroke bleeding primary_outcome composite ischemic_stroke major_bleeding bleeding academic research consortium cause_mortality follow year result af patient_treated laao significantly_lower risk primary composite_outcome compared patient_treated doacs hazard_ratio_hr_confidence_interval_ci total event event_rate per patient_year laao v doacs v_v respectively risk ischemic_stroke comparable group hr_ci risk major_bleeding hr_ci cause_mortality hr_ci significantly_lower patient_treated laao conclusion among high_risk af_patient laao comparison doacs may similar stroke prevention efficacy lower_risk major_bleeding mortality:0.0525496446098282", "99307": "atrial_fibrillation_af prevalent arrhythmic disease tends foster thrombus formation due hemodynamic disturbance leading severe disabling even fatal thromboembolic disease meanwhile patient_af may_also present acute_coronary_syndrome_ac coronary_artery_disease_cad requiring stenting creates clinical dilemma considering majority patient likely receive oral anticoagulant oacs stroke prevention require additional double antiplatelet treatment dapt reduce recurrent cardiac_event stent thrombosis case gentle balance bleeding risk atherothromboembolic event need carefully considered study shown congestive_heart_failure hypertension age_year doubled diabetes_mellitus previous stroke transient_ischemic_attack tia doubled vascular_disease age_year sex category female cha_d_vasc_score outperform scoring system asian population hypertension abnormal renal liver function point stroke bleeding history predisposition labile international normalized ratio inr elderly year drug alcohol concomitantly point bled score simple clinical score predicts bleeding risk patient_af particularly among asian performs better bleeding score high bled score used rule oac treatment instead prompt clinician address correctable risk_factor therefore current review attempted analyze available data_patient nonvalvular af underwent stenting ac cad elaborate direct acting oral anticoagulant doac antiplatelet management among_patient majority patient triple therapy comprising oac aspirin clopidogrel considered month following ac however optimal duration triple therapy would depend patient ischemic bleeding risk doacs obviously safer vitamin k antagonist:0.0518290794398865", "17902": "atrial_fibrillation_af common sustained cardiac rhythm disturbance found clinical_practice increasing prevalence age af often associated structural heart_disease although significant proportion detectable heart_disease last decade increase hospitalization af extremely costly public_health problem af associated_increased long_term risk stroke_heart_failure cause_mortality fact mortality_rate patient_af double patient normal sinus_rhythm antithrombotic therapy recommended patient_af prevent thromboembolism except lone af contraindication selection antithrombotic agent based upon absolute risk stroke bleeding relative_risk benefit given patient however despite oral anticoagulation vitamin k antagonist warfarin acenocoumarol patient still thromboembolic event furthermore majority patient international normalized ratio inr monitoring may inconvenience new anticoagulant direct thrombin inhibitor investigated result ly trial recently published study_population patient_af dabigatran mg b associated stroke systemic embolism rate similar associated warfarin lower rate major hemorrhage however dabigatran administered dose mg lower rate stroke systemic embolism similar rate major hemorrhage found compared warfarin aim review update information prevention thromboembolic event patient_af dabigatran may change daily clinical_practice:0.0512810338405984", "110299": "background several non vitamin k antagonist oral anticoagulant noac alternative warfarin available stroke prevention atrial_fibrillation_af aimed describe factor_associated selection noacs versus warfarin patient new_onset af method orbit af ii study national u prospective observational cohort_study anticoagulation treatment patient_af receiving noacs warfarin united_state measured factor_associated oral anticoagulant selection patient recently diagnosed af result baseline patient started warfarin noacs latter started dabigatran rivaroxaban apixaban receiving noacs slightly younger patient median_age v_p less_likely prior stroke v_p prior bleeding v_p better kidney_function mean estimated_glomerular_filtration_rate ml_min v ml_min p fewer patient_high stroke risk cha_d_vasc_score congestive_heart_failure hypertension age_year diabetes_mellitus prior stroke transient_ischemic_attack tia thromboembolism vascular_disease age_year sex category female v_p multivariable_analysis factor_associated noac selection versus warfarin included renal_function prior stroke valve replacement rhythm_control af management_strategy treatment cardiologist higher patient education level conclusion contemporary clinical_practice three fourth patient new_onset af initially treated noac stroke prevention selected noac treatment lower stroke bleeding risk profile likely treated cardiologist higher socioeconomic status trial_registration clinicaltrials_gov identifier_nct:0.0511350377140155", "136850": "background atrial_fibrillation_af chronic_kidney_disease_ckd associated_increased_risk ischemic_stroke aim_study compare clinical_characteristic incidence left_atrial appendage laa thrombus predictor spontaneous echo contrast sec population patient_af depending estimated_glomerular_filtration_rate egfr value method_study included patient_underwent transesophageal echocardiographic examination prior cardioversion ablation year three cardiac center result quarter af_patient decreased egfr_ml_min characterized high_risk population comorbidities higher thromboembolic bleeding risk compared normal renal_function oral anticoagulation oac prescribed patient decreased normal egfr respectively higher_prevalence prescribed non vitamin k antagonist oral anticoagulant noacs incidence laa thrombus sec increase simultaneously decrease egfr_ml_min respectively among_patient prescribed reduced dos noac decreased egfr often observed laa thrombus v non paroxysmal af heart_failure previous bleeding predictor laa thrombus irrespective egfr value ckd predictor laa thrombus patient including non paroxysmal af male without diabetes without hypertension cha_d_vasc conclusion despite oac patient concomitant af ckd remain high_risk laa thrombus formation:0.0510690886373229", "729": "atrial_fibrillation_af common cardiac_arrhythmia af paroxysmal persistent becomes permanent convert sinus_rhythm spontaneously attempted cardioversion fails prevalence af general_population increase age octogenarian men age adjusted prevalence generally higher woman af synchronous mechanical atrial activity disturbed resulting haemodynamic impairment give rise thrombus formation embolism systemic circulation thrombus associated af arises frequently left_atrial appendage cerebrovascular embolus af_patient often manifest transient ischaemic attack ischaemic stroke overall rate ischaemic stroke among_patient nonrheumatic af average per_year rate increase age patient_af higher_risk cerebrovascular event cause stroke one every six occurs patient_af including transient ischaemic attack silent stroke detected radiographically overall rate cerebrovascular event af_patient rise per_year although approximately one third due cause secondarily incidentally associated af related anticoagulant therapy antiarrhythmic therapy useful improve cardiac rate function af however reduce first recurrent embolus antithrombotic therapy paramount importance result several randomized_clinical_trial antithrombotic therapy shown adjusted dose warfarin reduces first recurrent stroke compared_placebo patient nonvalvular af anticoagulated odds ischaemic stroke intracranial bleeding favour inr acetylsalicylic acid less efficacious warfarin af_patient reducing risk stroke therefore antiplatelet agent used af_patient low_risk anticoagulation current treatment modality af_patient high intermediate risk e patient history transient ischaemic attack stroke aged_year history hypertension_diabetes heart_failure structural heart_disease valvular disease significant systolic_dysfunction benefit dual antiplatelet regimen af_patient unknown combining antiplatelet agent different mechanism_action important topic future investigation:0.0491001411474137", "168319": "importance u approximately million adult atrial_fibrillation_af af associated significantly increased_risk stroke_heart_failure myocardial_infarction dementia chronic_kidney_disease mortality observation symptom af include palpitation dyspnea chest_pain presyncope exertional intolerance fatigue although approximately people af asymptomatic af detected incidentally clinical encounter wearable device interrogation cardiac implanted electronic device patient_presenting ischemic_stroke without diagnosed af implantable loop recorder ie subcutaneous telemetry device evaluate patient intermittent af american college cardiology acc american heart_association aha american college clinical pharmacy accp heart rhythm society hr guideline writing group proposed stage af evolution stage risk defined patient_af associated risk_factor eg obesity hypertension stage pre af sign atrial pathology electrocardiogram imaging without af stage presence paroxysmal recurrent af episode lasting day persistent continuous af episode lasting day af subtypes stage permanent af lifestyle risk_factor modification including weight_loss exercise prevent af onset recurrence complication recommended stage patient estimated risk stroke thromboembolic event greater per_year anticoagulation vitamin k antagonist direct oral anticoagulant reduces stroke risk compared_placebo patient direct oral anticoagulant apixaban rivaroxaban edoxaban recommended warfarin lower bleeding risk compared anticoagulation aspirin associated poorer efficacy recommended stroke prevention early rhythm_control antiarrhythmic drug catheter_ablation restore maintain sinus_rhythm recommended acc aha accp hr guideline patient_af catheter_ablation first_line therapy_patient symptomatic paroxysmal af improve symptom slow progression persistent af catheter_ablation also recommended patient_af heart_failure_reduced_ejection_fraction_hfref improve quality_life left_ventricular systolic_function cardiovascular_outcome rate mortality heart_failure_hospitalization conclusion relevance af associated_increased rate stroke_heart_failure mortality lifestyle risk_factor modification recommended prevent af onset recurrence complication oral anticoagulant recommended estimated risk stroke thromboembolic event greater per_year early rhythm_control using antiarrhythmic drug catheter_ablation recommended select patient_af experiencing symptomatic paroxysmal af hfref:0.0489432959380549"}, "Topic 14": {"196975": "previous_study observed alteration excitation contraction ec coupling end_stage_heart_failure include action potential calcium ca transient prolongation reduction ca transient amplitude underlying phenomenon downregulation potassium k current downregulation sarcoplasmic_reticulum ca atpase serca increase ca sensitivity ryanodine receptor upregulation sodium calcium na ca exchanger however human heart_failure_hf debate continues relative contribution change calcium handling v change membrane current understand consequence change incorporated computational human ventricular myocyte hf model explore contribution spontaneous ca release sarcoplasmic_reticulum sr reduction transient outward k current main membrane current contributor decrease ryr open probability l type calcium_channel lcc density emphasizes importance phase action potential ap shape duration apd current clamp condition ryr hyperphosphorylation exhibit least amount ca release sr cytosol sr_ca fractional release dynamic slow rapid slow hz pacing display abundant lasting ca spark two fold longer normal cell hand voltage clamp condition hf decreased serca upregulated ncx show least sr_ca uptake ec coupling gain compared hf hyperphosphorylated ryr overall study demonstrates combined effect serca ncx b ryr dysfunction along downregulation cardiomyocyte potassium current could substantially contribute ca mishandling spark level lead heart_failure:0.0729332530807161", "36420": "myocytes failing myocardium exhibit depressed prolonged intracellular ca concentration ca transient part responsible contractile dysfunction unstable repolarization better understand molecular basis aberrant ca handling heart_failure_hf studied rabbit pacing tachycardia hf model induction hf associated action potential ap duration prolongation especially pronounced low stimulation frequency l type calcium_channel current ca l density v pa pf mv na ca exchanger ncx current v pa pf mv different myocytes control failing_heart amplitude peak ca depressed mv microm normal failing_heart respectively_p slowed rate decay reduced ca spark amplitude p myocytes isolated failing v control heart inhibition sarco endo plasmic reticulum ca atpase serca revealed greater reliance ncx remove cytosolic ca myocytes isolated failing v control heart p mrna level alpha c subunit ryanodine receptor ryr ncx unchanged control serca phospholamban plb significantly downregulated failing v control heart p alpha c protein_level unchanged ryr serca plb significantly downregulated p ncx protein significantly upregulated p result support prominent role sarcoplasmic_reticulum sr pathogenesis hf abnormal sr_ca uptake release synergistically contribute depressed ca altered ap profile phenotype:0.0700747006115169", "15259": "background congestive_heart_failure_chf common_cause atrial_fibrillation focal source unknown mechanism described chf related atrial_fibrillation author hypothesized abnormal calcium ca handling contributes chf related atrial arrhythmogenic substrate method_result chf induced dog ventricular tachypacing bpm x week cellular ca handling property expression phosphorylation status key ca handling myofilament protein assessed control chf atrium chf decreased cell shortening increased left_atrial diastolic intracellular ca concentration ca ca transient amplitude sarcoplasmic_reticulum sr_ca load caffeine induced ca release sr_ca overload associated spontaneous ca transient event triggered ectopic activity suppressed inhibition sr_ca release ryanodine na ca exchange mechanism_underlying abnormal sr_ca handling studied chf increased atrial action potential duration action potential voltage clamp showed chf like action potential enhance ca loading chf increased calmodulin dependent protein_kinase ii phosphorylation phospholamban potentially enhancing sr_ca uptake reducing phospholamban inhibition sr_ca atpase affect phosphorylation sr_ca release channel ryr total ryr calsequestrin main sr_ca binding protein_expression significantly_reduced potentially contributing sr dysfunction chf decreased expression total protein_kinase phosphorylated myosin binding protein c key contractile filament regulator potentially accounting decreased contractility despite increased ca transient complex phosphorylation change explained enhanced calmodulin dependent protein_kinase iidelta expression function type protein phosphatase activity downregulated regulatory protein_kinase subunit conclusion chf cause profound change ca handling regulatory protein produce atrial_fibrillation promoting atrial cardiomyocyte ca handling abnormality arrhythmogenic triggered activity contractile dysfunction:0.0664743862772910", "137348": "carvedilol fda approved beta_blocker commonly_used treatment high blood_pressure congestive_heart_failure cardiac tachyarrhythmias including atrial_fibrillation investigated cellular level mechanism carvedilol interferes sarcoplasmic_reticulum sr_ca release excitation contraction coupling ecc single rabbit atrial myocytes carvedilol caused concentration dependent microm failure sr_ca release failure ecc ca release result dose dependent inhibition voltage gated na na l type ca ca current responsible rapid depolarization phase cardiac action potential ap initiation ca induced ca release sr respectively carvedilol microm led ap duration shortening ap failure peak na inhibition whereas ca markedly affected carvedilol microm blocked na almost completely reduced ca effect ca transient amplitude ca na observed control experiment beta_blocker metoprolol suggesting carvedilol effect ecc unlikely result beta blocking property effect carvedilol microm subcellular sr_ca release spatially inhomogeneous selective inhibition peripheral subsarcolemmal ca release junctional sr accounted cell averaged reduction ca transient amplitude furthermore carvedilol significantly_reduced probability spontaneous arrhythmogenic ca wave without change sr_ca load data_suggest profound antiarrhythmic action carvedilol atrial myocytes resulting inhibitory effect sr_ca release channel new noteworthy show clinically widely_used beta_blocker carvedilol profound effect ca signaling ion current also antiarrhythmic effect adult atrial myocytes carvedilol inhibits sodium calcium current lead failure ecc also prevents spontaneous ca release cellular sarcoplasmic_reticulum sr_ca store form arrhythmogenic ca wave antiarrhythmic effect occurs carvedilol acting directly sr ryanodine receptor ca release channel:0.0663194268713795", "85272": "aim heart_failure_hf abnormal myocyte ca handling implicated cardiac_arrhythmia contractile dysfunction present_study investigated relationship ca handling reduced myocyte contractility enhanced arrhythmogenesis hf progression canine model non ischaemic hf method_result key ca handling parameter determined measuring cytosolic intra sarcoplasmic_reticulum sr_ca isolated ventricular myocytes different stage hf progression hf associated early continuous increase ryanodine receptor ryr mediated sr_ca leak increase ryr activity paralleled increase frequency diastolic spontaneous ca wave scws hf myocytes condition beta_adrenergic stimulation addition causing arrhythmogenic delayed afterdepolarizations scws decreased amplitude subsequent electrically evoked ca transient depleting sr_ca late stage hf ca release oscillated essentially independent electrical pacing increased propensity generation scws hf myocytes attributable reduced ability ryr channel become refractory following ca release progressive alteration ryr function ca cycling hf myocytes associated sequential modification ryr camkii dependent phosphorylation thiol oxidation conclusion finding_suggest destabilized ryr activity due excessive camkii phopshorylation oxidation resulting impaired post release refractoriness common mechanism involved arrhythmogenesis contractile dysfunction failing_heart:0.0640222906200830", "13463": "micrornas small endogenous noncoding rna regulate protein_expression hybridization imprecise complementary sequence target mrna change abundance muscle specific microrna mir implicated cardiac_disease including arrhythmia heart_failure however specific molecular target cellular mechanism involved action mir heart beginning emerge study_investigated effect increased expression mir excitation contraction coupling ca cycling rat ventricular myocytes using method electrophysiology ca imaging quantitative immunoblotting adenoviral mediated overexpression mir myocytes resulted marked increase amplitude inward ca current flattening ca transient voltage dependence enhanced frequency spontaneous ca spark reducing sarcoplasmic_reticulum ca content compared_control presence isoproterenol rhythmically paced mir overexpressing myocytes exhibited spontaneous arrhythmogenic oscillation intracellular ca event occurred rarely control myocytes condition effect mir completely reversed camkii inhibitor kn although phosphorylation phospholamban altered mir overexpression increased phosphorylation ryanodine receptor ryr ca calmodulin dependent protein_kinase protein_kinase overexpression mir accompanied selective decrease expression protein phosphatase pp regulatory subunit b alpha involved pp targeting specialized subcellular domain conclude mir enhances cardiac excitation contraction coupling selectively increasing phosphorylation l type ryr channel via disrupting localization pp activity channel:0.0633892620839684", "130771": "background reverse mode cardiac sodium calcium exchanger ncx increase cytoplasmic ca concentration response high intracellular na level may_contribute diastolic contractile dysfunction furthermore increased spontaneous ca release intracellular store activate forward mode ncx resulting transient inward current cause delayed afterdepolarization dad dependent arrhythmia moreover recently ncx associated impaired relaxation reduced cardiac_function heart_failure_preserved_ejection_fraction_hfpef since ncx upregulated human chronic atrial_fibrillation_af well heart_failure_hf specific inhibition may therapeutic potential objective tested antiarrhythmic lusitropic inotropic effect novel selective ncx inhibitor sar human atrial myocardium method_result right_atrial appendage biopsy patient_undergoing elective cardiac_surgery predominant hfpef cohort n investigated isolated human atrial cardiomyocytes sar reduced frequency spontaneous sr_ca release event increased caffeine transient amplitude accordance isolated atrial trabecula sar enhanced developed tension pause electrical stimulation consistent reduced diastolic sarcoplasmic_reticulum sr_ca leak moreover compared vehicle sar decreased steady state diastolic tension hz without impairing developed systolic tension importantly sar affect safety parameter resting membrane potential action potential duration measured patch clamp conclusion novel selective ncx inhibitor sar inhibits atrial pro arrhythmic activity improves diastolic contractile_function human atrial myocardium may therapeutic implication especially treatment hfpef:0.0633415958940414", "3224": "progressive deterioration cardiac contractility central feature congestive_heart_failure_chf human report review study addressed idea alteration intracellular calcium ca regulation primarily responsible depressed contractility failing_heart review point ca transient contraction similar non failing failing myocytes slow frequency stimulation low stress environment faster pacing rate high ca beta_adrenergic stimulation reveal large reduction contractile reserve failing myocytes underlying cellular basis defect considered study showing change abundance l type ca channel ca transport protein sarcoplasmic_reticulum ca atpase serca phospholamban plb na ca exchanger ncx ca release channel ryr excitation contraction coupling ca release uptake sarcoplasmic_reticulum sr reviewed observation support hypothesis defective ca regulation involves multiple molecule process one molecule ii initiation progression chf inolves defective ca regulation iii prevention correction ca regulatory defect early_stage cardiac_disease delay prevent onset chf:0.0629719711874814", "21947": "review_focus mainly study non ischemic animal_model heart_failure animal develop ventricular_arrhythmia mostly non sustained ventricular_tachycardia often die suddenly clinical_study suggest sudden_death due ventricular_tachycardia fibrillation case half bradyarrhythmias electromechanical dissociation electrophysiologic change heart_failure confined ventricle intrinsic sinus rate reduced due downregulation sensitivity acetylcholine enhanced upregulation muscarinic receptor reduction heart_rate may protective mechanism since rapid rate contractility reduced likelihood triggered activity due delayed afterdepolarizations enhanced beneficial_effect beta_adrenergic blockade patient may partly due reduction sinus rate although result different study often vary consistent electrophysiological change ventricle prolongation action potential especially slow rate reduction transient outward current ito rapid slow component delayed rectifier ikr iks inward rectifier ik abnormality intracellular calcium handling play major role genesis delayed afterdepolarizations triggered activity based delayed afterdepolarizations demonstrated failing myocardium caused spontaneous release calcium sarcoplasmic_reticulum sr especially presence noradrenaline three factor combine enhanced propensity occurrence delayed afterdepolarizations increased activity na ca exchanger reduced inward rectifier residual beta_adrenergic responsiveness required raise reduced sarcoplasmic calcium content level spontaneous calcium release occurs early afterdepolarizations also demonstrated especially human myocytes failing_heart presence noradrenaline mapping experiment shown ventricular_arrhythmia mainly due non reentrant mechanism likely triggered activity based delayed afterdepolarizations:0.0616572840384935", "34576": "alteration excitation contraction coupling recently shown play crucial role pathogenesis heart_failure_hf failing_heart abnormality neurohormonal mechanism included chronic activation sympathetic nervous_system renin_angiotensin_system result structural_functional change calcium ca regulatory protein change include decreased sarcoplasmic_reticulum sr load could caused reduced sr_ca atpase serca function increased sr_ca leak via cardiac ryanodine receptor ryr functional defect l type ca channel activation reversal mode na ca exchanger abnormal regulation intracellular ca affect troponin c binding actin myosin cross bridging modulates post signaling_pathway turn contributes contractile dysfunction heart hence progression hf moreover diastolic ca leak may develop delayed depolarization triggered activity substrate lethal arrhythmia sudden_cardiac_death review_focus underlying_mechanism defective ca regulation hf possibility proceeding clinical_application new treatment hf targeting ca regulatory protein:0.0611978041635205"}, "Topic 15": {"66951": "sacubitril_valsartan lcz supramolecular sodium salt complex neprilysin_inhibitor prodrug sacubitril angiotensin_receptor_blocker arb valsartan recently approved eu usa treatment chronic heart_failure_hf reduced_ejection_fraction_hfref nyha_class ii iv inhibition chronically activated neurohormonal pathway renin_angiotensin_aldosterone_system raas sympathetic nervous_system sn central treatment chronic hfref furthermore enhancement natriuretic_peptide np system favorable cardiovascular_cv renal effect hf desirable therapeutic goal complement raas sn blockade sacubitril_valsartan represents novel pharmacological approach act enhancing np system via inhibition neprilysin enzyme degrades np suppressing raas via receptor blockade thereby producing effective neurohormonal modulation achieved raas inhibition alone large randomized double_blind paradigm hf trial replacement angiotensin_converting_enzyme_inhibitor acei enalapril sacubitril_valsartan resulted significant_improvement morbidity_mortality patient_hfref sacubitril_valsartan superior enalapril reducing risk cv_death hf_hospitalization composite primary_endpoint cause_death limiting progression hf sacubitril_valsartan generally well_tolerated comparable safety profile enalapril symptomatic hypotension common sacubitril_valsartan whereas renal_dysfunction hyperkalemia cough less common compared enalapril summary sacubitril_valsartan superior alternative aceis arb treatment hfref recommendation reflected many hf guideline:0.0444373651317094", "146829": "aim patient_admitted acute heart_failure_hf high_risk readmission death especially day following discharge aimed assess safety_efficacy early optimization oral hf therapy beta_blocker bb angiotensin_converting_enzyme_inhibitor acei angiotensin_receptor_blocker arb angiotensin_receptor neprilysin_inhibitor arni mineralocorticoid_receptor_antagonist mra day clinical_outcome patient_admitted acute_hf method multicentre randomized open label parallel group study total_patient randomized ratio either usual_care high intensity care patient_enrolled usual_care arm discharged managed according usual clinical_practice site high intensity care arm dos oral hf medication including bb acei_arb mra titrated recommended dos discharge recommended dos within week discharge titration delayed patient develop worsening symptom sign congestion hyperkalaemia hypotension bradycardia worsening renal_function significant_increase n_terminal_pro_b_type_natriuretic_peptide visit primary_endpoint day cause_mortality hf readmission conclusion strong hf first study assess whether rapid titration evidence_based guideline recommended therapy close follow large cohort_patient discharged acute_hf admission safe affect adverse_outcome first day discharge clinical_trial registration clinicaltrials_gov identifier_nct:0.0399796137841260", "110556": "objective paragon hf prospective comparison arni arb global outcome hf preserved_ejection_fraction trial designed determine efficacy_safety angiotensin_receptor neprilysin_inhibitor sacubitril_valsartan compared valsartan patient_chronic_heart_failure preserved_ejection_fraction_hfpef background hfpef highly prevalent associated substantial morbidity_mortality need effective therapy improve_outcome angiotensin_receptor neprilysin_inhibitor arni sacubitril_valsartan shown benefit patient_heart_failure_hf reduced_ejection_fraction demonstrated favorable physiologic effect phase ii hfpef trial method paragon hf trial randomized double_blind parallel group active controlled event driven trial comparing long_term efficacy_safety valsartan sacubitril_valsartan patient_chronic hfpef left_ventricular_ejection_fraction new_york_heart_association_functional_class ii iv symptom elevated natriuretic_peptide evidence structural heart_disease randomization patient entered sequential single blind run period ensure tolerability drug half target dos e valsartan titrated mg bid followed sacubitril_valsartan mg mg bid primary_outcome composite cardiovascular_death total first recurrent hf_hospitalization conclusion paragon hf determine_whether sacubitril_valsartan superior angiotensin_receptor blockade alone patient_chronic symptomatic hfpef efficacy_safety lcz compared valsartan morbidity_mortality heart_failure_patient preserved_ejection_fraction paragon hf nct:0.0399284504396945", "101945": "background paradigm hf trial prospective comparison arni acei determine impact global mortality_morbidity heart_failure angiotensin_receptor neprilysin_inhibitor sacubitril_valsartan effective angiotensin_converting_enzyme inhibitorenalapril patient_heart_failure reduced_ejection_fraction examined whether benefit consistent irrespective background therapy method_result examined effect study treatment following subgroup diuretic yes digitalis glycoside yes mineralocorticoid_receptor_antagonist yes defibrillating device implanted defibrillating device yes also examined effect study drug according beta_blocker dose target dose according whether patient undergone previous coronary revascularization analyzed primary composite end_point cardiovascular_death heart_failure_hospitalization well cardiovascular_death randomized patient_n treated diuretic beta_blocker taking beta_blocker treated recommended dose addition treated mineralocorticoid_receptor_antagonist digoxin defibrillating device undergone coronary revascularization overall sacubitril_valsartan versus enalapril hazard_ratio primary composite end_point confidence_interval p cardiovascular_death p effect sacubitril_valsartan consistent across subgroup examined hazard_ratio primary_end_point ranged cardiovascular_death rangedfrom treatment subgroup interaction conclusion benefit sacubitril_valsartan angiotensin_converting_enzyme_inhibitor consistent regardless background therapy irrespective previouscoronary revascularization beta_blocker dose clinical_trial registration url http_www clinicaltrials_gov unique identifier_nct:0.0386065540195564", "166763": "recognition neurohormonal activation play central role pathogenesis heart_failure_hf led development angiotensin_converting_enzyme_inhibitor aceis angiotensin_receptor_blocker mineralocorticoid_receptor_antagonist beta_blocker substantial success neurohormonal blocking drug patient_hf reduced_ejection_fraction_hfref persistently high rate morbidity_mortality population underscore need effective therapy part systemic neurohormonal activation take place patient_hf system counteract adverse_effect renin_angiotensin_aldosterone_system raas sympathetic nervous_system sn also activated evidence neprilysin metabolizes many effector molecule produced counter regulatory system raised possibility inhibition enzyme might beneficial however since angiotensin_ii substrate neprilysin inhibition enzyme alone would increase level peptide thus treatment_strategy combine raas blockade neprilysin inhibition sought recent large_scale randomized_clinical_trial rcts provided compelling evidence sacubitril_valsartan angiotensin_receptor neprilysin_inhibitor arni superior acei reducing mortality hf_hospitalization improving quality_life patient stage c hfref trial sacubitril_valsartan found safe well_tolerated review present rationale using arnis describes rcts showing efficacy summarizes updated recommendation recent guideline provides practical point arni initiation titration:0.0384410909208877", "158525": "background important evaluate whether new treatment_heart_failure reduced_ejection_fraction_hfref provides additive benefit background foundational treatment aimed evaluate efficacy_safety empagliflozin patient_hfref addition baseline treatment specific dos combination disease modifying therapy method performed post_hoc analysis emperor reduced randomised double_blind parallel group trial took place centre hospital medical clinic country asia australia europe north america south america patient new_york_heart_association nyha classification ii iv ejection_fraction less randomly_assigned receive addition either oral empagliflozin mg per day placebo background therapy primary composite_outcome cardiovascular_death heart_failure hospitalisation secondary_outcome total heart_failure hospital_admission extended composite_outcome consisted inpatient outpatient hfref event also evaluated outcome analysed according background use angiotensin_converting_enzyme ace_inhibitor angiotensin_ii receptor_blocker arb angiotensin_receptor neprilysin_inhibitor arnis well beta_blocker mineralocorticoid_receptor_antagonist mras less target dos various combination study registered clinicaltrials_gov nct finding post_hoc analysis patient mean_age_year sd woman empagliflozin group placebo group assessed march may empagliflozin reduced risk primary_outcome participant empagliflozin group placebo group hr_ci regardless background therapy target dos ace_inhibitor arb dos less target dose hr dos target dose hr_p interaction similar result seen beta_blocker dos less target dose hr dos target dose hr_p interaction empagliflozin also reduced risk primary_outcome irrespective background use triple therapy ace_inhibitor arb arni plus beta_blocker plus mra given combination hr given combination hr_p interaction similar pattern benefit observed secondary extended composite_outcome empagliflozin well_tolerated rate hypotension symptomatic hypotension hyperkalaemia similar across subgroup interpretation empagliflozin reduced serious heart_failure outcome across dos combination disease modifying therapy hfref clinically data_suggest empagliflozin might considered foundational therapy patient_hfref regardless existing background therapy funding boehringer ingelheim eli lilly company:0.0382523312097718", "131783": "background digoxin one first agent used management heart_failure_reduced_ejection_fraction_hfref concern safety_efficacy introduction guideline_directed_medical_therapy gdmt relegated secondary role efficacy digoxin still debate use patient gdmt remains_unclear aim evaluate whether patient_hfref digoxin tolerate higher dos beta_blocker bb angiotensin_converting_enzyme_inhibitor aceis angiotensin_receptor_blocker arb mineralocorticoid_receptor_antagonist mras angiotensin_receptor neprilysin_inhibitor arni method_retrospective chart review performed patient_hfref managed tertiary care center cleveland ohio bivariate analysis_performed compare patient digoxin patient digoxin term ability progress dosing bb acei mra arb arni result thirty four patient_receiving digoxin baseline visit digoxin group likely lower initial last systolic_blood_pressure initial diastolic blood_pressure left_ventricular_ejection_fraction mean_follow duration baseline sodium level higher digoxin group significant_difference two_group term patient_receiving higher dos bb p acei_arb p mra p arni p_conclusion significant_difference dos bb acei_arb mra arni among hfref_patient digoxin compared randomized control trial larger sample needed establish finding digoxin significantly affecting ability titrate gdmt hfref_patient:0.0369981744001236", "187954": "background mineralocorticoid_receptor_antagonist mras improve_outcome patient_heart_failure reduced_ejection_fraction_hfref however mras often underused hyperkalemia concern objective purpose_study assess whether sodium zirconium cyclosilicate szc nonabsorbed crystal trap rapidly lower potassium enables mra use patient_hfref prevalent hyperkalemia high_risk method realize k prospective double_blind placebo controlled_trial patient_hfref nyha_functional_class ii iv left_ventricular_ejection_fraction optimal therapy except mra prevalent hyperkalemia high_risk open label run participant underwent protocol mandated spironolactone titration target mg daily prevalent cohort incident cohort hyperkalemia titration started szc participant achieving normokalemia spironolactone mg daily randomized continuing szc matching placebo month primary composite_endpoint proportion participant optimal response normokalemia spironolactone mg daily rescue hyperkalemia month result_patient run randomized baseline_characteristic included mean_age_year prevalent comorbidities estimated_glomerular_filtration_rate ml_min atrial_fibrillation flutter high n_terminal_pro_b_type_natriuretic_peptide median pg_ml high hfref therapy use sacubitril_valsartan beta_blocker sodium_glucose co transporter inhibitor randomization receiving spironolactone mg daily conclusion realize k first trial evaluate whether szc enable rapid safe mra optimization long_term continuation patient_hfref prevalent high_risk hyperkalemia study assess efficacy_safety szc management high potassium patient symptomatic hfref receiving spironolactone realize k nct:0.0369000706006737", "68883": "importance addition receptor neprilysin inhibition standard therapy including renin_angiotensin_system blocker demonstrated improve_outcome patient_heart_failure reduced_ejection_fraction_hfref compared standard therapy alone long_term absolute risk reduction angiotensin_receptor neprilysin_inhibitor arni therapy whether merit widespread use among diverse subpopulation well described objective calculate estimated year number needed treat nnt value overall different subpopulation prospective comparison arni angiotensin_converting_enzyme_inhibitor acei determine impact global mortality_morbidity heart_failure paradigm hf cohort design setting_participant overall subpopulation year nnt value estimated different end_point using data paradigm hf double_blind randomized_trial sacubitril_valsartan v enalapril multicenter international study_included men_woman hfref ejection_fraction study began december ended march analysis began march intervention random assignment sacubitril_valsartan enalapril main_outcome_measure cardiovascular_death hf_hospitalization cardiovascular_death cause_mortality result final cohort individual included woman white individual mean_sd age_year year estimated nnt primary_outcome cardiovascular_death hf_hospitalization arni therapy incremental acei therapy overall cohort year estimated nnt value calculated different clinically_relevant subpopulation ranged year estimated nnt cause_mortality overall cohort arni incremental acei value ranging among different subgroup compared imputed placebo year estimated nnt cause_mortality arni year estimated nnt value also calculated hfref therapy compared_control landmark trial cause_mortality found acei angiotensin_receptor_blocker beta_blocker mineralocorticoid antagonist implantable_cardioverter_defibrillator cardiac_resynchronization_therapy conclusion relevance year estimated nnt arni therapy incremental acei therapy overall clinically_relevant subpopulation patient_hfref comparable well_established hf therapeutic data support guideline recommendation use arni therapy among eligible patient_hfref:0.0364652560508357", "74365": "background describe baseline_characteristic patient_heart_failure preserved left_ventricular_ejection_fraction enrolled paragon hf trial prospective comparison angiotensin_receptor neprilysin_inhibitor angiotensin_receptor_blocker global outcome hfpef comparing sacubitril_valsartan valsartan reducing morbidity_mortality method_result report key demographic clinical laboratory finding baseline therapy_patient randomized paragon hf grouped factor influence criterion study inclusion compared baseline_characteristic patient_enrolled paragon hf_patient enrolled recent trial heart_failure_preserved_ejection_fraction_hfpef among_patient enrolled various region asia pacific central europe latin america north america western europe mean_age patient_enrolled paragon hf year patient female mean left_ventricular_ejection_fraction similar trial hfpef_patient new_york_heart_association_class ii hospitalization_heart_failure within previous month diabetes_mellitus chronic_kidney_disease prevalent previous trial hfpef many patient prescribed angiotensin_converting_enzyme_inhibitor angiotensin_receptor_blocker beta_blocker calcium_channel blocker mineralocorticoid_receptor_antagonist specified protocol virtually patient diuretic elevated plasma_concentration n_terminal_pro_b_type_natriuretic_peptide median pg_ml interquartile_range structural heart_disease conclusion paragon hf represents contemporary group_patient hfpef similar age_sex distribution compared prior hfpef trial higher_prevalence comorbidities finding provide insight impact inclusion_criterion regional variation hfpef_patient characteristic clinical_trial registration url http_www clinicaltrials_gov unique identifier_nct:0.0362020980610056"}, "Topic 16": {"105878": "background dilated_cardiomyopathy_dcm heritable genetically heterogeneous disorder typically exhibit autosomal dominant inheritance genomic strategy enable discovery novel unsuspected molecular underpinnings familial dcm performed genome wide mapping exome sequencing unique family wherein dcm segregated autosomal recessive ar trait method_result echocardiography adult descendant first cousin revealed dcm female sibling idiopathic left_ventricular enlargement brother genotyping linkage analysis mapped ar dcm locus chromosome arm q validated refined high density homozygosity mapping exome sequencing affected sister used complementary strategy mutation discovery iterative bioinformatics process used filter genetic variant revealing single shared homozygous missense mutation localized q critical region mutation absent hapmap genome ethnically matched_control altered conserved residue gatad encoding gata zinc finger domain containing protein thirteen relative heterozygous mutation carrier evidence myocardial disease even advanced age immunohistochemistry demonstrated nuclear localization gatad left_ventricular myocytes yet subcellular expression nuclear morphology aberrant proband conclusion linkage analysis exome sequencing used synergistic genomic strategy identify gatad gene ar dcm gatad bind histone modification site regulates gene_expression consistent murine dcm caused genetic disruption histone deacetylases data implicate inherited basis epigenetic dysregulation human heart_failure:0.0857729386493134", "27920": "dilated_cardiomyopathy commonly cause_heart_failure frequent precipitating cause heart_transplantation familial dilated_cardiomyopathy shown caused rare variant mutation gene genetic cause identified principally using linkage based candidate gene discovery approach multigenerational family autosomal dominant transmission employed whole exome sequencing proband three affected family member genome wide copy number variation proband affected father unaffected mother exome sequencing identified single point variant resulting missense nonsense splice site change genome wide copy number analysis identified insertion deletion copy number variant kb bp deletion encompassing exon heat shock protein cochaperone bcl associated athanogene bag found seven affected family member absent control establish relevance variant protein class genetic dcm sequenced coding exon bag unrelated dcm probands identified one frameshift two nonsense four missense rare variant absent control dna four familial segregated disease knockdown bag zebrafish model recapitulated dcm heart_failure conclude new comprehensive genomic approach identified rare variant bag causative dcm:0.0737621273534920", "28575": "aim dilated_cardiomyopathy_dcm major cause_heart_failure high familial recurrence risk far genetics dcm remains largely unresolved conducted first genome wide association study gwas identify locus contributing sporadic dcm method_result one thousand one_hundred seventy nine dcm patient control contributed discovery phase pool dna stratified disease status population age_gender constituted used testing association dcm single nucleotide polymorphism snp three dcm associated snp confirmed individual genotyping p two r r replicated independent sample dcm patient control p_value respectively r map region chromosome p encompasses several gene among hspb formerly suggested implicated dcm second identified locus involves r non synonymous snp c c p c r located within sequence bag chromosome q assess whether coding mutation bag might cause monogenic form disease sequenced bag exon independent index case diagnosed familial dcm identified four truncating two missense mutation mutation heterozygous present genotyped relative affected disease absent control_group healthy individual strongly suggesting mutation causing disease conclusion gwas identified two locus involved sporadic dcm one probably implicates bag result show rare mutation bag contribute monogenic form disease common variant gene implicated sporadic dcm:0.0699109168380068", "93988": "background familial dilated_cardiomyopathy_dcm genetically heterogeneous associated mutation least different gene apart ttn encoding giant protein titin none gene expected diagnostic yield complicating genetic diagnosis whole exome sequencing wes powerful alternative identification causal gene however variant interpretation remains challenging report wes large family autosomal dominant dcm complicated end_stage_heart_failure non sustained ventricular_arrhythmia causative mutation identified using targeted gene panel including gene method_result wes applied affected cousin stringent filtering identified genetic variant performed including population variant frequency silico analysis orthologous paralogous conservation subsequently sanger sequencing performed potential disease causing variant order confirm presence variant evaluate co segregation one variant exon rbm gene c p met lys nm showed full co segregation affected family member resulting maximum point lod score suggesting pathogenic mutation responsible phenotype recently mutation rbm linked arrhythmogenic dilated_cardiomyopathy caused defective splicing giant sarcomere protein titin abnormal calcium handling conclusion report identification novel mutation rbm wes large pedigree dcm:0.0697971316298157", "174334": "uterine fibroid uf common benign tumor woman associated cardiovascular_disease_cvd observational_study yet causal inference remains_unclear due confounding mendelian randomization mr study leveraged genetic variant instrumental variable iv evaluate causal relationship genetically predicted uf cvd risk exposure data derived uk biobank genome wide association study european uf case outcome data cvd subtypes obtained finngen ebi consortium sample size fourteen independent single nucleotide polymorphism strongly_associated uf p x selected iv pruned linkage disequilibrium r f statistic inverse variance weighted method_used primary analysis supplemented sensitivity approach weighted median mr egger mr presso robustness evaluated via cochran q test heterogeneity mr egger intercept pleiotropy leave one analysis genetically predicted uf showed causal effect ischemic_heart_disease e ci e_e p heart_failure e ci e_e p venous thromboembolism e ci e_e p stroke e ci e_e p sensitivity_analysis confirmed consistency p heterogeneity cochran q p horizontal pleiotropy mr egger intercept p leave one analysis indicated stable estimate mr study found insufficient evidence support causal link uf cvd contrasting previous observational report:0.0697487085915608", "113117": "pulmonary_arterial_hypertension pah refers rare progressive disorder characterized occlusive pulmonary vascular remodeling resulting increased pulmonary arterial_pressure right_sided heart_failure eventual death emerging evidence genetic investigation pediatric onset pah highlight strong genetic basis underpinning pah deleterious variant multiple gene found cause pah nevertheless pah substantial genetic heterogeneity genetic defect underlying pah overwhelming majority case remain elusive investigation consanguineous family suffering pah transmitted autosomal dominant trait identified whole exome sequencing bioinformatic analysis well sanger sequencing analysis pah family novel heterozygous sox mutation nm c c p gln found co segregate disease family complete penetrance nonsense mutation neither observed unrelated healthy volunteer retrieved population genetic database encompassing genome aggregation database exome aggregation consortium database single nucleotide polymorphism database biological analysis using dual luciferase reporter assay system revealed gln mutant sox protein lost ability transcriptionally activate target gene notch moreover gln mutant sox protein exhibited inhibitory effect function ctnnb encode beta catenin key player vascular morphogenesis research firstly link sox loss function mutation familial pah provides novel insight molecular pathogenesis pah suggesting potential implication genetic prognostic risk evaluation well personalized prophylaxis family member affected pah:0.0685441807400271", "14614": "objective sought identify novel gene dilated_cardiomyopathy_dcm background dcm heritable genetically heterogeneous disorder remains idiopathic majority patient familial case provide opportunity discover unsuspected molecular base dcm enabling pre clinical risk detection method two large family autosomal dominant dcm studied genome wide linkage analysis used_identify disease locus followed fine mapping positional candidate gene sequencing mutation scanning performed unrelated subject idiopathic dcm prospectively identified mayo clinic result overlapping locus dcm independently mapped chromosome q q deoxyribonucleic acid sequencing affected individual family revealed distinct heterozygous missense mutation exon rbm encoding ribonucleic acid rna binding motif protein comprehensive coding sequence analysis identified missense mutation clustered within exon additional dcm family mutation segregated dcm peak composite logarithm odds score absent control sample altered residue within highly conserved arginine serine r rich region expression rbm messenger rna confirmed human_heart tissue conclusion finding establish rbm dcm gene reveal mutation hotspot r domain rbm preferentially expressed heart encodes motif prototypical spliceosome protein regulate alternative pre messenger rna splicing thus implicating functionally distinct gene human cardiomyopathy rbm mutation associated young age diagnosis end_stage_heart_failure high mortality:0.0675259864136706", "177718": "dilated_cardiomyopathy_dcm characteristic left_ventricular biventricular dilation systolic_dysfunction common form cardiomyopathy leading_cause heart_failure sudden_cardiac_death aggregating evidence highlight underlying genetic basis dcm mutation gene causally linked dcm nevertheless due pronounced genetic heterogeneity genetic defect underpinning dcm case remain obscure hence study sought identify novel genetic determinant dcm investigation whole exome sequencing bioinformatics analysis conducted family suffering dcm novel heterozygous mutation vezf gene coding zinc finger containing transcription_factor critical cardiovascular development structural remodeling nm c p lys identified nonsense mutation validated sanger sequencing segregated autosome dominant dcm family complete penetrance mutation neither detected another cohort unrelated dcm patient observed unrelated healthy individual retrieved single nucleotide polymorphism database human gene mutation database genome aggregation database biological analysis utilizing dual luciferase reporter assay system revealed mutant vezf protein failed transactivate promoter myh et two gene associated dcm finding indicate vezf new gene responsible dcm provides novel insight molecular pathogenesis dcm implying potential implication personalized precisive medical management_patient affected dcm:0.0661595877985457", "76130": "dilated_cardiomyopathy_dcm characterized left bilateral ventricular dilation systolic_dysfunction without rational condition lead progressive heart_failure sudden_cardiac_death pathogenic gene reported adult population locus mapping familial case animal_model study however still remains challenging decipher role genetics etiology pediatric dcm applied whole exome sequencing wes sporadic pediatric dcm subject non dcm local control identified pathogenic mutation using bioinformatics tool based genomic strategy synergistically confirmed mutation sanger sequencing identified compound heterozygous nonsense mutation dsp c c p r x c g p e x sporadic case two heterozygous mutation xirp identified performed exome wide association study case_control subject interestingly could identify ttn truncating variant case collectively observed significant risk signal carrier ttn deleterious missense variant dcm risk odds_ratio_confidence_interval p x observation expanded spectrum mutation valuable pre postnatal screening genetic diagnosis dcm:0.0660469475962636", "72672": "dilated_cardiomyopathy_dcm common primary myocardial disease leading congestive_heart_failure arrhythmia sudden_cardiac_death increasing study demonstrate substantial genetic determinant dcm nevertheless dcm substantial genetic heterogeneity genetic basis dcm patient remains_unclear present_study sought investigate association genetic variant zbtb gene dcm cohort unrelated patient idiopathic dcm total unrelated ethnically matched healthy individual used control recruited coding exon splicing boundary zbtb sequenced study_participant functional effect mutant zbtb characterized dual luciferase reporter assay system novel heterozygous zbtb mutation p e x discovered index patient genetic scan mutation carrier available relative showed mutation present affected family member absent unaffected family member analysis proband pedigree revealed mutation co segregated dcm transmitted autosomal dominant pattern complete penetrance nonsense mutation absent control chromosome functional assay demonstrated truncated zbtb protein transcriptional activity compared wild_type counterpart study firstly associate zbtb loss function mutation enhanced susceptibility dcm human provides novel insight molecular_mechanism underpinning dcm implying potential implication genetic counseling personalized management dcm:0.0658084504305515"}, "Topic 17": {"157190": "introduction data heart_failure_hf mildly reduced_ejection_fraction hfmref still emerging especially asian population study_aim compare clinical_characteristic outcome asian hfmref patient hf_patient reduced_ejection_fraction_hfref preserved_ejection_fraction_hfpef method patient_admitted nationally hf included_study categorised according ejection_fraction_ef patient ef ef ef categorised following group hfref hfmref hfpef respectively patient_followed till december primary_outcome cause_mortality secondary_outcome included cardiovascular_death hf rehospitalisations result_total_patient included_study hfref n hfmref n hfpef n hfmref patient likely gender neutral mid range age concomitant diabetes_mellitus hyperlipidaemia peripheral vascular_disease coronary_artery_disease p two year overall mortality_rate hfref hfmref hfpef respectively hfmref patient significantly_lower overall mortality_rate compared hfref_patient adjusted hazard_ratio_hr_confidence_interval_ci_p significantly_higher overall mortality_rate adjusted hr_ci_p compared hfpef_patient similarly seen cardiovascular_mortality hf hospitalisation exception similar hf hospitalisation hfmref hfpef_patient conclusion hfmref patient account significant burden patient_hf hfmref represents distinct hf phenotype high atherosclerotic burden clinical_outcome saddled hfref hfpef therapeutic study guide management challenging group_patient warranted:0.0273766627645496", "140484": "aim proportion patient_hospitalized heart_failure_hf preserved left_ventricular_ejection_fraction_lvef rising approved treatment exists part owing incomplete characterization particular hf phenotype order better define characteristic hf phenotype finland large cohort year_follow time analysed method_result patient_diagnosed hospital district southwest finland stratified according lvef measure n_terminal_pro_b_type_natriuretic_peptide nt_probnp_level retrospective registry study previously diagnosed hf_patient defined follows patient reduced_ejection_fraction_hfref lvef n mid range ejection_fraction hfmref lvef nt_probnp pg_ml n preserved_ejection_fraction_hfpef lvef nt_probnp pg_ml n followed patient_year respectively cardiovascular_cv hospitalization mortality influence pre selected covariates hospitalization mortality proportion hfpef hfmref patient drop lvef hfref phenotype analysed data extracted electronic patient register hfref_patient rehospitalized slightly earlier hfpef hfmref patient second third fourth rehospitalization rate differ subgroup female gender better kidney_function associated_reduced rehospitalizations hfmref hfref non significant trend hfpef additional hospitalization associated two fold increased_risk death fold increased_risk cv_death cause_mortality higher patient_hfpef although cv mortality less frequent hfpef_patient associated_increased nt_probnp concentration index patient_group year following index date hfmref patient_hfpef patient progressed hfref phenotype conclusion finding_suggest disease_progression term increased frequency hospitalization relationship increased number hospitalization mortality similar lvef phenotype data highlight importance effective_treatment reduce hospitalization suggest role monitoring nt_probnp_level management hfpef_patient particular:0.0270355517161785", "176791": "background_objective heart_failure_hf chronic_kidney_disease_ckd frequently coexist closely interrelated significantly affecting clinical_outcome among ckd related marker albuminuria estimated_glomerular_filtration_rate egfr emerged key prognostic indicator hf however specific predictive_value across different hf phenotype namely hf preserved_ejection_fraction_hfpef hf reduced_ejection_fraction_hfref remains incompletely understood systematic_review aim evaluate prognostic significance albuminuria egfr patient_hf compare predictive role hfpef versus hfref population material_method conducted systematic search major database identify clinical_study evaluating association albuminuria egfr adverse_outcome hf_patient inclusion_criterion encompassed study reporting cardiovascular_event cause_mortality hf_related hospitalization subgroup_analysis based ejection_fraction data extraction quality assessment performed independently two reviewer result twenty one study met inclusion_criterion including diverse hf population various biomarker assessment method albuminuria reduced egfr consistently associated_increased_risk mortality hospitalization hfref population reduced egfr demonstrated stronger prognostic association whereas albuminuria predictive across hf phenotype heterogeneity study_design outcome definition limited comparability conclusion albuminuria egfr valuable prognostic biomarkers hf may enhance risk_stratification clinical decision_making particularly integrated clinical assessment model differential prognostic implication hfpef versus hfref highlight need phenotype specific approach research warranted validate finding clarify role guiding personalized therapeutic_strategy hf population limitation current evidence base consists primarily observational_study variable methodological quality inconsistent reporting effect estimate:0.0261242235549932", "70993": "aim significant recovery left_ventricular_ejection_fraction_lvef occurs proportion patient_heart_failure_hf reduced_ejection_fraction_hfref analysed outcome including mortality cause cardiovascular_cv hf_related sudden_death hf_related hospitalization_hf recovered group primary_endpoint composite cv_death hf_hospitalization method_result lvef assessed baseline year consecutive hf_patient patient classified three_group hf recovered lvef baseline year n ii hf preserved ef hfpef lvef throughout follow n iii hfref lvef throughout follow n mean_follow year hf recovered patient differed hfref hfpef group demographic clinical_characteristic mean lvef increase point hf recovered patient using hf recovered group reference risk primary composite_endpoint n non cv_death competing risk hfpef hfref group hazard_ratio_hr_confidence_interval_ci_p hr_ci_p respectively cause n cv n hf_related n sudden_death n significantly_lower hf recovered subject relative hfref p hf recovered patient also experienced less recurrent hf_hospitalization p_conclusion one four treated patient_hfref showed recovery systolic_function hf recovered patient significantly_improved mortality_morbidity relative hfpef hfref subject research needed identify optimal medication device indication hf recovered patient:0.0260746109385918", "168141": "aim understanding heart_failure_hf characteristic essential improve patient_outcome categorizing hf beyond left_ventricular_ejection_fraction_lvef challenging due heterogeneous clinical_presentation aetiology despite global study hf role lvef mortality remains controversial explored association lvef mortality considering sex difference comorbidities cohort largest tertiary cardiovascular centre switzerland method hf_patient admitted university_hospital bern january_december evaluated lvef used classify patient_hf preserved_ejection_fraction_hfpef hf mid range ejection_fraction hfmref hf reduced preserved_ejection_fraction hfref category cox_proportional_hazard_model time stratified analysis adjusted potential confounders employed result_total hf_patient included died median_follow time year mortality_rate across lvef category showed significant_difference overall woman showed significantly_higher mortality day_mortality lower hfpef category hazard_ratio_hr_confidence_interval_ci_p persistent effect upon stratification male hr_ci_p non diabetic hr_ci_p isolated reduction hfpef mortality observed female year hr_ci_p_conclusion prognostic role lvef cause_mortality remains_unclear difference mortality_rate distribution woman_men mirror established hf pathophysiological sex difference future hf study focus hf aetiology include measure beyond lvef comprehensive characterization:0.0258956915641063", "162704": "aim improvement ejection_fraction_ef observed subset patient_heart_failure_hf reduced_ejection_fraction_hfref analyzed compared patient_hf phenotype method based left_ventricular_ejection_fraction_lvef baseline follow hf_patient divided group hf preserved ef hfpef lvef occasion n hf mid range ef hfmref fluctuating lvef occasion n hfref lvef occasion n hf improved ef hfimpef defined lvef baseline lvef follow absolute improvement n composite hf readmission cause_mortality considered primary_endpoint secondary_endpoint cause_mortality result characteristic hfimpef differed hf phenotype beta_blocker aldosterone receptor_antagonist associated_improved lvef kaplan_meier curve showed lowest incidence composite_endpoint p cause_mortality p hfimpef risk cardiovascular_death lowest hfimpef controlling competing event p competing event p valvular_heart_disease vhd hr_ci_p increased_risk cause_death anemia increased_risk cause_death hr_ci_p cardiovascular_death hfimpef patient hr_ci_p_conclusion hfimpef independent hf phenotype prognosis similar hfmref superior hfpef hfref hfimpef patient vhd anemia endpoint event_rate increased:0.0257446557008761", "172730": "aim analyze contemporary registry heart_failure_hf_patient followed specialized hf unit spain difference clinical_feature treatment year outcome hf reduced mildly reduced preserved left_ventricular_ejection_fraction method_result analyzed data registry sec excelente ic quality accreditation program spanish society_cardiology patient_hf included specialized hf unit accredited sec treatment year_mortality hf_hospitalization decompensations hf used compared according type hf_patient hfref hfmref hfpef hfpef_patient older higher proportion woman atrial_fibrillation hypertension sacubitril_valsartan mineral receptor_antagonist used greater proportion hfref respectively_p also hfpef one year_mortality v_v person_year p year hf_hospitalization v_v person_year p year decompensations hf without hospitalization v v_p similar type hf conclusion contemporary cohort real life hf_patient slight difference observed clinical_feature treatment type hf prevalence major comorbidities year outcome mortality hospitalization decompensations hf similar group:0.0256061489454546", "95594": "background prognostic_value soluble suppression tumorigenecity sst novel circulating biomarker myocardial_fibrosis remains elusive heart_failure_patient preserved_ejection_fraction_hfpef method consecutive_patient heart_failure_hf enrolled prospectively grouped hf reduced_ejection_fraction_hfref n hf mid range ejection_fraction hfmref n hfpef n primary_endpoint composite_endpoint cause_death hf rehospitalization result median month patient reached primary_endpoint patient_died patient rehospitalized multivariate_analysis confirmed sst independent_risk_factor primary_endpoint hf_patient hazard_ratio_hr_confidence_interval_ci_p predicting efficacy sst outcome higher hfpef hr_ci_p compared hfref hr_ci_p association sst outcome hfmref statistical hr_ci_p combined use sst n_terminal_pro_b_type_natriuretic_peptide nt_probnp could improve prognostic_value compared using nt_probnp alone hfref auc v_p conclusion higher baseline sst level associated_increased_risk cause_death hf rehospitalization patient_hf independent ejection_fraction combined use sst nt_probnp could improve prognostic_value using two value alone especially hfref_patient:0.0255801078525897", "184073": "aim assess prevalence clinical_characteristic outcome_patient heart_failure_hf without moderate_severe aortic_valve disease avd aortic_stenosis aortic regurgitation ar mixed avd mavd method_result data prospective esc hfa eorp hf long_term registry including chronic acute_hf analysed patient_hf reduced_ejection_fraction_hfref mildly reduced_ejection_fraction hfmref preserved_ejection_fraction_hfpef patient ar mavd prevalence ar mavd hfpef hfmref hfref strongest association observed age hfpef left_ventricular_end_diastolic diameter ar adjusted hazard_ratio_hr_confidence_interval_ci mavd adjusted hr_ci ar adjusted hr_ci independently_associated month composite_outcome cardiovascular_death hf_hospitalization association composite_outcome observed regardless ejection_fraction category conclusion esc hfa eorp hf long_term registry one patient_hf avd mavd especially common hfpef ar similarly distributed across ejection_fraction category mavd ar independently_associated increased_risk hospital_mortality month composite_outcome regardless ejection_fraction category:0.0255794883189321", "131981": "worsening heart_failure_hf defined hospitalization worsening sign_symptom hf need urgent intravenous diuretic often considered surrogate poor_prognosis clinical_trial however data prognostic implication worsening hf_patient hf reduced_ejection_fraction limited patient first echocardiographic diagnosis left_ventricular_systolic_dysfunction defined left_ventricular_ejection_fraction_lvef identified worsening_hf defined hospitalization_hf urgent need intravenous diuretic cause_mortality chosen study end_point total_patient mean_age_year men analyzed worsening_hf observed_patient median_follow_month patient_died median_follow_month interquartile_range month year survival_rate significantly_lower worsening_hf cohort compared_non worsening_hf cohort log_rank_p significantly_different worsening_hf cohort nonworsening hf cohort lvef log_rank_p lvef log_rank_p lvef log_rank_p adjustment important clinical echocardiographic predictor worsening_hf independently_associated higher_risk cause_mortality hazard_ratio_confidence_interval p_conclusion worsening_hf defined hf_hospitalization urgent need intravenous diuretic independently_associated poor long_term prognosis patient_hf reduced_ejection_fraction:0.0255183368887378"}, "Topic 18": {"196818": "ethnopharmacological significance therapeutic efficacy ershen zhenwu decoction eszwd famous formulation xin patient_chronic_heart_failure heart kidney yang deficiency chf hkyd well_established still underlying molecular_mechanism clear aim_study study_investigated mechanism eszwd suppresses cardiac pathology including myocardial_fibrosis chf hkyd model rat ang_ii stimulated cardiac_fibroblast cf material_method component eszwd analyzed ultra high performance liquid chromatography coupled quadrupole time flight mass spectrometry uhplc q tof m chf hkyd model established male sprague dawley rat bilateral thyroidectomy intraperitoneal administration doxorubicin dox twice weekly week subsequently chf hkyd model rat randomly categorized model eszwd l g kg eszwd eszwd g kg eszwd eszwd h g kg eszwd sac val mg_kg sacubitril_valsartan group treated daily week control sham surgery group sham used primary cardiac_fibroblast cf categorized control model eszwd sac val group cf stimulated ang_ii eszwd sac val group incubated different concentration drug containing serum effect cf viability assessed via cck assay eszwd sac val group received drug containing serum concentration determined cck assay result cardioprotective_effect eszwd determined using echocardiography hematoxylin eosin h e staining masson staining sirius red staining enzyme linked immunosorbent assay elisa eszwd effect ra homolog gene family member rhoa rho associated coiled coil kinase rock signaling_pathway myocardial_fibrosis assessed western blotting quantitative real_time pcr qrt pcr analysis immunofluorescence used observe fibrotic marker cf result eszwd treatment improved cardiac_function chf hkyd rat significantly reducing myocardial_fibrosis ventricular_remodeling eszwd treatment increased rat body temperature b h urine volume left_ventricular_ejection_fraction_lvef lv fractional_shortening lvfs decreased lv internal systolic diameter lvids lv internal diastolic diameter lvidd heart weight body_weight hw bw compared model group comparison model rat eszwd treatment decreased serum_level b_type_natriuretic_peptide precursor nt_probnp tumor_necrosis_factor alpha tnf_alpha interleukin il il eszwd treatment significantly regulated protein mrna expression_level collagen alpha sma rhoa rock rock heart tissue chf hkyd rat ang_ii stimulated cf conclusion eszwd significantly_improved cardiac_function attenuated myocardial_fibrosis inflammation chf hkyd rat inhibiting rhoa rock signaling_pathway:0.0546944558945245", "73982": "objective observe therapeutic effect mechanism dunhuang liaofengxushouruo decoction lxd traditional chinese medicine chronic_heart_failure_chf rat method forty eight male wistar rat randomly divided normal group_n model group captopril group lxd traditional chinese medicine high medium low_dose group except normal group rat intravenous injected adriamycin mg_kg one day week captopril rat intragastric administrated captopril mg_kg lxd high medium low_dose group intragastric administrated lxd g kg consecutive week rat breathing coat color activity body_weight bw time exhaustive swimming measured heart_rate mean arterial_pressure map left_ventricular systolic_pressure lvsp left_ventricular_end_diastolic pressure lvedp maximal rate left_ventricular pressure dp dtmax dp dtmax rat examined power lab level interleukin il tumor_necrosis_factor alpha tnf_alpha measured rat sacrificed heart removed separation left right_ventricle antioxidant activity ventricular mass_index measured left_ventricular myocardium administrated paraformaldehyde staining morphological change observed microscope result body_weight group decreased time exhaustive swimming decreased modeling p day administration bw high middle dose lxd group increased swimming time rat lxd high_dose group increased p day bw lxd group increased exhaustive swimming time high middle dose lxd prolonged p map decreased lvsp dp dtmax dp dtmax increased lxd high middle group lvedp decreased high_dose lxd group_p p level creatine kinase ck aspartate aminotransferase ast middle low_dose lxd group decreased p_p serum_level il tnf_alpha malondialdehyde mda serum lxd high middle dose group lower activity superoxide dismutase sod serum increased lxd group lvmi rvmi decreased high middle dose lxd group_p p pathological result_showed myocardial fiber arrangement myocardial interstitial edema phenomenon obviously improved high_dose lxd group cmd decreased conclusion therapeutic effect lxd chf doxorubicin induced rat confirmed mechanism associated_improved hemodynamics myocardial_tissue:0.0521798467339284", "118175": "present_study investigated role parathyroid hormone pth non ischemic_cardiomyopathy cm underlying_mechanism total sprague dawley male rat randomly divided control_group n experimental group_n induce cm rat experimental group mg_kg adriamycin adr administered intraperitoneally equal injection every third day followed weekly injection resulting cumulative dose mg_kg following establishment model rat experimental group subdivided pth untreated cm group received daily normal saline subcutaneous injection day three treated cm group received daily subcutaneous injection microg kg recombinant pth day rat control_group accordingly received intraperitoneal subcutaneous injection normal saline blood sample analysis_revealed b_type_natriuretic_peptide_bnp troponin c_reactive_protein crp creatinine phosphorus concentration increased pth untreated cm group_compared control_group whereas pth calcium concentration decreased administration pth dose dependently decreased bnp crp creatinine phosphorus level increased pth calcium level notably significant_difference pth bnp troponin crp creatinine calcium phosphorus level among rat five group_p cardiac ultrasonography result indicated left_ventricular_ejection_fraction_lvef significantly_decreased rat treated adr compared rat control_group p however lvef gradually recovered elevated pth treatment dos overall difference lvef left_ventricular end_systolic_volume five experimental group statistically_significant p furthermore dose dependent increase lv mass left_ventricular_end_diastolic volume pth treated rat however difference two_group reach statistical significance p immunohistochemical staining western_blot analysis using anti pth polyclonal antibody performed evaluate protein_expression level pth myocardial_tissue mrna expression_level pth bnp measured_using reverse transcription quantitative polymerase chain reaction result demonstrated mrna protein_expression level pth myocardial_tissue significantly_decreased adr treated rat compared level control_group rat injection recombinant pth significantly_increased pth expression reduced bnp expression dose dependent manner p finding demonstrated pth improve cardiac_function rat adr induced cm suggesting potential therapeutic application pth non ischemic cm:0.0515412764837266", "70497": "background xinfuli granule xg compound chinese herbal medicine effectively used china treatment_heart_failure fifty year study_aimed_investigate effect underlying_mechanism xinfuli rat doxorubicin induced cardiotoxicity method sprague dawley rat treated intraperitoneal injection doxorubicin dox mg_kg per week six week randomly divided four group received intragastrically administration normal saline control_group different dosage xg g kg per day g kg per day g kg per day respectively six week transthoracic_echocardiography performed evaluate left_ventricular fractional_shortening lvfs left_ventricular_ejection_fraction_lvef xg treatment histopathologic change also examined myocardial cell apoptosis detected tunel staining expression related gene protein analyzed_using immunohistochemical staining result compared control_group rat xg treated group showed significantly_improved cardiac_function milder cardiac histopathological change lower cardiomyocyte apoptosis index higher expression bcl lower expression bax conclusion administration xg improves cardiac_function histopathological change rat doxorubicin induced cardiotoxicity effect associated inhibition cardiomyocyte apoptosis perhaps via regulation bcl bax protein_expression:0.0498809573086217", "132601": "background postinfarction cardiac_remodeling present compensatory mechanism aimed mitigating congestive_heart_failure distinguished progressive dilatation hypertrophy ventricular chamber fibrotic alteration prolonged apoptosis cardiomyocytes primary objective_study assess effect icariin myocardial_fibrosis ventricular_remodeling rat subjected myocardial_infarction_mi method male sprague dawley sd rat subjected randomization subsequently divided distinct group control_group sham group undergoing sham operation mi group experiencing ligation left_anterior_descending artery icariin group within icariin group rat categorized three different dose group based administered icariin dosage mi group mg_kg day mi group mg_kg day mi group mg_kg day cardiac_function evaluation carried using echocardiography histological examination including hematoxylin eosin staining masson staining immunohistochemistry study_conducted day occurrence mi additionally western blotting employed assess tgf_beta p smad p smad level result administration icariin revealed noteworthy enhancement cardiac_function among rat afflicted left_anterior_descending coronary_artery lad ligation comparison icariin group mi group exhibited reduced ef f along elevated lvedd lvesd furthermore cardiac_fibrosis level mi group rat exhibited considerable increase compared icariin group notably level collagen collagen iii mmp mmp significantly_higher mi group icariin group evident distinction moreover expression_level tgf_beta il p smad p smad notably upregulated mi group_compared icariin group_conclusion experimental rat_model mi administration icariin resulted amelioration cardiac_function remodeling process operating intricate tgf_beta smad signaling_pathway:0.0496082530416183", "103006": "objective investigate effect renal denervation rdn left_atrial fibrosis rat chronic_heart_failure method sixty healthy male sprague dawley rat randomly_assigned control_group n intraperitoneal injection mg_kg normal saline daily consecutive week sham group_n rdn group_n rat sham rdn group intraperitoneally injected mg_kg isoproterenol daily consecutive week rdn sham rdn procedure implemented week renal artery vein isolated nerve left intact sham group experiment ended week cardiac_function diastolic interventricular septal thickness ivsd left_atrial dimension lad evaluated echocardiography baseline week rat three_group sacrificed week left_atrial tissue used following analysis fibrosis detected masson staining plasma bnp measured elisa kit protein_expression angii tgf_beta mmp collagen determined western_blot result cardiac_function compared control_group lvef decreased p ivsd p lad p increased significantly sham rdn group week compared sham group week lvef ivsd significantly_improved p lad tended smaller p rdn group degree left_atrial tissue fibrosis masson staining collagen volume fraction cvf showed significantly_decreased fibrosis left_atrial tissue rdn group_compared sham group_p plasma bnp_level elisa assay revealed plasma bnp sham group significantly_increased compared control_group p similar rnd group control_group week protein_expression angii tgf_beta mmp collagen rat left_atrial western_blot analysis demonstrated expression angii tgf_beta mmp collagen significantly regulated rdn group_compared sham group_p still significantly_higher control_group p_conclusion rdn effectively attenuate left_atrial fibrosis rat isoproterenol induced chronic_heart_failure attenuation left_atrial fibrosis rdn rat may attributed improved cardiac_function downregulated pro fibrogenic factor angii tgf_beta mmp collagen:0.0494769392929467", "100258": "objective endoplasmic reticulum er stress play_important_role ischemia mediated cell_death aim current study investigate effect salubrinal sal selective eif dephosphorylation inhibitor heart_failure rat related mechanism method heart_failure induced coronary_artery ligation mi adult male sprague dawley rat ensure comparable mi size post coronary_artery ligation various group echocardiography examination performed minute ligation mi group rat randomly_assigned group sham group_n mi group_n mi plus vehicle injection group dmso group_n mi plus sal injection group sal group_n sal mg_kg dmso injected via tail vein daily first day starting minute ligation left coronary_artery followed subcutaneous injection twice per week week cardiac_function assessed echocardiography cell apoptosis assessed flow cytometric analysis week protein mrna level er stress marker evaluated immunohistochemistry real_time rt pcr respectively result eight week later lvef significantly_higher lvesd lvedd value significantly_lower sal group_compared mi dmso group_p lv bw ratio significantly_higher mi group sham group mg g v mg g p significantly_reduced sal group mg g dmso group mg g p v mi addition flow cytometric analysis_showed sal treatment significantly_reduced apoptosis necrosis post_mi immunohistochemistry real_time pcr analysis_showed myocardial protein mrna expression er stress marker significantly_lower sal group mi group myocardial caspase expression significantly upregulated mi group significantly_reduced sal treatment conclusion result_suggest reduction er stress myocardial apoptosis inhibition eif alpha dephosphorylation may serve potential mechanism improved cardiac_function attenuated cardiac_remodeling post sal treatment_heart_failure rat_model:0.0490451665801836", "35246": "well_established urotensin ii uii level increased several cardiovascular_disease previously demonstrated uii uii receptor ut protein_level significantly_increased heart human rat congestive_heart_failure_chf also recently demonstrated uii blockade selective uii antagonist improves heart_function rat_model ischemic chf evaluated attenuation cardiac_remodeling associated uii antagonism rat_model ischemic chf animal administered specific ut receptor_antagonist sb mg_kg day gavage vehicle min prior coronary_artery ligation followed daily treatment week myocardial interstitial fibrosis analyzed masson trichrome picrosirius red staining rt pcr analysis utilized mrna expression study used western blotting assess level collagen type iii mitogenic activity uii cultured neonatal cardiac_fibroblast also evaluated following coronary ligation sb significantly attenuated myocardial endocardial interstitial fibrosis reduced collagen type iii ratio p uii induced proliferation cardiac_fibroblast mitogenic effect significantly inhibited microm sb p demonstrate selective blockade ut reduces diastolic_dysfunction decreasing myocardial_fibrosis post coronary ligation vivo inhibits uii mediated fibroblast proliferation vitro:0.0483840308083213", "56687": "objective increased secretion atrial brain_natriuretic_peptide anp bnp heart known exhibit favorable effect patient animal heart_failure inhibition neutral endopeptidase nep enzyme degrades anp bnp may increase peptide level however still unknown whether elevation anp bnp may offer therapeutic benefit progression chronic_heart_failure_chf examined effect ono novel nep inhibitor change hemodynamic parameter nep activity neurohumoral factor rat chf induced left coronary_artery ligation cal method male wistar rat g subjected induction acute_myocardial_infarction cal rat orally treated ono mg_kg day st th week operation hemodynamic biochemical assessment performed st th week operation result single administration ono inhibited plasma kidney nep activity thereby augmented elevation plasma anp concentration rat cal st week operation rat cal th week operation left_ventricular_end_diastolic pressure lvedp increased cardiac_output index coi decreased compared sham operated rat change accompanied marked increase plasma anp bnp endothelin et chronic treatment ono attenuated increase lvedp decrease coi change associated decrease plasma anp bnp et concentration conclusion result_suggest chronic treatment nep inhibitor improves depressed cardiac_function rat chf ono may offer new possible therapeutic_approach patient_chf:0.0483028757590687", "27288": "objective observe effect combined beta_adrenergic receptor ar antagonist beta_ar agonist therapy cardiac_function cardiomyocyte apoptosis heart_failure rat method heart_failure induced isoproterenol rat randomly divided metoprolol group mg_kg twice daily gavage n combined treatment_group fenoterol microg kg metoprolol mg_kg twice daily gavage n placebo group saline n another normal male wistar rat served control_group week treatment cardiac_function apoptosis index ai caspase activity expression_level bcl bax protein organ weight body_weight collagen volume fraction cvf evaluated result left_ventricular_end_diastolic dimension left_ventricular end_systolic dimension e ratio significantly_increased fractional_shortening ejection_fraction significantly_reduced post isoproterenol p v control change significantly attenuated metoprolol alone p v placebo attenuated metoprolol fenoterol combination therapy p v placebo metoprolol left_ventricular weight body_weight ratio lung weight body_weight ratio cvf also significantly_reduced metoprolol combined treatment_group placebo group_p compared_placebo group ai caspase activity significantly_lower metoprolol group_p v placebo reduced combined treatment group_p v metoprolol expression_level bax protein significantly_lower metoprolol group bcl bax significantly_higher placebo group change significant combined treatment group_p v metoprolol conclusion beta_ar antagonist combination beta_ar agonist improved cardiac_function prevented cardiac_remodeling compared using beta_ar antagonist alone heart_failure rat downregulated bax upregulated bcl bax expression might contribute observed beneficial therapy effect reducing cardiomyocyte apoptosis animal:0.0482693233852909"}, "Topic 19": {"94999": "objective determine_whether patient discharged hospital_admission condition covered national readmission program received care emergency_department observation unit readmitted within_day increased_risk death evaluate temporal trend post_discharge acute care utilization inpatient unit emergency_department observation unit patient design retrospective_cohort_study setting medicare claim data united_state participant patient aged older admitted hospital heart_failure acute_myocardial_infarction pneumonia condition included u hospital_readmission reduction program main_outcome_measure post_discharge day_mortality according patient day acute care utilization acute care utilization inpatient observation unit emergency_department day_day post_discharge period result hospital_admission heart_failure acute_myocardial_infarction pneumonia occurred overall post_discharge day_mortality heart_failure acute_myocardial_infarction pneumonia risk adjusted mortality increased annually confidence_interval heart_failure decreased acute_myocardial_infarction significantly change pneumonia specifically mortality increased patient_heart_failure utilize post_discharge acute care increasing rate per_year exceeding overall absolute annual increase post_discharge mortality heart_failure without increase mortality observation unit emergency_department concurrent reduction day readmission_rate stay observation visit emergency_department increased across three condition beyond day post_discharge period overall day post acute care utilization change significantly conclusion condition increasing mortality study_period heart_failure increase preceded policy present among_patient received emergency_department observation unit care without admission hospital period overall acute care utilization day discharge significantly_decreased heart_failure pneumonia acute_myocardial_infarction:0.0541390433070039", "117357": "background hospital inpatient readmission patient_admitted initially primary diagnosis heart_failure_hf high within_day discharge however include admission observation emergency_department ed visit within time frame show time dependent hospital encounter following discharge index admission present data time dependent hospital encounter hf_patient discharged index admission primary diagnosis hf method_study recruited patient hospital within health system consecutive admission icd diagnosis hf reviewed inclusion exclusion screening criterion eligible remaining patient tracked post hospital_discharge encounter consisting hospital_admission observation stay ed visit primary diagnosis heart_failure included demographic recorded patient day hospital inpatient readmission hospital encounter displayed kaplan_meier plot result_total_patient met inclusion_criterion mean_age_year_male first day following index admission total follow visit per patient total hospitalization day per visit per patient per day risk_death day patient inpatient readmission hospital encounter respectively median time inpatient readmission day hospital encounter day conclusion time dependent excess day acute care unplanned inpatient admission outpatient observation ed visit rather day hospital inpatient readmission_rate realistic measure intensity care required hf_patient index admission:0.0487973610817127", "170601": "background_heart_failure_hf hospitalization characterized vulnerability functioning frequent post_discharge healthcare utilization acute post acute setting objective_determine patient_hospitalized decompensated hf association vulnerability detailed form post_discharge healthcare utilization day spent away home initial hospital_discharge design secondary analysis prospective longitudinal cohort_study single_center academic institution usa participant adult admitted acute decompensated hf discharged alive main measure vulnerable elder survey f measured functional vulnerability baseline primary_outcome highest healthcare utilization hhu day post_discharge following ordered category home emergency room visit skilled nursing facility stay hospital_readmission death secondary_outcome proportion day home dnah within first day analysis_performed using partial proportional odds model adjustment demographic health characteristic key result_total_patient included median_age interquartile_range iqr year fewer half n patient remained alive home day follow hospital_readmission participant died median dnah iqr increased vulnerability associated hhu higher odds utilizing healthcare dying versus home alive day post_discharge ci higher odds dnah first day ci_conclusion cohort patient_hospitalized decompensated hf vulnerability predicted higher_level healthcare utilization well total day home day following hospitalization vulnerability may clinical_application identify_patient greatest need comprehensive patient centered discharge planning:0.0483162675600506", "151481": "importance benefit primary_care physician pcp follow potential mean reduce readmission hospitalized_patient found medical condition among_patient receiving high_risk surgery however little_known implication pcp follow patient emergency general surgery egs condition objective_evaluate association pcp follow day readmission_rate hospital_discharge egs condition design setting_participant cohort_study used data center medicare medicaid service master beneficiary summary file inpatient carrier part b durable medical equipment file beneficiary aged_year older hospitalized egs condition managed operatively nonoperatively september november eligible patient_enrolled medicare fee service admitted emergency_department primary diagnosis egs condition received general surgery consultation admission data analyzed july june exposure follow pcp within_day hospital_discharge index admission main_outcome_measure primary_outcome readmission within_day discharge index admission inverse probability weighted regression_model used estimate risk adjusted association pcp follow day_readmission secondary_outcome readmission within_day discharge stratified treatment type operative v nonoperative treatment index admission result_study included medicare beneficiary mean_sd age_year female hospitalized egs condition patient follow pcp visit received operative treatment index admission received nonoperative treatment overall patient readmitted within_day discharge index admission risk adjustment propensity weighting patient pcp follow lower odds readmission adjusted_odds_ratio aor_ci compared patient_without pcp follow stratifying treatment type patient_treated operatively index admission subsequent pcp follow within_day discharge reduced odds readmission aor_ci similar association seen among_patient treated nonoperatively aor_ci infectious condition heart_failure acute kidney failure chronic_kidney_disease among frequent diagnosis prompting readmission overall among operative nonoperative treatment group_conclusion relevance cohort_study follow pcp within_day discharge egs condition associated significant_reduction adjusted odds day_readmission association similar patient_received operative care nonoperative care index admission patient_aged_year older egs condition primary_care coordination discharge may important tool reduce readmission:0.0479767631611378", "138002": "importance medicare hospital_readmission reduction program hrrp associated_reduced readmission_rate unknown decrease occurred objective examine whether hrrp associated change probability readmission emergency_department ed visit hospital_discharge ed revisits overall depending whether admission typically indicated patient condition ed revisit design setting_participant retrospective_cohort_study used hospital ed discharge data california florida new_york january_december difference difference analysis examined change readmission probability ed revisits recently discharged patient ed revisits clinical_presentation admission typically indicated v admission variable ie discretionary examined separately inclusion_criterion medicare patient_year older revisited ed within_day inpatient discharge data analyzed december september exposure hrrp implementation among_patient initially hospitalized targeted v nontargeted condition main_outcome_measure thirty day unplanned hospital_readmission ed revisit result_total index hospitalization identified california florida new_york discharge discharge woman discharge among_patient older year among_patient unplanned readmission within_day discharge patient_admitted ed total ed revisits identified adjusting patient demographic clinical_characteristic index hospitalization hrrp implementation associated fewer readmission ed difference difference estimate ci percentage point p relative decrease pre hrrp readmission_rate implementation hrrp associated fewer readmission ed revisit involving clinical_presentation admission typically indicated difference difference estimate ci percentage point p relative decrease pre hrrp rate result appear associated patient_presenting ed revisit congestive_heart_failure difference difference estimate ci percentage point p_conclusion relevance finding_suggest implementation hrrp associated_lower likelihood readmission recently discharged patient_presenting ed specifically congestive_heart_failure highlight critical role ed readmission reduction hrrp suggests patient_outcome hrrp implementation studied:0.0461077105068391", "134950": "objective impact pharmacy postgraduate year pgy resident led transition care toc pilot service targeting patient chronic_obstructive pulmonary disorder copd heart_failure_hf evaluated term day hospital_readmission primary objective university louisville hospital ulh day emergency_department ed visit ulh secondary objective setting study_conducted urban academic teaching hospital practice description pilot service formal toc service patient high_risk readmission ulh practice innovation toc pilot service providing coverage h week included_patient aged least year admitted ulh internal medicine team primary secondary diagnosis copd hf_patient discharged location home could contacted discharge excluded service consisted pharmacist patient interaction discharge within hour discharge telephone day discharge person evaluation data_collected retrospective chart review patient_enrolled november october comparison computer generated report identified_patient met criterion pilot service could enrolled result_patient enrolled toc pilot service none required readmission ulh within_day compared eligible patient similarly patient_enrolled toc pilot service presented ed within_day discharge compared comparator group completion rate postdischarge follow telephone call clinic visit conclusion pgy ambulatory care pharmacy resident implemented new toc service contributed lower rate day_readmission ed visit eligible patient:0.0452108203726538", "49534": "background center medicare medicaid service publicly report risk standardized mortality_rate rsmrs within_day admission risk standardized unplanned readmission_rate rsrrs within_day discharge patient_hospitalized acute_myocardial_infarction_ami heart_failure_hf pneumonia current publicly reported data focus variation national result annual change objective describe u hospital performance ami hf pneumonia mortality updated readmission measure provide perspective national performance variation design identify recent change variation national hospital level mortality readmission ami hf pneumonia performed cross_sectional panel analysis national hospital performance publicly reported measure participant fee service medicare veteran health administration beneficiary year older hospitalized principal discharge diagnosis ami hf pneumonia july june rsmrs rsrrs calculated using hierarchical logistic model risk adjusted age_sex comorbidities patient clustering among hospital result median range rsmrs ami hf pneumonia respectively median range rsrrs ami hf pneumonia respectively median rsmrs declined ami remained similar hf pneumonia median hospital level rsrrs declined ami hf pneumonia conclusion report first national unplanned readmission result demonstrating declining rate three condition simultaneously ami mortality continued decline pneumonia mortality stable hf mortality experienced small increase:0.0448473992205621", "199294": "importance comparative effectiveness transition care program improving health_status reducing readmission among_patient hospitalized heart_failure unknown objective compare effectiveness adding mobile integrated health mih transition care coordinator improving health_status reducing day cause readmission among_patient discharged heart_failure design setting_participant mighty heart randomized_clinical_trial included medicare medicaid enrolled adult year patient_hospitalized heart_failure new_york city new_york hospital january september participant randomized mih tocc tocc provided follow call nurse hour discharge mih included tocc postdischarge call added ongoing nurse care coordination community paramedic home visit facilitated synchronous telehealth emergency medicine physician data analysis occurred september june intervention receiving mih plus tocc tocc alone first day hospital_discharge main_outcome_measure coprimary outcome health_status day measured kansa city cardiomyopathy questionnaire overall summary score day cause hospital_readmission heart_failure specific readmission secondary_outcome result_among participant median iqr age_year female adjusted difference observed kansa city cardiomyopathy questionnaire overall summary score day mih tocc group mean_difference ci_p exploratory analysis_showed significant age treatment interaction effect younger participant received mih larger improvement health_status beta ci significant_difference overall day_readmission study group_v odds_ratio ci_p_conclusion relevance randomized_clinical_trial found mih conferred additional benefit health_status day_readmission postacute patient_heart_failure compared tocc alone preliminary subgroup_analysis suggest potential variation mih effect age_sex therefore research warranted trial_registration clinicaltrials_gov identifier_nct:0.0448377337028848", "147509": "importance hospital_readmission reduction program publicly report financially penalizes hospital according day risk standardized readmission_rate rsrrs exclusively among traditional medicare tm beneficiary person medicare advantage coverage exclusively reporting readmission_rate tm population may accurately reflect hospital readmission_rate older_adult objective examine inclusion patient hospital performance associated readmission measure eligibility financial penalty design setting_participant retrospective_cohort_study linking medicare provider analysis review file healthcare effectiveness data information set u acute care hospital admitting tm patient participant included_patient admitted discharged alive diagnosis acute_myocardial_infarction_ami congestive_heart_failure_chf pneumonia data analysis conducted april november exposure admission acute care hospital main_outcome_measure outcome readmission reason occurring within_day discharge hospital day rsrr computed basis tm patient estimated change hospital performance eligibility financial penalty including beneficiary calculating day rsrrs result tm patient mean_sd age_year woman patient mean_sd age_year woman hospitalized discharged alive ami tm patient mean_sd age_year woman patient mean_sd age_year woman chf tm patient mean_sd age_year woman patient mean_sd age_year woman pneumonia day rsrrs tm patient correlated correlation coefficient ami chf pneumonia tm based rsrr systematically underestimated rsrr medicare patient condition hospital_admission least outcome ami chf pneumonia change penalty status least condition including data change hospital performance penalty status inclusion patient greater hospital highest quartile admission conclusion relevance cohort_study inclusion data_patient changed penalty status substantial fraction u hospital least reported condition suggests policy maker consider including hospital patient regardless insurance status assessing hospital quality measure:0.0445028037889940", "59760": "objective describe hospital inpatient emergency_department ed outpatient department opd activity patient_year following first emergency admission heart_failure_hf assess proportion receiving specialist assessment within week hospital_discharge recommended guideline design observational_study national administrative data setting acute nh hospital england participant patient index emergency admission april march primary diagnosis hf main_outcome_measure cardiology opd appointment within week within_year discharge index admission emergency_department ed inpatient use within_year result died admission survivor readmitted within_day half within_year majority non hf diagnosis returned ed within week discharge majority admitted two common opd specialty year cardiology total appointment anticoagulant service although half patient cardiology appointment within_year proportion within recommended week discharge overall varied age aged aged p appointment specialty made shortfall comorbidity age associated_higher rate cardiology opd follow conclusion patient_hf high user hospital service postdischarge cardiology opd follow rate fell well current national institute health_care excellence guideline particularly elderly less comorbidity:0.0440538208243709"}, "Topic 20": {"1184": "background_aim present_study assess early clinical_outcome following primary coronary angioplasty elderly_patient aged_year compared younger patient_year method_study population included consecutive_patient mean_age_year acute st elevation myocardial_infarction_mi underwent primary percutaneous_coronary_intervention_pci within hour symptom onset elderly_patient accounted patient primary pci performed using balloon coronary stent well glycoprotein iib iiia inhibitor primary_endpoint hospital incidence major_adverse_cardiac_event including death stroke reinfarction target vessel revascularization new_onset heart_failure result elderly_patient frequently female v_p comorbid disease prior stroke v_p extensive cardiovascular_disease previous acute mi v_p multivessel disease v_p significantly_lower ejection_fraction v_p despite similar rate timi flow presentation v_p n similar use stent v_p glycoprotein iib iiia inhibitor infusion v_p comparable angiographic residual stenosis v_p n final rate timi flow significantly_lower elderly population v_p although hospital ischemic event_rate age significantly_different hospital_mortality higher elderly compared younger patient v_p even patient cardiogenic_shock time admission excluded v_p furthermore patient aged hospital heart_failure v_p whole population multivariate_analysis identified baseline killip class iii_iv independent_predictor event elderly_patient multivariate_analysis identified baseline killip class iii_iv time onset chest_pain pci independent_predictor event conclusion data_suggest elderly_patient acute st elevation mi primary pci yield positive result successful reperfusion achieved high proportion elderly_patient mortality_rate lower reported non pci registry high killip class late reperfusion therapy predict unfavorable outcome elderly patient_treated primary pci:0.0500984280611821", "149481": "background one promising biomarker received substantial interest evaluation suspected acute_coronary_syndrome_ac copeptin therefore goal assess additive value copeptin early_diagnosis prognosis non st_segment acute_coronary_syndrome nste ac method_study included ninety patient suspected ac patient typical ischemic chest_pain within six hour symptom onset without st_segment elevation electrocardiograph ecg included addition cardiac_troponin ctni copeptin assayed venous blood sample obtained admission followed serial troponin measurement six twelve hour later one year_follow performed major_adverse_cardiac_event mace including cardiac_death infarction hospitalization ischemic event heart_failure stroke target lesion revascularization tlr result seventy nine patient_included final analysis forty diagnosed unstable_angina ua thirty nine non st_elevation_myocardial_infarction nstemi copeptin level admission significantly_higher among nstemi patient ua regard correlation analysis copeptin positively correlated global registry acute_coronary event grace thrombolysis myocardial_infarction timi synergy percutaneous_coronary_intervention taxus cardiac_surgery syntax score sensitivity negative predictive_value npv combination admission copeptin ctn respectively versus respectively admission ctn alone area_curve auc combination copeptin ctn p significantly_higher auc ctn alone p admission copeptin independent_predictor mace multiple regression_analysis ci_p high value copeptin highest rate mace coronary revascularization one year_follow conclusion combination copeptin conventional troponin aid early rule nstemi virtually independent chest_pain onset cpo high npv patient_presenting within three hour chest_pain onset excellent prognostic_value risk_stratification prediction mace:0.0466530267526674", "105354": "background il emerges natural suppressor inflammatory_response potential role il pathology atherosclerosis unclear purpose_study assess il profile acute_coronary_syndrome_ac prognostic role cytokine patient st_segment elevation acute_myocardial_infarction stemi undergoing primary percutaneous_coronary_intervention ppci method case_control study prospectively enrolled patient_undergoing first coronary_angiography consisted group normal n stable angina sap n unstable_angina uap n non stemi n stemi n plasma il il serum amyloid saa measured_using commercially elisa kit besides prospective_cohort_study patient stemi onset h undergoing ppci enrolled divided group according concentration il pg_ml pg_ml hospital major_adverse_cardiac_event mace including nonfatal myocardial_infarction_mi target lesion revascularization acute_heart_failure cardiac_death estimated prognosis result il gradually increased accordance severity coronary_artery_disease circulating concentration il remarkably higher ac patient either normal sap patient_p especially higher ami patient including stemi non stemi angina pectoris subject matter sap uap p statistical difference il normal sap patient stemi non stemi patient_p trend change il consistent saa il higher circulating concentration il ppci accompanied decreased lvef increased nt_probnp concentration independently predictive hospital mace rate patient stemi undergoing ppci ci_p_conclusion demonstrated il profile patient acute_coronary_syndrome increased il concentration associated_worse clinical hospital outcome stemi patient_undergoing ppci:0.0453282170994108", "78241": "background traditionally acute_myocardial_infarction_ami described either stemi st_elevation_myocardial_infarction non stemi myocardial_infarction classification historically related use thrombolytic therapy effective stemi current era widespread use coronary_angiography cag usually followed primary percutaneous_coronary_intervention_pci put classification system question objective compare outcome_patient stemi st depression myocardial_infarction stdmi treated emergency pci method multicentre registry enrolled total consecutive_patient ami patient_divided following subgroup stemi n stdmi n left_bundle_branch_block lbbb ami n right bundle_branch_block rbbb ami n electrocardiographic ecg ami n baseline angiographic characteristic studied revascularisation therapy hospital_mortality analysed result acute_heart_failure present stdmi v stemi patient_p stdmi patient extensive coronary atherosclerosis patient stemi three vessel disease v_p left main coronary_artery infract related artery ira stdmi v stemi patient_p timi flow found stdmi v stemi patient_p primary pci performed stemi success rate v stdmi patient success rate p pci success rate hospital_mortality significantly_different stdmi v stemi p_conclusion data_suggest similar strategy emergency cag pci whenever feasible applied type ami:0.0443572220389189", "156596": "supersaturated oxygen sso one emerging therapy shown benefit patient suffering acute st_elevation_myocardial_infarction stemi term reducing infarct_size used prognostic indicator future heart_failure_hospitalization trial investigating sso therapy shown improvement infarct_size used adjunct therapy percutaneous trans luminal coronary angioplasty ptca percutaneous_coronary_intervention_pci patient_presenting acute_myocardial_infarction_ami present patient mid left_anterior_descending artery mlad stemi underwent sso therapy_patient presented new_onset angina st elevation ekg underwent emergent coronary_angiography confirmed mlad complete vessel occlusion successful pci done drug eluting stent followed supersaturated oxygen therapy follow evaluation patient improved left_ventricular_lv ejection_fraction case highlight safety_efficacy sso therapy_patient suffering acute anterior wall myocardial_infarction recommend investigation therapy routine use safety prognostic utility also recommend routine use adjunctive sso therapy_patient suffering acute anterior stemi:0.0441352744014253", "58301": "primary percutaneous_coronary_intervention_pci currently viewed preferred reperfusion strategy patient st elevation acute_myocardial_infarction stemi method introduced hospital january_december total consecutive_patient stemi admitted transferred non pci hospital prehospital emergency unit outpatient clinic patient_underwent urgent coronary_angiography primary pci platelet glycoprotein llb llla inhibitor used stent placement postprocedural thrombolysis myocardial_infarction timi flow documented intra aortic balloon counterpulsation used mechanical_ventilation inotropic drug vasopressor mortality_rate patient killip class ii ranged without negative influence ischemic time patient killip class iii_iv mortality_rate increased increasing ischemic delay hour p remained around afterward independent_predictor mortality age odds_ratio confidence_interval_ci_p resuscitated cardiac_arrest ci_p postprocedural timi flow ci overall mortality_rate patient_underwent primary pci strategy significantly_lower control_group consecutive patient_underwent thrombolysis v_p conclusion introduction primary pci strategy significantly_decreased hospital_mortality unselected group_patient stemi compared thrombolytic era study emphasized importance shortening myocardial ischemic time particularly presence severe_heart_failure admission:0.0439781147988292", "12775": "introduction patient_non st elevation acute_coronary_syndrome nste ac sometimes severely hemodynamicly compromised urgent coronary_angiography performed_patient percutaneous_coronary_intervention_pci center according esc nste ac guideline determine suitabilty percutaneous surgical revascularization case_report reported year_old male chest_pain admitted coronary care unit st_segment depression mm lead l v revealed electrocardiogram following hour patient chest_pain sign cardiogenic_shock despite therapy chest xray showed pulmonary_edema echocardiographic examination showed dyskinetic medium apical segment septum patient_underwent coronary_angiography immediately revealed stenosis left main coronary_artery thrombus use gpiib iii inhibitor tirofiban stent implantation resulted timi iii flow patient chest_pain acute_heart_failure subsided following day echocardiography done fourth day pci showed hypokinesis medium apical segment septum patient discharged day admission stable condition conclusion stenting left main coronary_artery stenosis patient cardiogenic_shock non st_segment elevation acute_coronary_syndrome may life saving procedure:0.0431642571482055", "74425": "background limited information available regarding relationship coronary vessel dominance outcome st_segment_elevation_myocardial_infarction stemi objective_study designed evaluate prognostic_value coronary arterial dominance primary percutaneous_coronary_intervention_pci hospital_stay month_follow regarding cardiac mortality heart_failure nonfatal myocardial_infarction revascularization stroke patient_method study_population consisted consecutive_patient mean_age_year men stemi admitted dallah hospital riyadh saudi arabia january_december patient_underwent successful primary pci thrombolysis myocardial_infarction timi iii flow divided three_group according angiographic coronary dominance right coronary dominant group left coronary dominant group balanced coronary dominant group evaluated two three dimensional echocardiography within hour admission month_follow stemi result right dominance present left dominance balanced dominance present patient main finding study left dominant system associated_increased_risk cardiac mortality heart_failure nonfatal myocardial_infarction revascularization stroke shortly primary pci hospital_stay month_follow stemi moreover significantly_lower left_ventricular_ejection_fraction admission observed echocardiography patient left dominant system conclusion_patient stemi treated primary pci left coronary_artery dominance confers higher_risk various adverse clinical_event primary pci hospital_stay month_follow compared right balanced coronary_artery dominance:0.0429875291298992", "50227": "background measurement n_terminal_pro_brain_natriuretic_peptide nt_probnp evaluation patient acute_coronary_syndrome appeared useful prognostic marker cardiovascular_risk aim work assess hospital prognostic_value nt_probnp patient acute_coronary_syndrome_ac relation severity coronary_artery_disease patient_method study_included consecutive_patient ac patient unstable_angina ua patient_non st_segment_elevation_myocardial_infarction nstemi patient st_segment_elevation_myocardial_infarction stemi ecg echocardiography pre post coronary_angiography measurement troponin creatine kinase ck c_reactive_protein crp nt_probnp done patient_divided two_group group nt_probnp less pg_ml group_b nt_probnp equal pg_ml result significant negative correlation nt_probnp ejection_fraction incidence heart_failure duration hospital_stay significantly_higher group_b nt_probnp equal pg_ml group nt_probnp less pg_ml moreover trend increased incidence cardiogenic_shock mortality group_b compared group number coronary vessel affected severity stenosis proximal left_anterior_descending artery lad disease higher group_b group timi flow grade significantly_higher group group_b conclusion nt_probnp valuable marker predicting prognosis severity coronary_artery_disease patient acute_coronary_syndrome:0.0427749544023384", "12661": "background controversy ideal type revascularization context primary angioplasty percutaneous_coronary_intervention_pci acute_myocardial_infarction_ami presence additional stenosis especially complex impact prognosis objective_evaluate medium term year prognosis according presence complex additional stenosis primary pci population method_retrospective study consecutive_patient admitted unit st_segment elevation ami underwent primary pci patient_followed year divided group without complex additional stenosis n year male complex additional stenosis n year male p n evaluated demographic characteristic risk_factor coronary_artery_disease previous cardiac history sign heart_failure admission angiographic characteristic medication pci outcome also evaluated impact variable combined end_point death reinfarction myocardial revascularization year assessed result angiographic success rate twenty four percent patient_aged_year total population killip class iv admission anterior ami slightly common non complex additional stenosis group_v_p inferior ami complex additional stenosis group_v_p one vessel disease prevalent group without complex additional stenosis expected v_p stent implantation also frequent group_v_p difference variable death reinfarction revascularization frequent group complex additional stenosis v_p sixty seven per cent event occurred first day follow year univariate predictor outcome killip class timi flow infarct related vessel pci non use glycoprotein iib iiia receptor_antagonist beta_blocker statin multivessel disease presence complex additional stenosis log_rank_p using multivariate regression_analysis independent_predictor outcome year killip class ci_p presence complex additional stenosis ci_p_conclusion presence complex additional stenosis primary pci worse prognosis year suggesting need intervention stabilize plaque particularly first day ami:0.0426144565112335"}, "Topic 21": {"156229": "background well_established obesity associated risk heart_failure_hf however data relationship visceral fat risk_hf limited aim aim evaluate association visceral obesity assessed visceral adiposity index vai incident_hf left_ventricular_lv structure_function atherosclerosis risk community aric study method included participant aged_year free history hf coronary_heart_disease baseline aric study used multivariable cox hazard regression_model assess association vai incident_hf explored effect vai lv geometry function among participant echocardiographic data using multivariable linear regression_analysis multinomial logistic_regression result median_follow_year total participant developed hf adjustment traditional hf risk_factor unit increase baseline vai associated_higher_risk incident_hf hazard_ratio_hr_confidence_interval_ci result similar participant categorized vai tertiles compared participant lowest tertile vai second tertile third tertile greater risk incident_hf hr_ci respectively analysis hf subtypes higher vai associated risk_hf preserved_ejection_fraction hf reduced_ejection_fraction addition greater vai associated_worse lv diastolic_function abnormal lv geometry including concentric remodelling concentric hypertrophy eccentric hypertrophy conclusion_study show higher vai independently_associated increased_risk incident_hf abnormal lv geometry lv diastolic_dysfunction:0.0467384547598579", "72104": "background reproductive factor reflective endogenous sex hormone exposure might effect cardiac_remodeling development heart_failure_hf objective_study examined association key reproductive factor incidence hf method woman cohort woman health initiative systematically evaluated incidence hf_hospitalization study enrollment reproductive factor number live birth age first pregnancy total reproductive duration time menarche menopause self_reported study baseline employed cox_proportional_hazard regression_analysis age multivariable adjusted model result_among woman average age_year baseline adjudicated incident hf_hospitalization average follow year adjusting covariates total reproductive duration year inversely associated incident_hf hazard_ratio_hr per_year confidence_interval_ci per_year per_year ci per_year conversely early age first pregnancy nulliparity significantly_associated incident_hf age adjusted model multivariable adjustment notably nulliparity associated incident_hf preserved_ejection_fraction fully adjusted model hr_ci conclusion post menopausal woman shorter total reproductive duration associated_higher_risk incident_hf nulliparity associated_higher_risk incident_hf preserved_ejection_fraction whether exposure endogenous sex hormone underlies relationship investigated future study:0.0442395750293175", "195171": "background tricuspid_regurgitation tr associated older_age heightened mortality_rate limited data exist tr prevalence prognostic significance community based older_adult method among participant aric atherosclerosis risk community study underwent echocardiography seventh study visit tr severity assessed none trace mild moderate_severe board certified cardiologist multivariable linear logistic_regression_model assessed association tr severity clinical_characteristic echocardiographic measure self_reported dyspnea multivariable cox_proportional_hazard_model evaluated association incident adjudicated heart_failure_hf death result mean_age_year woman reported black race tr prevalence mild moderate_severe greater tr severity associated older_age female_sex prevalent hf worse cardiac structure_function association dyspnea statistically different fully adjusted model median_follow interquartile_range year incident_hf event death higher tr severity associated heightened risk incident_hf adjusting demographic comorbidities measure left_ventricular structure_function hazard_ratio ci per increment severity category p greater tr severity associated cause_death adjusting demographic p adjustment p_conclusion tr common older_adult associated_worse cardiac structure_function greater tr severity independently_associated greater risk developing hf:0.0439509220551502", "142674": "background amyloid beta abeta may related cardiac_function however limited data association plasma abeta cardiac_function risk heart_failure_hf general_population objective_study sought determine association plasma amyloid beta abeta amyloid beta abeta echocardiographic measurement cardiac_dysfunction incident_hf general_population method_study included participant population_based rotterdam study mean_age_year woman plasma abeta sample collected established dementia hf baseline multivariable linear regression_model used explore cross_sectional association plasma abeta echocardiographic measure participant followed december cox_proportional_hazard_model used_assess association abeta level incident_hf model adjusted cardiovascular_risk_factor result per sd increase log transformed plasma abeta associated ci lower left_ventricular_ejection_fraction g ci larger left_ventricular mass indexed body surface area abeta significantly_associated echocardiographic measure cross sectionally follow median year incident_hf case identified per sd increase log transformed abeta associated greater risk_hf hr_ci association significant men_woman higher plasma abeta level associated_increased_risk hf hr_ci although association attenuated adjustment concomitant abeta hr_ci conclusion higher_level abeta associated_worse cardiac_function higher_risk new_onset hf general_population particular among men:0.0436425185511012", "101272": "background_objective growing evidence emerged role diet heart_failure_hf development data sparse inconclusive examined association mediterranean style diet component hf_risk subject method analysis carried middle aged participant european prospective investigation cancer nutrition epic potsdam germany including incident_hf case within_year traditional greek mediterranean diet score tmed used_assess dietary adherence cox_proportional_hazard regression applied estimate relationship adherence mediterranean style diet component hf_risk result adjustment age_sex energy intake unit increment tmed associated_lower risk_hf hr confidence_interval_ci multivariable adjustment association slightly attenuated lost significance hr_ci interestingly observed significant_association multivariable adjusted model milk product excluded score hr_ci three score component significantly_associated hf_risk alcohol hr_ci moderate versus low high intake meat fish highest versus lowest quintile conclusion tmed significantly_associated hf_risk low meat high fish moderate alcohol intake inversely associated hf_risk non mediterranean population minor dietary change could valuable primary_prevention measure particularly increase fish consumption reducing intake meat:0.0425631516117408", "59559": "objective_study sought examine association borderline left_ventricular_ejection_fraction_lvef cardiovascular morbidity_mortality community based cohort background guideline stipulate lvef normal optimal threshold remains uncertain prognosis borderline lvef unknown method_study evaluated framingham heart study_participant underwent echocardiography n person observation mean_age_year woman using pooled data year_follow multivariable cox_regression evaluated association borderline lvef continuous lvef risk developing composite_outcome heart_failure_hf death primary_outcome incident_hf secondary_outcome result follow median year hf developed participant died among participant lvef prevalence rate composite_outcome hf per year_follow respectively versus participant normal lvef multivariable adjusted analysis lvef associated_increased_risk composite_outcome hazard_ratio_hr_confidence_interval_ci hf hr_ci linear inverse relationship continuous lvef composite_outcome hr per lvef decrement ci hf hr per lvef decrement ci_conclusion person lvef community greater risk morbidity_mortality relative person lvef additional study warranted elucidate optimal management individual:0.0407942472772243", "141245": "background glyca nuclear magnetic_resonance composite marker systemic inflammation reflects serum concentration glycosylation state main acute phase reactant prior study shown plasma glyca level associated cardiovascular_disease even adjusting inflammatory marker however little_known association glyca heart_failure_hf subtypes heart_failure_preserved_ejection_fraction_hfpef heart_failure reduced_ejection_fraction examined association glyca incident_hf subtypes multiethnic cohort method studied multi ethnic study atherosclerosis participant aged without baseline cardiovascular_disease hf data glyca incident hospitalized hf used multivariable adjusted cox hazard model evaluate association glyca incident total hf hfpef heart_failure reduced_ejection_fraction model adjusted sociodemographics cardiovascular_disease risk_factor inflammatory biomarkers result mean_sd age_year glyca mumol l woman median_follow_year participant highest quartile glyca compared lowest experienced increased_risk developing hf hazard_ratio ci fully adjusted model however increased_risk seen hfpef heart_failure reduced_ejection_fraction significant interaction sex age race ethnicity conclusion glyca associated_increased_risk hf particular hfpef future study examine mechanism might explain differential association glyca hf subtypes whether therapeutic lowering glyca prevent hfpef development registration url http_www clinicaltrials_gov unique identifier_nct:0.0405454050491406", "128775": "aim body roundness index bri obesity related anthropometric index combine waist circumference height better reflect body fat study_aim prospectively explore relationship bri risk heart_failure_hf based community based cohort method_result total individual without tumour hf baseline included kailuan cohort_study demographic information anthropometric parameter biochemical index collected measured participant followed december death diagnosed hf whichever came first cox_proportional_hazard_model used calculate hazard_ratio_hr_confidence_interval_ci incident_hf restricted cubic spline analysis applied evaluate possible non linear dose response relationship bri risk_hf median_follow period year identified hf event participant grouped four group according quartile bri q q q q adjustment potential confounders compared group participant lowest quartile bri adjusted hr_ci ci_ci ci_ci subject q q q group respectively standard_deviation bri increasing risk_hf increased hr_ci subgroup_analysis indicated association bri hf prominent younger people hr_ci older hr_ci_p interaction significant linear dose response relationship bri hf also observed p non linearity conclusion_study suggests higher bri associated_increased_risk hf finding replicated population future study need examine whether lowering bri may lower_risk incident_hf:0.0402149649343639", "96459": "background type_diabetes_mellitus_dm associated_higher_risk heart_failure_hf impact lifestyle intervention change cardiorespiratory fitness crf body_mass_index risk_hf well_established method participant look ahead trial action health diabetes without prevalent hf included time event analysis used compare risk incident_hf intensive lifestyle intervention diabetes support education group association baseline measure crf estimated maximal treadmill test body_mass_index longitudinal change parameter risk_hf evaluated multivariable adjusted cox model result_among trial participant significant_difference risk incident_hf n intensive lifestyle intervention diabetes support education group hazard_ratio ci median_follow_year adjusted cox model risk_hf lower among moderate fit tertile hazard_ratio ci high fit tertile hazard_ratio ci group respectively referent group low fit tertile among hf subtypes adjustment traditional cardiovascular_risk_factor interval incidence myocardial_infarction baseline crf significantly_associated risk incident_hf reduced_ejection_fraction contrast risk incident_hf preserved_ejection_fraction lower moderate fit group lower high fit group baseline body_mass_index also associated risk incident_hf hf preserved_ejection_fraction hf reduced_ejection_fraction adjustment crf traditional cardiovascular_risk_factor among participant repeat crf assessment n improvement crf weight_loss year_follow significantly_associated lower_risk hf hazard_ratio per increase crf ci per decrease body_mass_index ci_conclusion among participant type_diabetes_mellitus look ahead trial intensive lifestyle intervention appear modify risk_hf higher baseline crf sustained improvement crf weight_loss associated_lower risk_hf registration url http_www clinicaltrials_gov unique identifier_nct:0.0398810068452787", "162349": "background prognostic_value n_terminal_pro_b_type_natriuretic_peptide nt_probnp heart_failure_hf well_established however whether could facilitate risk_stratification hf_patient implantable_cardioverter_defibrillator_icd still unclear objective_determine association baseline nt_probnp outcome cause_mortality first appropriate shock due sustained ventricular_tachycardia ventricular fibrillation vt vf icd recipient method_result n_terminal_pro_b_type_natriuretic_peptide measured icd implant patient mean_age_year men non ischemic dilated_cardiomyopathy_dcm primary_prevention median nt_probnp pg_ml interquartile_range iqr pg_ml categorized nt_probnp_level quartile used restricted cubic spline evaluate nonlinear association outcome incidence_rate mortality first appropriate shock respectively adjusting confounding factor multivariable cox_regression showed rise nt_probnp associated_increased_risk cause_mortality compared lowest quartile hazard_ratio hr_ci across increasing quartile nt_probnp p trend restricted cubic spline demonstrated similar pattern inflection point found pg_ml beyond increase nt_probnp associated_increased mortality p nonlinearity fine gray regression used_evaluate association nt_probnp first appropriate shock accounting competing risk_death unadjusted partial fully adjusted analysis however significant_association could found regardless nt_probnp categorical variable log transformed continuous variable p nonlinearity found either p_interaction nt_probnp predefined factor found p_conclusion hf_patient icd rise nt_probnp independently_associated increased mortality reach inflection point however association first appropriate shock found patient higher nt_probnp_level might derive less benefit icd implant:0.0398358572220158"}, "Topic 22": {"126183": "objective prior study suggest percutaneous access endovascular abdominal aortic aneurysm repair pevar offer significant operative postoperative benefit compared femoral cutdown cevar national data topic however limited compared_patient selection outcome elective pevar cevar method identified patient_undergoing either pevar bilateral percutaneous access whether successful cevar least_one planned groin cutdown abdominal aortic aneurysm january_december targeted vascular data set american college surgeon national surgical quality improvement program database emergent case rupture case iliac conduit case preoperative wound infection excluded group_compared chi test test mann whitney test appropriate result identified patient_undergoing elective evar cevar patient pevar patient evar patient bilateral percutaneous access attempted percutaneous access converted cutdown pevars remainder planned cutdown bilateral unilateral significant_difference age_gender aneurysm diameter prior open abdominal surgery patient_undergoing cevar less_likely congestive_heart_failure v_p likely undergo concomitant procedure surgery v_p patient_undergoing pevar postoperatively pevar patient shorter operative time mean v minute p shorter length_stay median day v day_p fewer wound complication v_p multivariable_analysis predictor percutaneous access failure performance concomitant procedure odds_ratio_confidence_interval p_conclusion currently one four patient_treated targeted vascular national surgical quality improvement program center getting pevar associated_high success rate shorter operation time shorter length_stay fewer wound complication compared cevar:0.0477981019853688", "58560": "background congestive_heart_failure_chf predicts surgical morbidity_mortality however study evaluate chf impact noncardiac operation chfs serious threat health survival surgeon must understand risk chf pose patient_undergoing diverse array operation study_design used american college surgeon national surgical quality improvement program ac nsqip participant use file estimate risk serious morbidity reoperation readmission mortality postoperative complication associated preoperative diagnosis chf multivariable logistic_regression_analysis provided odds_ratio confidence_interval_ci outcome ac nsqip procedure group controlling age_sex race emergency surgery status american society anesthesiologist classification body_mass_index selected laboratory value result unadjusted or indicate adverse_effect chf surgical outcome procedure considered adjusted age confounders chf persists adverse_effect outcome including serious morbidity ci_p reoperation ci_p readmission ci_p day_mortality ci_p impact chf morbidity_mortality substantially affected undergoing carotid endarterectomy lower extremity endovascular repair cardiac_arrest mortality unplanned intubation ventilator hour complication affected chf conclusion congestive_heart_failure strongly predicts serious morbidity unplanned reoperation readmission surgical mortality noncardiac operation surgeon must pay particular attention recognizing chf optimizing perioperative management considering surgery:0.0462903735097050", "104632": "objective unplanned hospital_readmission following surgical intervention associated adverse_event contribute increasing health_care cost despite numerous study defining risk_factor following lower extremity bypass surgery evidence regarding readmission endovascular intervention limited study_aimed identify predictor day unplanned readmission following infrainguinal endovascular intervention method identified patient_undergoing infrainguinal endovascular intervention targeted vascular module american college surgeon national surgical quality improvement program perioperative outcome stratified symptom status chronic limb threatening ischemia cli v claudication patient_died index admission remained hospital day excluded indication unplanned readmission related index procedure evaluated multivariable logistic_regression used_identify preoperative hospital index admission risk_factor day unplanned readmission result patient_underwent infrainguinal endovascular intervention cli tissue loss claudication unplanned readmission_rate cli claudication patient_n n respectively mortality index admission higher readmitted patient compared readmitted cli v_p claudication v_p approximately unplanned readmission related index procedure among cli patient common indication readmission related index procedure wound infection related whereas patient claudication mainly readmitted recurrent symptom peripheral vascular_disease patient cli predictor unplanned readmission included diabetes odds_ratio_confidence_interval congestive_heart_failure renal_insufficiency preoperative dialysis tibial angioplasty stenting hospital bleeding hospital unplanned return operating room discharge home risk_factor claudication dependent functional_status smoking diabetes preoperative dialysis procedure time exceeding minute hospital bleeding hospital unplanned return operating room conclusion unplanned readmission endovascular treatment relatively common especially patient cli associated substantially increased mortality awareness risk_factor help provider identify_patient high_risk may benefit early surveillance prophylactic measure focused decreasing postoperative complication may reduce rate readmission:0.0442342443120994", "105348": "objective emergency lower extremity embolectomy common vascular surgical procedure poorly defined outcome goal define perioperative morbidity emergency embolectomy develop risk prediction_model perioperative mortality method american college surgeon national surgical quality improvement database queried identify patient_undergoing emergency unilateral lower extremity embolectomy patient previous critical limb ischemia bilateral embolectomy nonemergency indication undergoing concurrent bypass excluded patient_characteristic postoperative morbidity_mortality analyzed multivariate_analysis predictor mortality performed risk prediction_model developed identify preoperative predictor mortality result_patient male met inclusion_criterion average age_year iliofemoral popliteal embolectomy performed_patient popliteal tibioperoneal embolectomy level fasciotomies performed concurrently embolectomy patient day postoperative mortality postoperative complication included myocardial_infarction cardiac_arrest pulmonary complication wound complication rate return operating room day hospital length_stay day_day readmission_rate perioperative mortality_risk prediction_model based factor identified multivariate_analysis included age_year male gender functional dependence history chronic_obstructive_pulmonary_disease congestive_heart_failure recent myocardial_infarction angina chronic renal_insufficiency steroid use model showed good discrimination c confidence_interval calibrated well conclusion emergency lower extremity embolectomy high morbidity_mortality resource utilization data provide benchmark complex patient_population may assist risk stratifying patient allowing improved informed consent goal care time presentation:0.0440465764218172", "67317": "background among_patient undergoing noncardiac surgery major vascular surgery associated high_risk perioperative myocardial_infarction_mi currently perioperative mi risk calculator accounting intraoperative postoperative risk_factor vascular surgery patient aimed investigate specific risk_factor perioperative mi major open vascular surgery determine patient highest risk mi association perioperative mi perioperative transfusion method statewide retrospective_cohort_study analyzed risk_factor perioperative mi major open vascular surgery july december using michigan surgical quality collaborative multicenter quality collaborative patient identified using current procedure terminology code including open abdominal aortic aneurysm repair oaaa aortobifemoral bypass afb lower extremity bypass leb rate myocardial_infarction described procedure priori preoperative intraoperative postoperative variable evaluated_using univariate multivariable statistic adjusting intraoperative factor including anesthesia type intraoperative blood loss intraoperative transfusion intraoperative vasopressor medication result_total_patient underwent major open vascular surgery including oaaa afb leb procedure overall incidence mi varying aortobifemoral bypass lower extremity bypass open abdominal aortic aneurysm repair although preoperative risk_factor myocardial_infarction included age american society anesthesiologist score diabetes coronary_artery_disease congestive_heart_failure use beta_blocker lower preoperative hematocrit surgical priority urgent emergent case adjusting intraoperative risk_factor preoperative risk_factor significant exception surgical priority adjusting intraoperative factor surgical priority odds_ratio confidence_interval_ci_p postoperative transfusion ci_p associated myocardial_infarction higher nadir hematocrit inversely associated myocardial_infarction ci_p_conclusion among vascular surgery patient_undergoing major open vascular surgery surgical priority preoperative risk_factor independently_associated mi postoperative variable nadir hematocrit postoperative transfusion associated mi suggests minimizing intraoperative blood loss prioritizing early intraoperative transfusion may potential target process improvement:0.0434431834839057", "91352": "objective blood transfusion common among_patient undergoing major vascular surgery prior study suggest association blood transfusion increased morbidity_mortality among_patient undergoing cardiac_surgery predictor perioperative transfusion impact patient_undergoing vascular surgery poorly defined method examined data large multicenter quality improvement vascular surgical registry patient_undergoing elective urgent open peripheral arterial disease procedure endovascular aneurysm repair open abdominal aortic aneurysm aaa repair january_december emergency case carotid endarterectomy carotid artery stenting excluded univariate multivariate logistic_regression modeling used_identify predictor transfusion association transfusion outcome regression_model hosmer lemeshow p area receiver_operating_characteristic_curve confirming excellent goodness fit discrimination result_study population comprised patient_underwent open peripheral arterial disease procedure n open aaa repair n endovascular aneurysm repair n hospital overall transfusion rate median nadir hemoglobin level g_dl independent factor predicting transfusion included female gender odds_ratio confidence_interval_ci nonwhite race ci preoperative admission status ie acute care hospital ci preoperative anemia ci congestive_heart_failure ci prior myocardial_infarction ci clopidogrel ci open aaa repair ci open bypass ci urgent procedure ci adjustment major covariates perioperative transfusion independently_associated death ci myocardial_infarction ci pneumonia ci_conclusion perioperative transfusion vascular surgical patient independently_associated increased day morbidity_mortality given indeterminate causation data_suggest need prospective transfusion threshold study vascular surgical patient:0.0417941439736118", "85903": "objective perioperative outcome endovascular repair evar abdominal aortic aneurysm aaa rigorously studied however inpatient postdischarge outcome separately analyzed objective_study examine postdischarge day outcome elective evar method patient_underwent elective evar aaa n identified american college surgeon national surgical quality improvement project database univariable multivariable logistic_regression_analysis performed result median length hospital_stay day interquartile_range day overall day_mortality n n patient dying discharge overall day morbidity n n morbidity postdischarge median time death complication day respectively surgery eighty eight percent wound infection n pneumonia n venous thromboembolism n postdischarge multivariable analysis_showed age congestive_heart_failure admission nursing facility postoperative pneumonia myocardial_infarction renal_failure independently_associated postdischarge mortality peripheral arterial disease female gender previous cardiac_surgery age smoking diabetes postdischarge morbidity p_conclusion patient_characteristic associated_higher_risk postdischarge adverse_event evar identified whether improved predischarge surveillance close postdischarge follow identified high_risk_patient improve day outcome evar need prospectively studied:0.0416138111987798", "48893": "object unplanned hospital_readmission represents large financial burden center medicare medicaid service commercial insurance payer hospital individual patient principal target cost reduction large_scale multi institutional study evaluates risk_factor readmission previously performed patient_undergoing lumbar decompression procedure goal multicenter retrospective_study find preoperative intraoperative postoperative predictive factor result unplanned readmission ur lumbar decompression surgery method national surgical quality improvement program nsqip database retrospectively reviewed identify patient_received lumbar decompression procedure risk adjusted multivariate logistic_regression_analysis performed estimate independent_predictor ur result overall rate ur among_patient undergoing lumbar decompression multivariate logistic_regression_analysis anemia odds_ratio dependent functional_status total operative duration american society anesthesiologist physical status class remained independent_predictor ur postoperative complication significantly_associated ur included overall complication pulmonary_embolism unplanned reoperation conclusion several risk_factor ur lumbar spine decompression surgery identification high_risk_patient appropriate allocation resource reduce postoperative incidence may reduce readmission_rate:0.0415533194327833", "142158": "objective peripheral artery disease common comorbidity patient end_stage_renal_disease esrd paucity data comparing outcome different intervention group_patient study examined perioperative outcome lower extremity endovascular revascularization er open revascularization dialysis patient critical limb ischemia cli method_patient dialysis undergoing er cli identified american college surgeon national surgical quality improvement program dataset patient demographic comorbidities anatomic feature perioperative outcome compared er procedure result lower extremity revascularizations performed dialysis patient cli group er procedure although demographic characteristic age_gender similar two_group higher proportion caucasian african_american group patient_undergoing open endovascular procedure similar rate hypertension congestive_heart_failure diabetes chronic_obstructive_pulmonary_disease bleeding disorder minority procedure emergency distributed equally two_group preoperative aspirin usage higher er group_v_p beta_blocker use higher group_v_p statin use similar two_group er p risk adjusted multivariate_analysis associated_lower rate major amputation v odds_ratio confidence_interval_ci higher_rate postoperative bleeding v odds_ratio ci wound complication v odds_ratio ci day_mortality cardiovascular morbidity similar two_group conclusion_patient esrd cli associated_lower risk major limb amputation higher_rate postoperative wound complication bleeding compared er cardiovascular_complication day_mortality reinterventions readmission similar two_group patient esrd cli considered option limb salvage feasible long_term_outcome comparing two type procedure needed:0.0413054872287110", "51289": "purpose national surgical database used determine risk_factor complication patient_undergoing open reduction internal fixation orif distal radius fracture method american college surgeon national surgical quality improvement program database year queried identify patient_underwent orif distal radius fracture based current procedural terminology code database statistically representative sample prospectively collected perioperative surgical data hospital primarily united_state demographic comorbidities preoperative laboratory value day complication compared_patient group without postoperative complication multivariate_analysis performed identify_patient characteristic comorbidities independently_associated early postoperative complication result retrospective analysis identified patient_underwent orif distal radius year number_patient complication within_day surgery totaling complication incidence return operative room entire study_population multivariate_analysis adjusting confounding variable showed patient complication likely hypertension congestive_heart_failure preoperative chemotherapy radiotherapy longer operating time manifest preoperative impairment independent living conclusion approximately patient sustained complication within_day following orif distal radius fracture recognition risk_factor may_help avoid complication identified high_risk_patient type study level evidence prognostic ii:0.0409052717644204"}, "Topic 23": {"52974": "objective aim_study investigate incidence predictor renal_failure requiring dialysis rf contemporary cohort patient_undergoing cardiac_surgery author also analyzed early late outcome_patient complication design retrospective_study consecutive patient_undergoing cardiac_surgery using computerized database based new_york state department health registry data collection performed prospectively setting university_hospital single institution participant six thousand four hundred forty nine patient_underwent cardiac_surgery january_december including isolated coronary_artery_bypass graft cabg surgery n single multiple valve surgery n combined valve cabg procedure n surgery involving ascending aorta aortic arch n intervention none measurement main result incidence rf n incidence per type procedure follows cabg surgery valve cabg surgery valve surgery aortic surgery p multivariate_analysis revealed preoperative renal_dysfunction odds_ratio hemodynamic instability diabetes aortic surgery congestive_heart_failure_chf peripheral vascular_disease pvd reoperation independent_predictor rf hospital_mortality rf n compared n control_group p long_term_survival rf significantly_decreased year_year survival v control_group p hypertension chf pvd independent_predictor late mortality conclusion author observed increase overall incidence rf compared previous_study probably related increased prevalence patient_undergoing complex procedure worsening risk profile postoperative rf associated_increased hospital_mortality morbidity also significant_reduction long_term_survival discharged patient seven independent_predictor rf identified future_research effort focus precise identification patient_risk development new treatment modality would potentially prevent occurrence complication:0.0814267440377645", "162794": "background data regarding post pneumonectomy patient assessment cardiac_surgery scarce retrospective study_conducted define early late outcome_patient identify risk_factor poor_outcome method_study included_patient previous history pneumonectomy undergoing pump cardiac_surgery median sternotomy institutional database reviewed result sixteen post pneumonectomy patient lung cancer identified age range year mean fev fvc mean euroscore ii four patient_heart_failure symptom week surgery seven patient isolated coronary_artery_bypass_grafting cabg six patient cabg aortic_valve_replacement avr major perioperative event affecting ease outcome surgical procedure structural shift extensive adhesion heart vessel extensive calcification heart component important postoperative complication respiratory infection acute_kidney_injury median hospital length_stay day five patient_died hospital none isolated cabg preoperative new_york_heart_association classification nyha iii_iv cardiopulmonary bypass time min aortic cross clamp time min long_term_survival data recorded mean_follow year range overall year_survival cardiac_surgery isolated cabg surgery cabg avr surgery respectively_conclusion post pneumonectomy patient acceptable postoperative outcome survival simple short surgery careful planning yield favorable outcome high_risk subgroup patient:0.0803990543073190", "48448": "objective united_state vascular surgeon frequently perform carotid endarterectomy cea given resource burden unplanned readmission ura sought identify predictor consequence ura common vascular surgery procedure identify potential point intervention method using prospective single institution database retrospectively identified consecutive patient_undergoing cea demographic perioperative factor prospectively collected primary_end_point day postdischarge ura cea secondary end_point year_survival performed univariable analysis ura followed multivariable cox model kaplan_meier analysis_performed year_survival result_study period patient_underwent ceas day postdischarge overall readmission_rate ura rate respectively ura patient_n readmitted cea related reason headache cardiac hypertension surgical site infection bleeding hematoma stroke transient_ischemic_attack dysphagia hyperperfusion syndrome seventeen patient one reason ura median time ura day interquartile_range day postoperative length_stay indication cea discharge destination associated ura multivariable_analysis hospital occurrence congestive_heart_failure hazard_ratio_hr_confidence_interval_ci_p stroke hr_ci_p bleeding hematoma hr_ci_p prior coronary_artery_bypass_grafting hr_ci_p significantly_associated ura patient ura group also decreased survival year v_p log_rank conclusion day ura rate cea low prior coronary_artery_bypass_grafting hospital postoperative occurrence stroke bleeding hematoma congestive_heart_failure identify increased_risk ura ura signal increased long_term risk postoperative mortality:0.0798722306088968", "21141": "objective incidence perioperative complication increased outcome poor young patient_undergoing vascular surgery extensively reviewed result lower extremity procedure group_patient define extent short_term long_term morbidity method_result vascular registry retrospectively reviewed lower extremity revascularization procedure performed january may patient younger year represents lower extremity bypass procedure performed period perioperative cardiac_complication long_term_survival graft patency limb salvage evaluated kaplan_meier curve generated significance determined cox mantel test result forty nine percent patient male_female mean_age presentation year range year preoperative morbidity included diabetes_mellitus smoking hypertension coronary_artery_disease hyperlipidemia renal_dysfunction overall rate day postoperative mortality myocardial_infarction congestive_heart_failure thirty day graft failure n year primary patency secondary patency limb salvage year rate respectively initial surgery n patient required least_one additional ipsilateral revascularization procedure n required bypass graft contralateral limb n ultimately required amputation patient required additional ipsilateral procedure year primary patency rate secondary patency rate limb salvage rate compared year rate respectively representing decrease patency compared primary revascularization procedure overall survival year compared year patient preexisting renal_disease significantly_decreased survival year compared_without renal_dysfunction v_p conclusion data_suggest age younger year associated_increased perioperative morbidity_mortality however patient significant rate early graft failure dismal long_term_survival especially patient preexisting renal_dysfunction addition ipsilateral repeat operation marginal success rate:0.0731907960922503", "175641": "background_aim lack data perioperative outcome patient_undergoing non cardiac_surgery nc transcatheter aortic_valve implantation tavi hence aimed determine incidence type surgery timing perioperative outcome individual undergoing elective nc tavi method_result hospitalization tavi identified u national readmission database patient_received nc within six_month included analysis incidence type timing planned readmission nc evaluated according surgical risk low intermediate high primary_outcome occurrence hospital major adverse_event mae defined composite death cardiac_complication stroke transient_ischemic_attack multivariable regression_model constructed identify independent factor_associated mae tavi procedure patient electively readmitted within_month tavi nc surgery classified low n intermediate n high_risk n median_age study_population year iqr participant male overall surgery occurred median day iqr index tavi procedure time period significantly shorter underwent high_risk surgery median iqr day_p overall rate post operative mae n rate differ surgical risk group_p primary_outcome driven primarily cardiac_complication rate death low almost identical surgical risk group_p factor independently_associated primary_outcome congestive_heart_failure aor ci_p liver_disease aor ci_p diabetes_mellitus aor ci_p cancer aor ci_p time readmission aor ci_p_conclusion elective nc occurred infrequently post tavi associated low rate mortality diabetes_mellitus congestive_heart_failure liver_disease cancer anemia time readmission associated postprocedural adverse_event surgical risk risk nc tavi balanced risk delaying operation:0.0724397441673854", "52977": "background skeletonized harvesting internal thoracic artery ita decrease severity sternal devascularization thus reducing risk postoperative sternal complication patient_undergoing bilateral ita grafting method_result consecutive patient_underwent skeletonized bilateral ita grafting male_female patient_year age diabetes_mellitus operative mortality early postoperative morbidity included sternal infection cerebrovascular accident perioperative myocardial_infarction multiple regression_analysis showed chronic_obstructive_pulmonary_disease odds_ratio confidence_interval_ci repeat operation odds_ratio ci diabetes_mellitus non insulin dependent odds_ratio ci insulin dependent odds_ratio ci associated_increased_risk sternal infection follow year revealed late death kaplan_meier year survival_rate patient_year age respectively cox_regression_analysis revealed increased overall mortality early late patient peripheral vascular_disease hazard_ratio hr_ci patient_year age hr_ci undergoing repeat operation hr_ci patient preoperative congestive_heart_failure hr_ci chronic renal_failure hr_ci operation performed without cardiopulmonary bypass associated better postoperative survival hr_ci conclusion bilateral ita grafting associated low morbidity good long_term result use skeletonized bilateral ita appropriate elderly_patient diabetes however recommended repeat operation patient chronic_obstructive_pulmonary_disease:0.0720720641317914", "88354": "introduction age superobesity cardiopulmonary comorbidities define patient high_risk bariatric surgery evaluated outcome following bariatric surgery extremely high_risk_patient material_method among_patient underwent laparoscopic bariatric surgery single academic center january june extremely high_risk_patient identified using following criterion age_year body_mass_index_bmi kg presence least two six cardiopulmonary comorbidities including hypertension ischemic_heart_disease congestive_heart_failure chronic_obstructive_pulmonary_disease obstructive_sleep_apnea history venous thromboembolism perioperative intermediate term outcome assessed result forty four extremely high_risk patient_underwent laparoscopic roux en gastric bypass n adjustable gastric banding n sleeve gastrectomy n patient mean_age_year mean bmi kg median two range two five cardiopulmonary comorbidities conversion laparotomy thirteen day postoperative complication occurred six major complication thirty day postoperative admission operation mortality_rate respectively within mean_follow time month late morbidity_mortality rate respectively mean percentage total weight excess weight_loss least year_follow respectively_conclusion laparoscopic bariatric surgery safe performed acceptable perioperative outcome extremely high_risk patient_advanced age bmi severe cardiopulmonary comorbidities exclude patient consideration bariatric surgery:0.0720203884608624", "9157": "objective prospectively assess early late morbidity_mortality patient_undergoing elective surgical repair abdominal infrarenal aortic aneurysm determine independent_predictor cardiac_event method consecutive year study analyzed patient_underwent routine standardized preoperative assessment always clinical surgical anesthesia team result hospital_mortality patient major cause_death mesenteric ischemia occurred_patient forty eight nonsurgical complication occurred follows cardiac_complication noncardiac complication common complication pulmonary one occurred_patient survival first third sixth postoperative year respectively variable significantly correlated morbidity_mortality clinical predictor mean_age_year presence heart_failure chronic renal_failure predictor late morbidity_mortality identified conclusion although considered highly complex surgery mortality low cardiac_complication significant patient good long_term evolution:0.0709352324433023", "27213": "aim evaluate outcome following cardiac_surgery nonagenarian method_retrospective analysis patient_year age undergoing cardiac_surgery barnes jewish hospital performed social security death index used determine late survival result twenty two subject identified mean_age_year range woman common comorbidities included hypertension heart_failure_hf mean new_york_heart_association_class mean left_ventricular_ejection_fraction range mean creatinine clearance cc min patient prior cardiac_surgery nine patient_underwent coronary bypass grafting valve replacement concurrent operation included ventricular septal_defect repair carotid endarterectomy ascending aortic patch angioplasty two case urgent emergent remainder elective one intraoperative death urgent mitral_valve replacement common postoperative complication included atrial_fibrillation need vasopressor hr mean length intensive_care total hospital_stay day respectively independent_predictor increased hospital_stay higher serum_creatinine p presence hf p survival day respectively study conclusion_patient alive mean_follow year conclusion despite higher morbidity_mortality carefully selected nonagenarian referred cardiac_surgery short_term complication rate long_term_outcome appear acceptable:0.0708078462150134", "55398": "background introduction transcatheter aortic_valve focused attention outcome open aortic_valve_replacement avr high_risk_patient study analyzes short_term midterm outcome avr patient cohort current surgical era method_retrospective review performed patient_underwent isolated primary avr sts prom society thoracic surgeon predicted risk mortality greater january_december four u academic institution patient previous valve operation excluded multivariable model constructed determine predictor hospital_mortality estimate cumulative event_rate mortality calculated kaplan_meier method_result mean_age patient_year men mean sts prom significant preoperative factor included following peripheral vascular_disease stroke renal_failure new_york_heart_association_class iii_iv heart_failure previous coronary_artery_bypass_grafting mean ejection_fraction median implanted valve size mm postoperative complication included following stroke heart block multisystem organ failure pneumonia dialysis postoperative length_stay day hospital_mortality one three year_survival respectively_conclusion current era high_risk surgical patient_undergoing open avr respectable short mid term survival result serve benchmark evaluating outcome transcatheter aortic_valve implantation:0.0706514767286496"}, "Topic 24": {"100861": "importance cardiovascular_risk assessment fundamental component prevention cardiovascular_disease_cvd however commonly_used prediction_model formulated primarily exclusively white population whether risk_assessment black adult dissimilar white adult uncertain objective develop validate risk prediction_model cvd incidence black adult incorporating standard risk_factor biomarkers subclinical disease design setting_participant jackson heart study jhs longitudinal community based study black adult jackson mississippi inclusive study date date participant first visit september march december median th percentile follow year date analysis august may measurement included standard risk_factor including age_sex body_mass_index systolic_diastolic blood_pressure ratio fasting total cholesterol high density_lipoprotein cholesterol estimated_glomerular_filtration_rate antihypertensive therapy diabetes_mellitus smoking blood biomarkers subclinical disease measure including ankle brachial index carotid intimal medial thickness echocardiographic left_ventricular_hypertrophy systolic_dysfunction main_outcome_measure incident cvd event defined first occurrence myocardial_infarction coronary_heart_disease death congestive_heart_failure stroke incident angina intermittent claudication model performance compared american college cardiology american heart_association acc aha cvd risk algorithm framingham risk_score fhs refitted jhs data evaluated atherosclerosis risk community aric multi ethnic study atherosclerosis cohort result_study cohort comprised participant mean_sd age baseline year n female median year participant woman experienced first cvd event simple combination standard cvd risk_factor b_type_natriuretic_peptide ankle brachial index model yielded modest improvement model without b_type_natriuretic_peptide ankle brachial index c_statistic ci relative integrated discrimination improvement ci however reclassification improvement substantially different model acc aha cvd pooled cohort risk equation model fhs model discriminated reasonably well aric multi ethnic study atherosclerosis data c_statistic range conclusion relevance finding using jhs data present_study valuable confirm current fhs acc aha risk algorithm work well black individual easily improved unique risk calculator black adult may necessary:0.0535419897685270", "35588": "objective_assess prospective association metabolic_syndrome mets cardiovascular_disease_cvd older people evaluate effect lowering threshold impaired fasting glucose ifg prevalence ifg mets risk cvd design prospective_cohort_study setting four field center u community participant three thousand five hundred eighty five subject cardiovascular health study free diabetes_mellitus cvd baseline mean_age female black measurement baseline measure mets component adjudicated incident cvd event mets defined first using original criterion third adult treatment panel report national cholesterol education program following large waist circumference woman cm men cm elevated triglyceride mmol_l low high density_lipoprotein cholesterol men mmol_l woman mmol_l elevated fasting glucose mmol_l high blood_pressure mmhg self_reported use medication hypertension subject also classified according revised definition mets applies lower threshold fasting glucose mmol_l result follow median year coronary_heart_disease chd stroke congestive_heart_failure_chf event occurred age race adjusted hazard_ratio_hr chd stroke chf confidence_interval_ci ci_ci woman ci_ci ci_ci men respectively overall woman_men mets likely experience cvd event subject without mets using lower cut point ifg resulted near tripling ifg prevalence additional classified mets hr similar estimated original mets criterion high blood_pressure component strongly_associated incident chd conclusion result_study elderly population_based cohort provide support earlier investigation primarily middle aged population link presence mets development cvd underscore importance recognizing treating individual component particularly high blood_pressure:0.0530921297942216", "119595": "importance little_known regarding association level blood_pressure bp young adulthood cardiovascular_disease_cvd event middle age objective_assess whether young adult developed hypertension defined american college cardiology acc american heart_association aha bp guideline age_year higher_risk cvd event compared maintained normal bp design setting_participant analysis conducted prospective cohort coronary_artery risk development young adult cardia study started march cardia enrolled african_american white participant aged_year u field center birmingham alabama chicago illinois minneapolis minnesota oakland california outcome available august exposure using highest bp measured first examination examination closest age_year participant categorized normal bp untreated systolic bp sbp mm_hg diastolic bp dbp mm_hg n elevated bp untreated sbp mm_hg dbp mm_hg n stage hypertension untreated sbp mm_hg dbp mm_hg n stage hypertension sbp mm_hg dbp mm_hg taking antihypertensive medication n main_outcome_measure cvd event fatal nonfatal coronary_heart_disease chd heart_failure stroke transient_ischemic_attack intervention peripheral artery disease pad result final cohort included adult mean_age follow outcome began year sd woman african_american taking antihypertensive medication median_follow_year incident cvd event occurred chd stroke_heart_failure pad cvd incidence_rate normal bp elevated bp stage hypertension stage hypertension ci_ci ci_ci ci_ci per_person_year respectively multivariable adjustment hazard_ratio cvd event elevated bp stage hypertension stage hypertension v normal bp ci_ci ci_ci respectively_conclusion relevance among young adult elevated blood_pressure stage hypertension stage hypertension age_year defined blood_pressure classification american college cardiology american heart_association acc aha guideline significantly_higher risk subsequent cardiovascular_disease event compared normal blood_pressure age_year acc aha blood_pressure classification system may_help identify young adult higher_risk cardiovascular_disease event:0.0495300002226272", "73022": "importance prior study_demonstrated lower cause_mortality individual overweight compared normal body_mass_index_bmi whether may come cost greater burden cardiovascular_disease_cvd unknown objective calculate lifetime risk estimate incident cvd subtypes cvd estimate year lived without cvd weight status design setting_participant population_based study used pooled individual level data adult baseline age_year across large u prospective cohort million person year_follow participant free clinical cvd baseline available bmi index cvd outcome data data analyzed october july exposure world health organization standardized bmi category main_outcome_measure total cvd cvd subtype including fatal nonfatal coronary_heart_disease stroke congestive_heart_failure cvd death height weight measured directly investigator study bmi calculated weight kilogram divided height meter squared performed modified kaplan_meier analysis estimate lifetime risk adjusted competing cox model estimate joint cumulative risk cvd noncardiovascular death irwin restricted mean estimate year lived free cvd result person examination included_study mean_sd age_year men year woman patient female compared individual normal bmi defined bmi lifetime risk incident cvd higher middle aged adult overweight obese group_compared normal weight among middle aged men_woman competing hazard_ratio incident cvd ci_ci respectively overweight bmi ci_ci obesity bmi ci_ci morbid obesity bmi higher bmi strongest association incident heart_failure among cvd subtypes average year lived cvd longer middle aged adult overweight obese group_compared adult normal bmi group similar pattern observed younger older_adult conclusion relevance study obesity associated shorter longevity significantly increased_risk cardiovascular morbidity_mortality compared normal bmi despite similar longevity compared normal bmi overweight associated significantly increased_risk developing cvd earlier age resulting greater proportion life lived cvd morbidity:0.0461453659963664", "193489": "importance nocturnal hypertension asleep associated substantial increase_risk cardiovascular_disease_cvd death whether hypertension supine risk_factor associated cvd independent seated hypertension remains unknown objective investigate association supine hypertension cvd outcome hypertension treatment status design setting_participant prospective_cohort_study used data atherosclerosis risk community aric study established examine cardiovascular_risk_factor among middle aged adult community u supine seated blood_pressure measured middle aged adult longitudinal surveillance cvd year participant history coronary_heart_disease chd heart_failure stroke excluded data analyzed may december exposure supine hypertension supine systolic_blood_pressure diastolic blood_pressure mm_hg without seated hypertension seated systolic_blood_pressure diastolic blood_pressure mm_hg main_outcome_measure cox_proportional_hazard_model adjustment cvd risk_factor performed investigate association supine hypertension without seated hypertension incident chd heart_failure stroke fatal chd cause_mortality result participant without known cvd female male black white mean_sd age_year ci without seated hypertension supine hypertension ci seated hypertension supine hypertension supine hypertension associated incident chd hazard_ratio hr_ci heart_failure hr_ci stroke hr_ci fatal chd hr_ci cause_mortality hr_ci median th th percentile follow year_year year_year year_year year_year year_year respectively meaningful difference seated hypertension status result similar hypertension medication use participant supine hypertension alone risk association similar participant hypertension position significantly_greater participant seated hypertension alone exception fatal chd seated v supine hr_ci chd ci heart_failure ci stroke ci cause_mortality conclusion relevance supine hypertension regardless seated hypertension higher hr cvd risk seated hypertension alone future_research evaluate supine hypertension setting nocturnal hypertension independent target blood_pressure treatment:0.0460867942329540", "78309": "context estimate lifetime risk total cardiovascular_disease_cvd may_provide projection future population burden cvd may assist clinician patient_risk communication date lifetime risk estimate total cvd reported objective calculate lifetime risk estimate total cvd index age_year risk_factor stratum estimate year lived free cvd across risk_factor stratum design setting_participant pooled survival analysis many person_year data national heart lung blood institute funded community based cohort framingham heart study framingham offspring study atherosclerosis risk community study chicago heart_association detection project industry study cardiovascular health study_participant free cvd baseline risk_factor data blood_pressure bp total cholesterol tc diabetes smoking status total cvd outcome data main_outcome_measure total cvd event including fatal nonfatal coronary_heart_disease form stroke congestive_heart_failure cvd death result index age_year overall lifetime risk total cvd ci men ci woman_men higher lifetime risk estimate woman across index age index age_year men_woman least elevated risk_factor bp mm_hg tc mg_dl diabetes smoking major risk_factor least major risk_factor bp mm_hg receiving treatment tc mg_dl receiving treatment diabetes_mellitus current smoking lifetime risk estimate age_year exceeded despite optimal risk_factor profile bp mm_hg tc mg_dl smoking diabetes men_woman index age_year lifetime risk year_age total cvd greater respectively compared participant least major risk_factor optimal risk_factor profile lived year longer free total cvd conclusion lifetime risk estimate total cvd high individual even optimal risk_factor middle age however maintenance optimal risk_factor level middle age associated substantially longer morbidity free_survival:0.0456797741424799", "181068": "importance education social determinant health quantifying association lifetime cardiovascular_disease_cvd risk public_health importance objective calculate lifetime risk estimate incident cvd cvd subtypes estimate year lived without cvd education design setting_participant included community based cohort_study adjudicated cardiovascular_event used pooled individual level data prospective_cohort_study study team assessed association education lifetime cvd risk modified kaplan_meier cox model accounting competing risk noncardiovascular death study team estimated year lived without cvd education irwin restricted mean utility adding educational attainment cvd risk_assessment participant baseline year_old year_old without cvd baseline complete education cardiovascular_risk_factor prospective cvd outcome data data analyzed january september exposure educational attainment less high school high school completion college college graduate main_outcome_measure cardiovascular_event fatal nonfatal coronary_heart_disease heart_failure stroke cvd related death total cvd encompassing event result participant female mean_sd age_year male year female compared college graduate less high school high school completion higher lifetime cvd risk among middle aged men competing hazard_ratio_hr cvd event ci_ci ci_ci less high school high school college respectively compared college completion among woman competing hr_ci ci_ci individual higher education longer duration life prior incident cvd education provided limited contribution toward enhancing cvd risk prediction conclusion relevance lower education associated lifetime cvd risk across adulthood higher education translated healthy longevity educational policy initiative may associate long_term health benefit:0.0456358150601206", "110355": "background data indicate majority incident cardiovascular_disease_cvd event occur among u adult systolic_diastolic blood_pressure sbp dbp mm_hg past several decade bp declined hypertension control improved method estimated percentage incident cvd event occur sbp dbp mm_hg pooled analysis contemporary u cohort regard study reason geographic racial difference stroke mesa multi ethnic study atherosclerosis jhs jackson heart study n regard mesa jhs baseline study visit conducted regard mesa jhs bp measured trained staff using standardized method antihypertensive medication use self_reported primary_outcome incident cvd defined first occurrence fatal nonfatal stroke nonfatal myocardial_infarction fatal coronary_heart_disease heart_failure event adjudicated study result mean_follow year participant incident cvd event overall confidence_interval_ci event occurred participant sbp dbp mm_hg ci_ci among taking taking antihypertensive medication respectively majority event occurred participant sbp dbp mm_hg among year_age ci year_age ci woman ci men ci white ci black ci hispanic ci chinese american ci among participant taking antihypertensive medication sbp dbp mm_hg ci eligible statin treatment ci taking one ci met sprint systolic_blood_pressure intervention trial eligibility criterion may benefit sbp target goal mm_hg conclusion although higher bp level associated_increased cvd risk modern era majority incident cvd event occur u adult sbp dbp mm_hg absolute risk cost_effectiveness considered additional cvd risk reduction measure adult sbp dbp mm_hg high_risk cvd may warranted:0.0453747485132299", "136490": "importance american heart_association ideal cardiovascular health cvh score associated risk cardiovascular_disease_cvd mortality however unclear whether number year spent ideal cvh associated morbidity_mortality objective_evaluate whether living longer higher cvh score midlife associated_lower risk hypertension_diabetes chronic_kidney_disease cvd subtypes coronary_heart_disease stroke congestive_heart_failure peripheral artery disease cause_mortality later life design setting_participant prospective_cohort_study used data participant participated community based framingham heart study offspring investigation conducted massachusetts cvh score participant assessed examination cycle respectively individual excluded analysis association duration cvh score outcome outcome interest seventh examination median_follow approximately year data analyzed april october cvh score category poor score intermediate score ideal score composite score derived based smoking status diet physical_activity resting blood_pressure level body_mass_index fasting blood glucose level total serum cholesterol level main_outcome_measure number event number risk main outcome including incident hypertension_diabetes chronic_kidney_disease cvd cause_mortality seventh examination result eligible participant mean_sd age_year woman number event number risk main outcome seventh examination incident hypertension_diabetes chronic_kidney_disease cvd cause_mortality seventh examination participant mostly poor intermediate cvh score antecedent examination cycle year duration participant intermediate ideal cvh less_likely develop adverse_outcome hazard_ratio ci incident hypertension ci diabetes ci chronic_kidney_disease ci cvd ci cause_mortality relative living amount time poor cvh referent group effect modification observed age_sex conclusion relevance result_suggest time spent better cvh midlife may salutary cardiometabolic benefit may associated_lower mortality later life:0.0453158699509979", "105097": "importance data sparse regarding blood_pressure bp component young adulthood optimally determine cardiovascular_disease_cvd middle age objective_assess bp component best determine incident cvd event young adult determine_whether association vary race age bp measurement design setting_participant using data coronary_artery risk development young adult cardia study study assessed longitudinal race stratified association bp cardiovascular_outcome cardia community based cohort recruited black white individual age range year march june cardia followed participant year surviving cohort completed least telephone interview examination august august exposure blood_pressure measubred baseline year later main_outcome_measure composite cvd event including coronary_heart_disease stroke_heart_failure vascular_disease result_total participant participated study mean_sd age_year year male_female black individual white individual mean sbp dbp mm_hg black mm_hg white mm_hg black mm_hg white year_follow cvd event occurred twice many event black n compared white black occurred adjustment covariates result cox_proportional_hazard_model including sbp dbp jointly suggested sbp hazard_ratio_hr per sd increase ci dbp hr_ci associated cvd risk black whereas dbp hr_ci sbp hr_ci associated cvd risk white sbp strongest indicator cvd black hr_ci white hr_ci conclusion relevance study question classic view dbp able identify future cvd event sbp individual younger year young adulthood sbp black individual dbp white individual robust indicator future cvd middle age sbp race identified risk incident cvd:0.0450542681430295"}, "Topic 25": {"41469": "trastuzumab monoclonal antibody block receptor improves survival woman positive early advanced breast_cancer given chemotherapy lapatinib dual tyrosine kinase inhibitor egfr approved treatment metastatic breast_cancer patient failure prior anthracycline taxanes trastuzumab therapy combination capecitabine importantly cardiac toxicity manifested symptomatic congestive_heart_failure asymptomatic left_ventricular_ejection_fraction decline reported patient_receiving novel anti therapy particularly drug used following anthracyclines whose cardiotoxic potential recognized decade review_focus incidence natural history underlying_mechanism management area uncertainty regarding trastuzumab lapatinib induced cardiotoxicity:0.0680305737177728", "9838": "cardiac toxicity chemotherapeutic agent rapidly evolving area increasing significance increasing pool long_term cancer survivor spectrum cardiotoxicity chemotherapeutic agent includes hypertension qtc prolongation acute cardiomyopathy bradyarrhythmias common issue arise cardiomyopathy anthracyclines preventative strategy met success included use less cardiotoxic analog epirubicin liposomal anthracycline preparation cardioprotectant agent dexrazoxane reduces cardiomyopathy significant toxicity issue therefore main strategy preventing cardiotoxicity remains careful monitoring radionuclide angiography echocardiography role investigational marker myocardial_injury troponin brain_natriuretic_peptide remains great interest management according conventional management congestive_heart_failure trastuzumab antibody therapy directed human epidermal growth_factor receptor receptor increase survival patient metastatic breast_cancer evaluation adjuvant setting also cause decrease left_ventricular_ejection_fraction_lvef minority patient incidence increased trastuzumab given conjunction paclitaxel anthracyclines differs anthracycline cardiotoxicity cumulative dose dependent often improves withdrawal treatment treatment trastuzumab often possible novel agent development offer different spectrum toxicity existing anticancer drug appears likely cardiovascular toxicity important issue many drug particularly target tumor vasculature:0.0678175248127805", "46710": "anticancer drug continue cause significant_reduction left_ventricular_ejection_fraction resulting congestive_heart_failure best known cardiotoxic agent anthracyclines anths doxorubicin dox several decade cardiotoxicity almost exclusively associated anths cumulative dose related cardiac damage use limiting step human epidermal growth_factor egf receptor erbb identified important target breast_cancer trastuzumab trz humanized anti monoclonal antibody currently recommended first_line treatment_patient metastatic tumor use trz may limited development drug intolerance cardiac_dysfunction cardiotoxicity attributed free iron based radical induced oxidative_stress many approach promoted minimize serious side_effect still clinically problematic new approach personalized medicine cancer involves molecular screening clinically_relevant genomic alteration genotype targeted treatment emerging:0.0665191149258084", "5321": "anthracyclines first introduced treatment metastatic breast_cancer still among active single agent treatment disease unfortunately clinical value limited late onset ventricular dysfunction epirubicin anthracycline analogue eliminate risk cardiotoxicity less cardiotoxic myelotoxic doxorubicin equimolar dos thereby allowing safe administration cumulative dos mg inclusion epirubicin combination regimen fluorouracil epirubicin cyclophosphamide fec shown safe active first_line treatment metastatic breast_cancer past year new drug including taxanes shown high_level activity single agent treatment advanced breast_cancer doxorubicin paclitaxel combination shown high overall response rate first_line chemotherapy advanced breast_cancer however congestive_heart_failure reported patient epirubicin paclitaxel combination associated grade cardiotoxicity one study report finding trial combination epirubicin paclitaxel first_line treatment advanced breast_cancer overall response rate orr complete response cr rate achieving cr first_line chemotherapy advanced breast_cancer appears predict survival adding active drug different mechanism_action nonoverlapping toxicity might increase percentage cr therefore tested feasibility activity course first_line treatment three drug combination gemcitabine mg_day epirubicin mg_day paclitaxel mg hour day phase ii study metastatic breast_cancer patient treatment well_tolerated orr confidence_interval cr considering retreating patient progress relapse receiving anthracycline taxane containing regimen active drug epirubicin appears ideal adjuvant metastatic breast_cancer setting:0.0629591101069717", "9234": "dexrazoxane cardioxane zinecard cyclic derivative edetic acid site specific cardioprotective agent effectively protects anthracycline induced cardiac toxicity dexrazoxane approved u european country cardioprotection woman advanced metastatic breast_cancer receiving doxorubicin country dexrazoxane approved use wider range patient_advanced cancer receiving anthracyclines shown clinical_trial intravenous dexrazoxane significantly reduces incidence anthracycline induced congestive_heart_failure_chf adverse cardiac_event woman advanced breast_cancer adult soft tissue sarcoma small cell lung cancer regardless whether drug given first dose anthracycline administration delayed cumulative doxorubicin dose mg drug also appears offer cardioprotection irrespective pre_existing cardiac risk_factor importantly antitumour efficacy anthracyclines unlikely altered dexrazoxane use although drug shown improve progression free overall patient survival present cardioprotective efficacy dexrazoxane patient childhood malignancy supported limited data drug generally well_tolerated tolerability profile similar placebo cancer patient_undergoing anthracycline based chemotherapy exception higher incidence severe leukopenia v_p dexrazoxane cardioprotective agent proven efficacy cancer patient_receiving anthracycline chemotherapy valuable option prevention cardiotoxicity patient_population:0.0625223840798871", "20254": "trastuzumab monoclonal antibody target human epidermal growth_factor receptor tyrosine kinase erbb agent shown highly significant antitumour effect patient positive breast_cancer considered part standard regimen treatment disease metastatic adjuvant setting cardiotoxicity associated trastuzumab issue studied documented number adjuvant trial data released cardiotoxicity shown potentiated agent used concurrently sequentially anthracycline limited use trastuzumab patient determining overall impact trastuzumab complicated administration cardiotoxic agent taxanes cyclophosphamide well pre_existing cardiac_disease incidence severe congestive_heart_failure new_york_heart_association_class iii_iv trastuzumab arm versus control arm five major randomized adjuvant trial one cardiac_death related trastuzumab whereas two cardiac_death occurred control arm ejection_fraction decline reported trastuzumab recipient trial patient affected trastuzumab related cardiotoxicity exhibit cellular death distinctive ultrastructural myocardial change seen electron microscopy anthracycline induced cardiotoxicity cardiotoxicity trastuzumab also differs traditional chemotherapy induced cardiotoxicity appears least partially reversible related cumulative dose challenge generally tolerated remain number uncertainty regarding diagnosis management trastuzumab related cardiotoxicity formal guideline consensus statement exist present regarding cardiac monitoring use trastuzumab proposed recommendation include careful assessment ejection_fraction prior initiating trastuzumab avoidance concurrent administration trastuzumab anthracyclines regular monitoring symptom cardiac_function several year therapy increased vigilance appropriate higher_risk patient:0.0607401216027951", "195120": "chemotherapy drug significantly_decreased breast_cancer morbidity_mortality associated_increased_risk adverse cardiovascular side_effect cardiotoxicity drug generally fall three broad category cell cycle inhibitor ex anthracyclines taxanes human epidermal growth_factor blocker ex trastuzumab pertuzumab well medication alkylating agent cyclophosphamide review analyzes occurrence specific cardiotoxic manifestation linked increased heart_failure risk chest discomfort edema dyspnea well mechanism_action anthracycline inducing generation reactive_oxygen_specie aforementioned three drug category particular attention given anthracyclines blocker two commonly prescribed medication hand cardiotoxic effect medication found able mitigated various exercise regimen aerobic exercise resistance training high intensity interval training review also examines effectiveness different regimen alleviating post chemotherapy cardiotoxicity breast_cancer patient well specific mechanism involved aerobic exercise able downregulate expression doxorubicin induced pro inflammatory factor ex interleukin cyclooxegenase etc moreover review point relative lack cardiac_rehabilitation program specifically addressing post chemotherapeutic cardiotoxicity risk breast_cancer patient therefore customized exercise regimen accounting breast_cancer patient specific medical profile developed counteract adverse cardiovascular effect chemotherapy:0.0595713324408216", "43543": "purpose high incidence congestive_heart_failure_chf observed_patient metastatic breast_cancer mbc receiving doxorubicin based chemotherapy trastuzumab herceptin cyclophosphamide epirubicin hercules trial evaluated trastuzumab plus cyclophosphamide less cardiotoxic anthracycline epirubicin patient_method prospective trial combined phase dose finding stage phase ii randomized stage total_patient human epidermal growth_factor receptor positive mbc adequate cardiac_function received first_line trastuzumab mg_kg intravenous loading dose mg_kg every week plus cyclophosphamide mg either epirubicin mg hec mg hec six cycle followed trastuzumab monotherapy progression sixty patient negative disease received epirubicin mg cyclophosphamide ec alone primary_end_point dose limiting cardiotoxicity dlc result incidence dlc hec hec ec arm respectively dlc event manageable cardiac related death adverse_event profile comparable across three arm except febrile neutropenia reported hec arm compared arm tumor response rate hec hec ec arm respectively median time progression month respectively_conclusion hec regimen promising treatment_option patient positive mbc lower incidence dlc hec compared historic incidence associated trastuzumab plus doxorubicin support evaluation regimen especially adjuvant neoadjuvant setting:0.0587382605193892", "118302": "anthracyclines doxorubicin daunorubicin epirubicin idarubicin among potent chemotherapeutic agent truly revolutionized management childhood cancer form backbone chemotherapy regimen used treat childhood acute lymphoblastic leukemia acute myeloid leukemia hodgkin lymphoma ewing sarcoma osteosarcoma neuroblastoma child cancer treated anthracyclines clinical utility anthracyclines compromised dose dependent cardiotoxicity manifesting initially asymptomatic cardiac_dysfunction evolving irreversibly congestive_heart_failure childhood cancer survivor five fold increased_risk congestive_heart_failure compared general_population diagnosed congestive_heart_failure year survival_rate less prediction_model developed childhood cancer survivor e exposure anthracyclines identify increased_risk cardiotoxicity study currently way test risk reducing strategy remains critical need identify_patient childhood cancer diagnosis e prior anthracycline exposure noncardiotoxic therapy contemplated:0.0585146594212842", "162546": "throughout last decade newly developed chemotherapeutic agent immunotherapy target signaling_pathway provided patient better prognosis improved quality_life increased survival_rate thus converting cancer stable chronic_disease however non anthracycline cancer chemotherapy agent immunotherapy including human epidermal growth_factor receptor inhibitor vascular endothelial growth_factor vegf inhibitor bcr abl tyrosine kinase inhibitor tki proteasome inhibitor immune checkpoint inhibitor chimeric antigen receptor cell car cell may cause cardiovascular toxicity event complication usually interrupt continuation appropriate treatment regimen induces life_threatening risk lead long_term morbidity heart_failure cardiac arrythmias cardiomyopathy common cardiovascular_event related cardiotoxicity due chemotherapy patient carefully assessed monitored administration chemotherapy address predisposing risk_factor new_onset cardiotoxicity manifestation early treat appropriately development novel anticancer agent cause minimal cardiovascular toxicity event novel agent ameliorate adverse_effect existing anticancer agent could drastically change field cardio oncology aim narrative review demonstrate new knowledge regarding screening diagnosis non anthracycline induced cardiotoxicity propose protective measure could performed order achieve delivery optimal care:0.0584987381189760"}, "Topic 26": {"2273": "objective create valid sensitive disease specific health_status measure patient congestive_heart_failure_chf background quantifying health_status becoming increasingly important chf kansa city cardiomyopathy questionnaire kccq new self administered item questionnaire quantifies physical limitation symptom self efficacy social interference quality_life method establish performance characteristic kccq two distinct patient cohort recruited stable decompensated chf_patient ejection_fraction upon entry study_patient administered kccq minnesota living_heart_failure questionnaire short form sf questionnaire repeated three month later result convergent validity kccq domain documented comparison available criterion standard r_p among stable chf remained stable predefined criterion n minimal change kccq domain detected three month observation mean change point p n contrast large change score observed among_patient whose decompensated chf improved three month later n mean change point p sensitivity kccqwas substantially greater minnesota living_heart_failure sf questionnaire conclusion kccqis valid reliable responsive health_status measure patient_chf may serve clinically meaningful outcome cardiovascular research patient management quality assessment:0.0534751697266491", "62081": "aim patient_heart_failure_hf commonly suffer severe impairment quality_life qol one main goal hf treatment improvement qol physical well essential component qol enable assessment physical well hf_patient validated questionnaire prospective_study patient cardiac insufficiency bisoprolol study elderly method_result hf_patient age_year male new_york_heart_association_class ii left_ventricular_ejection_fraction measured physical well qol item short form health survey sf depressive_symptom prime md patient health questionnaire german short version depression phq baseline two follow visit correlated score qol data clinical parameter mean score baseline_month year assessed data quality scale assumption construct validity reliability cronbach alpha subscales resilience ability enjoy vitality inner peace total score intraclass correlation coefficient icc ci icc pearson correlation sf phq significant six minute walking distance heart_rate correlated significantly total score conclusion showed good reliability internal consistency intraclass correlation score correlated well psychological physical well sf clinical marker exercise_tolerance min walk test heart_rate result indicate strong correlation self_reported physical well psychological factor value baseline predicted development several aspect qol beta_blocker titration:0.0522226688104942", "171754": "introduction kansa city cardiomyopathy questionnaire kccq one widely_used instrument measuring health_related_quality_life patient_heart_failure_hf however item version kccq sufficiently tested european population invariance patient reduced midrange preserved_ejection_fraction never assessed aim purpose_study examine validity reliability kccq large cohort italian patient_hf assess measurement invariance across level ejection_fraction method total_patient mean_age_year_male completed kccq alongside measure depression anxiety quality_life hf symptom burden construct validity assessed mean confirmatory factor analysis testing association kccq score clinical parameter ie ejection_fraction mortality month well measure anxiety depression symptom burden general quality_life multigroup confirmatory factor analysis implemented investigate invariance property across reduced midrange preserved_ejection_fraction omega model based internal consistency coefficient computed investigate internal consistency reliability result confirmatory factor analysis specified according original factor model ie physical social limitation symptom frequency quality_life yielded satisfactory fit index root mean square error approximation comparative fit index moderate high correlation found kccq mental physical component score short form well conceptually related construct indicating adequate facet construct validity multigroup confirmatory factor analysis tested across patient different ejection_fraction group established kccq invariant partial scalar level omega model based internal consistency coefficient adequate ranging subscales whole scale confirming strong internal consistency reliability conclusion kccq demonstrated satisfactory psychometric property european sample patient_hf providing evidence support use practice research:0.0489994981885856", "19501": "introduction objective minnesota living_heart_failure questionnaire mlhfq commonly_used instrument evaluating quality_life patient_heart_failure comprises item two dimension physical emotional aim_study assess psychometric property spanish version mlhfq method mlhfq item short form sf questionnaire administered one two month discharge patient_hospitalized heart_failure_patient classified either stable n unstable n basis new_york_heart_association nyha_functional_class three functional_capacity variable reliability evaluated_using measure internal consistency cronbach alpha reproducibility intraclass correlation coefficient icc validity assessed looking score nyha_class correlation score mlhfq sf dimension responsiveness change evaluated_using effect size result cronbach alpha three mlhfq score icc also large addition mlhfq score varied significantly functional_class p intermediate high correlation assumed corresponding sf dimension observed effect size small intermediate conclusion spanish version mlhfq demonstrated adequate metric property comparable original result support use mlhfq spanish heart_failure_patient although would advisable evaluate responsiveness change:0.0489327939118496", "51352": "background assessment health_related_quality_life widely recommended european health agency relevant research study well clinical care aim validate french version macnew heart_disease health_related_quality_life questionnaire method part international heartqol project french speaking patient ischaemic_heart_disease angina n myocardial_infarction_mi n heart_failure n mean_age_year recruited seven cardiac_rehabilitation centre patient completed french version macnew questionnaire short form health survey sf hospital anxiety depression scale evaluate psychometric property french version macnew instrument result mean macnew global scale score patient angina mi heart_failure respectively_p mi versus angina observed minimal missing item ceiling effect floor effect factor analysis confirmed three factorial structure explaining observed variance internal consistency reliability cronbach alpha ranged test retest reliability ranged convergent validity confirmed total group diagnosis although correlation macnew physical subscale sf mental component summary higher expected discriminative validity partially confirmed sf health transition item fully confirmed anxiety depression predictor variable conclusion french version macnew questionnaire recommended assessing health_related_quality_life french speaking patient ischaemic_heart_disease:0.0479734435016126", "155859": "background health_related_quality_life hrqol important outcome indicator chronic_disease study_aimed develop new instrument assessment hrqol chronic_heart_failure_chf evaluate psychometric property method_study included two step conceptualization item generation assessment psychometric property instrument measuring hrqol patient_chf sample patient confirmed diagnosis heart_failure participated study addition content validity exploratory confirmatory factor analysis concurrent validity convergent validity known group comparison performed assess construct validity internal consistency stability estimated cronbach alpha macdonal omega intraclass correlation coefficient result content validity developed chronic_heart_failure quality_life questionnaire assessed expert exploratory factor analysis indicated four factor solution instrument containing item jointly accounted variance observed confirmatory factor analysis confirmed four factor solution following fit index chi df cfi nfi tli ifi gfi agfi rmsea however stage one item removed concurrent convergent validity chfqolq established using short form health survey sf macnew heart_disease quality_life questionnaire respectively known group validity assessed_using new_york_heart_association nyha functional classification showed questionnaire discriminated well patient differed functional classification internal consistency test retest reliability chfqolq satisfactory cronbach alpha intraclass correlation coefficient icc value respectively_conclusion result confirmed chfqolq valid reliable instrument measuring quality_life qol patient_chf short easy use instrument also capable assessing cognitive functioning overlooked previous questionnaire:0.0475238131696266", "59762": "objective compare psychometric property heart_failure_hf specific quality_life questionnaire medical outcome study item short form health survey sf patient_hf design methodological study based month_follow data evaluating psychometric property health_related_quality_life hrqol questionnaire setting cardiac_rehabilitation center cardiovascular research institute participant eligible patient_hf n intervention exercise_training cardiac_rehabilitation main_outcome_measure sf macnew heart_disease questionnaire minnesota living_heart_failure questionnaire mlhfq new_york_heart_association functional classification result item mlhfq macnew questionnaire acceptable correlation r_p internal consistency test retest reliability adequate mlhfq subscales correlation mlhfq macnew sf similar item ranged respectively similar scale macnew mlhfq showed strong correlation baseline follow supporting convergent validity improvement hrqol significant mlhfq subscales p macnew emotional p social p subscales mlhfq demonstrated responsiveness change discriminated disease_severity best follow score mlhfq macnew subscales significantly_greater patient improved compared showed change deteriorated conclusion mlhfq responsive change hrqol macnew questionnaire time patient_hf macnew questionnaire responsive change sf:0.0468733581830719", "12983": "background_heart_failure_hf increasingly common condition affecting patient health_related_quality_life hrql however little literature comparing hf specific instrument aim evaluate compare data conceptual model metric property reliability validity responsiveness hf specific hrql instrument performing systematic_review_meta_analysis method_result article initially identified full text reviewed ninety four reported data five questionnaire minnesota living_heart_failure questionnaire mlhfq chronic_heart_failure questionnaire chfq quality_life questionnaire severe_heart_failure qlq shf kansa city cardiomyopathy questionnaire kccq left_ventricular_dysfunction lvd questionnaire metric property reliability validity responsiveness summarised using meta_analysis pool five estimate cronbach alpha coefficient generally high overall score scale measuring physical health association four validity criterion new_york_heart_association_nyha_class six minute_walk test mwt short form sf physical social functioning moderate strong except two chfq domain fatigue dyspnoea nyha pooled estimate change eight meta_analysis showed mlhfq highly responsive change overall score ranging confidence_interval_ci placebo ci pacing device chfq kccq also showed good sensitivity change conclusion questionnaire studied met minimum psychometric criterion though current evidence would primarily support use mlhfq followed kccq chfq:0.0467566568255979", "6710": "background_heart_failure_hf implication quality_life age range elderly simultaneously present limitation imposed multiple co_morbidity although several instrument measure health_related_quality_life hrql none specific elderly hf among disease specific instrument minnesota living_heart_failure lhfq studied extensively among elderly respect psychometric property objective purpose_study evaluate convergent divergent discriminative validity brazilian version lhfq applied elderly hf_patient method one_hundred seventy elderly interviewed lhfq capacity discriminate subject among new_york_heart_association_nyha_class ii iii_iv analyzed convergent divergent validity evaluated correlation domain lhfq generic instrument medical outcome study mo item short form health survey sf result lhfq total score physical dimension sub scale discriminated three sub group nyha_class ii iii_iv p emotional dimension discriminated nyha_class iii_iv p physical emotional dimension lhfq sf significantly correlated coefficient physical dimension emotional dimension however contrary expectation divergent validity totally confirmed difference magnitude correlation lhfq emotional physical dimension sf role physical social functioning role emotional thus result_suggest lhfq seems valid tool measure hrql elderly new study remain necessary gain better understanding discriminative validity advanced nyha_functional_class divergent validity:0.0467296344837863", "129452": "background health_related_quality_life hrqol known impaired individual coronary_artery_disease_cad especially recent acute_coronary_syndrome_ac heart_failure_hf common burden population significantly contributes worsening hrqol accurately measure level hrqol individual cad ac disease specific scale minnesota living_heart_failure questionnaire mlhfq recommended nevertheless date study would comprehensively evaluate psychometric property mlhfq large sample individual cad ac debate regarding internal structure mlhfq also still present hence study_aimed translate mlhfq evaluate internal structure reliability precision validity individual cad following ac lithuania method cross_sectional_study participant men age sd evaluated sociodemographic clinical_characteristic hrqol measured_using mlhfq short form health survey sf addition exercise_capacity ec also evaluated study_patient using standardized computer driven bicycle ergometer result internal consistency mlhfq subscales found good confirmatory factor analysis cfa provided support three factor model physical domain social domain emotional domain mlhfq showed acceptable fit comparative fit index cfi goodness fit gfi non normal fit index nfi root mean square error approximation rmsea regarding convergent evidence significant_association found mlhfq domain sf domain ec r range conclusion current study completed cultural validation provided information psychometric characteristic mlhfq lithuania suggesting mlhfq valid reliable instrument measure hrqol lithuanian version mlhfq best described three factor solution measuring physical social emotional dimension hrqol among individual cad following ac:0.0466926076474526"}, "Topic 27": {"150486": "introduction hospital quality improvement hospital performance commonly evaluated_using parameter average length_stay los patient safety measure rate hospital_readmission thirty day_readmission dr rate widely_used quality indicator quantifiable metric hospital since patient often readmitted exacerbation condition index admission quality patient education postdischarge care influence readmission_rate report dr rate patient asthma using national dataset year objective aim_study assess day_readmission dr rate well cause predictor readmission study_design method using nationwide readmission database nrd identified primary discharge diagnosis asthma using international classification disease ninth revision clinical modification code categorical continuous variable assessed chi test student test respectively independent_predictor unplanned dr detected multivariate_analysis used sampling weight provided nrd generate national estimate result weighted n inpatient asthma admission overall dr asthma associated factor dr age_year v_p enrolment medicare v_p extended los mean v day p_higher mean cost u v u p_higher disposition medical advice dama v_p factor increased chance dr advanced age v_year ci_p male sex ci_p higher charlson comorbidity index cci ci_p dama ci_p non compliance medication ci_p post traumatic stress disorder ci_p alcohol use ci_p gastro oesophageal reflux disease ci_p obstructive sleep apnoea ci_p hypertension ci_p_conclusion found overall dr rate asthma cause readmission major cause dr asthma exacerbation chronic_obstructive_pulmonary_disease respiratory_failure non specific pneumonia septicaemia congestive_heart_failure one fourth revisits occurred first week half revisits took place first week education regarding illness importance medicine compliance could play significant role preventing asthma related readmission:0.0541997929015406", "191315": "background canada one seven adult diabetes e million lifetime risk developing diabetes approximately age although patient_admitted hospital diabetes data inpatient hospitalization patient_diabetes lacking canada globally objective validate international classification disease th edition canadian version icd ca code identification patient_diabetes create multicenter database patient_diabetes hospitalized internal medicine ontario determine baseline_characteristic medication use admission characteristic study_design created database people diabetes hospitalized hospital ontario part general medicine inpatient initiative gemini hospital data sharing network patient_diabetes identified using chart review based upon either previous physician diagnosis diabetes ii recorded hemoglobin c iii outpatient prescription diabetes medication preceding hospitalization test characteristic icd ca code diabetes evaluated compared baseline demographic medication use hospitalization detail among_patient without diabetes hospitalization detail collected information admission diagnosis comorbidity index length_stay receipt icu level care inpatient mortality result admission within total study cohort icd ca diagnosis code diabetes e x e x e x e x sensitivity_specificity icd ca diagnostic code respectively patient icd ca code diabetes code type_diabetes code type_diabetes rare mean_age_year patient_without diabetes year icd ca diagnosis code diabetes patient_diabetes higher_prevalence hypertension v coronary_artery_disease v heart_failure v renal_failure v comparison without diabetes prevalent diabetes medication received hospital metformin dpp inhibitor sulfonylurea common reason admission among_patient diabetes heart_failure among_patient without diabetes pneumonia median length_stay longer patient_diabetes v day hospital_mortality similar group diabetes v without diabetes importance diabetes one prevalent chronic medical condition affecting roughly one third patient_hospitalized internal medicine ward associated comorbidities longer hospital_stay icd ca code highly accurate identifying patient_diabetes development inpatient cohort allow study hospital practice outcome among_patient diabetes:0.0501063630157823", "138009": "background early readmission important indicator quality care limited data exist describing hospital_readmission acute diverticulitis study_aimed describe unplanned day_readmission among adult acute diverticulitis patient assess readmission predictor method analyzed united_state national readmission database identified acute diverticulitis admission using administrative code adult_patient older year_age primary_outcome day unplanned readmission_rate used chi square test test wilcoxon rank sum test descriptive analysis survey logistic_regression calculate adjusted_odds_ratio aors confidence_interval association readmission adjusting confounders result cohort hospitalization acute diverticulitis primary diagnosis index admission least_one unplanned day_readmission sixty percent readmission occurred within first week index admission common reason unplanned day_readmission due diverticulitis colon postoperative infection septicemia intestinal infection due clostridium difficile digestive system complication bleeding fistula multivariable analysis_showed advance age_year discharge medical advice comorbidities renal_failure coronary_artery_disease atrial_fibrillation congestive_heart_failure hypertension_diabetes obesity weight_loss chronic lung_disease malignancy blood transfusion medicare medicaid insurance increased length_stay day associated significantly_higher odds readmission patient undergone abdominal surgery index admission less_likely get readmitted conclusion national level hospitalization acute diverticulitis followed unplanned readmission within_day admission occurring first week multiple modifiable non modifiable factor influencing readmission_rate noted study examine strategy address predictor decrease readmission:0.0494969257264725", "179502": "background_heart_failure_hf remains leading_cause hospitalization globally exerting significant strain healthcare system impacting patient quality_life seasonal change climate temperature known affect hf_related outcome study investigates seasonal variation hospitalization outcome among hf_patient united_state method_conducted retrospective analysis national inpatient sample ni database focusing patient_aged_year primary diagnosis hf using icd cm code primary_outcome interest included trend clinical_characteristic inpatient mortality_rate length hospital_stay los addition inflation adjusted healthcare cost patient also analyzed statistical analysis included weighted logistic linear regression adjusting patient level factor age_sex race comorbidities insurance type median household income hospital level factor bed size region teaching status inpatient mortality length_stay inflation adjusted hospital cost analyzed mortality risk_factor assessed_using multivariate model cost converted dollar using standardized inflation adjustment result identified weighted hf_hospitalization peak admission winter followed spring autumn summer mean patient age highest winter year lowest summer year p comorbidities showed seasonal variation hypertension_diabetes obesity prevalent summer acute_myocardial_infarction frequent winter white hispanic asian pacific islander patient_experienced higher winter hospitalization whereas black patient increased admission autumn hospitalization common among_patient lowest income quartile overall hospital_mortality rate highest winter lowest summer p average length_stay los day ci increasing day ci day ci inflation adjusted cost rose significant seasonal difference conclusion seasonal variation markedly influence hf_related hospitalization outcome winter showing highest hospitalization mortality_rate especially among white hispanic asian pacific islander patient:0.0476945568302052", "170953": "importance u canada woman comprise approximately one third people inject drug pwid however clinical_characteristic outcome injection drug use complication woman poorly described objective identify clinical_characteristic outcome infective_endocarditis ie among woman inject drug wwid design setting_participant retrospective_cohort_study pwid definite ie per duke international society cardiovascular infectious disease criterion admitted april march tertiary care hospital london ontario regina saskatchewan canada data analyzed june august descriptive analysis conducted baseline_characteristic index hospitalization stratified sex main_outcome_measure primary_outcome difference year_survival female male pwid ie secondary_outcome year_survival multivariable time dependent cox_proportional_hazard regression_analysis conducted variable clinical importance evaluate year_mortality result pwid ie woman non pwid ie woman wwid ie younger men median iqr age v_year pregnant index hospitalization although contraceptive use documented woman larger proportion right_sided ie men_woman v men wwid living urban area higher mortality wwid rural area adjusted_hazard_ratio ahr ci_p overall mortality lower among pwid referred substance use disorder counseling center inpatient service compared center outpatient referral ahr ci_p overall mortality lower right_sided heart_disease woman ahr ci_p men ahr ci_p higher congestive_heart_failure woman ahr ci_p men ahr ci_p_conclusion relevance cohort pwid ie woman overrepresented reason woman disproportionately high ie incidence need study inpatient substance use disorder service contraception counseling enhanced social support wwid living urban area need prioritized:0.0471242330345241", "146292": "background liver_disease increasing burden population health globally aim characterise burden liver_disease among general internal medicine inpatient seven toronto area hospital compare common medical condition method data april october obtained hospital participating gemini collaborative using cohort data hospital information system linked administrative data defined liver_disease admission using responsible discharge diagnosis categorised according international classification disease th revision enhanced canadian version icd ca identified admission heart_failure chronic_obstructive_pulmonary_disease_copd pneumonia comparators calculated standardised mortality ratio smrs ratio observed expected death result_among discharge liver_disease accounted responsible discharge diagnosis liver_disease associated marked premature mortality smr ci compared ci heart_failure ci copd ci pneumonia majority death among_patient younger year compared heart_failure copd pneumonia liver_disease patient_presented worse laboratory based acute physiology score frequently admitted intensive_care_unit incurred higher average total cost median cad higher hospital_mortality likely readmission day prior non alcoholic fatty liver_disease admission increased p_conclusion canada largest urban centre liver_disease admission resulted premature morbidity_mortality higher resource use compared common cardio respiratory condition evaluation approach caring inpatient liver_disease timely justified:0.0469273103647297", "137947": "objective extensive review literature discovered study addressed trend hospitalization people behcet disease bd hence study explore multiple variable patient bd u year method analyzed data relating hospitalized patient_year using national inpatient sample ni database listed discharge diagnosis bd based international classification disease th revision icd diagnosis code mean_age_year alive discharge lumbar puncture procedure type hospital charlson comorbidity index cci comorbidities mean length_stay los factor affecting total cost charge admission analyzed p_value considered statistically_significant result_total discharge diagnosis bd identified among million overall discharge among_patient hospitalized underlying bd majority white female mean hospital los day higher general_population statistically_significant day v day_p mean los patient_undergoing lumbar puncture day patient bd lower medical comorbidity burden cci v general_population cci p medical comorbidities statistically significant_difference prevalence two_group renal_disease dementia peptic ulcer disease heart_failure rheumatologic disorder malignancy dyslipidemia conclusion increased awareness rare condition inpatient setting help early identification disease associated complication help caregiver provide quality care timely manner thereby decreasing morbidity_mortality los hospital cost associated bd:0.0467280758703746", "181095": "objective aimed characterize healthcare utilization comorbidity outcome among hospitalized elderly stroke patient using nationally representative dataset united_state method using national inpatient sample patient_aged_year older without comorbidities hospitalized acute stroke identified using international classification disease tenth revision clinical modification code patient comorbidities identified use elixhauser comorbidity index prevalence comorbidities hospital_mortality length_stay total hospital cost analyzed patient result within patient mean_age_year woman white observed_patient minimum two comorbidities median number comorbidities iqr significant variation prevalence rate comorbidities five common comorbidities uncomplicated hypertension paralysis congestive_heart_failure various neurological illness complex hypertension adjusting patient hospital level characteristic statistically_significant association observed comorbidities various adverse_outcome specifically comorbidities found significantly_associated increased_risk inpatient mortality odds_ratio ci_p longer duration hospitalization day ci_p higher total cost ci_p_conclusion national data suggests comorbidity common among hospitalized older stroke patient substantially increase healthcare burden inpatient mortality united_state finding underscore integration comorbidity management care older stroke patient:0.0465017742427838", "157965": "background decreased readmission_rate largely seen indicator effective care improved resource management case management team st petersburg general hospital st petersburg florida identified chronic_obstructive_pulmonary_disease_copd exacerbation pneumonia sepsis leading diagnosis index admission later led day_readmission examining patient diagnosis index admission decided investigate potential readmission risk_factor including patient age_sex race body_mass_index_bmi length_stay index admission insurance type index admission discharge placement index admission coronary_artery_disease heart_failure type_diabetes method_conducted retrospective_study data_patient st petersburg general hospital index admission diagnosis copd exacerbation pneumonia sepsis univariate_analysis conducted patient sex race bmi length_stay index admission health insurance type index admission discharge placement index admission presence coronary_artery_disease presence heart_failure presence type_diabetes subsequently bivariate analysis run variable relation day_readmission multivariable_analysis completed using binary logistic_regression pairwise analysis determine significance variable within category discharge disposition insurance type result_patient included_study readmitted within_day discharge bivariate analysis race bmi mean length_stay index admission coronary_artery_disease heart_failure type_diabetes significantly_associated readmission bivariate analysis_revealed patient discharged skilled nursing facility highest readmission_rate followed home care p medicaid patient medicare patient demonstrated higher read mission rate private insurance p readmitted patient slightly younger v_year p bivariate analysis however multi variable analysis patient type_diabetes patient_non private insurance associated_increased readmission_rate pairwise analysis variable within insurance discharge disposition category demonstrates decreased readmission individual private compared insurance subtypes decreased readmission compared discharge disposition subtypes conclusion data demonstrate hospital_readmission associated diagnosis type_diabetes non private insurance status finding lead u suggest investigation change hospital policy procedure group aim decrease readmission_rate future:0.0459139982898882", "162063": "background five million american suffer heart_failure_hf associated multiple chronic comorbidities recurrent decompensation currently increased incidence vaccine preventable disease vpds aim investigate impact hf reduced_ejection_fraction_hfref patient_hospitalized vpds hypothesis patient_hfref higher_risk vpds carry higher_risk hospital complication method_retrospective analysis hospital_admission national inpatient sample ni using icd cm code patient_admitted primary diagnosis vpds hfref without reduced_ejection_fraction outcome evaluated hospital_mortality length_stay los healthcare utilization frequency admission hospital complication multivariate regression_analysis conducted adjust confounders result vpds discharge identified patient_hfref comorbidity common admission diagnosis vpds influenza virus iv infection v_p followed pneumococcal pneumonia pna v_p adjusting confounders patient_hfref higher odds diagnosis iv adjusted aor p pna aor p_patient vpds hfref significantly_higher odds mortality aor p los respiratory_failure requiring mechanical_ventilation mechanical_ventilation less h conclusion influenza pna common vpds admitted hospital patient concomitant diagnosis hfref associated_increased mortality hospital complication:0.0456880905908678"}, "Topic 28": {"122431": "background cardiomems r sensor wireless pulmonary_artery_pressure device used monitoring symptomatic heart_failure_hf use cardiomems associated reduction hospitalization hf_patient acquisition cost could high low middle income country evidence cost_effectiveness needed help decision maker allocate resource according value money study_aimed estimating cost_effectiveness cardiomems used hf_patient third party payer perspective social security s private sector p argentina method markov model developed estimate cost_effectiveness cardiomems versus usual medical care lifetime horizon model applied hypothetical population patient_hf functional_class iii least_one hospitalization previous month main outcome incremental cost_effectiveness ratio icer populate model retrieved clinical epidemiological utility parameter literature whilst direct medical cost estimated micro costing approach exchange rate usd ar uncertainty parameter assessed deterministic probabilistic scenario sensitivity_analysis result compared usual medical care cardiomems increased quality adjusted life year qaly increased cost per patient ar s ar p resultant icer ar per qaly ar per qaly s p respectively icer sensitive hazard_ratio hf hospital_admission acquisition price cardiomems probability cardiomems cost_effective one ar three ar five ar gross domestic product per caput s p_conclusion cardiomems effective costly usual_care class iii hf_patient since argentina current explicit threshold final decision determine cost_effectiveness depend willingness pay qalys health subsector:0.0942605448298899", "185765": "background heart_failure_preserved_ejection_fraction_hfpef imposes high disease burden patient primarily multimorbidity frequent hospitalization recently american college cardiology expert consensus recommended treating patient_diagnosed hfpef sodium_glucose_cotransporter_inhibitor dapagliflozin empagliflozin reduce_risk cardiovascular_death hospitalization improve health_status however managing hfpef expensive highlighting need assess therapeutic alternative minimize health_care cost optimizing patient_outcome objective compare cost_effectiveness dapagliflozin v empagliflozin managing patient_hfpef u health_care system perspective method developed markov model simulate cohort patient_hfpef defined left_ventricular_ejection_fraction treated dapagliflozin empagliflozin transition probability health state hfpef hospitalization_heart_failure death cost quality_life weight input variable obtained literature base case analysis estimated total expected cost quality adjusted life year qalys gained incremental cost_effectiveness ratio icer lifetime horizon future expected cost qalys discounted annual rate conducted sensitivity_analysis demonstrate robustness cost_effectiveness model finding result dapagliflozin incremental expected lifetime cost compared empagliflozin resulting icer qaly value based price threshold analysis suggested empagliflozin cost_effective would need discount annual price probabilistic sensitivity_analysis dapagliflozin would preferred cost_effective option willingness pay threshold qaly time conclusion cost_effectiveness analysis_showed u health_care system perspective dapagliflozin cost_effective empagliflozin uptake may enhance long_term outcome_patient hfpef:0.0915846139079625", "138473": "aim_study determine cost_effectiveness dapagliflozin heart_failure_reduced_ejection_fraction_hfref patient china perspective health_care payer method_result built markov model perform cost_effectiveness analysis comparing standard treatment dapagliflozin mg q standard treatment hfref base case simulation year_old hfref_patient modelled year input model derived dapagliflozin prevention adverse_outcome heart_failure trial relevant data china cost quality adjusted life year qaly incremental cost_effectiveness ratio icer estimated adding dapagliflozin relative standard treatment cost qaly discounted rate annually cost presented u dollar dapagliflozin would considered cost_effective icer lower willingness pay wtp threshold uncertainty assessed model using one way two way probabilistic sensitivity_analysis psa base case compared standard treatment adding dapagliflozin expensive v effective v qalys respondent icer per qaly gained year_follow simulated horizon longer year respondent icer became lower wtp threshold input largest impact icer cost dapagliflozin cardiovascular_mortality group cost hospitalization_heart_failure result sensitivity_analysis robust psa showed similar result base case icer per qaly gained monte carlo simulation wtp threshold per qaly dapagliflozin considered cost_effective simulation conclusion dapagliflozin cost_effective treatment_option hfref_patient china according result model finding help doctor health_care payer make decision clinical_practice future real_world study cost_effectiveness dapagliflozin based chinese population also needed:0.0911867683368238", "155731": "background_objective sacubitril_valsartan shown effectiveness reducing hospitalization compared valsartan hfpef patient_heart_failure preserved_ejection_fraction_hfpef aimed investigate cost_effectiveness sacubitril_valsartan alternative valsartan chinese patient_heart_failure hfpef method markov model built investigate cost_effectiveness sacubitril_valsartan alternative valsartan chinese patient_hfpef healthcare system perspective time horizon lifetime cycle length month cost obtained local information published paper discounted rate future cost transition probability utility based study primary_outcome study incremental cost_effectiveness ratio icer sacubitril_valsartan considered cost_effective icer obtained lower willingness pay threshold u dollar u per quality adjusted life year qaly one way probabilistic sensitivity_analysis well scenario analysis_performed test robustness result lifetime simulation year_old chinese patient_hfpef could gain qalys life year sacubitril_valsartan plus standard treatment administered qalys life year valsartan plus standard treatment prescribed corresponding cost group u u respectively icer u qaly u life year higher willingness pay threshold sensitivity_analysis scenario analysis_showed result robust conclusion adding sacubitril_valsartan standard treatment alternative valsartan treatment hfpef resulted effectiveness higher cost sacubitril_valsartan likely cost_effective chinese patient_hfpef cost sacubitril_valsartan need reduce current price cost_effective population study based real_world data needed confirm conclusion:0.0898897465947607", "107309": "objective chronic_heart_failure reduced_ejection_fraction hf ref represents major public_health issue associated considerable morbidity_mortality evaluated cost_effectiveness sacubitril_valsartan formerly lcz compared ace_inhibitor acei enalapril treatment hf ref perspective healthcare provider uk denmark colombia method cost utility analysis_performed based data multinational phase iii randomised controlled_trial decision analytic model developed based series regression_model extrapolated health_related_quality_life hospitalisation rate survival lifetime horizon primary_outcome incremental cost_effectiveness ratio icer result uk cost per quality adjusted life year qaly gained sacubitril_valsartan using cardiovascular_mortality pound euro versus enalapril denmark icer sacubitril_valsartan kr euro colombia icer cop million euro per qaly gained deterministic sensitivity analysis_showed result sensitive extrapolation mortality duration treatment_effect time horizon robust structural change scenario associated icers willingness pay threshold three country setting probabilistic sensitivity_analysis suggested probability sacubitril_valsartan cost_effective conventional willingness pay threshold uk denmark colombia conclusion analysis suggests three country sacubitril_valsartan likely cost_effective compared acei current standard_care patient_hf ref:0.0892847264896237", "51670": "background objective_study assess cost_effectiveness ivabradine plus standard_care soc chronic_heart_failure chf_patient sinus_rhythm baseline heart_rate b p greece comparison current soc alone method existing cost_effectiveness model consisting two health state adapted greek health_care setting clinical input model e mortality_rate hospitalization rate nyha_class distribution utility value estimated shift trial data costing data used model reflects year euro incremental cost_effectiveness ratio icer per quality adjusted life year qaly gained calculated deterministic probabilistic sensitivity_analysis psa conducted horizon analysis patient life time cost outcome discounted per_year analysis conducted greek third party payer perspective result markov analysis_revealed discounted quality adjusted survival qalys ivabradine plus soc soc alone treatment arm respectively cumulative lifetime total cost per patient euro euro ivabradine plus soc soc alone respectively icer ivabradine plus soc versus soc alone estimated euro per qaly gained psa showed likelihood ivabradine plus soc cost_effective threshold euro qaly found conclusion ivabradine plus soc may regarded cost_effective option treatment chf_patient greece:0.0891305147760154", "128083": "background effect empagliflozin cardiovascular_outcome consistent heart_failure_reduced_ejection_fraction_hfref patient regardless presence absence diabetes evidence needed regarding cost_effectiveness empagliflozin hfref_patient study sought evaluate economic outcome adding empagliflozin standard treatment hfref_patient perspective chinese healthcare system thus provide information decision maker method based emperor reduced clinical_trial published literature data direct medical cost quality adjusted life year qalys patient_hfref year study_period simulated markov model incremental cost_effectiveness ratio icer calculated price empagliflozin referred data released menet hospitalization expense utility value derived published study china one way sensitivity_analysis probabilistic sensitivity_analysis conducted evaluate robustness model result result cost_effectiveness analysis_showed cost combination arm utility qalys cost standard arm utility qalys equated icer per qaly gained subgroup analysis_showed patient_hfref diabetes empagliflozin group higher qaly v lower cost v standard group corresponding icer non diabetic_patient per qaly deterministic sensitivity analysis_showed robust result willingness pay threshold time gross domestic product gdp per caput almost scattered point three scenario threshold line conclusion willingness pay threshold adding empagliflozin standard treatment cost_effective option hfref patient_without diabetes china:0.0884766591884875", "143453": "purpose research examined cost_effectiveness adding empagliflozin standard_care soc compared soc alone treatment_heart_failure reduced_ejection_fraction_hfref perspective healthcare payer united kingdom uk spain france method lifetime markov cohort model developed simulate patient progression health state based kansa city cardiomyopathy questionnaire clinical summary score model predicted risk_death hospitalisation worsening_heart_failure hhf treatment related adverse_event treatment discontinuation monthly cycle clinical input utility derived emperor reduced trial data supplemented published literature national costing database cost pound sterling euro quality adjusted life year qalys discounted annually uk spain france result uk spain france empagliflozin plus soc yielded additional qalys higher cost pound euro euro per patient soc alone yielding incremental cost_effectiveness ratio pound qaly euro qaly euro qaly respectively reduced hhf incidence provided cost offset empagliflozin plus soc similar result obtained range subgroup sensitivity_analysis probabilistic sensitivity result indicated empagliflozin plus soc remained cost_effective v soc willingness pay threshold pound qaly euro qaly euro qaly model run uk spain france respectively_conclusion empagliflozin added soc lead health benefit patient_hfref cost_effective treatment_option payer multiple european country uk spain france:0.0881821240892773", "185729": "introduction efficacy_safety empagliflozin treatment heart_failure_preserved_ejection_fraction_hfpef demonstrated emperor preserved trial showed reduction combined risk cardiovascular_death hf_hospitalization hazard_ratio_hr_confidence_interval_ci_p reduction total number hf_hospitalization hr_ci_p compared_placebo basis result present study_aimed assess cost_effectiveness empagliflozin standard_care soc compared soc alone treatment hfpef method published markov model adapted compare health economic outcome france considering collective perspective patient_treated empagliflozin addition soc versus patient_treated soc alone model simulated intention treat itt population trial transitioning four mutually exclusive health state representing quartile kansa city cardiomyopathy questionnaire clinical summary score kccq cs arm model estimated lifetime time horizon economics health_outcome hf_hospitalization avoided life year quality adjusted life year qalys gained calculate incremental cost_effectiveness ratio icers resource used derived pairing french survey hf fresh cohort data french health insurance claim data utility derived basis eq l questionnaire valued french tariff economic health_outcome discounted annual rate result model predicted treatment hfpef_patient empagliflozin would prevent patient_treated hf_hospitalization death attributable cardiovascular_event resulting average gain month overall survival versus year placebo qalys versus placebo empagliflozin cost partially offset cost saving avoided hospitalization icers euro per life year gained euro per qaly gained sensitivity_analysis conducted showed empagliflozin probability cost_effective euro qaly threshold conclusion base case result_showed empagliflozin cost_effective strategy management hfpef addition impact public_health preventing hf_hospitalization death france sensitivity_analysis suggest simulation euro qaly threshold:0.0874491689898270", "193440": "background heart_failure complex clinical syndrome high morbidity_mortality become significant burden public_health recently new class antidiabetic agent sodium_glucose_cotransporter sglt_inhibitor associated significant_reduction mortality hospitalization_hf reduced_ejection_fraction_hfref added standard pharmacological treatment considering lack data cost_effectiveness present_study aim estimate incremental cost_effectiveness ratio add dapagliflozin treatment hfref brazilian public healthcare system perspective method built markov model estimate clinical_outcome cost hypothetical subject established hfref lifetime horizon model input based dapagliflozin prevention adverse_outcome heart_failure dapa hf trial local data main outcome incremental cost_effectiveness ratio icer per quality adjusted life year qaly gained deterministic probabilistic sensitivity_analysis well scenario analysis_performed finding addition dapagliflozin standard_care treatment hfref_patient yielded expected value additional qalys incremental cost u resulting icer u per qaly gained cost_effective strategy considering brazilian official cost_effectiveness threshold u qaly probabilistic sensitivity_analysis simulation also cost_effective scenario analysis result similar individual without diabetes interpretation dapagliflozin likely cost_effective added standard hfref therapy brazil funding study supported national institute science technology health technology assessment instituto de avaliacao de tecnologias em saude iats:0.0872076365844796"}, "Topic 29": {"5199": "objective important identify_patient risk atherosclerotic renal artery stenosis renal artery stenosis progressive disease potentially correctable problem study evaluate prevalence angiographically determined renal artery stenosis patient_population undergoing routine coronary_angiography identify risk_factor renal artery stenosis method procedure demographic data medical_history physical finding laboratory data obtained coronary_angiography abdominal aortography performed screen presence renal artery stenosis month period patient male_female mean_age_year univariate multivariate logistic_regression_analysis made explore association clinical_variable renal stenosis result renal artery narrowing identified_patient significant renal artery stenosis defined narrowing diameter found patient insignificant diameter narrowing stenosis found patient significant unilateral stenosis present patient bilateral stenosis present patient univariate multivariate logistic_regression_analysis association clinical_variable renal artery stenosis assessed multivariable predictor included age ci approximately p severity coronary_artery_disease ci approximately p peripheral vascular_disease ci approximately p variable sex body_mass_index hypertension smoking history hyperlipidemia myocardial_infarction congestive_heart_failure renal_insufficiency diabetes_mellitus associated conclusion renal artery stenosis frequent finding patient_undergoing coronary_angiography especially older people generalized atherosclerosis:0.0315673273367566", "115340": "background renal artery stenosis ra increasingly recognized recent_year especially patient coronary_artery_disease_cad ra affect patient hypertension htn exact prevalence known objective_study performed determine prevalence identify predictor ra hypertensive patient_undergoing coronary_artery angiography patient_method cross_sectional_study august august patient htn suspected cad underwent selective coronary renal angiography screening predicting ra ra defined higher stenosis renal artery lumen multivariate_analysis factor_associated presence ra examined using logistic_regression_model result mean standard_deviation age_year men according angiographic data_patient cad normal coronary_artery ra seen patient cad multivariate logistic_regression_analysis identified age p number significant coronary lesion p independent_predictor ra gender smoking congestive_heart_failure diabetes_mellitus dm hyperlipidemia hlp body_mass_index_bmi independent_predictor conclusion_study suggests management_patient ra risk_factor likely considered beneficial addition clinical angiographic feature helpful predicting presence elderly_patient cad:0.0309731869401101", "130882": "purpose ewgsop defines probable sarcopenia presence low muscle strength without non muscle cause association probable sarcopenia studied report date intention study identify association probable sarcopenia common geriatric syndrome sample older_adult attended geriatric outpatient clinic istanbul university_hospital method present_study designed retrospective cross_sectional_study performed comprehensive geriatric assessment participant univariate analysis_performed determine relationship probable sarcopenia age_sex common geriatric syndrome e frailty fall polypharmacy malnutrition comorbidities e diabetes_mellitus hypertension chronic_kidney_disease chronic_obstructive_pulmonary_disease_copd congestive_heart_failure_chf depression osteoporosis variable found significant included logistic_regression_analysis result presented odds_ratio confidence_interval_ci result included_study participant mean_age_year female probable sarcopenia identified n sample multivariate_analysis carried factor_associated probable sarcopenia identified male sex ci frailty ci chronic_kidney_disease ci_conclusion probable sarcopenia significantly_associated frailty geriatric syndrome signifying importance marker frailty study identified chronic renal_failure factor significantly_associated probable sarcopenia among variety studied disease frequently accompany aging:0.0300564082104895", "85852": "background chronic_kidney_disease_ckd progression associated multiple risk_factor ckd prevalent nursing home resident factor related ckd setting defined method cross_sectional study_conducted n data abstracted using standardized form analyzed sa chi square test statistic used compare proportion mean correlation coefficient used describe association logistic model fit data determine multivariate association modification diet renal_disease mdrd formula used estimate gfr ckd defined according established standard cutoff point chosen analysis result twenty three percent subject ckd mean_age egfr egfr frequent co_morbidity hypertension gerd obesity dyslipidemia depression anemia diabetes conclusion population unique term age reason nursing home admission factor_associated ckd study include age_year old male positive history cardiovascular_disease including congestive_heart_failure coronary_artery_disease anemia polypharmacy obese bmi analysis_showed age anemia strongest factor_associated ckd population management targeted ckd risk_factor reduction may play vital role controlling magnitude disease prospective_study investigate relationship gender bmi greater cardiovascular_disease ckd complication warranted:0.0296736935969308", "29392": "atrial_fibrillation_af common sustained arrhythmia clinical_practice associated_increased mortality cardiovascular morbidity nonuremic recently dialysis patient aim_study assess prevalence af risk_factor predictor presence cohort incident hemodialysis hd patient greece ii report current practice management_patient prospective cross_sectional multicenter study_patient regular hd program month demographic characteristic cause renal_disease cardiovascular_risk_factor medication use dialysis data kt v dialysis method type dialysate lead electrocardiogram ecg interdialytic day cardiac echo data_collected pertinent demographic ecg echocardiographic data entered univariate multivariate_analysis evaluate association af chad score congestive heart_failure_hf hypertension age diabetes previous stroke transient_ischemic_attack tia estimated clinical_practice high_risk chad score patient evaluated cohort included men_woman mean_age_year mean duration dialysis month hypertension coronary_artery_disease commonest cardiovascular_risk_factor af prevalence af showed age dependent increase patient_year af present patient_year prevalence increased furthermore patient permanent persistent paroxysmal af prevalence paroxysmal atrial flutter sick sinus syndrome respectively logistic_regression_analysis showed age smoking left_atrial aortic root diameter beta_blocker alpha calcidol use hf presence valvular calcification vc cardiac echo independently_associated presence af vc cardiac echo almost sevenfold increased association af odds_ratio_confidence_interval p high_risk chad score patient_receiving anticoagulant af frequent arrhythmia hd patient apart well_known risk_factor vc merit special attention patient_population less one third high_risk af_patient receive anticoagulant possibly reflecting absence definite guideline management af hd patient:0.0294719977830340", "30440": "introduction knowledge characteristic patient atypical presentation acute_coronary_syndrome may_contribute increased sensitivity diagnosis given population purpose_study quantify prevalence atypical presentation identify determinant describe presenting symptom case acute_coronary_syndrome emergency_department hospital sao joao porto population method systematic sample emergency admission confirmed diagnosis acute_coronary_syndrome atypical presentation defined absence chest_pain syncope result prevalence atypical presentation confidence_interval_ci important variation gender increased age frequent case st_segment_elevation_myocardial_infarction multivariate_analysis atypical presentation associated age versus year odds_ratio ci four time less_likely presence history ischemic_heart_disease hypertension dyslipidemia smoking history heart_failure independently_associated higher likelihood acute_coronary_syndrome atypical presentation ci among case chest_pain discomfort growing oppressive prolonged longer minute recurrent episodic pain prevailed among symptom dyspnea frequently reported either main symptom case atypical presentation concurrently typical symptom discussion factor_associated atypical presentation consistent described population using routine clinical_data allowed access large data base representative sample patient_admitted emergency_department third level hospital serf large part local urban population medical_record data unstandardized heterogeneous validity detail conclusion one fifth episode acute_coronary_syndrome atypical presentation proportion higher older_age previous history ischemic_heart_disease classical risk_factor associated typical symptom heart_failure associated atypical presentation presentation atypical case highly variable allow identification pattern would justify lowering threshold suspicion acute_coronary_syndrome:0.0290218239302469", "125593": "introduction systemic acute respiratory syndrome coronavirus sars_cov associated acute_kidney_injury aki retrospectively studied incidence outcome aki patient_hospitalized covid king abdulaziz medical city kamc riyadh kingdom saudi arabia method_retrospective cohort_study conducted ethical approval institutional review board king abdullah international medical research center kaimrc subject identified data management office kaimrc data extracted electronic medical_record using customized data collection sheet study_included adult patient_year tested positive covid polymerase chain reaction admitted kamc march end september patient history end_stage kidney_disease patient adequate data_available establish diagnosis aki excluded patient demographic comorbid_condition medication use mechanical_ventilation day_mortality recorded result_study period march september patient_hospitalized kamc diagnosis covid excluding patient met exclusion criterion data_collected patient male_female univariate_analysis increasing age male gender use angiotensin_converting_enzyme_inhibitor angiotensin_receptor_blocker diuretic vasopressor presence chronic_kidney_disease coronary_artery_disease chronic_obstructive_pulmonary_disease dyslipidemia diabetes_mellitus heart_failure hypertension kidney transplant status mechanical_ventilation associated development aki multivariate logistic_regression_analysis independent_predictor aki restricted increasing age presence chronic_kidney_disease hypertension kidney transplant status use vasopressor mechanical_ventilation patient_developed aki day_mortality compared develop aki p_conclusion hospitalized_patient covid observed incidence aki increasing age presence chronic_kidney_disease hypertension kidney transplant status use vasopressor mechanical_ventilation independently_associated development aki presence aki associated_higher day_mortality v:0.0288220495592155", "136876": "introduction study_aimed evaluate hospital_mortality patient st_segment_elevation_myocardial_infarction stemi according gender likely risk_factor method_study report data relating consecutive_patient stemi registered june may western iran stemi registry data_collected using standardized case_report developed european observational registry program eorp relationship hospital_mortality potential predicting variable assessed multivariable logistic_regression difference group mortality_rate compared using chi square test independent test result_patient female woman different men term age v prevalence hypertension htn v diabetes_mellitus dm v hypercholesterolemia v history previous congestive_heart_failure_chf v smoking prevalent among men v although hospital_mortality rate higher woman v adjusting risk_factor female_sex independent_predictor hospital_mortality multivariable_analysis identified age higher killip class ii significantly_associated hospital_mortality rate conclusion hospital_mortality stemi woman higher men however role sex independent_predictor mortality disappeared regression_analysis gender based difference hospital_mortality stemi may related poorer cardiovascular_disease_cvd risk_factor profile woman:0.0286041636700678", "124089": "objective existing data showed left_ventricular diastolic_dysfunction common individual type_diabetes_mellitus_dm however study_included diabetic_patient prior cardiovascular_disease might compounding factor ventricular dysfunction study_aimed determine prevalence predictor left_ventricular diastolic_dysfunction asian population dm without prior cardiovascular_disease using latest recommended echocardiographic assessment left_ventricular diastolic_dysfunction design participant cross_sectional_study eligible patient dm without history coronary_artery_disease heart_failure valvular_heart_disease recruited demographic data diabetic control comorbidities microvascular macrovascular complication medication prescribed recorded venous blood sent test b_type_natriuretic_peptide transthoracic_echocardiography performed assess left_ventricular_dysfunction setting study performed tertiary healthcare center located kuala lumpur malaysia result_patient dm year poorly controlled comorbidities include hypertension hyperlipidemia pre obesity obesity majority absence microvascular albuminuria retinopathy neuropathy macrovascular peripheral vascular_disease stroke complication none raised b_type_natriuretic_peptide level symptom heart_failure echocardiographic assessment left_ventricular diastolic_dysfunction grade mild severity age ethnicity insulin therapy presence hypertension hyperlipidemia significantly_associated left_ventricular diastolic_dysfunction older dm patient chinese ethnicity insulin two time likely develop left_ventricular diastolic_dysfunction conclusion high_prevalence asymptomatic left_ventricular diastolic_dysfunction among_patient dm without prior known cardiovascular_disease older_age insulin therapy chinese ethnicity risk_factor left_ventricular diastolic_dysfunction dm:0.0283491519622532", "175537": "background anemia frequent comorbidity patient_heart_failure associated_increased morbidity_mortality reduced quality_life however data anemia prevalence associated factor prognostic significance limited region study_aimed determine prevalence anemia outpatient heart_failure reduced_ejection_fraction identify contributing factor evaluate impact quality_life university gondar comprehensive specialized hospital northwest ethiopia method institution based cross_sectional study_conducted using interviewer administered questionnaire data_collected included demographic lifestyle clinical biochemical echocardiographic characteristic health_related_quality_life assessed_using minnesota living_heart_failure questionnaire data entered epidata analyzed_using spss version bivariable multivariable binary logistic_regression_analysis performed identify factor_associated anemia variable p_value multivariable_analysis based aors ci considered statistically_significant result_among participant mean_age_year prevalence anemia heart_failure reduced_ejection_fraction patient ci anemia significantly_associated age_year aor_ci hypotension aor_ci hf duration year aor_ci recent hospitalization aor_ci presence comorbidities aor_ci severely reduced_ejection_fraction aor_ci poor quality_life aor ci_conclusion anemia highly prevalent among heart_failure reduced_ejection_fraction patient study strongly_associated factor indicating advanced disease comorbidity burden importantly anemia significant_predictor poor health_related_quality_life finding highlight need recognize anemia key determinant morbidity reduced well hfref_patient:0.0279678485333074"}, "Topic 30": {"170248": "objective examine characteristic outcome_patient inflammatory bowel disease ibd hospitalized pulmonary_embolism pe method cross_sectional observational_study analyzed data national inpatient sample investigate hospitalization pe usa stratified presence absence ibd adult_patient selected using international classification disease tenth revision code pe crohn disease ulcerative colitis data_patient demographic comorbidities hospital characteristic collected statistical analysis included univariable multivariable logistic_regression using stata focusing hospital_mortality complication pe patient_without ibd adjusted_odds_ratio aor corresponding confidence_interval_ci calculated appropriate result pe ibd group younger mean_age v_year p_higher proportion white patient v_p greater prevalence chronic liver_disease v_p compared pe non ibd patient pe ibd group lower prevalence rate coronary_artery_disease congestive_heart_failure obesity chronic_obstructive_pulmonary_disease hypertension_diabetes regarding primary_outcome significant_difference hospital_mortality two_group aor ci_p however ibd pe group higher_risk acute_kidney_injury sepsis septic shock cardiac_arrhythmia deep vein thrombosis secondary_outcome pe ibd patient extended hospital_stay higher healthcare cost compared pe non ibd patient conclusion hospitalized pe patient ibd differ demographically different comorbidity profile compared_without ibd pe ibd patient demonstrate greater use healthcare resource elevated risk hospitalization adverse_event pe non ibd patient highlighting necessity individualized management approach population:0.0430337721961160", "189560": "aim aimed analyse characteristic hospital outcome_patient hospitalized heart_failure_hf co morbid systemic sclerosis ssc compare without ssc using data national inpatient sample year method_result international classification disease tenth revision diagnosis code used_identify hospitalized_patient primary diagnosis hf secondary diagnosis ssc national inpatient sample database patient_divided two_group without secondary diagnosis ssc baseline_characteristic including demographic co_morbidity outcome mortality length_stay los cost compared two_group multivariable logistic_regression_analysis performed adjust confounders assess impact ssc hospital_mortality cost los total hospitalization_hf identified secondary diagnosis ssc patient predominantly female v_p younger mean_age v_p significantly_lower rate traditional cardiovascular_risk_factor coronary_artery_disease v_p hyperlipidaemia v_p diabetes v_p obesity v_p hypertension v_p higher_rate co morbid pulmonary_disease form interstitial lung_disease v_p pulmonary_hypertension v_p noted ssc cohort unadjusted hospital_mortality significantly_higher hf ssc group_v odds_ratio confidence_interval_ci_p unadjusted mortality also higher among female v_p black v_p hispanic v_p patient ssc cohort adjusting potential confounders ssc remained independently_associated higher hospital_mortality adjusted_odds_ratio ci_p patient_hf ssc also longer los v adjusted mean_difference amd ci_p higher hospitalization cost v amd ci_p_conclusion patient_hospitalized hf ssc noted higher odds hospital_mortality without ssc patient_hf ssc likely younger female higher_rate co morbid interstitial lung_disease pulmonary_hypertension baseline fewer traditional cardiovascular_risk_factor:0.0414544747128080", "175197": "background acute pancreatitis ap common gastrointestinal condition frequently necessitates hospitalization aim_study investigate whether gender affect outcome adult patient_hospitalized ap method using nationwide inpatient sample ni database international classification disease tenth revision clinical modification icd cm code performed retrospective_study adult patient_admitted ap compared inpatient outcome ap male_female primary_outcome cause inpatient mortality secondary_outcome length_stay los total healthcare cost utilization incidence acute renal_failure arf sepsis shock need intensive_care_unit icu admission used stata version perform statistical analysis multivariate logistic_regression_analysis conducted assess gender independent_predictor outcome adjust confounders result_total adult patient_admitted ap mean_age_year patient male_female patient higher_prevalence chronic_kidney_disease v_p congestive_heart_failure v_p obesity v_p male patient higher_prevalence diabetes_mellitus type v_p diabetes_mellitus type v_p liver cirrhosis v_p smoking tobacco use v_p female significantly_lower likelihood hospital_mortality aor ci_p arf aor ci_p sepsis aor ci_p shock aor ci_p male statistically significant_difference los total hospitalization charge icu admission two gender conclusion found female significantly_improved clinical_outcome including lower mortality arf sepsis shock compared male statistical difference two gender los total hospitalization charge icu admission prospective_study needed accurately understand difference guide clinical_practice:0.0404437516531927", "191035": "background prior research linked cardiovascular_disease higher covid mortality worse hospital outcome particularly severe_heart_failure large population_based data regarding impact pre_existing ischemic_heart_disease ihd covid outcome well_established objective_study impact covid infection ihd hospital_mortality outcome method_study included_patient cohort national inpatient sample ni database propensity_score_matching used match study cohort covid ihd control covid without ihd using matching ratio outcome analyzed hospital_mortality rate acute_kidney_injury aki acute myocardial_injury ami cardiogenic_shock cardiac_arrest mechanical_ventilation tracheal intubation pulmonary_embolism pe ventricular_tachycardia vt ventricular fibrillation vf length_stay los total hospitalization charge result_total_patient met inclusion_criterion female predominantly caucasian mean_sd age including patient history ihd following propensity matching covid patient_without ihd matched ihd patient higher_rate ami adjusted_odds_ratio aor ci_p cardiogenic_shock aor ci_p vt aor ci_p vf aor ci_p odds_ratio hospital_mortality aki pe mechanical_ventilation tracheal intubation resource use significantly_different conclusion history ihd impact covid mortality increase_risk hospital cardiac_complication:0.0404255757373844", "196066": "incidence prevalence obesity rising u known affect course treatment variety gastrointestinal disorder proposed particularly worsen symptom inflammatory bowel disease ibd put patient_risk treatment failure study seek understand better impact obesity morbidity_mortality hospital length_stay los charge patient ibd national inpatient sample ni used_identify patient_diagnosed ibd using international classification disease icd code record weighted per ni algorithm produce accurate population estimate patient classified obesity status analyzed baseline_characteristic age_gender race insurance status various comorbidities various primary_outcome analyzed outcome compared group odds_ratio or calculated using weighted logistic_regression or adjusted common co founder weighted total_patient admitted ibd included_study obese obese obese patient older complex charlson comorbidity index cci v likely female p non obese patient compared_non obese patient ibd patient obesity higher_prevalence coronary_artery_disease v hyperlipidemia v hypertension v diabetes_mellitus type v congestive_heart_failure v gastroesophageal reflux disease v cci v obese ibd patient slightly higher odds shock p acute_myocardial_infarction_ami p acute_kidney_injury aki p chronic steroid treatment p conversely obese ibd patient lower odds intestinal fistula ci_p obesity pose diverse set complication ibd patient study found obese patient_admitted ibd significantly_higher odds shock aki chronic steroid treatment interestingly patient less_likely develop intestinal fistula finding_suggest research obesity affect disease course:0.0394838989898682", "151100": "risk arrhythmia high patient covid current literature limited understanding clinical impact arrhythmia extent healthcare utilization covid patient nationwide patient sample database ni queried identify covid patient_developed arrhythmia v without multivariate regression adjusted_odds_ratio aor propensity_score_matching psm done compare outcome among cohort total_patient weighted hospitalized covid infection diagnosed arrhythmia propensity matching covid arrhythmia higher_rate hospital_mortality v_p acute_kidney_injury psm v_p acute_heart_failure_ahf v_p acute stroke v_p cardiogenic_shock v_p cardiac_arrest v_p acute_myocardial_infarction_ami v_p intracerebral hemorrhage v_p major_bleeding v_p endotracheal intubation v compared arrhythmia without covid cohort also lower odds receiving intervention cardiac pacing aor cl p cardioversion aor ci_p defibrillator aor cl p compared arrhythmia patient_without covid cardiac_arrhythmia associated covid resulted longer length hospital_stay higher total cost hospitalization arrhythmia associated covid worse clinical_outcome increased rate hospital_mortality longer length hospital_stay higher total cost patient also lower odds receiving intervention index hospitalization:0.0384057203425940", "191878": "background sepsis patient_acute myeloid leukemia aml one cause acute_kidney_injury aki available data outcome aml related aki patient_method researched national inpatient sample ni database collect data hospitalization patient year_old sepsis aml admission divided two weighted group without aki multivariable logistic_regression used adjustment possible confounders generate adjusted_odds_ratio outcome study p_value considered significant primary_outcome cause inpatient mortality secondary_outcome septic shock fluid electrolyte disorder length_stay los vasopressor support requirement mechanical_ventilation result hospital_admission patient sepsis aml aki patient aki older mean_age v_year male v black individual affected v also comorbidities significantly_higher percentage diabetes_mellitus congestive_heart_failure cardiac_arrhythmia cerebrovascular_disease chronic_kidney_disease tumor lysis syndrome present compared patient_without aki patient aki longer los day v_p multivariable analysis_showed patient aki higher odds mortality ci_p also higher_risk fluid electrolyte disorder ci_p septic shock ci_p vasopressor requirement ci_p mechanical_ventilation ci_p_conclusion aki patient sepsis aml associated_higher mortality compared sepsis alone well complication large study required identify factor could improve_outcome:0.0381338611718430", "130595": "background hypoglycemia associated poorer outcome hospitalized patient_undergoing surgical intervention cholangitis endoscopic retrograde cholangiopancreatography ercp often critical adjunct surgery capable diagnosing treating various biliary pancreatic pathology technically less invasive surgery effect hypoglycemia clinical_outcome patient cholangitis undergoing ercp elucidated methodology data extracted national inpatient sample ni database using international classification disease tenth revision clinical modification icd cm code patient_diagnosed cholangitis underwent ercp identified baseline demographic data comorbidities hospital_mortality hospital charge hospital length_stay los extracted compared based presence absence hypoglycemia statistical analysis done using test chi square analysis multivariate_analysis mortality odds_ratio calculated adjust possible confounders result_total_patient cholangitis underwent ercp identified hypoglycemia hospitalization mean_age hypoglycemia group year patient female white patient hypoglycemia group history alcoholism congestive_heart_failure_chf hypoglycemia associated_higher odds hospital_mortality confidence_interval_ci_p addition hypoglycemia age_year non white race chf independently_associated higher mortality moreover patient hypoglycemia higher total hospital charge v_p significant_increase los v day p_conclusion previous_study surgical literature linked hypoglycemia increased incidence atrial_fibrillation usage mechanical_ventilation application circulatory_support hypoglycemia may_also affect metabolism heart leading myocardial_ischemia malignant arrhythmia however unclear hypoglycemia represents proxy severity patient illness septic shock renal_insufficiency common etiology may strongly impact mortality therefore careful glycemic control hospitalization practiced hypoglycemia serf poor prognostic indicator overlooked:0.0380936539930952", "190153": "patient immune thrombocytopenia itp admitted non st_elevation_myocardial_infarction nstemi present unique therapeutic challenge due increased_risk bleeding antiplatelet anticoagulation therapy limited evidence studying hospital_mortality complication population study included_patient cohort national inpatient sample database propensity_score matched nstemi patient_without itp using matching ratio outcome analyzed hospital_mortality rate diagnostic angiogram percutaneous_coronary_intervention_pci acute_kidney_injury aki congestive_heart_failure_chf cardiogenic_shock cardiac_arrest mechanical_ventilation tracheal intubation ventricular_tachycardia vt ventricular fibrillation vf major_bleeding need blood platelet transfusion length_stay los total hospitalization charge total_patient met inclusion_criterion female predominantly caucasian mean_sd age including patient itp following propensity matching nstemi patient_without itp matched itp patient higher_rate inpatient mortality aor ci_p cardiogenic_shock aki mechanical_ventilation tracheal intubation red blood_cell platelet transfusion longer los higher total hospitalization charge rate diagnostic angiogram pci chf vt vf major_bleeding different two_group patient itp demonstrated higher odds hospital_mortality nstemi need platelet transfusion difference rate diagnostic angiogram pci:0.0375514805432210", "151947": "background acute pericarditis ap considered cardiovascular_complication patient covid aimed as es incidence associated complication clinical impact ap hospitalized_patient covid method_result retrospective_cohort_study international classification disease tenthth revision clinical modification icd code used identify_patient covid without ap national inpatient sample database compared outcome ap non ap group propensity_score_matching patient hospital demographic relevant comorbidities total_patient primary diagnosis covid identified including patient secondary diagnosis ap matching patient covid ap younger year_old versus year_old likely anemia versus cancer versus chronic_kidney_disease versus_p matching patient covid ap n compared matched non ap group_n higher_rate mortality versus_p cardiac_arrest versus_p cardiogenic_shock versus_p ventricular_arrhythmia versus_p acute_kidney_injury versus_p acute congestive_heart_failure versus_p longer length_stay day versus day p_higher total charge versus p_conclusion hospitalized_patient covid ap rare severe hospital complication associated_worse hospital outcome:0.0373761103008815"}, "Topic 31": {"157348": "background cardiopulmonary_exercise testing cpx essential assessment exercise_capacity patient chronic_heart_failure_chf respiratory gas hemodynamic parameter ventilatory efficiency vco slope peak oxygen_uptake peak_vo heart_rate recovery established diagnostic prognostic marker clinical population previous_study suggested clinical value metric related respiratory gas collected recovery peak exercise particularly recovery time peak_vo current study explores metric detail recovery peak exercise chf method patient_chf referred cpx healthy individual without formal diagnosis assessed inclusion subject performed cpx cycle ergometer volitional exhaustion monitored least five minute recovery cpx data analyzed overshoot respiratory exchange ratio rer vco vo ventilatory equivalent oxygen vo end tidal partial pressure oxygen peto peak_vo vco result thirty two patient_chf control included peak_vo differed significantly patient control v ml_kg_min p mean left_ventricular_ejection_fraction_lvef patient_chf compared control_group vo vco significantly_higher patient control p overshoot peto vo rer significantly_lower patient control p recovery metric significantly correlated peak_vo chf_patient lvef conclusion patient_chf significantly blunted recovery peak exercise reflected delay vo vco peto rer vo reflecting greater energy required return baseline abnormal respiratory gas kinetics chf negatively correlated peak_vo baseline lvef:0.0621854756792694", "110207": "background cardiopulmonary_exercise testing cpet gold_standard evaluation patient chronic_heart_failure_chf however test relatively expensive assessment result requires experience poland available tertiary health_care center many heart_rate hr parameter taken standard electrocardiographic ecg exercise test also show prognostic_value thus aim_study compare prognostic_value ventilatory hr parameter exercise testing chf_patient find hr parameter used instead ventilatory evaluation prognosis method one_hundred thirty two men mean_age_year chf reduced left ventricu lar ejection_fraction underwent treadmill cpet using modified bruce protocol hr ventilatory parameter measured patient_followed month cpet result mortality n non survivor demonstrated significantly shorter exercise time v_p lower maximal hr v bpm p smaller difference maximal hr rest v bpm p lower hr recovery rate hrr v bpm p chronotropic index chi v_p peak oxygen_consumption v ml_kg_min p oxygen_uptake efficiency slope oues value v_p higher ventilation carbon dioxide production vco slope value v_p two parameter showed good prognostic_value availability routine cpet chosen receiver_operating_characteristic analysis vco slope chi showed cut value sensitivity_specificity p sensitivity_specificity p respectively_conclusion heart_rate parameter show significant prognostic_value chi best however weaker vco slope hr parameter show somewhat weaker prognostic_value comparison ventilatory parameter yet may_useful case cpet unavailability:0.0616146705754231", "23835": "purpose_study investigates relationship ventilatory expired gas cardiac parameter measured exercise testing patient_heart_failure method twenty five subject male_female diagnosed compensated heart_failure underwent symptom limited exercise testing ventilatory expired gas analysis metabolic cardiac measure interest collected testing result mean peak oxygen_consumption vo minute ventilation carbon dioxide production vco slope percentage age predicted maximal heart_rate achieved exercise testing apmhr peak respiratory exchange ratio ml_kg_min respectively vco slope significantly correlated following apmhr r_p peak_vo r_p vo ventilatory threshold r_p dead space tidal volume ratio vd vt r_p ability peak_vo apmhr predict vco slope significant r r p_conclusion study demonstrates importance analyzing multiple exercise test parameter including metabolic measure patient_heart_failure:0.0613705885440530", "17566": "background cardiopulmonary_exercise testing ventilatory expired gas analysis cpet proven valuable tool assessing patient chronic_heart_failure_chf maximal oxygen_uptake peak v used risk_stratification patient_chf minute ventilation carbon dioxide production relationship vco slope recently demonstrated prognostic significance patient_chf method january_december performed cpet pt f mean_age_year stable chf coronary_artery_disease dilated_cardiomyopathy nyha_functional_class ii n iii n left_ventricular_ejection_fraction_lvef ability peak_vo vco slope predict cardiac related mortality cardiac related hospitalization within_month evaluation examined result peak_vo vco slope demonstrated univariate cox_regression_analysis significant_predictor cardiac related mortality hospitalization p respectively non survivor lower peak_vo ml_kg_min v ml_kg_min p steeper vco slope v_p survivor multivariate survival analysis_revealed vco slope added additional value vo peak independent prognostic_factor chi relative_risk ci_p result kaplan_meier analysis_revealed year cardiac related mortality_patient vco slope vco slope log_rank chi p_patient peak_vo ml_kg_min peak_vo ml_kg_min log_rank chi p one_year cardiac related hospitalization patient vco slope vco slope log_rank chi p_patient peak_vo ml_kg_min peak_vo ml_kg_min log_rank chi p vco slope demonstrated receiver_operating_characteristic_curve analysis equivalent peak_vo predicting cardiac related mortality v although area receiver_operating_characteristic_curve vco slope greater peak_vo predicting cardiac related hospitalization v difference statistically_significant p_conclusion result add present body knowledge supporting use cpet chf_patient vco slope index ventilatory response exercise excellent prognostic parameter improves risk_stratification chf_patient easier obtain parameter maximal exercise_capacity equivalent prognostic importance peak_vo:0.0598170025634278", "124350": "objective cardiopulmonary function patient chronic_heart_failure_chf severely limited holistic integrative exercise pathophysiology still unclear method signed consent form eighty three patient_severe chf october october fuwai hospital performed ramp incremental loading program cardiopulmonary_exercise testing cpet normal subject served control cpet performed according standard harbor ucla mc circulatory respiratory metabolic parameter cpet measured analyzed result peak oxygen_uptake peak_vo chf ml_min kg pred significantly_lower control ml_min kg pred core parameter cpet anaerobic threshold peak oxygen pulse oxygen_uptake efficiency platform ouep lowest carbon dioxide output ventilation ratio lowest vco carbon dioxide output ventilation slope vco slope chf significantly_different control_group p core parameter lung function forced expiratory volume first second fev forced vital capacity fvc fev fvc carbon monoxide diffusion dlco significantly_decreased p systolic_blood_pressure stage cpet chf significantly_lower control_group p heart_rate peak recovery stage significantly_lower control p minute ventilation tidal volume respiratory frequency rest warm significantly_higher control p tidal volume recovery significantly_higher control p vo peak recovery stage chf significantly_higher control p oxygen pulse peak significantly_higher control p pulse oxygen saturation stage cpet chf significantly_lower control p_conclusion decreased holistic functional_capacity cardiogenic chf dominantly due circulatory limitation secondly due respiratory metabolic limitation:0.0590366642059939", "30942": "background cardiopulmonary_exercise testing cpet response heart_failure preserved left_ventricular_ejection_fraction hfpef incompletely understood aimed describe cpet response hfpef assess invasive hemodynamic determinant method_result ten patient_hfpef asymptomatic control underwent resting exercise right_heart_catheterization maximal symptom limited cpet slope minute ventilation carbon dioxide production relationship vco slope v_p steeper peak oxygen_consumption peak_vo v ml_kg_min p lower heart_rate recovery minute exercise termination hrr v beat min p slower hfpef compared_control steeper vco slope r_p lower peak_vo r_p slower hrr r_p significantly related higher ratio change pulmonary_capillary wedge_pressure per change work rate measure left_ventricular pressure volume relationship conclusion hfpef_patient fundamental alteration cpet profile occur may part result rapid rise left_ventricular filling_pressure accompanies exercise patient:0.0586532584059817", "46496": "objective_study sought discover key determinant exercise_capacity maximal oxygen_consumption oxygen_uptake vo ventilatory efficiency ventilation carbon dioxide output vco slope assess prognostic potential metabolic exercise testing hypertrophic_cardiomyopathy hcm background intrinsic mechanism leading reduced functional tolerance hcm unclear method_study sample included hcm patient consecutively enrolled january january complete clinical assessment including rest stress echocardiography cardiopulmonary_exercise test cpet impedance cardiography patient also followed composite_outcome cardiac related death heart_transplant functional deterioration leading septal reduction therapy myectomy septal alcohol ablation result abnormality cpet response frequent n sample showing reduced exercise_tolerance vo max predicted n characterized impaired ventilatory efficiency vco slope variable strongly_associated exercise_capacity expressed metabolic equivalent peak cardiac_index r_p age r_p male sex r_p indexed right_ventricular end_diastolic area r_p resulting r_p peak cardiac_index main predictor peak_vo r_p variable strongly related vco slope e_e r_p indexed left_atrial volume_index lavi r_p model r composite_endpoint occurred_patient exploratory analysis variable independently_associated composite_outcome mean_follow month peak_vo predicted hazard_ratio confidence_interval_ci_p vco slope hazard_ratio_ci_p lavi ml hazard_ratio ci_p_conclusion hcm peak cardiac_index main determinant exercise_capacity significantly related ventilatory efficiency peak_vo ventilatory inefficiency lavi associated_increased_risk major event short_term follow:0.0581530111818682", "33694": "background skeletal_muscle wasting associated altered catabolic anabolic balance poor_prognosis patient chronic_heart_failure_chf study_evaluated catabolic anabolic abnormality relation disease_severity chf_patient method forty two stable chf_patient men aged_year body_mass_index kg receiving optimal medical_treatment underwent incremental symptom limited cardiopulmonary_exercise testing cycle ergometer blood sample drawn within_day determine serum cortisol plasma adrenocorticotropin acth serum dehydroepiandrosterone sulfate insulin like growth_factor growth hormone total testosterone men result_patient higher cortisol level presented impaired peak oxygen_uptake vo peak v ml_kg_min p ventilatory response exercise carbon dioxide output vco slope v_p chronotropic reserve peak heart_rate hr resting hr age resting hr x v_p compared lower serum cortisol cortisol inversely correlated vo peak r_p correlated vco slope r_p chronotropic reserve r_p multivariate regression_analysis cortisol independent_predictor vo peak r f se p vco slope r f se p accounting age body_mass_index sex chf etiology creatinine left_ventricular_ejection_fraction acth patient men cortisol dehydroepiandrosterone level independent_predictor vo peak r f se p accounting also measured hormone whereas cortisol remained independent_predictor vco slope r f se p_conclusion enhanced catabolic status significantly_associated exercise intolerance ventilatory inefficiency chronotropic incompetence chf_patient suggesting significant contributing mechanism limited functional_status:0.0579245652742599", "159321": "background peak oxygen_consumption vo measured cardiopulmonary_exercise testing cpet significant_predictor mortality future transplantation heart_failure_patient severely reduced_ejection_fraction_hfref present_study evaluated difference peak_vo prognostic variable treadmill cycle cpets patient_method cross study_design thirty male severe hfref underwent cpet treadmill cycle ergometer within_day apart important cpet parameter two exercise test modality compared result peak_vo higher treadmill cycle v_p respectively minute ventilation carbon dioxide production vco slope different two cpet mode p strong positive correlation vco slope treadmill cycle testing r_p vco slope related peak respiratory exchange ratio rer either modality treadmill r_p cycle r_p rer level significantly_higher cycle ergometer p_conclusion peak_vo higher treadmill cycle ergometer severe hfref_patient addition vco slope modality dependent parameter related patient effort cpet:0.0577613367026398", "4185": "descriptive study analyzed serial individual change exercise pattern breathing pob patient_stable chronic_heart_failure_chf twenty two chf patient_underwent maximal symptom limited cardiopulmonary_exercise test treadmill minute ventilation tidal volume vt breathing frequency f ventilatory equivalent carbon dioxide vco estimated dead space tidal volume ratio vd vt continuously recorded vco slope calculated every subject slope regression line relating vco exercising testing pattern breathing investigated constructing individual vt f relationship patient separately patient_group vt f plot initially linear subsequently exhibited inflection point vt stopped increasing increase f six patient_group inflection point evident vt f relation four patient vt f relation remained linear shifted right throughout testing two_patient decreased vt peak exercise achieving high breathing frequency comparing group group_patient higher vemax v l_min p vo max v ml_min kg p contrast two_group differ term age weight height diagnosis ejection_fraction vco slope conclusion patient_chf adopt variable breathing pattern exercise specific pattern associated greater impairment functional_capacity:0.0576442226654049"}, "Topic 32": {"175765": "background bicuspid aortic_valve bav stenosis pose several challenge transcatheter aortic_valve implantation tavi performed including risk high residual gradient hrg objective identify incidence predictor outcome hrg tavi sievers type bav stenosis method consecutive_patient sievers type bav stenosis undergoing tavi international center enrolled hrg defined mean transvalvular gradient mmhg day according valve academic research consortium varc criterion primary_endpoint major_adverse_cardiovascular_event_mace defined composite cause_death neurologic event hospitalization_heart_failure assessed year tavi secondary_endpoint included single component primary_outcome endpoint assessed according presence hrg covariate adjustment clinically_relevant confounders result_total_patient enrolled hrg post tavi found patient_patient hrg higher preprocedural aortic_valve gradient interquartile_range mmhg v mmhg p received smaller transcatheter heart valve thv mm v mm p compared_patient normal residual gradient nrg independent_predictor hrg bioprosthesis size mm year mace occurred hrg patient nrg patient adjusted hazard_ratio_hr_confidence_interval_ci_p hrg patient higher_risk neurologic event compared nrg patient versus adjusted hr_ci_p_conclusion tavi sievers type bav stenosis hrg occurred around case associated_increased_risk mace neurologic event:0.0369097918681948", "188829": "background prior study investigating impact residual mitral_regurgitation mr tricuspid_regurgitation tr elevated predischarge transmitral mean pressure gradient tmpg outcome mitral transcatheter edge edge repair teer assessed parameter isolation sought examine prognostic_value combining predischarge mr tr tmpg study long_term_outcome teer method_result reviewed record patient_underwent successful mitral teer institution march june using well_established outcome related cutoff predischarge mr moderate tr moderate tmpg mm_hg echo profile developed based number risk_factor present optimal risk_factor mixed risk_factor poor risk_factor discrimination profile predicting primary composite end_point cause_mortality heart_failure_hospitalization year examined using cox_regression overall mean_age_year woman primary mr two year event free_survival predischarge tr moderate mr moderate tmpg mm_hg risk_factor associated primary_end_point compared optimal profile incremental risk year event_rate worsening profile optimal reference mixed profile hazard_ratio hr_ci_p poor profile hr_ci_p echocardiographic profile statistically associated year_mortality end_point optimal reference mixed profile hr_ci_p poor profile hr_ci_p_conclusion echocardiographic profile integrating predischarge tr mr tmpg present novel prognostic stratification tool patient_undergoing mitral teer:0.0349043502391241", "143743": "background lack available data specific prognostic comparison transcatheter aortic_valve_replacement tavr using self expandable valve sev patient stenotic type type bicuspid aortic_valve bav tricuspid aortic_valve tav objective_evaluate association aortic_valve morphology outcome following self expandable tavr method consecutive_patient aortic_stenosis undergoing self expandable tavr enrolled categorized three_group type type bav tav according sievers classification primary_endpoint composite cause_mortality rehospitalization heart_failure_hf within_year secondary_outcome included procedural complication major cardiovascular_event observed clinical follow ups clinical_outcome year following tavr compared among three_group using kaplan_meier curve multivariable cox_proportional_hazard regression_model result_total_patient type type tav enrolled presence moderate_severe paravalvular leak pvl significantly_higher patient type type bav versus tav v v_p cause day_mortality v v_p year_mortality v v_p comparable among three_group however rehospitalization hf within_year significantly_higher type bav v v_p multivariate cox analysis_showed higher sts score type bav morphology excess leaflet calcification median calcium volume cv entire population independent_predictor hf rehospitalization additional intragroup kaplan_meier analysis_showed excess leaflet calcification could predict higher long_term_mortality rehospitalization risk_hf hr_ci log_rank_p type bav patient conclusion outcome self expandable tavr bav patient might vary depending valve subtypes bav patient excess leaflet calcification raphe especially calcified increased_risk moderate pvl hf readmission mid long_term_follow ups:0.0347726766464244", "66933": "background early_stage chronic_kidney_disease associated_increased cardiovascular_risk patient established type_diabetes macrovascular disease role early_stage chronic_kidney_disease macrovascular outcome prediabetes early type_diabetes_mellitus known outcome reduction initial glargine intervention origin trial introduction insulin effect cardiovascular_outcome compared standard therapy post_hoc analysis origin compared cardiovascular_outcome subject without mild stage moderate chronic_kidney_disease stage method tauwo co primary composite cardiovascular_outcome assessed first composite end_point nonfatal myocardial_infarction nonfatal stroke death cardiovascular cause second composite event plus revascularization procedure hospitalization_heart_failure several secondary_outcome prespecified including microvascular outcome incident diabetes hypoglycemia weight cancer result complete renal_function data_available origin participant total chronic_kidney_disease chronic_kidney_disease stage compared nonchronic kidney_disease participant risk developing composite primary_outcome nonfatal myocardial_infarction nonfatal stroke cardiovascular_death mild_moderate chronic_kidney_disease higher hazard_ratio_hr_confidence_interval_ci_p presence chronic_kidney_disease also associated greater twofold higher_risk cause_mortality hr_ci_p cardiovascular_mortality hr_ci_p moreover patient mild_moderate chronic_kidney_disease significantly_higher risk nonfatal myocardial_infarction nonfatal stroke stroke composite primary_end_point plus revascularization heart_failure requiring hospitalization major coronary_artery_disease event furthermore patient chronic_kidney_disease early diabetes_mellitus type primary_end_point occurred frequently compared nonchronic kidney_disease participant hr_ci_p patient prediabetes chronic_kidney_disease frequently hr_ci_p_conclusion high_risk_patient dysglycemia prediabetes early diabetes mild_moderate chronic_kidney_disease significantly_increased cardiovascular_event:0.0344754683866932", "155534": "background data regarding impact tricuspid_valve gradient tvg tricuspid transcatheter edge edge repair teer scarce objective_study sought evaluate association mean tvg clinical_outcome among_patient underwent tricuspid teer significant tricuspid_regurgitation method_patient significant tricuspid_regurgitation underwent tricuspid teer within trivalve international multisite transcatheter tricuspid_valve therapy registry divided quartile based mean tvg discharge primary_endpoint composite cause_mortality heart_failure_hospitalization outcome assessed year_follow result_total_patient included center patient_divided quartile mean tvg follows quartile n mm_hg quartile n mm_hg quartile n mm_hg quartile n mm_hg baseline tvg number implanted clip associated_higher post teer tvg significant_difference across tvg quartile year composite_endpoint quartile respectively_p proportion_patient new_york_heart_association_class iii_iv last follow p result similar adjustment clinical echocardiographic characteristic composite_endpoint quartile v quartile quartile adjusted hr_ci_p exploring post teer tvg continuous variable conclusion retrospective analysis trivalve registry increased discharge tvg significantly_associated adverse_outcome tricuspid teer finding apply explored tvg range year_follow investigation higher gradient longer follow needed better guide intraprocedural decision_making process:0.0341602312428487", "161790": "background data regarding prognostic_value left_atrial la strain aortic_stenosis scarce especially asian population moderate method left_ventricular global_longitudinal_strain lvgls la reservoir strain lasr conduit strain lascd contractile strain lasct measured_using automated speckle_tracking echocardiography consecutive_patient moderate_severe primary_endpoint composite cause_death acd major_adverse_cardiovascular_event_mace myocardial_infarction syncope heart_failure_hospitalization result_patient mean_age_year moderate_severe average lv_ejection_fraction lvef sd median_follow_month interquartile_range month primary_endpoint occurred_patient death mace patient_underwent surgical transcatheter aortic_valve_replacement avr entire cohort separate multivariable model adjusted age charlson index symptomatic status time dependent avr severity la volume_index lvef demonstrated lasr associated mace acd hazard_ratio p subgroup_analysis mace acd demonstrated consistent prognostication lasr moderate_severe lvgls prognostic severe p optimal mace acd cutoff lasr spline curve adjusted kaplan_meier curve demonstrated better event free_survival patient lasr versus lasr p_conclusion moderate_severe lasr robustly predicted outcome thus including lasr staging algorithm considered:0.0336243875074608", "149969": "background ventricular arterial coupling predicts outcome patient_heart_failure arterial elastance end_systolic elastance ratio ea ee noninvasively assessed index reflects ventricular arterial coupling aimed determine prognostic_value ventricular arterial coupling assessed ea ee transcatheter aortic_valve_replacement predict clinical_event method_result retrieved data_patient woman underwent transcatheter aortic_valve_replacement october may ocean tavi optimized transcatheter valvular intervention japanese multicenter registry determined association ea ee composite end_point hospitalization_heart_failure cardiovascular_death classifying patient quartile based ea ee value group group group group midterm follow transcatheter aortic_valve_replacement median_follow period day interquartile_range cause_death cardiovascular_death hospitalization_heart_failure composite event hospitalization_heart_failure cardiovascular_death incidence composite end_point significantly_higher group hazard_ratio hr_ci_p group hr_ci_p group hr_ci_p group adjusted multivariable cox analysis ea ee significantly_associated composite event hr per unit increase ci_p_conclusion finding_suggest higher ea ee discharge transcatheter aortic_valve_replacement associated adverse clinical_outcome midterm follow registration url http_www upload umin ac jp unique identifier umin:0.0331125195769646", "162316": "background myocardial_infarction non obstructive coronary_artery minoca heterogeneous entity varying underlying etiology occurs patient acute_myocardial_infarction sleep disorder short sleep duration common phenomenon experienced patient coronary_heart_disease associated poor clinical_outcome however association sleep quality sleep duration minoca prognosis less clear method performed prospective observational_study patient minoca february june mean_follow period year sleep quality sleep duration measured chinese version pittsburgh sleep quality index primary_endpoint cause_mortality secondary_endpoint major_adverse_cardiovascular_event_mace defined composite cardiovascular_death non_fatal myocardial_infarction_stroke heart_failure_hospitalization result follow_period cause_death occurred participant participant developed mace kaplan_meier survival analysis demonstrated significant_association poor sleep quality cause_mortality log_rank_p mace log_rank_p multivariable cox regression_model indicated poor sleep quality independent_predictor cause_mortality well mace adjusted hazard_ratio_hr_confidence_interval_ci_p adjusted hr_ci_p respectively sleep duration short sleep duration h significantly_associated increased_risk cause_mortality mace adjusted hr_ci_p adjusted hr_ci_p respectively whereas long sleep duration h poorer sleep profile including poor sleep quality short sleep duration associated_increased_risk death hr_ci_p increased_risk mace hr_ci_p neither conclusion sleep disorder common among chinese patient minoca poor sleep quality short sleep duration independently_associated increased_risk cause_mortality mace minoca population meanwhile poor sleep profile additive effect regard cardiovascular_risk population effort made improve sleep quality sleep duration secondary cardiovascular prevention clinical_trial registration http_www chictr org cn identifier chictr:0.0330366122720496", "128343": "background transcatheter edge edge mitral_valve repair tmvr increasingly performed however efficacy comparison surgical mv treatment smv unknown method consecutive_patient severe mitral_regurgitation mr undergoing tmvr functional degenerative smv functional degenerative enrolled account difference baseline_characteristic propensity_score_matching performed including age euroscore ii left_ventricular_ejection_fraction nt_probnp composite heart_failure_hf hospitalization death served primary_endpoint kaplan_meier curve cox_regression_analysis used investigate association baseline imaging procedural parameter outcome result july april patient_enrolled patient could adequately matched female euroscore ii p despite matching tmvr patient co_morbidity baseline higher_rate prior myocardial_infarction coronary revascularization pacemaker defibrillator diabetes_mellitus p_patient followed month event death hf_hospitalization occurred postprocedural mr reduction mr grade tmvr v smv v_p freedom hf_hospitalization death log_rank_p similar year multivariable cox analysis euroscore ii adj hr_ci_p residual mr adj hr_ci_p remained significantly_associated outcome conclusion propensity matched comer cohort two year outcome tmvr versus smv similar given reported favorable long_term durability tmvr interventional approach emerges valuable alternative substantial number_patient functional degenerative mr:0.0327244338413648", "158162": "tricuspid transcatheter edge edge repair teer severe tricuspid_regurgitation tr emerged novel treatment_option patient amenable surgery however knowledge regarding independent_risk_factor worse prognosis rarely available study sought investigate impact right_ventricular cardiac power index rvcpi year outcome_patient severe symptomatic tr underwent teer consecutive_patient severe tr underwent teer august march included followed prospectively baseline clinical invasive hemodynamic variable change echocardiographic_parameter new_york_heart_association_functional_class periprocedural hospital major adverse_event assessed primary_end_point defined composite cause_mortality heart_failure_hospitalization year teer multivariable cox_proportional_hazard regression_analysis performed identify independent_risk_factor combined primary_end_point rvcpi calculated cardiac_index x mean pulmonary pressure x k conversion factor x w receiver operator characteristic analysis used determine discriminative capacity rvcpi prognostic_value rvcpi threshold tested using kaplan_meier analysis total_patient mean_age_year woman high operative risk underwent teer severe tr primary_end_point occurred_patient receiver operator characteristic curve analysis demonstrated rvcpi associated area_curve confidence_interval p rvcpi threshold w maximally selected rank statistic event free_survival significantly_higher rvcpi w group_compared rvcpi w v log_rank_p multivariable cox_regression_analysis rvcpi independent_predictor combined primary_end_point hazard_ratio_confidence_interval p_conclusion rvcpi associated outcome patient_underwent teer severe tr hemodynamic predictor useful risk_stratification teer candidate:0.0320504953681905"}, "Topic 33": {"28609": "aim myostatin mstn member transforming growth_factor tgf_beta family regulate skeletal_muscle growth identified regulator cardiomyocyte growth aim_study measure mstn plasma_concentration patient congestive_heart_failure_chf evaluate relationship neurohormone released chf method_result concentration mstn measured_using competitive immunoassay chf_patient receiving optimal treatment healthy_control circulating level neurohormone n_terminal_pro atrial natriuretic_peptide nt proanp b_type_natriuretic_peptide_bnp n_terminal_pro_b_type_natriuretic_peptide nt_probnp big et also measured plasma mstn higher chf_patient control v ng_ml p chf mstn level correlated positively nt proanp r_p bnp r_p nt_probnp r_p big et r_p significant_correlation observed age creatinine conclusion_result demonstrate plasma_concentration mstn significantly_increased chf_patient mstn correlate biomarkers related hf severity study confirms activation mstn patient_heart_failure:0.0404436285860837", "57717": "background c type_natriuretic_peptide cnp vasodilator produced vascular endothelium share structural physiological property cardiac hormone atrial natriuretic_peptide brain_natriuretic_peptide_bnp little_known pathophysiological role chronic_heart_failure_chf assessed hypothesis cnp produced heart patient_chf method_result myocardial cnp production determined difference plasma_level aortic root coronary sinus c patient_undergoing right left heart catheterization part chf assessment male age_year new_york_heart_association_class left_ventricular_ejection_fraction creatinine micro mol l value mean sem bnp established originating myocardium assessed sample positive control analysis_performed blinded operator using standard competitive radioimmunoassay kit peninsula laboratory bachem ltd uk step plasma cnp concentration found aorta c versus pg_ml respectively_p mean increase cnp pg_ml range pg_ml bnp_level increased aorta c versus pg_ml_p c cnp level correlated mean pulmonary_capillary wedge_pressure r p_conclusion shown cnp produced heart patient_chf although evaluation required define full pathophysiological role condition cnp may represent important new local mediator heart:0.0356444414017581", "55678": "background promoting salt water excretion corin atrial natriuretic_peptide anp system help maintain fluid balance heart_failure yet development fluid retention despite high_level anp related peptide suggests compensatory system limited method_result level circulating corin pro anp converting_enzyme pro anp measured hospitalized patient_heart_failure using novel immunoassay patient_n severe_heart_failure new_york_heart_association_class iii_iv median ejection_fraction median brain_natriuretic_peptide level pg_ml heart_failure median plasma corin level fold lower measured plasma normal control subject versus pg_ml_p contrast patient_heart_failure level plasma n_terminal anp peptide n anp pro anp level markedly elevated versus ng_ml p level uncleaved pro anp measured novel immunoassay significantly_higher patient_heart_failure p suggesting corin cleavage pro anp impaired median plasma_level cyclic guanosine monophosphate elevated patient_heart_failure versus pmol ml_p plasma cyclic guanosine monophosphate level positively correlated fractional amount cleaved pro anp r_p level uncleaved pro anp implying cellular response anp remained intact conclusion taken together data_suggest may patient low corin level impaired pro anp cleavage contribute acute decompensation:0.0350710478892733", "6187": "background plasma measurement cardiac natriuretic_peptide biosynthetic precursor helpful chronic_heart_failure patient contrast information circulating b_type_natriuretic_peptide_bnp molecular precursor probnp patient cardiogenic_shock scarce therefore examined probnp derived peptide plasma patient myocardial_infarction complicated cardiogenic_shock method_result patient referred early invasive therapy myocardial_infarction complicated cardiogenic_shock n plasma probnp measured automated assay nt_probnp house radioimmunoassay probnp bnp concentration quantitated immunoradiometric assay median nt_probnp concentration fold higher corresponding bnp concentration pmol l range versus pmol l p moreover nt_probnp concentration fold higher compared probnp pmol l p despite molar difference strong correlation nt_probnp probnp r_p bnp r_p concentration gel filtration chromatography suggested probnp immunoreactivity reflect molecular form larger n_terminal fragment conclusion_study reveals plasma profile probnp derived peptide myocardial_infarction complicated cardiogenic_shock peripheral concentration nt_probnp probnp bnp highly correlated despite marked difference assay result also suggest increase cardiac probnp processing myocardial_infarction cardiogenic_shock:0.0349679943412203", "23376": "measurement plasma_level natriuretic_peptide used_assess left_ventricular_dysfunction prognosis recently level n_terminal peptide fragment precursor brain_natriuretic_peptide reported present peripheral plasma increased chronic_heart_failure patient aim_study develop radioimmunoassay n_terminal probnp compare plasma_concentration control subject patient end_stage_heart_failure define relation brain_natriuretic_peptide_bnp polyclonal antibody raised rabbit human n_terminal probnp fragment amino acid plasma n_terminal probnp concentration assayed directly without extraction detectable cross reactivity existed natriuretic_peptide bnp anp n_terminal proanp assay detection limit sd zero pmol l plasma n_terminal probnp median range pmol l control_group gender difference male v female pmol l p n positive correlation age r_p patient end_stage_heart_failure median n_terminal probnp level increased significantly pmol l p pooled data n_terminal probnp showed close correlation bnp r_p size exclusion plasma extract indicated probnp may circulate intact prohormone split product n_terminal probnp bnp result support concept n_terminal probnp measurement could valuable tool biochemical indication increased cardiac wall stress:0.0349419042446528", "42195": "background urinary excretion currently regarded main mechanism elimination n_terminal prohormone brain_natriuretic_peptide nt_probnp clinical implication value measurement urinary nt_probnp patient_heart_failure largely unknown method_result studied patient age_year men chronic_heart_failure_chf age_sex matched healthy_control subject glomerular_filtration_rate effective renal plasma flow measured clearance iothalamate hippuran respectively nt_probnp_level determined plasma hour urine collection mean left_ventricular_ejection_fraction chf_patient plasma nt_probnp_level higher chf_patient compared_control subject median versus pg_ml_p urinary nt_probnp excretion however substantially lower chf_patient median versus ml_min p urinary nt_probnp excretion independent estimated_glomerular_filtration_rate chf_patient control subject strong inverse relation plasma nt_probnp concentration urinary nt_probnp excretion r r respectively_p decreased renal plasma flow chf significantly_associated lower excretion nt_probnp p_conclusion urinary nt_probnp excretion lower patient_chf compared_control subject inversely related plasma nt_probnp urinary nt_probnp associated renal plasma flow estimated_glomerular_filtration_rate elevated level plasma nt_probnp patient_chf might explained myocardial stress also marked decrease urinary excretion:0.0347564562984881", "86016": "background b_type_natriuretic_peptide_bnp n_terminal probnp nt_probnp useful biomarkers management heart_failure peptide secreted circulation cleavage precursor probnp excreted kidney active form metabolite investigated effect kidney_function level association peptide material_method plasma_concentration bnp serum concentration nt_probnp measured outpatient cardiology department male_female mean_age_year hospital outpatient chronic haemodialysis year kidney_function nondialysed patient assessed estimated_glomerular_filtration_rate egfr_ml_min categorised across five stage effect kidney_function bnp nt_probnp relationship investigated result deterioration kidney_function increased bnp nt_probnp_level well nt_probnp bnp ratio value highest patient haemodialysis egfr inversely correlated bnp r nt_probnp r nt_probnp bnp ratio r_p significant_correlation observed bnp nt_probnp stage kidney_function including patient haemodialysis correlation significantly affected kidney_function conclusion although circulating level bnp nt_probnp increased deteriorating kidney_function impact kidney_function nt_probnp much pronounced bnp kidney_function taken account interpreting data bnp nt_probnp relationship:0.0333660009390615", "29402": "aim copeptin c terminal part vasopressin pro hormone elevated myocardial_infarction predicts adverse_outcome present_study investigated whether complementary role copeptin cardiac_troponin ctnt could used identification high_risk patient_chronic stable heart_failure method_result measured copeptin high_sensitivity ctnt h ctnt level consecutive_patient stable chronic_heart_failure patient_followed cause_mortality hospitalization due heart_failure median day interquartile_range univariate_analysis plasma copeptin showed moderate significant_correlation h ctnt r_p age r_p creatinine r_p amino terminal pro b_type_natriuretic_peptide nt_probnp r_p copeptin p h ctnt p concentration significantly_increased patient higher new_york_heart_association_class patient h ctnt concentration normal pg_ml patient copeptin concentration normal pmol l survival analysis elevated copeptin h ctnt concentration significant_predictor outcome p combination marker showed graded highly significant_association impaired clinical_outcome independent plasma nt_probnp_level adjusted_hazard_ratio ci_p adding copeptin concentration prediction_model nt_probnp h ctnt resulted significant_improvement model performance net reclassification improvement p_conclusion data_suggest combined use h ctnt copeptin might predict clinical_outcome patient_chronic stable heart_failure:0.0331717716777827", "10077": "background increased plasma_level atrial natriuretic_peptide anp brain_natriuretic_peptide_bnp identified predictor cardiac_dysfunction prognosis congestive_heart_failure ischemic_heart_disease severe sepsis patient however information available yet prognostic_value natriuretic_peptide therefore aim present_study determine role n_terminal prohormone form anp nt proanp bnp nt_probnp context outcome septic patient furthermore effect treatment recombinant human activated protein c drotrecogin alfa activated plasma_level natriuretic_peptide severe sepsis evaluated method_result fifty seven patient_severe sepsis included level nt proanp nt_probnp measured second day sepsis elisa septic patient nt_probnp_level pmol l time likely relative_risk rr_ci die sepsis patient lower nt_probnp value p nt proanp level however predictive survival patient_population highly significant_correlation found troponin level plasma_concentration nt_probnp septic patient r_p addition troponin significantly accounted variation nt_probnp_level p suggesting important_role nt_probnp context cardiac injury dysfunction septic patient twenty three septic patient_received treatment drotrecogin alfa activated presented significantly_lower concentration nt proanp nt_probnp troponin compared patient_receiving drotrecogin alfa activated conclusion nt_probnp may serve useful laboratory marker predict survival patient_presenting severe sepsis:0.0320605456497277", "51291": "objective purpose_study examine change broad panel biomarkers following left_ventricular_assist_device_lvad support advanced heart_failure_hf background lvad therapy mechanically unloads failing_heart may result reversal certain aspect end_stage hf phenotype change marker myocardial stress fibrosis inflammation fluid homeostasis renal injury setting unknown method amino terminal pro b_type_natriuretic_peptide nt_probnp galectin st copeptin growth differentiation factor gdf c_reactive_protein crp neutrophil gelatinase associated lipocalin ngal level measured frozen plasma collected individual prior continuous_flow lvad_implantation median interquartile_range day implantation result median_age patient year_old lvad therapy associated significant_decrease nt_probnp pg_ml_p st ng_ml p galectin ng_ml p gdf ng_l p h crp mg l p copeptin pmol l p ngal ng_ml p despite improvement time absolute value biomarker remained extremely abnormal greater reduction biomarkers noted individual decrease nt_probnp concentration reached statistical significance case galectin p_conclusion biomarker profile patient lvad placement improves nonetheless remains significantly abnormal result_suggest need targeted therapeutic_intervention mitigate abnormality potentially increase rate myocardial recovery:0.0319370049929764"}, "Topic 34": {"731": "congestive_heart_failure remains major public_health problem frequently end result cardiomyocyte apoptosis fibrous replacement myocardial_infarction process referred left_ventricular remodeling cardiomyocytes undergo terminal differentiation soon birth generally considered irreversibly withdraw cell cycle response ischemic insult adult cardiomyocytes undergo cellular hypertrophy nuclear ploidy high degree apoptosis small number human cardiomyocytes retain capacity proliferate regenerate response ischemic injury however whether cell derived resident pool cardiomyocyte stem_cell renewable source circulating bone_marrow derived stem_cell home damaged myocardium present known replacement regeneration functional cardiac muscle ischemic insult heart could achieved either stimulating proliferation endogenous mature cardiomyocytes resident cardiac stem_cell implanting exogenous donor derived allogeneic cell fetal embryonic cardiomyocyte precursor bone_marrow derived mesenchymal stem_cell skeletal myoblasts newly formed cardiomyocytes must integrate precisely existing myocardial wall order augment synchronized contractility avoid potentially life_threatening alteration electrical conduction heart major impediment survival implanted cell altered immunogenicity prolonged ex vivo culture condition addition concurrent myocardial revascularization required ensure viability repaired region prevent scar tissue formation human adult bone_marrow contains endothelial precursor resemble embryonic angioblasts used induce infarct bed neovascularization experimental myocardial_infarction result protection cardiomyocytes apoptosis induction cardiomyocyte proliferation regeneration long_term salvage survival viable myocardium prevention left_ventricular remodeling sustained improvement cardiac_function reasonable anticipate cell therapy strategy ischemic_heart_disease need incorporate renewable source proliferating functional cardiomyocytes b angioblasts generate network capillary larger size blood vessel supply oxygen nutrient chronically ischemic endogenous myocardium newly implanted cardiomyocytes:0.0508166984442857", "188962": "background adult human_heart following large myocardial_infarction unable regenerate heart muscle instead form scar risk progressive heart_failure large animal study shown intramyocardial injection human pluripotent stem_cell derived cardiomyocytes hpsc cm following myocardial_infarction result cell graft also ventricular_arrhythmia hypothesized intramyocardial injection committed cardiac progenitor cell ccps derived ipscs combined cardiac_fibroblast derived extracellular_matrix cecm enhance cell retention form cardiomyocyte containing functional graft ii free ventricular_arrhythmia iii restore left_ventricular contractility post myocardial_infarction_mi cardiomyopathy swine model method hipscs differentiated using bioreactors small molecule produce population committed cardiac progenitor cell ccps mi created using coronary_artery balloon occlusion reperfusion model yucatan mini pig four week later epicardial needle injection ccps cecm performed small initial feasibility cohort transendocardial injection tei ccps cecm ccps alone cecm alone vehicle control peri infarct region larger randomized cohort drug immunosuppression regimen administered prevent rejection human ccps arrhythmia evaluated_using implanted event recorder magnetic_resonance_imaging mri invasive pressure volume assessment used_evaluate left_ventricular anatomic functional performance including viability detailed histology performed heart detect human graft result scalable biomanufacturing protocol developed generating ccps efficiently differentiate cardiomyocytes endothelial_cell vitro intramyocardial delivery ccps post_mi porcine heart resulted engraftment differentiation ccps form ventricular cardiomyocyte rich graft significant_difference cardiac mri based measured cardiac volume function control ccp ccp cecm group however dobutamine stimulated functional reserve improved ccp ccp cecm group tei delivery ccps without cecm result tumor trigger ventricular_arrhythmia conclusion ccps promising cell source post_mi heart repair using clinically_relevant tei low_risk engraftment ventricular_arrhythmia:0.0497982126138981", "70326": "myocardial_infarction_mi lead loss cardiomyocytes left_ventricle lv dilation cardiac_dysfunction eventually developing heart_failure strategy mi therapy require biomaterials support tissue regeneration study hypothesized extracellular_matrix ecm derived collagen hydrogel loaded histone deacetylase hdac derived phosphorylated amino acid peptide ap could restrain lv_remodeling improve cardiac_function mi mi model established ligation left_anterior_descending coronary_artery lad c b mouse ap loaded collagen hydrogel intramyocardially injected infarcted region lv wall heart local delivery ap collagen increased neo microvessel formation enhanced stem_cell antigen positive sca stem_cell recruitment differentiation decreased cellular apoptosis promoted cardiomyocyte cycle progression furthermore ap collagen restricted fibrosis lv wall reduced infarct wall thinning improved cardiac performance significantly week post_mi result highlight promising implication ap collagen novel candidate mi therapy statement significance mammalian myocardium limited regenerative capability following myocardial_infarction_mi mi lead extensive loss cardiomyocytes thus culminating adverse cardiac_remodeling congestive_heart_failure situ tissue regeneration endogenous cell mobilization great potential tissue regeneration amino acid peptide domain encoded short open reading frame sorf hdac gene phosphorylated ap reported promote situ tissue repair via mobilization recruitment endogenous stem_cell antigen positive sca l stem_cell study ap shown improve h_c cell survival vitro vivo investigation mouse mi model demonstrated intra myocardial delivery ap loaded collagen hydrogel promoted neovascularization stimulated sca l stem_cell recruitment differentiation reduced cardiomyocyte apoptosis promoted cell cycle progression result treated infarcted heart increased wall_thickness improved heart_function exhibited attenuation adverse cardiac_remodeling observed week overall result highlighted positive impact implanting ap collagen novel constituent mi repair:0.0494766478971623", "12903": "objective_study designed determine_whether controlled release basic fibroblast growth_factor bfgf might improve human cardiosphere derived cell hcdc therapy pig model chronic myocardial_infarction background current cell therapy cardiac repair limited loss transplanted cell poor differentiation method_conducted randomized placebo controlled study immunosuppressed pig anterior myocardial_infarction four week coronary reperfusion pig randomly_assigned receive intramyocardial injection placebo medium without bfgf incorporating hydrogel implantation second study pig randomized receive controlled release bfgf combined without hcdcs bone_marrow derived mesenchymal stem_cell transplantation week reperfusion result controlled release bfgf ischemic myocardium significantly augmented formation microvascular network enhance myocardial perfusion contractile_function combined cell transplantation additive effect bfgf confined hcdc injected animal observed animal receiving human bone_marrow derived mesenchymal stem_cell transplantation shown increased donor cell engraftment enhanced cardiomyocyte differentiation transplanted heart resulting synergistically improved ventricular_function regional wall motion reduced infarct_size conclusion controlled delivery bfgf modulates post ischemic microenvironment enhance hcdc engraftment differentiation novel strategy demonstrates significant functional improvement myocardial_infarction may potentially represent therapeutic_approach studied clinical_trial human heart_failure:0.0472053435308706", "91330": "heart_failure one prominent cause morbidity_mortality worldwide according world health organization coronary_artery_disease myocardial_infarction_mi responsible death worldwide mi result obstruction blood supply heart scar formation cause substantial death cardiomyocytes infarct zone followed inflammatory_response current treatment methodology mi heart_failure include organ transplantation coronary_artery_bypass_grafting ventricular_remodeling cardiomyoplasty cellular therapy methodology associated risk benefit cellular cardiomyoplasty viable option decrease fibrosis infarct scar adverse post ischemic remodeling improve heart_function however low rate cell survival shortage cell source donor tumorigenesis ethical issue hamper full exploitation cell therapy mi treatment consequently mobilization recruitment endogenous stem progenitor cell bone_marrow peripheral circulation cardiac_tissue immense potential harnessing host reparative capacity result interplay among cytokine chemokines adhesion molecule therapeutic treatment enhance mobilization homing stem_cell development review present state art approach pursued stem_cell mobilization recruitment regenerate infarcted myocardium potential therapeutic_intervention delivery strategy discussed detail:0.0464956123163546", "159082": "rapid percutaneous_coronary_intervention acute_myocardial_infarction_ami reduces acute mortality urgent need treatment left_ventricular_dysfunction remodeling ami improve prognosis myocardium high regenerative capacity important minimize loss cardiomyocytes maintain cardiac_function ami overcome problem attention focused myocardial regeneration therapy using cell derived bone_marrow clinical use bone_marrow stem_cell considered low safety concern based experience using bone_marrow transplantation blood disease clinical_practice reported bone_marrow mononuclear cell bm mnc mesenchymal stem_cell bm msc differentiate cardiomyocytes vitro vivo considered promising source stem_cell therapy prevent heart_failure human ami study_conducted regenerate myocardial_tissue transplanting bone_marrow stem_cell bm msc bm mncs therapy using cell administered animal_model ami effective extent effect clinical_trial limited recently reported multilineage differentiating stress enduring cell muse cell endogenous pluripotent stem_cell obtainable various tissue including bone_marrow markedly reduced myocardial infarct_size improved cardiac_function via regeneration cardiomyocytes vessel paracrine effect compared bm msc describe stem_cell therapy using conventional bm mncs bm msc muse cell potential clinical use treatment ami:0.0458758569976885", "60079": "heart_failure remains leading_cause_death worldwide burgeoning problem public_health due limited capacity postnatal heart self renew pathophysiological change injured heart sometimes manifested scar formation myocardial degradation rather supplemental muscle regeneration replenish lost tissue healing process stem_cell therapy investigated possible treatment approach child adult potentially fatal cardiovascular_disease respond current medical_therapy although heart one least regenerative organ mammal discovery made past decade improved understanding cardiac development resident stem progenitor pool may lineage restricted subpopulation post neonatal stage cardiac morphogenesis recently investigation specifically focused factor activate either endogenous progenitor cell preexisting cardiomyocytes regenerate cardiovascular cell replace damaged heart tissue discovery induced pluripotent stem_cell advanced technological capability direct cardiac reprogramming essential factor crucial heart field completion stage cardiac_tissue engineering technology recently shown progress generating myocardial_tissue human native cardiac extracellular_matrix scaffold review summarizes recent advance field cardiac cell therapy emphasis cellular mechanism bone_marrow stem_cell cardiac progenitor cell show high potential success preclinical clinical meta_analysis study expanding current understanding mechanism self renewal neonatal mammalian heart may_lead development novel cardiovascular regenerative medicine pediatric heart_disease:0.0456429368726114", "84036": "cell based myocardial regenerative therapy undergoing experimental clinical_trial order limit consequence decreased contractile_function compliance damaged ventricle owing ischemic nonischemic myocardial disease variety myogenic angiogenic cell type proposed skeletal myoblasts mononuclear mesenchymal bone_marrow cell circulating blood derived progenitor adipose derived stromal cell induced pluripotent stem_cell umbilical cord cell endometrial mesenchymal stem_cell adult testis pluripotent stem_cell embryonic cell current indication stem_cell therapy concern patient left right_ventricular infarction idiopathic dilated_cardiomyopathy indication potential application include patient diabetic_cardiomyopathy chaga heart_disease american trypanosomiasis ischemic mitral_regurgitation left_ventricular noncompacted myocardium pediatric cardiomyopathy suitable source cell cardiac implant depend type disease treated acute_myocardial_infarction cell reduces myocardial necrosis augments vascular blood_flow desirable heart_failure cell replace promote myogenesis reverse apoptopic mechanism reactivate dormant cell process useful important note stem_cell alternative heart_transplantation selected patient early_stage heart_failure goal regenerative approach avoid delay organ transplantation since cell niche provides crucial support needed stem_cell maintenance interesting realistic perspective include association intramyocardial cell transplantation tissue engineered scaffold multisite cardiac pacing order transform passive regenerative approach dynamic cellular support promising method creation bioartificial myocardium:0.0455171794677391", "91090": "heart_failure due myocardial_infarction_mi remains leading_cause_death worldwide due inability myocardial_tissue regenerate following infarction current therapy could retard progression disease fails bring functional improvement cardiac regeneration present_study analyzes potential poly glycerol sebacate fibrinogen pgs fib core shell fiber structural support initial entrapment cell vivo porcine model using echocardiography histology immunohistochemistry echocardiography result_showed increased ejection_fraction_ef pgs fib vegf cell compared mi control percentage increase end_diastolic volume edv dimension post_mi period week follow least pgs fib vegf cell group_compared mi cell control_group proving pgs fib vegf cell group restored left_ventricle lv_function mi evident improvement ef prevention lv enlargement immunohistochemistry result demonstrated transplanted mesenchymal stem_cell msc within pgs fib vegf scaffold expressed cardiac marker protein troponin actinin endothelial_cell marker protein cd indicating differentiation human bone_marrow msc cardiac cell endothelial_cell developed nanofibrous cardiac patch pgs fib vegf cell provides functional structural integrity infarcted myocardium also serf suitable matrix entrapment msc clinical_application cardiac_tissue engineering:0.0454773388988169", "131892": "cardiomyocyte death dysfunction frequently caused myocardial_infarction_mi heart_failure leading_cause morbidity_mortality modern society paradoxically limited non curative therapy heart_failure mi currently available result past two decade research focused developing cell based approach promoting regeneration infarcted tissue cell based therapy myocardial regeneration include powerful candidate multipotent stem_cell mesenchymal stem_cell msc bone_marrow derived stem_cell endothelial progenitor cell hematopoietic stem_cell induced pluripotent stem_cell ipscs possess unique property potency differentiate desired cell type proliferation capacity patient specificity preclinical clinical_study demonstrated modest improvement myocardial regeneration reduced infarcted area upon transplantation pluripotent multipotent stem_cell another cell population need considered potential source cardiac regeneration telocytes found different organ including heart therapeutic effect studied various heart pathology mi arrhythmia atrial amyloidosis recent cell free therapeutic tool relies cardioprotective_effect complex cargo carried small membrane bound vesicle exosomes released stem_cell via exocytosis msc ipsc derived exosomes could considered novel exosome based therapy cardiovascular_disease thanks unique content also cell free approach e_g gene therapy acellular cardiac patch therefore review provides recent insight novel strategy myocardial repair based regenerative potential different cell type cell free approach:0.0451928948391292"}}